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Abstract 
 
 
Background  
????????????????????????????????????????and lives around the world. Particularly, there 
is a large increase in its prevalence in the Middle East, especially type 2 diabetes. 
Knowledge, beliefs and attitudes are the major contributing factors to medicine 
misuse and poor glycaemic control. Insulin is the last treatment option that patients 
with type 2 diabetes might require to control their disease. In addition to traditional 
injections, newer insulin delivery methods, such as pens and pumps are available, 
which may impact medicine use.  
Aim 
To identify factors that impact the management of type 2 diabetes by examining 
??????????experiences about their medicine/device use and lifestyle and exploring the 
perspectives of healthcare providers (HCPs) to inform service development.  
Method  
The study was conducted in hospitals in Kuwait. All patients (n=43) using medical 
treatment for the management of type 2 diabetes and HCPs (n=10) who were 
involved in management of those patients were invited to participate. Data were 
collected primarily through semi-structured interviews. Data analysis was performed 
using MAXQDA-11.   
Results  
Non-adherence to medicines was prevalent in this study. Interviews with patients 
revealed that poor health awareness, health beliefs and culture influenced health 
behaviour, in terms of medicine use and lifestyle. Some of the emergent beliefs 
were about the disease (downplaying its seriousness), medicines (disbelief in their 
efficacy) and self-beliefs. Using pens and pumps improv??? ?????????? ?????????, 
quality of life and satisfaction. Interviews with HCPs revealed that some barriers 
affected management of the disease, such as lack of staff, incentives and 
equipment. Recommendations to inform healthcare provision were identified. 
Conclusion  
To improve the management of type 2 diabetes and health outcomes, many issues 
need to be considered. For example, addressing ??????????beliefs, and the benefits 
of insulin pens and pumps and expanding their use. Taking into account concerns of 
HCPs would be valuable to inform service development.  
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Overview of the project  
 
This project is a study of the management of type 2 diabetes with medicines and 
devices by adults living in Kuwait, and receiving healthcare services in the Ministry 
of health (MOH). The study was conducted in secondary-care units in Kuwait, 
including the main five hospitals in the five health regions: Mobarak Al-Kabeer, 
Amiri, Adan, Jahra and Farwaniya. Semi-structured interviews were conducted with 
adult patients and HCPs. In addition, the study involved the completion of MMAS-8 
and BMQ-Specific by the patients, and their HbA1c levels were obtained from the 
medical notes. The study aimed to identify the factors that affected the management 
of type 2 diabetes in the region, in particular, it examined the role of health 
awareness, beliefs and culture in shaping the management behaviour of patients. In 
addition, as a relatively new delivery methods and options for type 2 diabetes in the 
MOH, the study investigated the advantages and problems of insulin pens and 
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support were also investigated from the perspectives of patients and were 
discussed with HCPs. HCPs reported the challenges facing better management of 
type 2 diabetes and provided their recommendations. The study will inform the 
decisions of policy makers, in order to propose service developments, inform 
healthcare provision and to improve health outcomes. 
 
Organisation of the thesis 
 
The thesis is divided into nine chapters, a description for each is provided below: 
 
Chapter 1: Introduction and background  
This chapter contains an overview of diabetes in the Middle East, an overview of the 
research subject (adherence), and a description of healthcare services in Kuwait, 
where this project was based. 
 
Chapter 2: Systematic review of studies conducted on adherence of patients 
with diabetes 
This chapter contains an overview of the literature from studies of the adherence of 
patients with diabetes in the Middle East, and this study aim and objectives.  
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Chapter 3: Methodology  
The chapter describes the methods applied in order to achieve each of the study 
objectives and justification for selecting these methods.  
 
Chapter 4: Response rate and sample characteristics 
The chapter describes the response rate of the participants and their demographic 
and clinical characteristics.  
 
Chapter 5: Medication adherence, health beliefs and the management of type 
2 diabetes  
This chapter contains the results of all the study participants (patients; n=43), and 
discusses their beliefs and other factors that affected their management behaviour.  
 
Chapter 6: Management of type 2 diabetes with insulin injections (syringe/vial 
and pens) 
This chapter includes the results of the participants (patients; n=26) who were using 
insulin injections (syringe/vial) and pens, and describes their views and experiences 
of pen use, advantages and problems.  
 
Chapter 7: Management of type 2 diabetes with insulin pumps  
This chapter describes the results of the participants (patients; n=8) who were using 
insulin pumps, and illustrates their views and experiences of pump use, advantages 
and problems.  
 
Chapter 8: The perspectives of healthcare providers on the key findings and 
their recommendations  
This chapter includes the results of semi-structured interviews with the HCPs 
(n=10), and describes their perspectives on the study findings and 
recommendations.  
 
Chapter 9: Discussion and Conclusion  
The chapter provides a discussion to the results of this study, a conclusion and 
proposals for future work.  
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Chapter 1: Introduction and background 
 
This chapter provides a background for the project and explains the research 
subject. It includes five major sections, describing an overview of diabetes mellitus, 
particularly type 2 diabetes, the epidemiology of diabetes in the Middle East, 
medicine-taking behaviour, public health and policy of type 2 diabetes management 
in Kuwait and the use of technology in the management of diabetes.   
  
1.1 An overview of diabetes mellitus  
 
1.1.1 The pathology of diabetes mellitus   
Diabetes mellitus is a chronic disease that involves lack of insulin secretion from 
pancreatic beta-cells and/or insulin resistance, which results in abnormal glucose 
levels in the blood (Alhyas et al., 2011). It is a major contributor of morbidity, e.g. 
kidney and cardiovascular diseases, limb amputations and blindness and mortality 
(Badawi et al., 2015). Diabetes is classified into two main types: type 1 diabetes or 
insulin-dependent diabetes (IDDM), which results from a complete deficiency of 
insulin secretion due to a destruction of pancreatic beta-cells and type 2 diabetes or 
non-insulin dependent diabetes (NIDDM). Type 2 diabetes occurs when the body 
has an inadequate insulin secretion that results in the insulin’s inability to move 
blood sugar to cells for energy use, which is called a resistance to insulin. Unlike, 
individuals with type 1 diabetes, patients with type 2 diabetes have measurable 
levels of circulating insulin. Figure 1.1 shows the pathophysiology of type 2 diabetes 
(Ozougwu et al., 2013). There are independent environmental factors in the 
pathogenesis of type 2 diabetes. These are aging, obesity, low activity levels, 
alcohol drinking and smoking. Obesity, particularly in individual’s waist area is 
accompanied by a reduction in muscle mass resulting in insulin resistance. Poor 
diet, particularly increased fat and simple sugars intake and reduced starch and 
fibre intake cause obesity and glucose tolerance deterioration (Ozougwu et al., 
2013). There is another type of diabetes, which is called gestational diabetes. This 
type involves glucose intolerance and is firstly diagnosed in women during 
pregnancy. Subclinical diabetes or ‘pre-diabetes’ is known as impaired glucose 
tolerance (IGT) or impaired fasting glucose (IFG) (American Diabetes Association, 
2014).  
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Figure 1.1: The pathophysiology of type 2 diabetes  
 
1.1.2 Diagnosis and management of diabetes  
The criteria for the diagnosis of diabetes, as published in the American Diabetes 
Association (ADA) in 2012 are shown in Table 1.1.  Blood tests used in the 
diagnosis of diabetes and pre-diabetes are the glycated haemoglobin A1c test 
(HbA1c), a fasting plasma glucose test (FPG) test, an oral glucose tolerance test 
(OGTT) and the random plasma glucose (RPG). The RPG is used during regular 
check-ups, if an individual has 200 micrograms per decilitre in the RPG and shows 
symptoms of diabetes, such as increased thirst, increased urination and 
unexplained weight loss, then diabetes may be diagnosed. HbA1c test is used to 
detect type 2 diabetes and pre-diabetes but is not recommended to diagnose type 1 
diabetes or gestational diabetes. It reflects the average of an individual’s blood 
glucose levels in the past 3 months and it can be performed at any time of the day. 
A normal HbA1c level is below 5.7%, from 5.7 to 6.4% indicates pre-diabetes and a 
level of >6.5% indicates diabetes (ADA, 2014). 
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Table 1.1: Criteria for the diagnosis of diabetes  
 
• A1c=glycated haemoglobin, which identifies average plasma glucose concentration, 
mg=milligram, dL=decilitre. 
• For all three tests, within the pre-diabetes range, the higher test result, the greater risk of 
diabetes. 
Source: ADA. Standards of medical care in diabetes-2012. Diabetes Care. 
2012;35(Supp1):S12, table 2. 
 
Patients with type 1 diabetes do not respond to interventions, such as dietary 
changes, exercise and oral hypoglycaemic agents (OHAs) other than insulin 
(Atkinson et al., 2014). In order to achieve target therapeutic goals, the medical 
treatment of type 2 diabetes starts with diet and exercise and ends with the 
requirement of insulin initiation. In type 2 diabetes, the function of pancreatic beta-
cells drops over time due to cell exhaustion resulting from long-time insulin 
resistance, leading to elevated lipids and glucose that induce toxic effects on these 
cells (Inzucchi et al., 2015). This decline in glycaemic control make most patients 
require insulin treatment eventually even with good adherence to OHAs (Inzucchi et 
al., 2015). The aim of the treatment of both types of diabetes is to achieve 
glycaemic control and reduce the risks of micro and macro-vascular complications. 
It has been shown that improving glycaemic control has a role in decreasing rates of 
retinopathy, neuropathy and nephropathy. The findings of The United Kingdom 
Prospective Diabetes Study (UKPDS) showed that intensive glycaemic control (with 
a sulphonylurea or insulin) remarkably decreased the risks of micro-vascular 
complications compared to conventional glycaemic control (primarily with diet) in a 
group of patients with type 2 diabetes (Inzucchi et al., 2015). The UKPDS 41 has 
also shown that intensive glycaemic control significantly reduced the cost and 
increased the time free of complications (Gray et al, 2000).  
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1.2 Epidemiology of diabetes in the Middle East  
Diabetes has become a major public health issue that affects 415 million adults 
worldwide and this number is expected to increase to 642 million by 2040 
(International Diabetes Federation, 2013). In the Middle East and North Africa 
(MENA) region (Figure 1.2), diabetes becomes one of the most rapidly growing 
non-communicable diseases. It affects approximately 35 million of adult population 
in the region and this number is expected to double to 68 million by 2030 (Badawi et 
al., 2015). Type 1 diabetes accounts for 5-10% of all diabetes cases, and usually 
presents in children and young people, although it can present at any age. Type 2 
diabetes accounts for around 90% of all diabetes cases. It mostly affects adults and 
is associated with obesity, hyperlipidaemia and hypertension (Alhyas et al., 2012). 
Prevalence of type 2 diabetes has dramatically increased over the past 3-4 
decades. The most prevalent type of diabetes in Middle Eastern countries is type 2 
diabetes (IDF, 2013).  
 
Source: www.iavireport.org 
Figure 1.2: The MENA region  
 
Diabetes has also become one of the leading causes of mortality in industrialised 
and developing countries (Alhyas et al., 2011). In 2011, diabetes contributed to 
280,000 of deaths in the Gulf Co-operation Council countries (GCC). Kuwait, 
Lebanon, Qatar, Saudi Arabia, Bahrain, United Arab Emirates (UAE), Oman and 
Egypt are among the ten countries in the world with the highest prevalence of 
diabetes (Alhyas et al., 2012). A recent study reported that three of the ten countries 
with the highest prevalence of diabetes in the world are in the Arabian Gulf region. 
The estimated percentage of the prevalence of diabetes in each of these countries 
is 24, 23.3 and 22.9 for Saudi Arabia, Kuwait and Qatar respectively (Awad and 
Alsaleh, 2015). In a study by Alarouj et al. (2013), the prevalence of diabetes among 
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Kuwaiti nationals aged between 20 and 65 years was 17.9%, which has exceeded 
the IDF projections for the year 2030. Diabetes also becomes one of the significant 
risk factors for cardiovascular diseases in the country (Alarouj, 2013).  
 
According to a study in the UAE, the annual direct treatment costs of diabetes 
without complications was  $1,605 (£1,115), which is 3.2 times higher than the per 
capita expenditure for healthcare in the country (Boutayeb et al., 2012). That cost 
increased 2.2 times in the presence of microvascualr complications, 6.4 times in the 
presence of macrovascular complicationas, while presence of both micro and 
macrovascualr complications increased the cost 9.4 times. Another study showed 
that the annual treatment costs for patients above 60 years old is higher compared 
to those between 20 and 60 years old. In that study, it has been shown that overall 
costs increase with age, duration of the disease, presence of other complications 
and are higher for patients using insulin compared to those using OHAs (Al-Maskari 
et al., 2010). In a more recent study, it has been estimated that patients with 
diabetes have healthcare expenditures ten times higher than what expenditures 
would be in the absence of diabetes (Alhowaish, 2013). 
 
The Middle Eastern diabetes pandemic has been the result of several social and 
economic changes that have occurred in the region since the 1980s. Social changes 
occurring in the region are the population’s adoption of elements of Western 
cultures, such as eating habits and urbanisation. Economic changes have resulted 
from the region’s increased wealth resulting from increased oil production and 
demand from the United States and other countries around the world. Increased 
wealth has led to an increase in automobile purchases, decreased physical activity, 
increased obesity and smoking (Mabry et al., 2010; Williams, 2012). In particular, in 
the GCC countries, rapid socio-economic growth led to a shift towards sedentary 
lifestyles, increasing rates of obesity and diabetes in the population. Also, it has 
been noted that lack of health awareness, beliefs, attitudes and cultural factors 
contribute to the high prevalence of obesity and diabetes in the Middle East 
(Musaiger, 2004). 
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1.3 Medicine-taking behaviour  
 
1.3.1 Definitions of medicine-taking behaviour  
Several terms have been used to describe adherence to treatment, the most 
commonly used definitions are: compliance and adherence. At the end of the 
1970’s, compliance is defined as “the extent to which a person’s behaviour 
coincides with medical or health advice” (Silva et al., 2011). Although this term is the 
most helpful in searching the literature, it has been criticised by some researchers, 
as it lacks patient involvement in the process (Vermeire et al., 2001). In 1997, the 
Royal Pharmaceutical Society of Great Britain introduced the term “concordance”. 
This term describes process of achievement of an agreement with the healthcare 
professional in the whole process of medicine taking rather than describing the 
extent to which medication is taken (da Silva et al., 2011).  
 
Adherence is “the extent to which a person’s behaviour- taking medication, following 
a diet and/or executing lifestyle changes corresponds with agreed recommendations 
from a healthcare provider” (WHO, 2003). This term signifies the patient’s right to 
choose whether to follow the doctor’s recommendations or not. It also removes the 
blame, which the term “compliance” brings on the patient for not following the 
treatment (Horne et al., 2005). As “adherence” requires the patient’s agreement to 
the recommendations, it has been seen to be more respectful and will be used in 
this thesis. In this thesis, participants considered to have good medicine-taking 
behaviour when they were using their medicines in a way that suits them and was in 
line with their doctors’ recommendations.  
 
Adherence is a complex behavioural process that is influenced by the environment 
in which the patient lives, healthcare providers and the healthcare system. It is also 
affected by patients’ health beliefs, motivation and confidence in managing their 
illness, and their satisfaction about the treatment outcomes (WHO, 2003). Table 1.2 
shows the factors that affect medication adherence. Researchers worldwide have 
identified some of these factors among patients with type 2 diabetes through 
different methods including qualitative interviews with patients and/or doctors. For 
example, Vermeire et al. (2003) have reported the deficit or inaccurate knowledge of 
diabetes and its complications, lack of motivation and the frustration due to failure to 
achieve control despite of perfect adherence. Hayes et al. (2006) and Aflakseir 
(2012) have reported the fear of side effects and the cost of treatment. The 
complexity of the treatment regimens has been reported by all the previous 
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researchers. In Kuwait, Jeragh-Alhaddad et al. (2015) have identified cultural 
factors, such as social stigma, healthcare system-related factors, such as 
unavailability of medicines and HCP-related factors, such as discontinuity of care as 
barriers to adherence to treatment among patients with type 2 diabetes.    
 
Table 1.2: Factors reported to affect patient’s adherence  
 
Source: World Health Organisation, 2003 
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1.3.2 Health Behaviour Models  
Consideration of health behaviour models is crucial for this study, because patients’ 
beliefs impact on their medicine-taking behavior and are associated with their 
adherence (Vermeire et al., 2003; Horne et al., 2013). Patients may intentionally 
choose not to adhere to their therapeutic regimens due to different beliefs regarding 
their medications (Horne et al., 2005). In a study of chronic conditions, there was a 
relationship between health beliefs and behaviour, as 60% of patients had 
intentionally stopped taking their medicines completely (Barber et al., 2004). In order 
to understand this relationship, it is crucial to study the socio-psychological 
approaches that explain the impact of health beliefs on behaviour (Glanz et al., 
2002).  
 
Different theories have been established, such as the Social Learning/Cognitive 
Theory (SCT; Bandura, 1997). This theory indicates that people go through different 
mental stages, e.g. problem solving and decision-making before changing behaviour 
(Bosworth and Voils, 2006). Furthermore, according to this theory, the individuals’ 
attitude is influenced by beliefs in their capabilities to perform a specific action and 
motivation, which comes from the person’s evaluation of the values/benefits of 
taking such action (Luszczynska et al., 2005). There are several Social Cognition 
Models that are based on the social cognition theory. For example, the Health Locus 
of Control (HLOC) theory has been used in several studies as a predictor of health 
behaviour (De Jesus and Xiao, 2014). Researchers used this theory to examine the 
medication adherence behaviour in patients with hypertension (Kretchy et al., 2014) 
and patients with diabetes (O’Hea et al., 2005). In patients with diabetes, the use of 
HLOC theory showed that patients with low internal HLOC beliefs and high external 
HLOC beliefs, such as beliefs in God, luck, HCPs or other people had poorer HbA1c 
levels as a consequence to poor adherence to medicines than those with high 
internal HLOC beliefs (Theofilou and Saborit, 2012).  
 
However, Conner and Norman (2005) have pointed out the weakness of the HLOC 
theory in predicting health behaviour. In a study on a group of community-dwelling 
patients with rheumatoid arthritis and osteoarthritis, HLOC beliefs showed less 
influence on health status than self-efficacy (Cross et al., 2006). Likewise, in a study 
on 4,013 Latino adults, HLOC beliefs weakly impacted on healthcare use, while 
access factors, such as having health insurance coverage were more predictable for 
healthcare use than HLOC beliefs (De Jesus and Xiao, 2014).  
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Self-efficacy is the belief of someone regarding his/her ability to engage in a 
behaviour that is necessary to achieve a desired outcome. It is a part of a self-
regulatory reciprocal process that interacts with personal, behavioural and 
environmental factors to determine behaviour (Cross et al., 2006). It may act as a 
mediator between personality components, such as negative affectivity and poor 
medication adherence (Molloy et al., 2012). There is some evidence that self-
efficacy is correlated with illness perceptions, both of which are useful predictors of 
diabetes self-management behaviour. Patients with high self-efficacy are more likely 
to adopt health-related behaviour and consequently have better health outcome 
measures (Cross et al., 2006). Aljasem and colleagues (2001) have used this theory 
to predict medication adherence behaviour in patients with diabetes. The authors 
found that patients with high self-efficacy showed better medication adherence. On 
the other hand, low self-efficacy significantly correlated to high resistance to 
treatment (Mishali et al., 2010). Self-determination theory in contradiction to self-
efficacy indicates that health-related self-regulation behaviour is dependent upon 
the development of a “sense of autonomy and competence”, which is critical to the 
processes of “internalisation and integration” (Ryan et al., 2008).  
 
Self-regulation models view the patient as central to the management of their 
disease; the more the patients are motivated to achieve a health-related goal, the 
more likely they will engage in actions that they believe will help to accomplish that 
goal (Clark and Zimmerman, 2014). According to the common-sense self-regulation 
model (CS-SRM), patients’ illness/treatment representations can be categorised into 
five types of beliefs based on identity, cause, timeline, control and consequences 
(Cameron and Leventhal, 2003). These representations are dynamic and patients 
may adapt these beliefs through a better medical understanding of their condition 
and how to manage it (Phillips et al., 2012). The CS-SRM of illness perceptions has 
been used to predict health behaviour in type 2 diabetes and other chronic 
conditions (Ashur et al., 2015). It refers to the mental representations and personal 
beliefs that individuals have about an illness.  
 
Illness Perception Questionnaire (IPQ) is used to measure patients’ illness 
perception beliefs (Broadbent et al., 2015). Patients’ drawings can also be used to 
visualise how they perceive their illnesses (Broadbent et al., 2004). Together with 
the variations of the IPQ, these have been used to support the illness perception 
model. According to this model, patients’ self-management behaviour is guided by 
their cognitive representation of their illnesses (Petrie and Weinman, 2012). Phillips 
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et al. (2012) stated that greater adherence and more positive outcomes at a one-
month follow-up were associated with greater use of CS-SRM behaviour by primary 
care providers to help patients have an adaptive understanding of their conditions.  
 
Another predictor of behaviour is the Theory of Planned Behaviour (TPB; Ajzen, 
1991) (Ajzen, 2011). This theory refers to the extent to which people believe in their 
control over performing the behaviour. Such beliefs impact the individuals’ 
motivation/intention (an immediate mediator of behaviour) (Ajzen, 2011). The theory 
has been used effectively to predict medication adherence in patients with diabetes 
(Jannuzzi et al., 2014). One such model that identifies motives that influence health-
related actions is the HBM (Glanz et al., 2002). Figure 1.3 summarises the 
dimensions of this model.  
 
 
 
 
 
 
 
 
 
 
 
  
Figure 1.3: The dimensions of the HBM 
 
The model was developed in 1950 by a group of psychologists (Hochbaum, 
Kegeles, Leventhal and Rosenstock) and has been widely used to predict health 
related behaviour for different conditions, such as hypertension, diabetes and 
coronary artery diseases (Kartal and Ozsoy, 2007). The HBM has become one of 
the most effective models of health education. Its use in adherence studies 
increases the understanding of the factors that affect the individuals’ health 
behaviour and estimates the factors that are most influential and strong 
determinants of health behaviour (Dehghani-Tafti et al., 2015). The HBM clarifies 
that the interest of patients in taking a specific behaviour, e.g. medication adherence 
Perceived 
severity 
Perceived 
threat 
Perceived 
benefits vs. 
perceived 
barriers 
Motivation to take 
health 
action/change 
behaviour Perceived 
susceptibility 
Self-
efficacy 
Chapter 1: Introduction and background 
 
is a function of their beliefs about the perceived (threat) of the disease and an 
evaluation of the value (benefits) of taking health action weighed against its 
psychological costs (barriers) (Green and Murphy, 2014). The perceived threat split 
into two dimensions, the perceived (susceptibility) and the perceived (severity). 
Perceived susceptibility indicates that the individuals must believe that they are 
susceptible to the disease. Perceived severity indicates that individuals should 
understand the seriousness of their disease (Dehghani-Tafti et al., 2015).  
 
For example, if patients believe that diabetes is serious, they are vulnerable to its 
complications, following medical recommendations will reduce threats, their 
medications are effective and the benefits of using medicines properly outweigh 
their risks, they will have the appropriate motives to undertake recommended 
health-related actions, e.g. medication adherence. Self-efficacy construct was 
added to the original four beliefs of HBM in 1998 and recognised as an important 
predictor of health behaviour in diabetes management (Green and Murphy, 2014). It 
indicates the individuals’ beliefs in their abilities to take an action required to achieve 
a certain goal (Bayat et al., 2013). 
 
1.3.3 Adherence of patients with diabetes  
 
1.3.3.1 Adherence to medicines  
Adherence to therapeutic regimens is important in the management of type 2 
diabetes but is often neglected (Bailey and Kodack, 2011). It has been concluded 
that a large proportion of patients with diabetes, using OHAs and/or insulin 
experienced difficulty in managing their disease. Complexity of the health regimen in 
this group and polypharmacy, as many as five medications or more daily, which are 
required to achieve good metabolic control constitute a significant barrier to effective 
use of medicines and adherence (Vermeire et al., 2003; Cramer, 2004; Khattab et 
al., 2010; Bailey and Kodack, 2011). 
 
In a review of studies on medication adherence in Middle Eastern countries, it was 
found that non-adherence is prevalent among patients with chronic conditions 
including diabetes. Top reasons for patients’ non-adherence ranged from 
forgetfulness to confusion about required medication duration to disbelief about the 
overall effectiveness or purpose of the medication (Al-Qasem et al., 2011). Studies 
have estimated an average adherence rate of 68% among patients with diabetes in 
Middle Eastern countries (de Villiers and Halabi, 2015). Poor adherence among 
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patients with diabetes has led to severe consequences in the region. For example, a 
study conducted in Saudi Arabia has found that poor adherence contributed to 54% 
of diabetic ketoacidosis (DKA) cases (Qari, 2002). Another study in the same 
country has recorded proteinuria cases among patients with poor scores of 
adherence (Al-Homrany and Abdelmoneim, 2004). In Jordan, depression was more 
prevalent among patients with diabetes who had increased barriers to adherence 
(Al-Amer et al., 2011). Because diabetes is a relatively new issue for the Middle 
Eastern areas, some of the healthcare systems do not have sufficient resources 
(e.g. educational services) for properly addressing the disease. As a result, almost 
half of the deaths that are caused by diabetes occur in people under age 60 
because of late diagnosis due to lack of early detection. People in the Middle East 
are still not knowledgeable about the seriousness of the disease, its complications 
or early detection signs (IDF, 2013). 
 
In Kuwait, although the policy of the Ministry of Health (MOH) has focused on 
establishing diabetes-specialised clinics in primary and secondary healthcare units, 
the prevalence of type 2 diabetes is sharply increasing. Despite the availability and 
accessibility of healthcare serveries to all patients with diabetes, the intended 
medical care targets are difficult to achieve. The majority (60%) of patients who 
manage their type 2 diabetes with insulin could not achieve glycaemic targets of 
HbA1c<7%; the mean HbA1c level among patients was 8.1% (Amiri Hospital 
Statistics, 2013). The same result was also reported in Jordan, where more than 
half of patients with type 2 diabetes exceeded target HbA1c levels (HbA1c>7) (Al-
Khawaldeh et al., 2012). Failure in attaining treatment goals and the sharp increase 
in the prevalence of diabetes suggests a defect in the disease management 
process, which could be attributed to patients’ non-adherence to their treatment 
regimens (Blackburn et al., 2013). Al-Qazaz et al. (2010) have reported a significant 
association between the eight-item Morisky Medication Adherence Scale (MMAS) 
scores and HbA1c levels in patients with type 2 diabetes. Use of insulin has shown 
to be a statistically significant predictor of glycaemic control (Al-Khawaldeh et al., 
2012). It has been indicated that each 10% reduction in patients’ medication 
adherence was associated with a 0.14 increase in HbA1c levels (Pladevall et al., 
2004).  
 
In the context of medication adherence in Kuwait, it has been found that patients 
with chronic diseases experience difficulties in adhering to their medications. This 
includes patients with psychiatric disorders (Fido and Husseini, 1998; Al-Saffar et 
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al., 2003; Al-Saffar et al., 2005), hypertension (Al-Mehza et al., 2009) and diabetes 
(Jeragh-Alhaddad et al., 2015). This paucity of medication adherence studies 
highlights the need for research to be performed in this field, particularly for a highly 
prevalent disease, such as diabetes. Specifically, patients with type 2 diabetes who 
manage their disease with insulin should be targeted because it has been shown 
that non-adherence rates to insulin (20-40%) are higher than those of OHAs among 
this group (Wallia and Molitch, 2014). In addition, there is little known about 
interventions that can improve adherence to insulin regimens (Doggrell and Chan, 
2015). Therefore, targeting those patients will help to inform policy about the needed 
interventions that help patients to improve their health outcomes.  
 
1.3.3.2 Adherence to lifestyle modifications  
Following healthy lifestyle, such as healthy diet, maintaining normal body weight, 
regular exercise and smoking cessation is crucial for prevention and management of 
type 2 diabetes (de Villiers and Halabi, 2015). Unfortunately, in the Middle East, 
poor adherence among patients with type 2 diabetes extends to healthy lifestyle 
behaviour and constitutes a barrier to achieving glycaemic control in the region (Al-
Kaabi et al., 2008). The majority of patients with diabetes in the Middle East neither 
followed a diet plan nor regularly exercised (Khattab et al., 1999; Abahussain and 
El-Zubier, 2005; Khattab et al., 2010; Al-Amer et al., 2011). Most patients with 
diabetes are physically inactive as a consequence of their obesity (Musaiger, 2004). 
Qualitative studies have reported that adherence to an appropriate diet and healthy 
lifestyle among patients with diabetes is more difficult than taking medications 
(Vermeire et al., 2003). Recent studies have shown that patients with diabetes 
experienced difficulty in applying multiple self-care behaviours simultaneously and 
that patients adhere better to medications compared with lifestyle interventions 
(Mishali et al., 2010; de Villiers and Halabi, 2015).  
 
In the GCC countries, people highly consume energy-dense foods rich in fat, free 
sugars, sodium content and deficient in complex carbohydrates. It has been found 
that daily energy intake exceeds 3,000-kcal/per capita (Musaiger, 2004; Al-Sarraj et 
al., 2010; Sibai et al., 2010; Badran and Laher, 2012; Elliott et al., 2013). In 
particular, people in Kuwait experience difficulty in following a regular diet due to 
lack of motivation and awareness and frequent social gatherings (Badran and 
Laher, 2012; Karageorgi et al., 2013). Moreover, people in the GCC countries are 
considered physically inactive (Mabry et al., 2010). People spend much of their time 
in sedentary activities, e.g. watching television, playing video games, etc. 
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Furthermore, the availability of housemaids and sophisticated household appliances 
also limits physical activity. Extreme climate conditions, e.g. being very hot in the 
summer and very cold in the winter limits outdoor activities and encourages using 
cars instead of walking (al-Mahroos and al-Roomi, 1999; Benjamin and Donnelly, 
2013). A study in Kuwait in 2013 reported the prevalence of obesity among Kuwaiti 
nationals aged between 20 to 65 years to be 48.2% and 62% of participants had a 
sedentary lifestyle (Alarouj et al., 2013). 
 
Smoking which contributes to an increased risk of coronary artery diseases is highly 
prevalent in the MENA region. Smoking rates in the region ranged from 15.3% in 
Morocco to 53.9% in Lebanon (Khattab et al., 2012). In a study among Kuwaiti 
nationals aged between 20 and 65 years, 17.8% of participants were smokers 
(Alarouj et al., 2013). Although it increases risk of micro-vascular complications, 
some patients with diabetes decide to smoke or continue smoking cigarettes. In 
Libya, it has been found that 26.7% of patients with diabetes are smokers (Roaeid 
and Kablan, 2007). Approximately the same percentage (27.6%) has been reported 
in Egypt (Kamel et al., 1999). The rate of smoking in each of these countries has 
been raised to 45% in Libya and 46% in Egypt (WHO, 2015). 
 
1.4 Public health and policy of diabetes management in Kuwait 
Kuwait is a small country located in the northeast of the Arabian Peninsula. It has a 
population of approximately 3,695,316, of which 33% are Kuwaiti and 67% are from 
different origins (e.g. Arabian, Asian, African, European, American and Australian). 
Most of Kuwait’s areas are urbanised and about 97% of people have access to safe 
water and sanitation (Central Statistical Bureau, 2013). Kuwait is divided into five 
governorates: Capital, Hawalli, Ahmadi, Jahra and Farwaniya (Figure 1.4). In terms 
of health, the MOH regulates the delivery of healthcare services via primary health 
care centres, general and specialised hospitals. The healthcare delivery system is 
regionalised; each region comprises a general hospital and a number of primary 
healthcare centres that refer to it. Table 1.3 shows the healthcare facilities in the 
MOH by health region (Health, Kuwait, 2010).  
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Source: Karageorgi et al., 2013 
Figure 1.4: The map of Kuwait including the main five health districts  
 
The delivery of healthcare services is free of charge for all Kuwaiti nationals and all 
other nationalities from the Arabian Gulf (e.g. Saudi Arabia, Bahrain, Qatar, Oman 
and United Arab Emirates). Non-Kuwaiti nationals from other than Arabian Gulf 
countries have to pay a small standard administration fee, about 1-2 KD (equivalent 
to £2-4) for admission to polyclinics and hospitals. This fee covers consultations as 
well as medications.  
 
Table 1.3: Health care facilities in the MOH by health region, Health, Kuwait, 2010 
 
 
Health 
regions 
 
 
General 
hospitals 
 
Primary health care centres 
  Diabetes 
care 
General 
health & 
child care 
Maternal 
health 
care 
Dental 
care 
Preventiv
e care 
Capital 1 17 22 5 19 12 
Hawalli 1 8 15 5 14 13 
Ahmadi 1 15 17 7 18 15 
Jahra  1 7 13 8 10 9 
Farwaniya  1 12 19 9 17 17 
Total  5 59 86 34 78 66 
 
The MOH has provided all primary care units with an electronic system, the Primary 
Care Information System (PCIS) to store patients’ medical records. By using the 
PCIS software, physicians can access patients’ data including: past medical history, 
drug history and allergies. Also, it provides physicians with clinical measurements of 
patients, such as body mass index (BMI), blood pressure (BP), HbA1c and other 
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laboratory results. Patients’ prescriptions are sent electronically to the pharmacy by 
physicians. However, in diabetes care, paper records are still used in some settings 
and in hospitals as well. 
 
In addition to primary-care units and hospitals, Kuwait established the Islamic 
Medicine Centre in 1978, which is part of the MOH. A national programme for the 
regulation of herbal medicines was created in 1989. The Centre supplies herbal 
medicines to all patients in Kuwait free of charge and it includes medicines for the 
treatment of 15 different diseases, such as rheumatoid arthritis, asthma, kidney 
diseases and diabetes. Herbal medicines are available in different forms, such as 
capsules, granules, powders, creams, ointments and liquids. No referral letters are 
required for patients to receive treatment in the Centre but the patients have to show 
blood tests or other laboratory investigations relevant for their disease (WHO, 2005).   
 
1.4.1 Diabetes care  
Diabetes is managed in Kuwait through diabetes clinics that are available in primary 
healthcare settings and they provide patients with consultation and treatment. 
Hospitals provide outpatient diabetes care, annual eye and feet check-ups as well 
as inpatient services. Patients with diabetes are usually managed in their local 
polyclinics. The MOH provides most of the specialised polyclinics with a wide range 
of anti-diabetic medications. Patients are usually seen every 2-3 months for a follow-
up and to dispense their prescriptions. In cases where patients fail to achieve 
glycaemic control in the polyclinic or if they need medicines that are not provided 
there, the physician refers the patient to the hospital. In hospitals, patients go for 
further investigations by a diabetologist, who follows their case. Patients then are 
managed in the hospital and collect their prescriptions from the outpatient pharmacy 
of the hospital. Figure 1.5 shows number of patients with diabetes in each health 
region.  
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Figure 1.5: Number of patients with diabetes in each health region, Health, Kuwait, 
2010 
 
In 1999, the Kuwait Diabetes Care Programme (KDCP) was established. The aim of 
this programme was to improve the quality of care provided to patients with diabetes 
in primary care settings. Briefly, the programme involved the development of clinical 
guidelines, standards of care, training courses and monitoring system (Al-Wotayan, 
2011). It has been shown that the implementation of KDCP was associated with 
improvements in diabetes care quality (Al-Adsani et al., 2009).  
 
In 2006, Sheikh Sabah Al-Ahmad, the current Amir of Kuwait, inaugurated the 
Dasman Diabetes Institute (DDI), one of the leading centres of diabetes research in 
the Middle East. The project was funded by the Kuwait Foundation for the 
Advancement of Sciences (KFAS). The main aim of the Institute was to improve 
quality of life of patients with diabetes through preventing, controlling and alleviating 
the impact of diabetes in Kuwait by conducting research, training programmes, 
education and health promotion (Dasman Diabetes Institute, 2016). One of the 
important achievements of the Institute was the Kuwait Health Network (KHN) 
Informatics system. This system provides education to students and clinical 
decision-making tools to HCPs. It also links all primary healthcare polyclinics and 
hospitals in the Capital region through electronic records (Ben Nakhi and Morris, 
2014). In 2010, DDI collaborated with DAFNE UK, the Dose Adjustment for Normal 
Eating project (Alozairi, 2011). In 2011, the Institute, in collaboration with University 
of Dundee, officially started to deliver a joint Masters course in Diabetes Care and 
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Education. The Institute receives referrals from all Kuwait’s governmental hospitals, 
when patients fail to achieve clinical targets, although referrals are not strictly 
defined. Figure 1.6 summarises the pathway of patients for the management of 
diabetes.  
 
Patient firstly diagnosed with diabetes in primary care 
 
 
 
 
 
 
 
If un-controlled 
referred to secondary 
care by doctor 
 
 
 
 
Doctor releases prescription 
 
Prescription taken/sent to 
pharmacy 
 
Prescription dispensed by 
pharmacist 
 
Medicines collection/ 
Patient takes medicines to home 
 
Figure 1.6: Pathway of patients for diabetes management   
 
1.4.2 Pharmaceutical care  
Different types of OHAs in addition to insulin injections are distributed regularly to 
pharmacies of all governmental primary healthcare units and hospitals by medical 
stores. Examples of OHAs that are available in Kuwait are: metformin and 
sulfonylureas, such as glibenclamide, gliclazide, glimepiride and glipizide. Different 
types of insulin are provided to all primary healthcare units along with traditional 
syringes, which are also provided to hospitals along with insulin pen devices. In 
addition, the MOH supports patients with diabetes by providing them with blood 
glucose meters, stripes and lancets at half price, available at Kuwait Diabetes 
Society (KDS). Very recently, the MOH has introduced a new option for treating 
people with diabetes; insulin pumps. However, the use of insulin pumps is still 
limited in Kuwait. This limitation can be attributed to the restrictions presented in the 
If controlled 
continue 
management 
in primary 
care  
Patient managed in 
primary care   
Patient 
adheres/does 
not adhere to 
treatment  
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KDCP guidelines, which enforce complex procedures for prescribing insulin pumps. 
According to these guidelines, candidates for pump therapy should have type 1 
diabetes and be evaluated by a diabetes consultant in a well-established unit. The 
diabetes consultant should also assess the patient’s understanding, willingness and 
ability to undertake self-care behaviour, e.g. frequent SMBG, carbohydrate counting 
and dose adjustments. Then, two diabetes-specialists must sign the form for 
dispensing the pump from Medical Stores. However, during the preliminary fieldwork 
for this study, which was conducted in February 2013, it was found that the use of 
insulin pumps has been extended to patients with type 2 diabetes, but they are very 
few compared to patients with type 1 diabetes. In addition to conventional medicines 
for the treatment of diabetes, Kuwait created a national programme for the 
regulation of herbal medicines, which are supplied to patients as over the counter 
medicines by the Islamic Medicine Centre. Herbal medicines are also sold in private 
pharmacies and herbal shops as over the counter medicines without restriction 
(WHO, 2005).  
 
Regarding pharmacy education in Kuwait, there is one School of Pharmacy at 
Kuwait University, where students spend 5 years to obtain a bachelor academic 
degree. Clinical pharmacy is taught in the final 2 years of study, but in practice 
clinical activities are still limited. Extensive search in databases have not revealed 
any national research that covers pharmaceutical care plans in Kuwait. There are 
only three studies that discuss general pharmacy practice in governmental hospitals 
and describe barriers to implementation of pharmaceutical care and the enthusiasm 
of motivated pharmacists to be involved in the process. Unfortunately, the shift 
towards introducing clinical activities into pharmacy practice in Kuwait has been 
discussed for many years with no success of it being achieved yet. Pharmacists are 
still perceived by some doctors and patients as dispensers only. The role of 
pharmacists is limited to dispensing prescriptions and clarifying to patients how to 
use their medicines. In most cases and particularly during rush hours, some 
pharmacists do this job by only swiping with pens on the medicine package and 
avoid oral interactions with patients (Awad et al., 2006; Al-Taweel et al., 2014; 
Katoue et al., 2014). 
 
1.4.3 Management of type 2 diabetes   
According to the Kuwaiti Clinical Practice Guidelines for diabetes (Al-Wotayan, 
2011), once a diagnosis of type 2 diabetes has been confirmed, the patient is 
assessed for the need for an inpatient management. If inpatient management is not 
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needed, the patient is allocated for non-pharmacological therapy (e.g. diet, exercise 
and weight management). If treatment goals have not been met, the patient starts 
the pharmacological treatment. The management algorithm starts with metformin as 
a first-line treatment, unless medically contraindicated. If treatment goals have not 
been met with the mono-therapy with metformin, a second OHAs is added or insulin. 
In addition to pharmacological therapy there is a surgical option for patients with 
type 2 diabetes called bariatric surgery. The criteria for the surgery are adults with 
type 2 diabetes with BMI>35 kg/m2 especially, in patients with co-morbidities. It is 
recommended when all non-surgical measures have been tried but failed to achieve 
or maintain adequate weight loss for at least 6 months, the patient is generally fit for 
anaesthesia and surgery and there is a commitment for long-term follow-up and 
medical monitoring. Figure 1.7 describes the management algorithm.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 1: Introduction and background 
 
 
                                                                             
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.7: The management algorithm for type 2 diabetes  
 
1.5 Use of technology in diabetes management  
Despite the extensive studies on the importance of early insulin treatment in patients 
with type 2 diabetes, and its efficacy in delaying complications, insulin is still 
considered as the last resort for treating this group of patients in the Middle East 
(Lakkis et al., 2013). Different reasons may contribute to the delay of insulin 
initiation, such as fear of injections and weight gain. In correlation with the increased 
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rates of type 2 diabetes in the world and its severe complications, the optimisation of 
glycaemic control has become a fundamental aspect of diabetes management. 
Different researchers have reported higher adherence rates among patients using 
OHAs compared to those using insulin only or as a concomitant therapy (Cramer, 
2004; Lee et al., 2006). A recent review showed that adherence to OHAs reached 
93% in patients remaining on treatment for 6-24 months and adherence to insulin 
was 62% and 64% for long-term and new-start insulin users respectively (Garcia-
Perez et al., 2013). So, adherence to insulin continues to be a challenge for 
optimum diabetes management. However, it has been suggested that simplifying 
the insulin delivery method can overcome barriers to insulin use and improve 
patients’ adherence. Technological devices, such as insulin pens and pumps have 
been introduced as insulin delivery methods instead of traditional injections (syringe 
and vial) (Figure 1.8). The aim of using insulin pens and pumps is to help insulin-
dependent patients to cope with their disease and treatment, and to make it easier 
for them to take better care of their condition (Shaghouli et al., 2009).  
 
An insulin pen is a device that contains a cartridge of insulin and a needle (dial a 
dose cartridge injector); it may be reusable or disposable (Figure 1.9). Most insulin 
pens have been designed to be socially accepted, ease the use of the injection and 
reduce injection pain. Therefore, they play a pivotal role in insulin delivery by 
providing patients with convenience compared to conventional insulin syringes (Luijf 
et al., 2010). An insulin pump is a mechanical device that connected to a tubing 
system (cannula) (Figure 1.10), which is inserted under the skin and used to 
continuously (24 hours a day) deliver the insulin (usually a rapid-acting insulin). The 
cannula remains in situ and should be changed every 2-3 days. Insulin pumps have 
the feature of delivering basal insulin (increased or decreased based on the 
patient’s activity) and bolus insulin (calculated according to carbohydrate intake) that 
simulate physiological insulin delivery (Nicholls and Partridge, 2015).  
 
           Source: cornerstones4care.com                        Source: bd.com                                                  
        Figure 1.8: Syringe and vial                           Figure 1.9: Insulin pen 
Chapter 1: Introduction and background 
 
 
Source: madisonclinic.ucsf.edu  
Figure 1.10: Insulin pump 
 
In the 1920s, when insulin was firstly discovered, the only delivery method available 
for clinical use was syringe and vial. Then, the first manufactured insulin pump was 
introduced in the 1970s and the first manufactured insulin pen (NovoPenR) was 
introduced in 1985 (Selam, 2010). Subsequently several insulin pens have been 
manufactured to deliver rapid- and long-acting insulin and insulin premixes. Newer 
types of insulin pens have more advantages than older ones by having finer needles 
and requiring lower injection force, e.g. FlexPenR. In addition, many patients find the 
disposable prefilled pens more convenient than the reusable ones (Selam, 2010). 
To enhance convenience for patients, many improvements have been made since 
the introduction of the first pump 35 years ago (Alsaleh et al., 2010). Technological 
advances in the 1990s have transferred continuous subcutaneous insulin infusion 
(CSII) into a practical alternate to MDIs (Lepore and Tommaselli, 2015). Pager-sized 
pumps have taken the place of the brick-sized old ones. OneTouchR and MiniMed 
ParadigmR are examples of the currently available insulin pumps. A newer type of 
insulin pumps is the patch or tubeless pump (Figure 1.11) that is attached directly to 
the skin. It consists of a patch (a reservoir of insulin and a tiny pump) attached to the 
skin with the smart calculator and glucose monitor as a separate device connected 
by Bluetooth (Selam, 2010). As technology in diabetes management is rapidly 
progressing, a new generation of insulin pumps (OmiPodR) have been developed 
(glucose sensor-augmented insulin pump), providing a continuous glucose monitors 
resulting in the adjustment of insulin delivery based on detected variability of blood 
glucose levels (Cengiz et al., 2011).  
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Source: healthline.com  
Figure 1.11: The patch pump  
 
The cost-effectiveness of insulin pens and their acceptability by patients with type 2 
diabetes have been reported in several studies (Lee et al., 2006; Chandran et al., 
2015). In the United States, the improved adherence among patients with type 2 
diabetes who used insulin pens reduced the diabetes care costs when compared 
with the use of traditional injections (Chandran et al., 2015). The use of insulin 
pumps has been examined worldwide and their efficacy in achieving glycaemic 
control compared with optimised insulin injection therapy has been shown in both 
types of diabetes (Bode, 2010; Pickup, 2014). Furthermore, physiological 
continuous delivery of insulin provides control using less insulin and thus, reduces 
weight gain and hypoglycaemic events, which improves patients’ quality of life and 
wellbeing (Lepore and Tommaselli, 2015). However, insulin pump therapy is 
primarily considered for patients with type 1 diabetes who have suboptimal 
glycaemic control despite maximum control using multiple daily injections (MDIs) 
(Nicholls and Partridge, 2015). The routine use of insulin pump therapy in patients 
with type 2 diabetes is not usually recommended and it differs between countries 
(Roze et al., 2015). In a review of studies, it has been shown that CSII is cost-
effective in patients with type 1 diabetes who have poor glycaemic control and/or 
problematic hypoglycaemia with MDIs (Roze et al., 2015). In type 2 diabetes, the 
cost-effectiveness of CSII versus MDIs has been shown in the Netherlands, in 
patients who continue to have poorly controlled HbA1c despite optimisation of MDI 
(Roze et al., 2016). 
 
Studies examining the psychosocial impact of insulin pump therapy on patients have 
reported improved patient’ satisfaction, preference and acceptance over the years 
(Lepore and Tommaselli, 2015). Other studies have also indicated a preference for 
insulin pumps in adults with type 2 diabetes (Bode, 2010; Rubin et al., 2010). 
Overall, both insulin pens and pumps offer advantages to patients by improving their 
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convenience, preference, adherence and health outcomes (Selam, 2010). However, 
it has been shown that most patients with type 2 diabetes had not been offered 
insulin pens by their doctors (Rubin and Peyrot, 2008). This could be due to the lack 
of awareness of doctors about the benefits of such devices. Improving awareness of 
physicians about the benefits of theses devices is the key for better diabetes 
management. However, although there are many advantages for the use of insulin 
pens and pumps, there are many disadvantages (Dansinger, 2015). These are 
discussed compared to traditional injections in Table 1.4. 
 
The use of insulin devices among adults in the Middle East has not been widely 
investigated. Five studies examined the use of insulin pens and pumps among 
adults in Lebanon, Israel and Egypt (Chapter 9, Sections 9.2.2, 9.2.3). In Kuwait, 
insulin pumps have recently been provided to patients in the MOH (since 2006). The 
Medtronic Company provides a definite number of insulin pumps every year to the 
Medical Stores of the MOH, where patients can obtain their pumps. Number of 
adults using this delivery method is expanding but unfortunately, information on how 
these devices are being used in this population and their advantages and problems 
in use is lacking.  
Table 1.4: The advantages/disadvantages of the different insulin delivery systems  
Pros/cons Syringe and vial Insulin pen Insulin pump 
Cost A box of 100 
syringes= £7-10 
Costs £21-28 Costs £2000-3000 
Preparation  -Mix different types 
of insulin in one 
injection 
-Inaccurate mixing is 
probable  
-Inability to mix 
preparations 
-Some types of 
insulin are not 
available  
-No preparation is 
needed 
Administration -Complex 
administration 
procedures  
-Dosing inaccuracy is 
probable 
-Ease of 
administration 
-More dosing 
accuracy 
 
-Automatic delivery of 
doses  
-Avoid frequent injections 
  
Carrying burden Carry several items  Carry less items   Constant wear  
Requirements  -Simple skills are 
required 
-Needs to know how 
to calculate doses  
-Simple skills are 
required 
-Needs to know 
how to calculate 
doses  
-Advanced education and 
skills are required for 
proper use 
-Needs carb counting  
-Automatic doses 
calculation 
Risks  -Pain/ bruising/ 
bleeding at injection 
site  
-Less pain/ 
bruising/ bleeding 
at injection site  
 
-Irritation/ inflammation at 
cannula insertion site 
-Equipment breakdown/ 
blocked needle/ folded 
catheter 
Efficiency  Requires larger 
amounts of insulin to 
provide control  
Requires larger 
amounts of insulin 
to provide control 
Provide control with less 
amount of insulin  
Chapter 1: Introduction and background 
 
Summary of what is known about the topic? 
Non-adherence to medicines among patients with chronic conditions including type 
2 diabetes is a problem in a number of Middle Eastern countries. Many factors have 
been identified, through questionnaires and interviews, as contributors to poor 
adherence. The HBM is effective in assessing health-related behaviour and is useful 
in explaining factors that influence patients’ behaviour. The use of technology in 
diabetes management has not been widely discussed in Eastern Mediterranean 
literature. However, use of insulin pens and pumps had some advantages among 
patients with type 2 diabetes. Use of insulin pens improved patients’ quality of life 
and insulin pumps improved patients’ glycaemic control. 
 
What this thesis adds? 
In the context of wider diabetes management in the Middle East, some adult 
patients with type 2 diabetes poorly manage their disease. This includes improper 
use of medicines and insulin devices. In relation to factors that influence patients’ 
health behaviour, describing these in the context of the HBM helped in organising 
patients’ beliefs, explaining the relation between patients’ attitudes and health-
related behaviour and evaluating the most influential beliefs on behaviour. In 
addition, barriers to appropriate insulin devices use were also investigated. 
 
Overall, this thesis aims to identify gaps in knowledge of patients using different 
therapies and to compare between the use of technology and the traditional 
methods of insulin delivery. Also, this study aims to identify different factors that 
influence patients’ behaviour, in terms of healthcare profession and system, in order 
to design the most practical interventions that address patients’ beliefs and 
attitudes. This thesis provides an evidence-based guidance for future service 
development and to inform policy and practice implications to the MOH, Kuwait. 
Therefore, it was important to conduct a literature search regarding how patients 
with diabetes manage their disease in similar populations (in the Middle East). 
Literature review of the studies is discussed in the next chapter. 
Chapter 2: Systematic review  
 
Chapter 2: Systematic review of studies on adherence of patients with 
diabetes  
 
 
2.1 Introduction  
This chapter describes the literature search process, which was conducted to review 
the published studies relating to diabetes management in Middle Eastern countries 
and discussing ?????????? adherence. Studies that discuss cultural factors affecting 
people with diabetes were also reviewed. Because it has been noted that some 
patients with diabetes lack ?????????? ??? ?????? ????????? ???? ????? ?????????? ????????
played a role in their ability to use medicines ?????????? ??? ????? ??????? ??????????
medication adherence in the region is still challenging. As this project is based in 
Kuwait, the aim of this review was to: reveal areas of research in the context of 
diabetes management among adults in the Middle East, consider local literature in 
which adherence of adults with type 2 diabetes have been discussed from the 
perspectives of patients, review evidence regarding the association between 
?????????? ???????ge, beliefs, cultural factors and health behaviour, and identify 
methods that have been employed ??????????????????????????????????????? 
 
A systematic search was undertaken using electronic databases. The literature 
search was conducted in the beginning of this study (January 2013) and continued 
until the completion of this thesis (April 2016).  
 
2.2 Methods  
 
2.2.1 Search terms and strategy 
A systematic search of studies relating to medicine use and medication adherence 
in diabetes in the Middle East was performed using the following databases: 
Embase, PubMed, Web of Science and Index Medicus for the Eastern 
Mediterranean Region (IMEMR). The search was selected for the period from 1990 
to 2015. The search terms were: (diabetes AND adherence or compliance AND 
medicine use AND Middle East or Kuwait or United Arab Emirates or Saudi Arabia 
or Bahrain or Qatar or Oman or Jordan or Egypt or Lebanon or Syria or Iraq or Iran 
or Palestine or Israel or Turkey or Libya), with or without the combination of the 
search terms: (health beliefs, lifestyle, patient behaviour, insulin). Studies that 
discussed medicine use during the holy month of Ramadan were searched using 
the search terms: (Ramadan fasting AND diabetes mellitus). In addition, the Google 
search engine was used to identify clinical journals in Middle Eastern areas. These 
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journals were searched for relevant papers and the bibliographies of relevant papers 
were hand searched for additional articles. In addition, an expert in diabetes in the 
area was contacted to help in identifying relevant articles. This helped in identifying 
the most recent studies that conducted among patients with diabetes in Kuwait.  
 
2.2.2 Inclusion/exclusion criteria   
The electronic database search yielded 833 studies and nine studies were identified 
from other sources, such as contact with an expert (n=2), searching reference lists 
(n=4) and Google search engine (n=10). Removing duplicates yielded a total of 822 
studies. The summary of the literature search process is illustrated in Figure 2.1. 
Titles and abstracts were evaluated to determine eligibility for full screening. Studies 
that employed acceptable quantitative (e.g. questionnaire) and qualitative methods 
(e.g. interviews), including randomised controlled trials and observational studies 
(e.g. cross-sectional, experimental and interventional) and review articles were 
included. The inclusion criteria were adults (18 years and above) with diabetes, and 
from an Eastern Mediterranean country (e.g. Kuwait, Iran, Saudi Arabia, Turkey, 
Palestine, Israel, Jordan, Oman, Libya, Egypt and UAE). Studies that involved all 
sexes and ethnicities, urban and rural, residents and expatriates, and all 
socioeconomic and educational backgrounds were included. In addition, the review 
includes studies at different healthcare levels.  
 
Overall, all studies with topics of interest (n=39), discussing the management of 
diabetes among adults in the Middle East were reviewed. All studies wherein 
?????????? ????-management behaviour, and determinants of this behaviour were 
explored from the perspectives of patients were eligible for inclusion. The views and 
experiences of HCPs on the management of diabetes in the region, and factors 
affecting this management were also included. As the requirements and 
experiences varied from those of adults, studies related to young people, 
adolescents and pregnant women were beyond the scope of this research and were 
not reviewed. In addition, case studies were excluded from this literature review.   
 
2.2.3 Data extraction 
Once all relevant studies had been identified, full-text manuscripts were retrieved as 
hard copies for assessment. The quality of each study was assessed using 
checklists adapted from the Critical Appraisal Skills Programme (CASP). The 
researcher used the relevant checklist for each type of study (e.g. systematic review 
checklist for review articles). Another researcher (A.A) undertook the quality 
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assessment process for the identified papers. Then, the researchers met and any 
disagreements were discussed and resolved. Information was extracted into a pro 
forma, this enabled identification of papers which addressed specific topics and 
issues relevant to the study objectives, and facilitated the retrieval of information. 
The pro forma included primary author name, date of publication, setting, country of 
the study, number of participants, study design, and the main study findings about 
the determinants of adherence to medicines and lifestyle among patients with 
diabetes in the Middle East, and socio-cultural factors relevant to the prevalence 
and management of type 2 diabetes in the region (Appendix 1). 
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Figure 2.1: Summary of literature search process for this review 
 
 
 
 
Records identified through 
database searching (n=833): 
-Embase (n=127)  
-PubMed (n=565) 
-Web of Science (n=119)      
-IMEMR (n=22)  
 
Additional records identified 
through other sources (n=16): 
-From contact with an expert (n=2) 
-From searching reference list (n=4) 
-From Google search engine (n=10) 
Records after duplicates 
removed (n=822) 
Studies included in the 
review (n=39) 
Full-text articles 
assessed for eligibility 
(n=47) 
Records screened 
(n=822) 
Records excluded 
(n=784) 
Quantitative studies (n=28) 
Qualitative studies (n=3) 
Mixed methods studies (n=3) 
Review articles (n=5) 
Full text articles 
excluded (n=8): 
-Full access to the study 
unavailable (n=3) 
-Data analysis (n=3) 
-Excluded subjects (e.g. 
pregnant women) (n=2) 
Reasons: 
-Articles were not on 
medicine-taking 
behaviour, e.g. on 
efficacy of a drug, or 
specific to the disease 
complications (clinical 
trial) 
-Articles were not in a 
Middle-Eastern country, 
e.g. Canada or England  
-Articles were on 
diseases other than 
diabetes, e.g. depression, 
hypertension, heart 
diseases, 
hypercholesterolaemia, 
hyperparathyroidism or 
hyperkalaemia   
-Articles were on 
adherence to medicines 
other than anti-diabetics, 
e.g. statins, anti-
hypertensive, laxatives    
-Articles were on 
surgery 
-Articles were on 
children with type 
1diabetes  
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2.3 Results  
A total of 39 studies were identified from all regions of the Middle East: Kuwait (2 
studies), Iran (3), Saudi Arabia (7), Turkey (1), Palestine (3), Israel (3), Jordan (2), 
Oman (6), Libyan Arab Jamahiriya (2), Egypt (3) and United Arab Emirates (4). 
Three studies were across Middle Eastern countries and one focused on the GCC 
countries.  
 
Thirteen of the 39 studies discussed issues related to type 1 and type 2 diabetes 
(Kamel et al., 1999; Khattab et al., 1999; Al-Saeedi et al., 2002; Turan et al., 2002; 
Al-Saeedi et al., 2003; Salti et al., 2004; Abahussain and El-Zubier, 2005; Roaeid 
and kablan, 2007; Al-Kaabi et al., 2008; Elis et al., 2008; Mishali et al., 2010; 
Jamous et al., 2011; Yekta et al., 2011), whilst 17 focused on type 2 diabetes only 
(Abdulhadi et al., 2006; Abdulhadi et al., 2007; Ali et al., 2010; Hui et al., 2010; 
Khattab et al., 2010; Shams and Barakat, 2010; Al-Shookri et al., 2011; Aflakseir, 
2012; Al-Khawaldeh et al., 2012; Badran and Laher, 2012; Alhyas et al., 2013; Elliott 
et al., 2013; Jimmy et al., 2014; Sweileh et al., 2014; Ashur et al., 2015; de Villiers 
and Halabi, 2015; Jeragh-Alhaddad et al., 2015). Six of the studies addressed other 
long-term diseases alongside diabetes (Serour et al., 2007; Biderman et al., 2009; 
Al-Qasem et al., 2011; Ibrahim et al., 2011; Aflakseir, 2013; AlHewiti, 2014), and 
one focused on lifestyle issues and obesity (Mabry et al., 2010). All of the studies 
were conducted among adult populations (>18 years of age). The settings of the 
research studies were primary healthcare centres (n=14), hospitals (n=5) and 
diabetes centre/clinic (n=13), and retirement club (n=1). The sample sizes of the 
reviewed studies ranged from 91 to 41,936 participants for the quantitative studies, 
and from 9 to 75 for the qualitative ones. 
      
Most studies (n=28) employed survey methods to collect data and applied 
quantitative an?????????????????????????????????????????????????????????????????????-
taking behaviour, such as health awareness and beliefs. Only three studies applied 
qualitative methods (focus groups and interviews) (Abdulhadi et al., 2007; Ali et al., 
2010; Alhyas et ???????????????????????????????????????????????????????????????????????
management behaviours from the perspectives of patients themselves (n=2), and 
from the perspectives of healthcare professionals (n=1). Three studies combined 
quantitative and qualitative methods (questionnaires and interviews) (Kamel et al., 
1999; Shams and Barakat, 2010; Al-Khawaldeh et al, 2012). All of the studies were 
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original articles except five, which were reviews (Hui et al., 2010; Mabry et al., 2010; 
Al-Qasem et al, 2011; Al-Shookri et al., 2011; Badran and Laher, 2012).  
 
The main findings about determinants of medication adherence among the studies 
were lack of knowledge, illness perceptions, treatment misconception and 
satisfaction, self-efficacy, beliefs about necessity/safety of medicines, beliefs about 
herbs, forgetfulness and beliefs about HCPs. Determinants of adherence to lifestyle 
modifications were poor health awareness, lack of social support and lack of time. 
Details about each determinant are provided below. 
 
2.3.1 Lack of health awareness about diabetes  
Knowledge is a prerequisite of preventive health behaviour and it motivates patients 
to take actions for treating their illnesses (van den Arend et al., 2000). Because 
patients with type 2 diabetes are responsible for their self-control behaviour, it is 
important that they understand the disease and how to treat it (Saadi et al., 2010). 
Many studies have discussed the knowledge of patients with diabetes in the Middle 
East. Overall, poor knowledge levels have been recorded in all of these studies. For 
example, Roaeid and Kablan (2007) have reported poor knowledge among patients 
about the effects of diabetes on the eye and kidney, and about the symptoms of 
hypoglycaemia and its treatment. Further, a study in Oman revealed that a 
significant proportion of people had no information regarding preventive measures 
needed to cope with diabetes (Al Shafaee et al., 2008). Another study has noted 
that a substantial number of patients did not mention any signs of abnormal glucose 
levels or did not know how to detect hypoglycaemia (Elliot et al., 2013).  
 
2.3.1.1 Health awareness and medicine use  
Kamel et al. (1999) in Egypt reported that 90% of patients had poor knowledge 
about diabetes; 83.7% had poor knowledge about its complications and 96.3% had 
poor awareness of how to control the disease. Another study by Al-Saeedi et al. 
(2002) concluded that patients thought that cure from diabetes could be expected 
after a short course of treatment, and that they could eat whatever they want as long 
as medications were taken. It was reported that patients demonstrated better 
treatment adherence when they received sufficient information on the disease, 
medicines, dosage, complications and their prevention (Kamel et al., 1999; Al-
Saeedi et al., 2002; AlHewiti, 2014). Other studies have shown that knowledge and 
health awareness may encourage patients to be serious in following their 
therapeutic regimens (Pinhas-Hamiel and Zeitler, 2003; Jamous et al., 2011). 
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Abahussain and El-Zubier (2005) reported poor knowledge of general diabetes 
characteristics and low perceptions of its consequences among patients. However, 
in that study the authors noticed that some patients used herbs to control their 
diabetes and abstained from their conventional medical treatment. This could be 
because patients lacked the awareness of the importance and role of their 
medicines. Other authors have also reported a significant relationship between 
knowledge about diabetes and adherence to treatment, in which poor diabetes-
related knowledge led to poor adherence to treatment (Shams and Barakat, 2010; 
Sweileh et al., 2014; Ashur et al., 2015). In one study, it was reported that the 
patients had poor glycaemic control and had developed diabetes-related 
complications, as a consequence to poor knowledge and low treatment adherence 
(Ashur et al., 2015). 
 
?????????????????????????????????????????????????????????????????????????????????????
dangerous actions practised by patients, which might affect their glycaemic control. 
For example, Roaeid and Kablan (2007) reported that some patients omitted their 
insulin evening doses, did not keep their insulin in a refrigerator or did not shake it 
before use, did not change the injection site and used the insulin syringe more than 
once. Another study by Elliot et al. (2013) reported that one-third of patients using 
insulin, self-adjusted their doses when eating smaller or larger meal portions, or if 
experiencing frequent hyper or hypoglycaemic attacks. In that study it was also 
reported that one in five patients using insulin adjusted their doses according to their 
physical activity. Although such behaviour could be good practice, and it is 
recommended for patients to self-adjust their insulin doses according to their 
lifestyle (Leontis and Hess-Fischl, 2016), patients in that study reported dangerous 
responses. The responses of those patients were against their blood glucose 
requirements, for example they were increasing doses of oral anti-diabetics or 
insulin or going to sleep when experiencing hypoglycaemia. Other responses were 
drinking juice or eating sour food to counteract hyperglycaemia. Other practices that 
could be fatal were not taking any corrective measure for an abnormal glucose level 
or when a hypoglycaemia was detected (Elliot et al., 2013). 
 
However, there were contributing factors to poor knowledge among patients. Some 
of these factors were illiteracy and frequency of visits to healthcare services. 
Literacy levels of patients were associated with their understanding of diabetes and 
willingness to adhere to anti-diabetic medications. Most patients with a high level of 
education were found to comply with their treatment plans and achieve target 
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outcomes (Alhyas et al., 2013). Aflakseir (2013) in his study has concluded that the 
majority of older adults who had low education levels did not adhere to their 
medications. Illiteracy affects the ability of patients to comprehend the information 
provided by multiple resources and constitutes a barrier for good communication 
and management. In a qualitative study in Oman, it has been found that some 
patients did not perceive diabetes as a serious disease due to the lack of symptoms, 
and because they were inadequately educated about the disease (Abdulhadi et al., 
2007). In addition, patients who had first-degree relatives, who were diagnosed with 
diabetes, showed better adherence to their therapeutic regimens because they 
shared the experiences, which improved their knowledge (Al Shafaee et al., 2008). 
Patients who frequently visited educators and doctors have been found to have 
better adherence because information was reinforced during each visit (Khan et al., 
2012). 
 
2.3.1.2 Health awareness and self-care behaviour  
Management behaviours, which form the cornerstone of diabetes care, were 
mentioned in three studies. In all these studies, it was reported that good knowledge 
led to good management behaviours?? ???? ????????? ?????????? ?????????? ??????
hypertension as a diabetic complication motivated them to have regular blood 
pressure checks. K????????? ?????? ???????????? ???? ??????????? ????? ??????????
attendance at eye screenings, and knowledge about foot ulcer also encouraged 
patients to have regular foot check-ups. Only a small proportion of insulin-
dependent patients were found to regularly monitor their blood glucose levels. This 
was because patients lacked an understanding of the importance of this practice, or 
simply they did not know how, and did not have the desire to do so. Also, it has 
been reported that some patients did not know that they could buy the blood 
monitoring device themselves, and believe it is only sold to healthcare 
professionals. Patients with more knowledge are motivated to control their disease, 
linking their symptoms with readings of their blood glucose and hence monitor their 
blood glucose regularly (Kamel et al., 1999; Roaeid and Kablan, 2007; Elliot et al., 
2013). This in turn may ? ???????????????????????????? ??? ????????????????????????
them to make other appropriate behavioural changes such as healthy eating 
(Abdulhadi et al., 2007). 
 
2.3.2 ???????????????????????? ???????????????????????????? 
Patient adherence is believed to be significantly affected by health beliefs, and it is 
believed that there is a relationship between beliefs and behaviour (Alhyas et al., 
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2013). Psychologists have studied this relationship extensively, revealing several 
socio-psychological approaches that may be used to explain the impact of health 
???????????????????????haviour (Horne et al., 2005). Vermeire et al. (2003) have noted 
that patients with diabetes might intentionally misuse their medicines or not adhere 
to their therapeutic regimens as a result of their beliefs. However, the Middle 
Eastern population has unique beliefs that impact on their behaviour as discussed 
below.  
  
2.3.2.1 Religious beliefs  
Despite the cultural diversity among the Middle Eastern countries, Islam is the most 
practised religion in the region. Because Muslim people constitute the predominant 
portion of the Middle Eastern population, medical practices are based on Islamic 
????????? ?????????? ???????? ????????? ????? ?????? ??? ????? ??? ?????? ?????? ???????
explanations about the seriousness and urgency of making lifestyle changes and 
taking appropriate actions challenging. In other words, diabetic patients in the 
Middle East are highly affected by their religious beliefs specifically fatalism (Khoury, 
2001; Klautzer et al., 2014). Fatalism is a psychological mechanism that identifies 
the relationship ??????????????????????????????????????????????????????????????????????? 
?belief that events are controlled and predetermined by Allah, and that humans have 
little, if any, control over their destinies? (Khoury, 2001). Severe untreated cases of 
diabetes can lead to death but religious b?????????????????????????????? discourage 
patients from engaging in activities that are perceived as against ???????????? ?????
may ????? ??? ??? ?????? ???????????????? ???????????????????? non-adherence. It has 
????????????????????????????????????????????????????? ????????? ??????????????????????a 
reduced level of trust in scientific medical knowledge prevented them from 
committing to a course of oral anti-diabetic drugs (Bener et al., 2009; Ashur et al. 
2015; de Villiers and Halabi, 2015). 
 
Another study has reported that a proportion of Middle Eastern patients did not 
adhere to their medications because of instilled cultural beliefs. In the Middle 
Eastern culture, there is a strong belief in the ?evil eye?, which refers to the belief 
that an envious party inflicts negative events, such as illnesses and accidents on 
individuals or their families out of jealousy or envy (Lipson and Meleis, 1983). Often, 
patients prefer seeing religious and spiritual healers for the removal of the ?evil eye? 
that they assume is causing their illness. Because removal of the misfortune plays a 
role in Middle Eastern culture, patients do not adhere to their medications until they 
are certain that other healers cannot assist with their situation (Yahia et al., 2012).  
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The association between religious beliefs and ?????????? ??????? ?????????? can be 
explained by HLOC theory. According to this theory, when patients have high 
external HLOC beliefs, and that an external factor is responsible for their cure (e.g. 
God, healers), they are less likely to adhere to their medications.  
 
2.3.2.2 Beliefs about Ramadan fasting  
Despite the Islamic exemption from fasting for ill individuals, which may provide 
some level of relief for patients and physicians, most patients with diabetes exempt 
themselves from this rule. Patients during Ramadan prioritise the religious 
obligations over the advice of doctors and religious authorities (Salti et al., 2004). 
This is supported by findings of Hui et al. (2010), who noted t???????????????????????
fasting were based extensively on religious faith and perception of God. Some 
patients perceived religious, spiritual and psychological benefits of observing fast 
during the holy month of Ramadan were viewed to outweigh the risks of diabetes 
complications. 
 
???? ?????????? ???????? ??? ???? ??????????? ???????? ??? ???????? ??? ???????? ??????? ??????
medicine-taking behaviour. Since fasting during Ramadan obliges people to abstain 
from eating and drinking from sunrise to sunset, patients may change their insulin or 
oral anti-diabetic use without consulting their doctors. Some patients think that their 
medicine-taking behaviour during Ramadan is a private issue and there is no need 
to consult their doctors about it (Hui et al., 2010; Mygind et al., 2013). A study by 
Salti et al. (2004) revealed that 19.7% of patients using oral anti-diabetic drugs and 
36.7% of patients using insulin changed their doses during Ramadan. For instance, 
some patients reported that they reduced their oral anti-diabetic doses because they 
believed that as long as they were not eating traditional foodstuffs, they did not need 
to take their medicines. Another study by Lawton et al. (2005) reported that patients 
think that their oral anti-diabetic drug will affect and expose them to more side 
effects if they take them as usual. 
 
A qualitative study by Mygind et al. (2013) has reported some practices of patients 
regarding their medicine use during Ramadan. Some patients reported taking doses 
as usual, but delaying the evening doses and taking the morning ones earlier. Other 
patients reported missing their morning doses because they believed that taking 
their medicines without eating would further reduce their blood glucose level and 
affect their health. However, feeling normal even when not taking morning doses 
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was the main concern of those patients that encouraged them not to take their 
morning doses. In addition, some patients believed that insulin counteracts the 
effect of sugar; so they ate large portions of sweet in their Iftar; the meal in which 
Muslims break their fast, and then compensate for that by increasing their insulin 
doses. 
 
???? ???????????? ???????? ???????? ?????? ???????? ???????? ???? ?????????? ???????
behaviour can be explained by the HBM. According to this model, when patients 
perceive barriers (e.g. fear of hypoglycaemia) to outweigh the benefits (e.g. 
maintaining glucose control), they become less motivated to take a health action 
(e.g. medication adherence).  
  
2.3.2.3 Beliefs about the efficacy and necessity of medicines  
Several studies have mentioned beliefs about the necessity and efficacy of the 
treatment. For instance, in the studies of Jamous et al. (2011), Alhyas et al. (2013), 
Jimmy et al. (2014) and Sweileh et al. (2014), it has been concluded that these 
types of beliefs, along with beliefs that the benefits of medicines outweigh their costs 
and risks resulted in better medication adherence. According to the HBM, patients 
might undertake a specific behaviour, e.g. medication adherence, when they believe 
that their medicines are effective (Bosworth and Voils, 2006). Therefore, beliefs 
about the necessity of treatment and quality of care provided are associated with 
important health outcomes (Stack et al., 2011; Petrie and Weinman, 2012; Alhyas et 
al., 2013). 
 
However, other studies have concluded that beliefs about the efficacy of medicines 
negatively impact on other aspects of diabetes management. A qualitative study 
among Emiratis with type 2 diabetes has revealed that patients who believed that 
their condition could be managed only with drugs did not spend sufficient time with 
their healthcare professionals to discuss other important behaviours (Alhyas et al., 
2013).  
 
On the other hand, patients who believe that their medications are no longer 
effective might stop taking their medicines. This is supported by findings of Khattab 
et al. (1999), Khattab et al. (2010) and Ibrahim et al. (2011) who have found that 
patients with longer duration of diabetes and more complications were non-adherent 
to their medications. Also, it has been found that concerns about the negative 
effects of medicines prevented patients from complying with their treatments 
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(Aflakseir, 2012; AlHewiti, 2014). The same result was reported by Aflakseir (2013), 
where patients who had fear of side effects had poor adherence to their treatments. 
In addition, belief in the efficacy and safety of traditional herbs is highly prevalent 
among Middle Eastern patients with diabetes, especially the elderly. This type of 
belief has been mentioned in many studies, which reported that many patients 
abstained from their conventional medical treatments and used herbs to control their 
disease (Al-Saeedi et al., 2003; Abahussain and El-Zubier, 2005; Alhyas et al., 
2013). 
 
2.3.2.4 Perceptions about healthcare system/provider 
Three studies have reported the role of beliefs about the quality of care in affecting 
the medicine-taking behaviour of patients. A study by Abdulhadi et al. (2007) has 
reported better glycaemic control among patients who attended hospitals than those 
attended primary care clinics. In that study, patients who attended hospitals believed 
that care provided in secondary care settings was better. Therefore, they adhered to 
their appointments and treatments and consequently achieved their glycaemic 
control. Also, it has been concluded that patients who continued their care with one 
??? ????????????????????????????????????????????????????????????????????????????????
behaviour (Abdulhadi et al., 2007). Patients preferred to be seen by the same doctor 
because they believed that they would get better advice regarding their problems. 
Also, some patients perceived the continuity of care with the same HCP as a salient 
element in building their confidence and trust and improving their relationship with 
???????????????????????????belief in the competence of doctors and nurses significantly 
impacted on health outcomes (Abdulhadi et al., 2007).  
 
The same finding was reported by Alhyas et al. (2013), who found that patients who 
had confidence in diabetes specialists only, discontinued their appointments when 
they were seen by doctors, in which their diabetes management was affected. 
Aflakseir (2013) has also concluded that a poor relationship between doctor and 
patient was associated with medication non-adherence. The association between 
?????????? ??????????? ?????? healthcare system/provider and medication adherence 
can be explained by the CS-SRM. According to this model, when patients have 
negative perceived consequences of their illness, they will be less likely to engage 
in self-management behaviour. For instance, according to findings of this review, 
patients lack trust in primary-care units and in HCPs other than specialists. As a 
result, they became less satisfied with the services provided. The less satisfaction 
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level and the more negative perceived consequences they would get from the 
system/provider lead to poor management behaviour (Jin et al., 2008).    
 
2.3.2.5 Self-efficacy and coping with diabetes  
Self-??????????????????????????????????????????s in their ability to change and succeed, 
has been mentioned in two studies. In two studies, it was noted that self-efficacy 
????????????????????????????????????????????adherence to treatment recommendations 
(Mishali et al., 2010; Al-Khawaldeh et al., 2012). Another study by Yekta et al. 
(2011) has reported that patients might not adhere to their medical treatments due 
to their belief that their self-care practices, such as maintaining sufficient levels of 
physical activity and controlling dietary intake are effective. However, despite having 
such belief, not all patients were found to follow such practices. Results revealed 
that only 52% of patients maintained physical activity levels that were sufficient for 
controlling diabetes and 65% monitored and controlled their dietary intake. On the 
other hand, believing that healthy lifestyle behaviour, e.g. diet and exercise do not 
result in immediate better health outcomes could discourage patients from making 
essential changes. 
 
Besides the role of beliefs and self-efficacy in influencing the medicine-taking 
behaviour, coping with diabetes and satisfaction with treatment are essential in 
improving medicine use. Patients, particularly with type 2 diabetes, perform most of 
their disease management without consulting HCPs (Alhyas et al., 2013). Thus, they 
have to cope with challenges that they face in their daily lives In addition, coping 
with diabetes played a crucial role in ? ???????????????????????????????????????????
and glycaemic control especially in insulin-treated patients (Turan et al., 2002). 
Aflakseir (2012) noted that patients who believed that diabetes would last a long 
time had better medication adherence. In addition, patients who perceived that they 
had control of their medicines, better adhered to the therapeutic regimens (Aflakseir, 
2013). On the other hand, patients with negative attitudes towards diabetes had 
more barriers to adherence and poor glycaemic control (Khattab et al., 2010).  
  
According to the SRM, patients monitor their health behaviour, in order to transfer 
themselves from a current status (disease) to a future goal (control/cure) (Bosworth 
and Voils, 2006). Thus, medication adherence is the coping response in which 
patients achieve their goal (e.g. cure/controlled disease). However, the lack of 
immediate threat to life could discourage patients from complying with medications 
and lifestyle changes (Pinhas-Hamiel and Zeitler, 2003). Treatment satisfaction of 
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patients with diabetes in the Middle East has been studied by Biderman et al. 
(2009). The authors concluded that insulin-treated patients were the least satisfied 
with their treatments and thus, had more difficulties in taking medications. Patients 
of all ages have the fear of injections and there is a common belief that is ?insulin 
means the deterioration of health status? (Kunt and Snoek, 2009).  
 
2.3.3 ???????????????????????? ??????????????????????????? 
 
2.3.3.1 Social norms 
Several studies have shown that cultural patterns and infrastructure prevent the 
achievement of target glycaemic control in patients with diabetes. For instance, 
according to a cross-sectional survey in Saudi Arabia, medication adherence 
differed between males and females (Khan et al., 2012). The reason for this was not 
established; however, one possible explanation could be that, in this region, females 
are predominantly housewives and this may enable them to monitor their medicine 
intake better than men. Furthermore, it has been reported that cultural factors 
prevent females from travelling alone to the diabetic care centres, and lack of 
adequate means of transport between rural and urban areas of Saudi Arabia 
prevent routine checks of blood glucose levels (Azab, 2001; Khan et al., 2012). 
 
Individuals in the Middle East associate diabetes with impotence and infertility, both 
men and women are ashamed of their diagnosis and avoid engaging in 
conversations about diabetic medications, changing their eating habits from 
?????????? ?????? ???? ????????? ??? ??????????? ????????? ??????? ?????????? ????? ?????????
2001). 
 
2.3.3.2 Family support 
Family ties ranks highly on the values list among Middle Eastern people. Middle 
Eastern cultures consider family involvement almost mandatory for individual 
??????????? ?????? ?????????? ??? ??????? ?????????? ???? ?????????????? ??? ???????????
??????????????????????????????????????????????????????????????????-groups from birth 
onwards. These groups are usually extended families, which continue supporting 
patients in exchange for unquestioning loyalty (Abdulhadi et al., 2007; Al-Shookri et 
al., 2011). Demanding behaviour is common in Middle Eastern culture and it is 
associated with the requirement for family to show that they care for patients, will 
never leave the patient alone and to show care and attention for their well-being. 
Most patients rely heavily on other people during times of crisis and illness. This is 
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often evident during medical care visits, where patients are frequently accompanied 
by one or more people, who are present during interviews and examinations to 
listen and answer questions for the patient. 
 
The role of family support in affecting the management of diabetes has been 
obtained in three studies. In one study, it was reported that patients with severe 
symptoms, whom their family or doctors were concerned about their health, showed 
higher responsibility and adherence towards their medications (Elis et al., 2008). 
Another study concluded that effective self-management behaviours would be 
impossible without support of other family members. High prevalence of unhealthy 
lifestyles among family members constituted a barrier to effective treatment of 
patients with type 2 diabetes (Pinhas-Hamiel and Zeitler, 2003). Abdulhadi et al. 
(2007) in their qualitative study concluded that families were not supportive in terms 
of cooking and preparing food and they suggested education programmes to 
address family members. In that study, some patients blamed themselves and their 
families ????????????????????????????????????????????????????????? families were not 
supportive and always makes sweets like dates available in their homes. However, 
family support is dependent on the ??????? ????????? ????????? ??? ?????????? ???????
support or pressure (Lipson and Meleis, 1983). 
 
2.3.3.3 The doctor-patient relationship 
Cultural differences in Middle Eastern countries result in patients and physicians 
having different relationships from those expected in Westernised cultures. Patients 
in the Middle East have their cultural issues such as requirements to communicate 
certain types of news to families, respect, honor and shame. Unlike Westernised 
cultures where physicians disclose illness diagnosis to patients only to protect their 
privacy, this practice is not adopted in the Middle East. Physicians in Middle Eastern 
?????????? ????????????????? ????????? ??? ???? ??????????????? ?????? ???????????????? ???
because of the family-oriented model and values that require family members to 
play a significant role in all as??????????????????????????????????????????????????????????
to dictate if a patient should be informed about certain types of illnesses. For that 
reason, when patients are diagnosed with diabetes, their family members may be 
aware of the diagnosis before the patient. In some instances, patients are never 
informed about the diagnosis because physicians are required to establish 
relationships with certain family members, and their preferences override those of 
the physicians (Rosner, 2004; Back and Huak, 2005; Mobeireek et al., 2008). 
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In addition, in Muslim communities, cultural heritage affects the relationship between 
physicians and patients. Physicians are considered the main source of information 
for patients seeking advice and they are responsible for pati??????????????????ome 
patients have concerns about taking responsibility for their own health, and not 
depend too much on doctors (Abdulhadi et al., 2007; Al-Shookri et al., 2011). In a 
study by Mohamed et al. (2013), it was noted that patients who changed their locus 
of control from an external one to an internal one, and took control of their own 
disease had improvements in diabetes knowledge, attitude and practice. This in turn 
improved their adherence to treatments and follow-ups and consequently, their 
clinical outcomes and psychological well-being. 
 
The growing diabetes pandemic in the Middle East has led to discussions about 
adjusting healthcare systems to allow physicians to use a patient-centred approach 
that could reduce costs, mortality rates and prevalence of the disease. A patient-
centred approach is the concept of promoting the partnership between the patient 
and the healthcare team, where patients are given full information about their 
disease (e.g. history of the disease, its signs and symptoms, results of 
investigations, and how the diagnosis has been reached) (Abdulhadi et al., 2007). 
 
2.3.3.4 The lack of a multidisciplinary approach 
The lack of a ?????????????????? ????????? ??? ?????????? ????? ???? ????? ????????? ???
several studies. Three studies concluded that HCPs, such as dieticians, chiropodists 
or ophthalmologists did not see patients after their diagnosis (Abdulhadi et al., 2006; 
Roaeid and kablan, 2007; Al-Kaabi et al., 2008). Another qualitative study reported 
comments made by patients during interviews; these raised concerns about not 
being referred to dieticians or health educators since their diagnosis (Abdulhadi et 
al., 2007). In Kuwait, pharmacists identified barriers to the delivery of 
pharmaceutical care to patients with type 2 diabetes, such as pharmacist-physician 
????????????? ????????????? ??????????? ???? ????????????? ? ???? ??? ????????? ????
physicians as a dispenser only (Al-Taweel et al., 2014). A study by Biderman et al. 
(2009) reported that physicians are the most involved HCPs in diabetes care. 
However, doctors usually concentrate on the disease rather than the whole person 
???? ???????? ???? ? ????????? ??? ?????????? ???????????? ???? ?????????????? ??????????
dissatisfaction is a major factor contributing to medicine misuse and non-adherence 
(Vermeire et al., 2003). Competent professionals must cooperate in order to provide 
patients with the required skills for maintaining untraditional and desired behaviours. 
The involvement of other team members such as counselors, physical therapists 
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and psychologists is considered essential for effective behavioural change (Dean, 
2008). 
 
Management of type 2 diabetes: current and future developments   
??? ????????? ??? ???? ?????? ????????? ???????? ????? ? ??????? ????????? behaviour, it was 
found that HCPs in the Middle East had specific beliefs, which might impact the 
disease management as well. Alhyas et al (2013), have found that beliefs and 
attitudes of some HCPs might constitute an obstacle in the management of diabetes 
in the Middle East. For example, HCPs who believed that diabetes is a complex 
disease, needs intensive care and that the complications are hard to control once 
they have ??????????????????????????????????????? ?????????????????????????????????
healthcare professionals perceived the poor compliance of patients to treatment 
plans and not achieving the target goals as barriers to their motivation and 
contribution to the management process and to the provision of high quality of 
diabetes care. 
 
The culture in Middle Eastern society has a ???????????????????????????????????????????
the necessity of insulin and other anti-diabetic medications. In a study by Elliot et al 
(2013), it was found that most physicians in the Middle East believe that insulin is a 
treatment of last resort. Another study also found that some Middle Eastern 
physicians are hesitant to prescribe insulin and other medications to patients despite 
their knowledge of the benefits and necessity (Lakkis et al., 2013). In that study, the 
authors examined the attitudes of physicians towards insulin therapy for type 2 
diabetes. Results revealed that more than 73% of physicians preferred delaying 
insulin initiation until other methods were proven ineffective. However, the majority 
of physicians admitted that they were reluctant to initiate or suggest insulin as a 
treatment option because of perceived patient reluctance. Surprisingly, almost 74% 
of the participated physicians believe that the benefits of insulin outweighed the risk 
of hypoglycaemia and weight gain and approximately 14% have neutral responses 
in this area. 
 
In addition, Middle Eastern physicians have preferences for the type of 
pharmacological therapy that is most effective and poses less threat and 
complications for patients. Metformin, an oral anti-diabetic medication that 
addresses insulin resistance in the liver and skeletal muscle and reverses 
hyperglycaemia by reducing hepatic glucose production, is one of the favoured 
????????????????????? ????????????????????????????????????????????????????prescribing 
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metformin. One factor is the lack of the full distribution of this medicine in the body 
and targeting only one area, in such that side effects are reduced. Some studies 
have found that patients may experience gastrointestinal symptoms such as 
increased weight loss and diarrhoea, which can be minimised with low doses. 
Additionally, metformin is inexpensive, making it more affordable for patients and 
????????? ???? ????????????? ???????? ??????? ??????? ????????? ???? ????? ??????? ????????
the medication with other anti-diabetic drugs such as insulin, incretin enhancers and 
incretin mimetics (Al-Maatouq et al., 2010). 
 
Another medication that is preferred by Middle Eastern physicians is acarbose, an 
alpha glucosidase inhibitor. Physicians prescribe acarbose for diabetic patients who 
have/or at risk of developing cardiovascular problems. This therapy is preferred 
because it reduces postprandial blood glucose, cardiovascular events and provides 
glycaemic control when combined with sulfonylurea and biguanides. Physicians also 
prefer this drug due to the reversal of impaired glucose tolerance and the low 
incidence of adverse effects. Like metformin, patients do experience gastrointestinal 
symptoms such as diarrhoea and flatulence but the occurrence of these effects is 
rare and can be controlled by minimising the dosage (Shihabi et al., 2013). 
 
Non-pharmacological treatments, such as bariatric surgery that promotes weight 
loss, has recently become an option for treating type 2 diabetes in the Middle East. 
However, such treatment is considered as the last option for managing poorly 
controlled patients (Keidar, 2011). Because the problem of type 2 diabetes relates to 
high fat levels in the pancreas, and that reducing calorie intake by losing weight 
would help in reducing fat levels, there is a debate that the surgery may be regarded 
in the future as a medical emergency (Hobbs and Taylor, 2013). Whether the 
emergency concept of the surgery will be familiar in the Middle East is still unclear.  
 
2.3.4 ???????????????????? 
Poor knowledge affects ????????????????????? ???????-care behaviours, such as diet 
and exercise. Literate subjects have been found to adopt healthier lifestyle, e.g. 
increased physical activity (Alarouj et al., 2013). People with higher literacy levels 
are more aware of the risk factors and more able to avoid and prevent them from 
affecting their health (Shah et al., 2010). It has been noted that patients who do not 
fully understand the necessity of exercise and healthy diet to either control or reduce 
their chances of acquiring diabetes may adhere to one healthy behaviour only; 
either diet or exercise. A study in the UAE revealed that 48% of participants 
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exercised to maintain or lose weight, 36% changed their eating habits, while only 
26% participated in both activities as a preventive measure for controlling diabetes 
(Booz Allen Hamilton, 2012). In Saudi Arabia, most of females with diabetes in one 
study were overweight or obese and they lacked the awareness of the importance of 
diet and exercise (Abahussain and El-Zubier, 2005). 
 
2.3.4.1 Physical inactivity 
Wealth and increased income contribute to high obesity rates in the Middle East. 
The direct association between being overweight and increased income is that 
??????? ?????????? ????????????? ??????????? ??? engage in weight loss activities 
(Klautzer, et al., 2014). Despite the general awareness about health complications 
arising from obesity, patients in the region have difficulties following healthy lifestyle 
patterns. Several social environmental barriers have been identified, for example, 
households in the Middle Eastern countries like Saudi Arabia, Qatar and Kuwait 
have a common practice of employing household maids which further reduces 
physical activity associated with domestic chores (Bener et al., 2009). This has also 
been highlighted by Ali et al. (2010) in their qualitative study, where participants 
found that dependence on housemaids resulted in their weight increasing. Patients 
with type 2 diabetes in Kuwait reported several cultural barriers that interfere with 
their engagement in recommended levels of physical activity. The main barriers 
were lack of time, co-existing diseases, extreme weather conditions, abundance of 
maids and excessive use of cars (Serour et al., 2007). Another study reported 
physical inactivity due to another reason. Badran and Laher (2012) have noted that 
after marriage, couples become less active and consume more food during cultural 
joint meals. 
 
Cultural barriers also ????????? ???????? ??????? ??? ???????? ??????????, and the 
availability of culturally acceptable exercise facilities is limited and expensive, 
thereby increasing women sedentary time (Musaiger, 2004). This is supported by 
the findings of Ali et al. (2010), where some participants raised their concerns about 
the unavailability of exercise places and the unacceptability of walking in the street 
alone. Women, in particular, face objections from their husbands if they walk outside 
alone, but if there is a closed place (e.g. gym), it is usually accepted. In addition, 
there are some traditional cultural norms that oblige couples to have a high number 
of children, which means high pregnancy rates of women and short spacing 
between pregnancies. T???? ??? ????? ???????? ?? ???? ??????? physical activity and 
increases their chances of obesity (Musaiger, 2004). 
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2.3.4.2 Dietary habits 
Dietary habits in the region have undergone drastic changes with low dietary fibre 
and high fat intake leading to obesity and diabetes (Al-Nozha et al., 2004; Klautzer 
et al. 2014). In addition, in Arab-speaking countries, the social processes of 
gatherings require consumption of mainly meat, fat, rice and carbohydrates (Badran 
and Laher, 2012). Hospitality and generosity are high on the list of Islamic values. 
This value requires individuals to engage in rituals where hosts serve guests large 
amounts of food as a sign of hospitality and demonstration of honor. During these 
meals, guests are often encouraged and persuaded to consume more than normal 
portions of food as an appreciative and friendly gesture. Guests who refuse food 
that is offered may raise suspicions that they have some form of illness or diabetes, 
or are exhibiting a poor gratitude (Khoury, 2001). Regarding this, Ali et al. (2010) 
have reported that some participants found it difficult to control their weights due to 
having many guests all the time. Other individuals found it difficult to keep eating 
healthy food when they visit their relatives and friends, because they might get 
upset if they do not eat everything they put for them on the table. Serour et al. 
(2007) have reported some barriers to following a healthy diet as perceived by 
patients. These barriers were unwillingness, stress, traditional food, difficulty to 
adhere to a diet different from other family members and the high frequency of 
social gatherings. 
 
In some Middle Eastern countries, especially the GCC countries, people strongly 
believe in the nutritional and economic value of dates, which they consume 
frequently with coffee during the day as part of their culture. Consuming large 
amounts of dates may affect the glycaemic control of patients with diabetes due to 
their high sugar content (Abdulhadi et al., 2007; Al-Shookri et al., 2011; Alhyas et 
al., 2013). In addition, the Middle Eastern population lacks knowledge on nutrition 
and healthy food eating which is crucial for type 2 diabetes management. In relation 
to this, Ali et al. (2010) in their qualitative study reported that some participants did 
not know how to cook healthy food, while others needed a programme which helps 
them to lose and maintain weight. A study by Al-Kaabi et al. (2008) reported that 
patients with diabetes could not calculate their calorie intake, and only a small 
proportion of them read food labelling. The majority of patients were also unable to 
distinguish between low and high carbohydrate index food items.  
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2.4 Discussion  
The results of this review indicate that the problem of non-adherence to treatment is 
prevalent among patients with type 2 diabetes in the Middle East. This review has 
????????????? ???? ????????????? ??? ????? ?????????? ??????????? ??? ?????? ??? ????????
services and recommendations targeted at those determinants, and help in 
counteracting such behaviour, leading to improved health outcomes in the region. 
The review revealed that lack of health awareness, health beliefs and culture had a 
significant influence on pa???????? ?????????? ??? ????? ???? ???? ?????????? ??????????
Different methodologies were employed to obtain the results of the reviewed 
studies; most studies used questionnaires to collect data, while a few studies 
applied interviews and focus group. All the reviewed studies were conducted with 
adult patients with diabetes (predominantly type 2 diabetes), one study was 
conducted with participants at high risk of type 2 diabetes, and two studies 
conducted with healthcare professionals.  
 
In studies that covered the knowledge of patients and their awareness regarding the 
seriousness of the disease and its related complications, it was found that lack of 
health awareness was common among patients with diabetes (Kamel et al., 1999; 
Al-Saeedi et al., 2002; Roaeid and kablan, 2007; Al Shafaee et al., 2008; Elliott et 
al., 2013; Shams and Barakat, 2010; AlHewiti, 2014; Sweileh et al., 2014; Ashur et 
al., 2015). This lack of health awareness was associated with different practices that 
? ??????? ?????????? ??????????? ??????our, such as use of herbs instead of 
conventional treatment (Al-Saeedi et al., 2003; Alhyas et al., 2013). Also, lack of 
health awareness of the role of diet and exercise led to difficulties in weight 
management and obesity (Abahussain and El-Zubier, 2005; Al-Kaabi et al., 2008; 
Ali et al., 2010). Some beliefs which were specific to Middle Eastern population were 
????????????????????????????????????????????????????????????????????????????????????????????
???????????????????? ???????? ????????????????-beliefs, and beliefs about necessity of 
treatment and in the healthcare providers. From the studies that discussed these 
beliefs, it was clear ???? ?????? ???????? ? ????? ?????????? ?????????? ???? ????
management of diabetes (Khattab et al., 1999; Khoury, 2001; Salti et al., 2004; 
Lawton et al., 2005; Abdulhadi et al., 2007; Biderman et al., 2009; Mishali et al., 
2010; Shams and Barakat, 2010; Yekta et al., 2011; Aflakseir, 2012; Al-Khawaldeh 
et al., 2012; Petrie and Weinman, 2012; AlHewiti 2014; Jimmy et al., 2014; Sweileh 
et al., 2014; de Villiers and Halabi, 2015). Cultural factors that were found to 
?????????? ?????????? ?????????? ??? ???????????????????? ????, diet and physical activity 
which led to high obesity rates in the region and consequently poor health outcomes 
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were also identified (Musaiger, 2004; Serour et al. 2007; Ali et al., 2010; Al-Shookri 
et al., 2011; Badran and Laher, 2012; Klautzer et al., 2014).  
 
There was a factor which repeatedly appeared in the literature that might contribute 
to the poor knowledge in the region, which is the lack of sufficient diabetes 
education and educators (Klautzer et al., 2014). For instance, Al-Elq (2009) found 
that in Saudi Arabia, 63-86% of patients with type 2 diabetes were not screened for 
complications for a year in the given period of time. In Kuwait, diabetic retinopathy 
has been identified as the main cause of visual impairment (Dean, 2008). Alhyas et 
al. (2013) concluded that patients with diabetes do not attend appointments with 
podiatrists because they misunderstand their role. One suggestion made by patients 
that could benefit those with poor health literacy is to provide continuous education 
about diabetes complications and anti-diabetic medications by appropriate audio-
????????????????????????????????????????????????????????????????????????7). Al-Nozha et 
al. (2004) noted that service providers were underperforming in providing adequate 
levels of information to patients and their families, such that patients felt the lack of 
support from society. This was consistent with the findings of Abdulhadi et al. 
(2006), that the performance of doctors and diabetes nurses in Oman was 
suboptimal and needed improvements. Also, it has been found that patients with 
type 2 diabetes were dissatisfied with primary healthcare services provided in Oman 
in terms of providing sufficient information (Abdulhadi et al., 2007). 
 
Therefore, enhancing educational efforts by healthcare professionals to improve 
health awareness and modify health beliefs of patients, and addressing socio-
????????? ?????????????? ????? ?? ?????? ????? ??? ? ???????? ?????????? ?????????? ??????????
their medicine use and other management responsibilities, and consequently 
improving the management of type 2 diabetes in the region and health outcomes. In 
addition, implementing strategies for assessing and improving the quality of 
healthcare services provided may ???????? ? ??????????????????????????-making by 
enhancing their trust in the quality of healthcare services (Alhyas et al., 2013; 
Sweileh et al., 2014; Badawi et al., 2015). Also, at the governmental level, 
reinforcing and strengthening strategies for prevention and early diagnosis of type 2 
diabetes should be taken into consideration.  
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2.5 Practice implications  
The increased prevalence of type 2 diabetes and the poor glycaemic control among 
the Eastern Mediterranean population calls for further research, particularly to 
????????? ???? ????????????? ??? ?????????? ??????????? ?or better management of this 
disease, a collaborative approach between patients, their families, healthcare 
professionals and government should be adopted. Physicians, educators and other 
government health officials can provide forms of relief and decrease the recurrence 
of diabetes. The health awareness of patients, which is a determinant of their 
behaviour should be improved by increasing education efforts, modifying physician-
patient communication to accommodate health beliefs and culture and implementing 
strategies that allow patients to understand both the benefits and risks associated 
with the disease and their culture. Because a lack of cultural understanding of health 
beliefs may affect the quality of diabetes care, it is crucial to provide healthcare 
professionals with knowledge about culture-specific health beliefs related to 
diabetes through culturally sensitive training programmes (Saadi et al., 2010; Alhyas 
et al., 2013). 
 
Alhyas et al (2013) found that the beliefs and attitudes of some HCPs might 
constitute an obstacle in the management of diabetes in the Middle East. For 
example, HCPs who believed that diabetes is a complex disease, needs intensive 
care and that the complications are hard to control once they have occurred had 
reduced motiva????????????????????????????????????????In addition, poor compliance of 
patients to treatment plans and not achieving the target goals reduced the 
motivation of some HCPs and contribution to the management process to provide 
high quality of diabetes care. Therefore, stressing the need for continuous education 
and training for HCPs, and applying a system for credit and qualifications would 
motivate them to feel more responsible in providing better management.  
 
The lack of a multidisciplinary approach in pat??????? ????? ???? ????? ????????? ?n 
several studies. Four studies concluded that healthcare professionals such as 
dieticians, chiropodists, ophthalmologists and health educators did not see patients 
following their initial diagnosis (Abdulhadi et al., 2006; Abdulhadi et al., 2007; Al-
Kaabi et al., 2008; Saadi et al., 2010). Biderman et al. (2009) reported that 
physicians are the most involved healthcare providers in diabetes care in all health 
sectors. However, doctors usually focus on the disease rather than the whole 
??????? ???? ???????? ???? ? ????????? ??? ?????????? ???????????? ???? ??????????????
?????????????????????????? ?????????????????????????????????????????????????????????-
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adherence (WHO, 2003). Competent professionals should cooperate in order to 
provide patients with the required skills for maintaining non-traditional and desired 
behaviour. Therefore, implementing behavioural strategies, psychological 
interventions and services that incorporate healthcare professionals other than 
doctors, such as dieticians, nurses, pharmacists and psychologists in the 
management process would potentially ????? ?? ?????? ?????????? ??? ??????????
behaviour and health outcomes. Pharmacists can assist patients in linking their 
therapeutic regimens to their routine activities (Al Mazroui et al., 2009; Jarab et al., 
2012). Individualisation of care, taking into consideration the patient and societal, 
cultural, and economic variables would also be paramount in helping patients to 
initiate and maintain behavioural change, particularly in lifestyle aspects (Elis et al., 
2008). 
  
2.6 Strengths of this review  
The strengths of the review were that it incorporated data related to the wider 
management of diabetes in the Middle East, and not only focused on the adherence 
studies. It is the first review that provides a mixture of all factors such as knowledge, 
??????? ???????? ???? ????????? ??????? ????? ?????? ??????? ?????????? ?????????? ???? ????
management of diabetes in the region. A description of the applied healthcare 
system in the region and how this system affects the management of the disease is 
also outlined. Previous studies described either knowledge and health beliefs or the 
culture and lifestyle behaviours. In addition, findings provided here could be 
considered adequate to comment on the potential implications for type 2 diabetes 
care in the Middle Eastern region.  
 
2.7 Limitations of this review  
Identification of papers was through electronic databases, and hand searching. All 
of the reviewed studies were published in English. One limitation of this review was 
related to the heterogeneity of the reviewed studies. The studies were of different 
populations (although they were mostly from Eastern Mediterranean countries), from 
varied levels of healthcare provision, used different methodologies, adherence 
measurements and follow-up duration, and reported variable outcome measures 
(e.g., some studies covered both type 1 and type 2 diabetes, while others focused 
on type 2 diabetes only). In addition, due to the lack of published studies, this review 
did not include data from all the Middle Eastern countries. Therefore, the outcomes 
of the review are of a broad nature and their relevance to population groups in other 
countries, societies and contexts is unclear. 
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2.8 Conclusion 
Managing diabetes is challenging specifically in Middle Eastern countries, where 
????????????????????????????????????????????????????????????????????????????????????????
patients. This review affirms that lack of health awareness, beliefs, attitudes and 
????????????????? ???????????????????????????????????????????????????????????????????
and lifestyle interventions. This has implication at a governmental and health 
professional level for treatment outcomes in diabetes. Educational interventions that 
?????????????????????????????????????????????????????????? ??????????????????????????
behaviours and outcomes.  
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2.9 Aim and objectives of the main study 
 
Rationale for this study 
Non-adherence to medicines is a common problem among patients with diabetes. 
Particularly, patients with type 2 diabetes in the Middle East had poor management 
behaviour. In Kuwait, the rate of non-adherence among adults with type 2 diabetes 
was 43% (Alhaddad, 2010). Statistics about diabetes are still increasing and 
diabetes has become a pandemic (a leading cause of morbidity and mortality) in the 
Arab world, especially the GCC countries. Based on information from preliminary 
fieldwork, patients with type 2 diabetes in Kuwait are still experiencing difficulties in 
achieving glycaemic control, and they have poor health outcomes (Amiri Hospital 
Statistics, 2013). 
 
2.9.1 Research aims   
1. This study aims to explore experiences of adults with type 2 diabetes in managing 
their disease with different therapies (e.g. OHAs, insulin injections, pens and 
pumps) and to identify ways in which health awareness, beliefs and culture impact 
???????????????????. 
2. To examine the extent to which using insulin pens and pump??? ?????????????????
behaviour and quality of life, and enables health targets (e.g. normal HbA1c levels) 
to be achieved. Also, it aims to identify the most practical targeted interventions that 
could be employed in the MOH. 
 
This will reveal the requirements and problems that arise in the context of the wider 
disease management from the perspectives of patients, allow evidence-based 
recommendations to be made and barriers to implement such recommendations, 
from the perspectives of HCPs, to be identified. Thus, findings of this study will help 
to:  
? Inform healthcare provision  
? ????????????????????????????????????? 
? Target educational interventions 
? Inform guidelines modifications regarding insulin pumps 
? Inform prescribing decisions for insulin pens and pumps  
?  Identify which group of patients should be offered insulin pumps and when 
? ???????????????????????????????????????????? ??????????  
? Inform better utilisation of healthcare resources  
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2.9.2 Research objectives  
There were five objectives for this study: 
1. To identify, within the context of socio-cultural life, how adults with type 2 
diabetes manage their disease in terms of medicine use and lifestyle 
modifications, and what problems they are experiencing, in order to inform 
recommendations. 
2. ??? ????????? ????? ??? ?????? ??????????? ???????? ???? ???????? ?????????? ??????????
medicine-taking behaviour, lifestyle and treatment outcomes, in order to 
recommend ????????? ?????????????? ???? ? ???????? ?????????? ???????????
behaviour.  
3. To identify whether the use of insulin delivery technology (pens and pumps) has 
an impact on medicine use and treatment outcomes by ??????????????????????????
and experiences, in terms of satisfaction and quality of life compared to their 
previous therapeutic regimens, in order to inform recommendations for 
improving ??????????????? 
4. To investigate how the use of insulin pens and pumps affects the daily social 
lives of patients and other family members, and to identify problems associated 
???????????????????????????????????????????????????????? ??????????????????????? 
5. To gain the perspectives of HCPs regarding the key findings of the study, 
assess the practicality of required recommendations and obtain barriers to 
optimum diabetes management in the MOH, in order to inform policy 
implications and propose service development. 
 
Methods employed to achieve these objectives are described in the next chapter.   
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This chapter describes the methods employed to meet the study aim and objectives, 
and justifies the selection of specific measures and instruments. It starts with 
describing the preliminary fieldwork, the methodological design, the sampling and 
recruitment procedures, the development of the instruments, the translation 
procedures and piloting of the instruments, the procedures of data protection and 
ethical considerations, the data processing and analysis and finally, the measures 
used to ensure the validity and reliability of the data.  
 
3.1 Preliminary fieldwork 
  
3.1.1 Aims of preliminary fieldwork  
There were four aims for conducting the preliminary fieldwork: 
• To determine the most appropriate sites for data collection, discuss methods of 
patients’ recruitment and realise how patients’ medical records could be 
accessed for obtaining clinical data. 
• To demonstrate priorities of local stakeholders to include them in the main study.  
• To investigate the procedures and duration required for attaining ethics approval 
for the study.  
• To gain insight into the procedures applied to dispense insulin devices 
(pens/pumps) to patients with type 2 diabetes and obtain an estimate about 
number of adults currently using such delivery methods.  
 
3.1.2 Meetings with healthcare authorities and providers  
Meetings were arranged with different HCPs (e.g. doctors and pharmacists), 
working in different authorities (e.g. Ministry of Health, Dasman Diabetes Institute 
and Kuwait Diabetes Society), in addition to academic staff at Kuwait University to 
discuss the focus of the main study. The individuals highlighted a number of 
priorities and concerns, from which the study objectives emerged. The discussions 
involved the management procedures of patients with type 2 diabetes in the MOH, 
in terms of available treatment regimens and policies for dispensing 
medicines/devices to patients. The most crucial areas in the context of management 
of type 2 diabetes in adults, the most convenient methods for recruiting participants 
to the study and accessing their medical notes and the ethical considerations were 
also discussed.  
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3.1.3 Impact of preliminary fieldwork on the main study 
The preliminary fieldwork helped in designing the structure of the main study and 
planning the most appropriate sites and methods for patients’ recruitment (Figure 
3.1). Also, it aided in addressing the priorities and concerns of HCPs in Kuwait. 
However, a decision on the appropriateness of the settings and justifications for the 
selection is provided for each study site as follows: 
• Kuwait Diabetes Society, which was considered as a recruitment site at the 
beginning, was excluded. It was found that including patients from the Society 
might introduce bias to the results, because patients who are regularly visiting 
the Society are more likely to be highly motivated and adhere to their treatment 
and self-care behaviour, such as SMBG, and they might not experience any 
problems or barriers as others who do not visit the Society.  
• The Ministry of Health, including the main five hospitals in Kuwait was chosen 
for conducting this study. Approaching these five hospitals granted the coverage 
of all health districts of Kuwait.  
 
3.2 Methodological design  
In order to achieve the study aim and objectives, a cross-sectional study design 
using mixed methods (qualitative and quantitative) was employed. An explanation of 
each employed method is provided below. 
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  *Final stage of data collection: -Semi-structured interviews  
-Same setting, in addition to Medical Stores and Management Department  
-Invitation letter and information leaflet sent by e-mail or given at clinic working hours 
-Population: HCPs: physicians, pharmacists, dieticians, nurses and psychologists 
-Response: 10 HCPs 
-Similar procedure for HCPs’ interview transcripts 
 
Figure 3.1: Overview of structure of the main study 
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3.2.1 Qualitative methods   
Qualitative methods involved conducting semi-structured interviews with patients 
and HCPs. The study objectives (from 1 to 4) required exploration of the real 
determinants of medicine-taking behaviour and the role of newer insulin delivery 
methods in improving health behaviour. This was achieved by exploring patients’ 
views and experiences regarding their medicine/device use in the management of 
their disease, obtaining information regarding their knowledge and beliefs and 
identification of the problems experienced. Objective 5 required discussion of the 
issues identified, in order to gain the perspectives of HCPs, include their 
recommendations and address their needs to propose service development. 
 
Semi-structured interviews allowed to gain the most valuable data by asking 
patients open questions that allowed them to explain their perceptions and enabled 
the researcher to explore further the responses. In addition, semi-structured 
interviews allowed the HCPs to discuss freely the issues, highlight their 
recommendations, and the barriers envisaged for initiating them. This flexibility 
would not have been achieved if structured interviews, which lack the flexibility in 
two-way communication between the interviewer and the interviewee, were 
employed. Employing unstructured interviews also would not ensure the covering of 
topics of interest to all participants (Pope and Mays, 2007). 
 
3.2.2 Quantitative instruments  
The quantitative procedures involved the completion of two questionnaires and 
accessing medical records of patients to collect clinical data (e.g. HbA1c). 
 
3.2.2.1 Self-report questionnaires 
In order to achieve objectives 1 to 4 (exploring how patients manage their disease in 
terms of medicine use), a questionnaire that examined patients’ adherence to 
medications was used (Morisky Medication Adherence Scale, MMAS) (Morisky et 
al., 2008). A part of objective 2, concerning identification of how beliefs affect 
medicine-taking behaviour necessitated the use of a questionnaire that examines 
patients’ beliefs (Beliefs about Medicines, BMQ) (Horne et al., 1999).  
 
However, questionnaires could not reveal the meanings behind the participants’ 
responses and did not enable to get a complete picture about the barriers to 
adherence. For instance, although MMAS is considered suitable for measuring 
adherence, it was not designed to describe a patient’s long-term continuity on 
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therapy, which is an important factor in the long-term management of type 2 
diabetes and it may overestimate adherence or underestimate non-adherence. 
Therefore, the interviews were essential and used in this study. 
 
3.2.2.2 Clinical data (HbA1c) 
In order to fulfil objectives 1 to 4 (to identify the impact of medicine use on treatment 
outcomes), collection of HbA1c levels was considered. This would help to relate 
these readings to the qualitative data and to that obtained from self-report 
questionnaires. Also, this would help to assess the clinical effectiveness of using 
insulin devices, such as pumps in the management of type 2.  
 
Using all those methods to collect data was a form of triangulation. Triangulation 
involves employing a range of methods to obtain information on different aspects 
and is recommended (Smith, 2002). In addition, obtaining data to describe the same 
issue using different methods is a way of data validation, and allowed retrieval of 
deeper information about the area under investigation. Table 3.1 summarises the 
methods employed to achieve each of the study objectives. 
 
Table 3.1: The methods applied to achieve the study objectives  
Study objective Methods used to achieve the objective 
(1) To identify how patients manage their 
type 2 diabetes in terms of medicine use 
-Semi-structured interviews with patients 
-MMAS-8 
-HbA1c levels  
(2) To identify the impact of knowledge, 
beliefs and culture on medicine-taking 
behaviour and treatment outcomes 
-Semi-structured interviews with patients 
-MMAS-8 
-BMQ-Specific 
-HbA1c levels  
(3) To identify the role of insulin pens and 
pumps in improving medicine use and 
treatment outcomes through exploring 
patients’ views and experiences 
-Semi-structured interviews with patients 
-MMAS-8 
-HbA1c levels  
(4) To identify problems associated with the 
use of insulin pens and pumps 
-Semi-structured interviews with patients 
(5) To gain the perspectives of HCPs on 
the key findings and obtain their 
recommendations 
-Semi-structured interviews with HCPs 
 
3.3 Sampling and recruitment  
 
3.3.1 Sampling strategy and sample size  
All adults with type 2 diabetes were using medical treatment for the management of 
their disease, and treated at the main five hospitals in Kuwait (Mobarak Al-Kabeer, 
Amiri, Adan, Farwaniya and Jahra) were considered eligible for this study. Since the 
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secondary-care units are the major centres in Kuwait providing adults with type 2 
diabetes with different treatment regimens, such as OHAs, traditional insulin 
injections, insulin pens and pumps, approaching the main five hospitals allowed to 
recruit patients using different therapies and to achieve all the study objectives. 
Moreover, in secondary-care units, all the healthcare team required for the 
management of type 2 diabetes can be approached. Therefore, to meet objectives 1 
and 2, all adults receiving any medical treatment for the management of type 2 
diabetes were eligible. To meet objectives 3 and 4, adults using insulin pens and 
pumps, and for different durations were eligible. Accordingly, all patients who met 
the eligibility criteria and visited the diabetes outpatient clinics during the data 
collection period were invited to participate. To achieve objective 5, HCPs who were 
involved in the management of adults with type 2 diabetes, and worked in the MOH 
were invited to take part. In addition to the main five hospitals, the Management 
Department and Medical Stores of the MOH were also included as sites for the 
recruitment of HCPs.  
 
All the five hospitals have diabetes outpatient clinics. Number of diabetologists in 
each hospital ranged from 1-11. Number of other HCPs, such as nurses (mean=5), 
dieticians (mean=5), pharmacists (mean=34), and psychologists (mean=1) who 
were involved in the management of type 2 diabetes varied between hospitals. 
Number of eligible patients registered with a diagnosis of type 2 diabetes, and 
prescribed medicines and/or devices, differs between the hospitals (mean=2,200).  
 
Approaching the main five hospitals in Kuwait ensured the generalizability of the 
results to all patients with type 2 diabetes receiving care in the MOH. In addition, 
covering all the health districts allowed patients from different socio-cultural 
backgrounds and geographical areas (e.g. rural and urban) to be recruited, which 
ensured the coverage of different perspectives and experiences. All patients 
regardless of their origins (e.g. White and Black) were invited to participate.  
 
Regarding the sample size, the researcher continued interviewing patients and 
HCPs until no new experiences and perspectives were raised. This is called data 
saturation level, which was reached within 43 interviews with patients and 10 with 
HCPs. This sample size would allow analysis of the clinical data.  
 
The study aimed to recruit adults aged 18 years or older, who were diagnosed with 
type 2 diabetes, used different treatment regimens for different durations and 
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attended the outpatient clinics at secondary-care units, MOH. Also, the study aimed 
to recruit HCPs who work in the MOH and were involved in the management of 
adults with type 2 diabetes. The listed inclusion and exclusion criteria, which were 
used in this study, reflected this: 
 
Inclusion criteria 
The inclusion criteria for patients were: 
• A diagnosis of type 2 diabetes  
• Age of 18 years or older  
• Attending diabetes outpatient clinics at secondary-care units 
• Receiving medical treatment (e.g. OHAs and/or insulin injection/pen/pump) 
• Signing the consent form   
 
The inclusion criteria for HCPs were: 
• Working in the MOH 
• Managing adults with type 2 diabetes  
• Agreeing to participate  
 
Exclusion criteria  
• Patients were excluded in the following cases: a diagnosis of type 1 diabetes or 
gestational diabetes, as they have different requirements and self-management 
behaviour that might bias the results. In addition, patients with type 2 diabetes 
who attended primary care units were excluded. Since primary care units lack 
the availability of all treatment regimens, such as insulin pens and pumps, they 
were not considered as recruitment sites.   
 
• HCPs who were excluded were those who did not respond.   
 
3.3.2 Sampling procedures  
All patients, except insulin pumps users were identified and approached during their 
clinical visits to the outpatient clinics of the five hospitals. For patients using insulin 
pumps, the researcher obtained their names from their consultants and prepared a 
list of their names, numbers and ages. Diabetes outpatient clinics run at different 
days of the week in each hospital, a time schedule for each clinic was prepared by 
the researcher. Accordingly, patients’ recruitment was conducted on a daily basis 
based on working hours of each clinic throughout weekdays.  
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3.3.3 Sample recruitment  
Before commencing data collection, the researcher met with the Heads of the 
diabetes units in each hospital. The consultants were provided with a leaflet 
prepared previously, which explained briefly the nature of the study, the aim and 
objectives and the researcher contact details for any further information (Appendix 
2). It was important to undertake this step, in order to ensure the cooperation of the 
HCPs.  
 
Recruitment of patients  
Initially, the researcher prepared a timetable for the clinics’ working hours 
throughout weekdays. The researcher then, visited the diabetes clinics in the 
hospitals in the mornings between 7 am and 2 pm, as this was the time for diabetes 
clinic appointments. The sample was chosen at different days of the week, which 
minimised selection bias and ensured that the study sample was representative and 
diverse (Bowling, 2009). Patients were approached as they attended their 
appointments with the consultants. During the pilot period, the researcher was 
present in the clinic, and after each eligible patient finished his/her consultation, the 
consultant allowed the researcher to introduce herself to the patient, briefly explain 
the study, obtain their approval to participate, and agree on when and where to be 
interviewed. Following such a procedure required the researcher to be present the 
whole day in the clinic, meeting all patients who were within/outside the eligibility 
criteria, and obtaining their approvals to participate. This was considered overly 
time-consuming and inefficient. Thus, a different procedure was adopted, where by 
the researcher presented in the clinic early in the morning before patients’ 
appointment commenced, and checked the patients’ list with the cooperation of the 
clinic nurse, identifying patients who met the eligibility criteria from their medical 
notes. Then, the patients were approached as they were waiting in the waiting area.  
 
Upon approaching the patients, the researcher introduced herself as a PhD student 
and provided them with previously prepared invitation letters (Appendix 3) and 
information leaflets (Appendix 4). The forms were designed to explain the study 
purpose, the benefit of participating, what the study would involve and how data 
would be collected, confidentiality procedures and the researcher contact details. All 
patients responded directly, and those who were unwilling to participate were 
thanked by the researcher. With those who agreed to participate, the researcher 
agreed on a time and place for conducting the interview and completing the 
questionnaires.  
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Based on information from consultants, patients using insulin pumps were few, and 
not all of them were regularly visiting their doctors. Therefore, due to the limitation of 
the data collection period, and to ensure reaching a convenient sample from this 
group of patients, it was necessary to apply a different recruitment procedure. 
Accordingly, the researcher obtained contact details of those patients from their 
doctors/nurses, and contacted them. HCPs were not included in the recruitment 
process to avoid bias resulting from selection of certain patients, and to give the 
patients the choice to decide whether to participate and not to be embarrassed or 
persuaded by their doctors. Also, this reassured patients about the independence of 
the research and the researcher from the healthcare system, so that they could 
disclose any negative experiences they have regarding HCPs freely. Thus, upon 
calling the patients, the researcher introduced herself, explained briefly the aim of 
the study and what was required from them, and agreed on a time and place for 
conducting the interview and completing the questionnaires. Recruitment of patients 
commenced in March 2014 and continued until September 2014. 
 
Recruitment of HCPs 
The researcher aimed to meet different HCPs who were involved in the 
management of adults with type 2 diabetes and worked in different departments of 
the MOH. Accordingly, a list of the specialities/departments of those HCPs was 
initially prepared by the researcher based on her experience as a pharmacist in the 
MOH. Once final stage of data collection commenced, the researcher approached 
the HCPs by their specialities and departments. One more speciality (psychologist), 
which was not included in the list, was then added as recommended by a physician. 
Psychology was not included initially because this speciality has been recently 
involved in diabetes clinic team. Table 3.2 shows the final list of the HCPs who were 
approached and agreed to take part.  
 
Table 3.2: The specialities of the HCPs and their department/working area  
HCP Speciality Organisation/Area 
1 Dietician Hospital/urban 
2 Dietician Hospital/rural 
3 Nurse Hospital/urban 
4 Nurse Hospital/rural 
5 Physician Hospital/urban 
6 Physician Hospital/rural 
7 Psychologist Hospital/urban 
8 Pharmacist Hospital/urban 
9 Pharmacist Medical Stores/mixed 
10 Pharmacist Management Department /mixed 
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Seven HCPs were contacted by telephone before conducting the interview with 
them, and four were approached during working hours in their clinics. The 
researcher introduced herself as a PhD student, who would like to conduct a final 
stage of data collection that involved interviewing with HCPs for 10-20 minutes. It 
was clarified to the HCPs that they were free to choose the type of the interview, 
e.g. face-to-face or telephone, and the time, according to their convenience. Also, it 
was explained that the information would be treated confidentially and would be 
anonymous.  
 
Before commencing this stage of data collection, the researcher prepared an 
invitation letter (Appendix 5), information leaflet (Appendix 6), and interview topic 
guide for HCPs. The invitation letter included information about the aim of the 
interview, what was needed from the HCP, the duration of the interview, and the 
contact details of the researcher and the academic supervisors. The information 
leaflet explained briefly the key findings of the study and the main identified issues. 
It was divided into three parts: part one related to all patients who participated in the 
study, part two discussed issues particular to patients using syringes/vials and pens 
for insulin delivery, and part three discussed findings raised from patients using 
insulin pumps. All those documents were sent by e-mail to the HCPs before 
interviewing them, except two, who were approached in their clinics, and agreed to 
be interviewed directly. Recruitment of HCPs commenced in June 2015 and 
continued until July 2015. 
 
3.4 Data collection methods  
Qualitative, semi-structured interviews were undertaken to explore knowledge, 
beliefs, views and experiences of adults about their disease, medicine and device 
use to mange type 2 diabetes. In addition, semi-structured interviews were used in 
this study to investigate the views and experiences of HCPs about the identified 
issues and address their recommendations to propose service development.  
 
Quantitative measurements were undertaken for the participants’ responses to the 
questionnaires (MMAS-8 and BMQ-S). HbA1c values were collected from medical 
records of patients; the latest three readings reported in each patient’s note were 
recorded.  
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3.4.1 Interviews  
 
3.4.1.1 Development of the research instruments (interview schedules) 
To achieve the study objectives 1 to 4  (Section 2.6), an interview topic guide for 
patients was developed. The preliminary fieldwork and the literature review assisted 
in structuring the schedule and designing some of the questions. The review of the 
studies helped in highlighting issues that were relevant to the study objectives and 
the preliminary investigations helped in addressing issues of interest and that were 
relevant to the area of the study. The topic guide was revised many times by the 
research team, comments regarding the contents and the structure of the guide 
were incorporated and the final version of the schedule was agreed by all. 
 
The schedule included closed questions for obtaining demographic data (e.g. what 
is your residence area? how old are you?). The main part of the schedule comprised 
open questions, which allowed access to issues that were important to the 
participants rather than those that the researcher would have expected. This type of 
question was used for obtaining patients’ views and experiences regarding their use 
of medicines/devices during their daily life (e.g. for your diabetes, what 
medicines/device are you using currently? how do you use them? tell me in what 
ways have you found your medicines/device helpful?). In addition, the open 
questions allowed the researcher to investigate the health behaviour of participants, 
and the factors that impacted on it, e.g. beliefs, culture, etc. For example, by asking 
question 9 (Do you remember a time when you have not used your medicines as 
prescribed, please tell me what you did? why did this happen?), this allowed 
participants to recall events when they misused their medicines and why they did 
so. For further obtaining and exploring factors affecting management behaviour this 
question was followed by asking participants about their medicine use during special 
occasions, e.g. Ramadan. To minimise bias, the researcher avoided leading 
questions, which may restrict the discussion of unacceptable attitudes. For example, 
in question 9, in order to make participants not feel that there is an expected or 
acceptable answer, the researcher started the question (in order to make life easier, 
patients sometimes use their medicine in their own ways).  
 
In order to encourage participants to say more and provide rich information, probing 
techniques were adopted. Prompts and probes were written in italics in the interview 
schedule to help the researcher obtaining information on particular issues in the 
areas of interest. For example, under question 14 (can you tell me how do your 
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family and friends support you in managing your diabetes?), the following probes 
were used (collecting medicines from pharmacy, accompanying in appointments, 
calculating doses, administering doses, checking site of injection, monitoring blood 
glucose level, eating special food, exercising).  
 
The interview schedule of patients who were not using an insulin device included 
questions on: knowledge about diabetes, lifestyle issues (e.g. diet and exercise), 
current therapy and duration of using it, views and experiences about use of 
medicines during daily life and in special occasions, SMBG, social support and 
HCPs and system-related issues. Answers to the questions allowed the researcher 
to achieve objectives 1 and 2 of the study through investigating the determinants of 
patients’ decision-making, such as health awareness, beliefs and cultural factors in 
terms of medicine-taking behaviour and other management responsibilities, such as 
diet, exercise and SMBG. The interview schedule of patients who were using an 
insulin device included similar questions to those of others in addition to questions 
on: the ease/difficult of using the device, its acceptance, impact of using the device 
on daily activities and families, efficacy of using the device in improving glycaemic 
control and quality of life, training provided for using the device and satisfaction with 
the device use. Answers to questions related to the use of insulin pens and pumps 
allowed the researcher to achieve objectives 3 and 4 of the study through 
interpreting whether the use of such devices introduced benefits to patients in terms 
of adherence, satisfaction and quality of life (e.g. achieving glycaemic control and 
avoiding serious complications), or they introduced new problems.  
 
After conducting the first 7 interviews (3 with patients using OHAs only, 2 with 
patients using OHAs and/or traditional insulin injections and 2 with patients using 
insulin device), some minor amendments were introduced to the interview 
schedules (Section 3.4.1.3). A sample of the amended schedule is shown in 
Appendix 7. 
 
Overall, the interview schedules of patients were designed to obtain information 
about the most important issues to this group of population and to prepare an 
interview schedule for the final stage of data collection. This involved addressing the 
key findings to discuss them with different HCPs, in order to propose 
recommendations and inform policy about the most practical interventions and 
services (objective 5) that should be applied to improve the management of the 
disease and the health outcomes. Below is a description for the development of the 
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interview schedule of the HCPs. A sample of the HCPs’ schedule is shown in 
Appendix 8.  
 
As mentioned above, outlining the key findings from the interviews with patients 
helped in structuring the interview schedule of the HCPs and designing the 
questions. The interview schedule was developed by the researcher, revised by the 
academic supervisors and comments regarding the contents and structure were 
discussed and introduced. In the covering page of the schedule, there was a list of 
the HCPs’ specialities, their working area and the type of the interview. The topic 
guide included two parts: the first part included 10 statements representing the key 
findings (the issues identified to impact health behaviour of patients with type 2 
diabetes). These included personal factors (e.g. beliefs about the disease and 
medicines), healthcare provider-related factors (e.g. neglecting patients’ social 
needs) and healthcare system-related factors (e.g. unavailability of certain 
medicines/items and prescribing issues). In this part, HCPs were asked to rate their 
responses to each statement on a four-point Likert scale for the agreement 
(1=Agree, 2=Agree to a certain extent, 3=Disagree, and 4=Uncertain), and for the 
importance of taking the statement into consideration (1=Most important, 2=Very 
important, 3=Important, and 4=Least important). Answers to questions of this part 
helped to evaluate the extent to which the issues raised by patients were correct, 
and to address the most important issues highlighted and need to be taken into 
consideration.  
 
The second part of the topic guide included 10 suggestions made by the researcher 
to meet the patients’ identified needs and develop the services provided. This 
contained the implementation of services, such as educational campaigns, training 
courses for HCPs, diabetes clinics managed by different HCPs other than doctors 
and a 24-hours help-line service led by diabetes specialists/educators. In this part, 
the HCPs were asked to rate their responses for each of these suggestions on a 
four-point Likert scale, for the importance (1=Most, 2=More, 3=Less, and 4=Least), 
and for the feasibility (1=Yes, now, 2=Yes, within a year, 3=Yes, within 5-10 years, 
and 4=No). Answers to this part helped to evaluate the most important and practical 
service developments that could be considered by policymakers and initiated in the 
MOH. Then, this was followed with open questions, such as “Do you have any 
further recommendation that you found helpful to improve patients’ awareness, 
beliefs, medicine-taking behaviour and health outcomes”.  
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Interviews with the HCPs were not limited to answering the questions solely by 
ticking the appropriate box. Also, the HCPs were allowed to explain their responses, 
report the barriers and challenges for the management of patients and provide their 
recommendations in terms of service development. Overall, answers to the 
questions of the interview schedule of the HCPs enabled the researcher to appraise 
the existence of the issues identified, address the barriers experienced in terms of 
disease management and recognise the most feasible interventions that can be 
applied from the perspectives of the HCPs. After conducting the first 2 interviews (1 
with a dietician and one with a nurse), some minor amendments were introduced to 
the interview schedule (Section 3.4.1.3). 
 
3.4.1.2 Conduct of interviews 
 
Interviews with patients  
Patients who agreed to participate in the study were free to choose when and where 
to be interviewed, allowing them to interact in an appropriate and relaxed manner. In 
order to ensure patients’ privacy and convenience, the researcher suggested the 
following options: a private room at KDS, a coffee shop, or any other setting that the 
patient prefer. Most participants preferred to conduct the interview before or after 
their appointment with the doctor, or while they were waiting for their prescriptions to 
be dispensed, other patients preferred to be interviewed in their spare times. 
Regarding the place of the interview, some participants preferred for it to take place 
outside the clinic, e.g. coffee shops, which they identified. One participant, preferred 
to conduct the interview at his home, while most preferred to be interviewed in the 
clinic. When the interview was conducted in the clinic, the researcher was careful to 
obtain the appropriate place for its conduct, such as the waiting area or a room, 
which was unoccupied during the clinic working hours. 
 
Before commencing the interview, the researcher explained briefly the nature of the 
study, gave the participants the chance to ask any question, assured them that their 
participation was voluntary and that they could withdraw at any time without giving 
any explanation. Some patients may not disclose certain issues, such as low 
adherence, if they feel that their doctors might know about it. Therefore, to minimise 
social desirability bias and ensure that participants would discuss their feelings truly 
and comfortably, the researcher ensured that participants were relaxed by 
reminding them about the confidentiality of procedures and the independence of the 
researcher. In order to obtain rich information, the researcher also clarified to 
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participants that the aim of the study was to investigate their views and experiences 
regarding their disease, medicines/devices, and that the main focus of the research 
was to find out about the problems they experience with HCPs and system and that 
there were no right or wrong answers. Participants were reassured that their 
participation would not affect the care services they received because their 
responses would be anonymous and would not be communicated to HCPs. Then, 
participants were asked to sign a written consent (Appendix 9) for being 
interviewed and for audio-recording, all the participants agreed to be audio-
recorded. The average duration of the interview was anticipated to be 30-45 minutes 
based on the participants’ views and experiences.  
 
Audio-recording was employed to facilitate data analysis. Manual transcription of 
data during the interview was avoided, as this might jeopardies the 
comprehensiveness of data and inhibit the interviewer from developing issues 
raised by the participants. The researcher followed the interview schedule as a 
guide throughout the interview. To save time during the interview, the researcher 
highlighted the heading points of the schedule previously and used the probes when 
necessary to obtain responses from the participants. It should be noted that 
participants were allowed to talk freely and without following the particular sequence 
of the questions, by which, topics could be explored according to issues raised by 
participants. In order to capture all the information that might assist in the analysis, 
the researcher took into consideration the facial expressions and body language of 
the participants and took hand-written notes, which were added as memos in the 
transcripts.  
  
At the end of the interviews, it was very important to conclude the discussion clearly, 
because some participants may provide rich information towards the end. Thus, the 
researcher ended with the following question “finally, would you like to add anything 
about your disease, medicines/device, HCPs or system that we have not 
discussed”. Then, the researcher thanked the participant and asked him/her for 
permission to obtain data from his/her medical notes. After finishing the interview, 
the recorder was switched off and the participant was thanked again for 
participating. However, some participants provided information such as suggestions, 
comments or statements after switching off the recorder. The researcher was very 
careful to take hand-written notes of such information as soon as the participant had 
left and then added them into the transcripts, to incorporate them into the data 
analysis. Generally, participants were happy to co-operate, being interviewed and 
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tape recorded. All interviews were conducted, audio-recorded and transcribed 
precisely in Arabic by the principal researcher only.  
 
Interviews with HCPs 
The researcher asked the HCPs to identify the type (face-to-face or telephone) and 
time of the interview they preferred. Seven HCPs were interviewed face-to-face and 
three were interviewed via telephone. The researcher followed the interview 
schedule as a guide throughout the interview. Before commencing the face-to-face 
interviews, the researcher asked the HCPs whether they would like to read the 
questions themselves or that the researcher read them loudly. Some HCPs (n=3) 
preferred that they go through the questions and mark their answers themselves, 
while others (n=4) preferred that the researcher read the questions loudly and mark 
their answers. The HCPs were asked during the interviews to provide their views 
and experiences regarding the issues raised from this study and to highlight 
recommendations on how to develop healthcare services based on the study 
findings.  
 
To facilitate the analysis of data, the researcher employed audio-recording for all the 
conducted interviews. The permission of all HCPs to record the interview was 
sought at that point. All the interviews were recorded except one, where the HCP 
declined to be audio-recorded. In that interview, manual transcription of data 
obtained during the interview was undertaken. At the end of the interviews, the 
researcher thanked the HCPs for the participation and for their time. Some HCPs 
provided information after switching off the audio-recording, the researcher took 
hand-written notes of some reports soon after finishing the interview. All interviews 
were conducted and transcribed by the principal researcher only.  
 
3.4.1.3 Piloting and amendments of the interviews schedules  
 
Interview schedule of patients  
In order to ensure the practicability, comprehensibility and consistency of the 
interview schedule and the appropriateness of the language from a cultural 
perspective, a pilot period was considered. Therefore, after conducting the first 7 
interviews with participants, the instrument and procedures were revised with the 
research team. The aim of this piloting was to ensure that the design of the interview 
schedule was acceptable in terms of format, content and terminology and that it was 
optimal in obtaining adequate information to meet the study aim and objectives. 
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Also, the pilot was conducted to address new issues that emerged before 
completing the rest of the interviews. Therefore, after piloting, a discussion was 
conducted with the research team and overall, the interview schedule was 
considered appropriate for obtaining relevant information. However, some minor 
amendments were considered and applied, in regard to the order of the questions. 
Thus, those participants included in the piloting period were not excluded from the 
study sample and the interviews were incorporated into the data analysis.    
 
Based on the initial seven interviews, questions were removed or re-organised. For 
instance, it was noticed that the patients were spending a lot of time in responding 
to question 1, which was about recalling the first time they had been diagnosed with 
type 2 diabetes: (Tell me about when you were first diagnosed with diabetes, how 
did you feel and what did you do?). The question included some probes for 
obtaining participants’ awareness about the seriousness of the disease such as 
(How long ago? What actions you took to manage it?). Also, it was noticed that 
there were overlaps, as answers to that question also re-emerged in responses to 
other questions; therefore, that question was removed. Another question (question 
12), which was about participants’ beliefs concerning different brands of medicines 
was re-organised as a probe under question 4, which examined different beliefs 
about medicines. In addition, the interview schedule was expanded over the course 
of data collection. The researcher added more probes, as issues emerged. For 
example, under question 4, which examined beliefs about medicines, the following 
probe was added for insulin-dependent participants (How would you describe your 
life using insulin compared to using tablets only). Under question 14, which was 
about social support, the following probes were added: (Accompanying in 
appointments, collecting prescriptions).  
  
Interview schedule of HCPs  
After the researcher had tested the interview topic guide with a competent person 
(B.A; an assistant professor), minor amendments were introduced. The interview 
was formed to take longer than the indicated time (25-30 minutes). Accordingly, 
amendments were introduced to make the questions more condensed and the 
framework more structured. Further minor amendments were introduced after 
conducting the first two interviews with the HCPs. The design of the guide was re-
organised, in order to prevent any confusion when answering some questions. 
Overall, the interview topic guide was considered convenient for obtaining relevant 
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information that meet objective 5 (Section 2.6) of this study. Therefore, those two 
interviews were included and incorporated into data analysis.    
 
3.4.2 MMAS and BMQ 
The second employed method for collecting data in this project involved the 
completion of two questionnaires (MMAS and BMQ). MMAS is a valid and reliable 
tool that showed adequate psychometric properties (Morisky et al., 2002). It is 
simple, practical and has a sensitivity of 93% in identifying low versus high 
adherence and a specificity of 53% (Morisky et al., 2008). Researchers in the Middle 
East have used MMAS, as a translated international scale, among patients with 
diabetes and reported its benefits in improving clinical pharmacy research (Jamous 
et al., 2011; AlHewiti, 2014; Bener et al., 2014; Sweileh et al., 2014; Ashur et al., 
2015). Using MMAS in this study helped in classifying the adherence of the 
participants and examining the extent of non-adherence among this group of 
population. This would be difficult to achieve if other scales, such as (Medication 
Adherence Rating Scale, MARS), which is more specific for patients with psychiatric 
disorders, or the Hill-Bone Scale, which is more specific for patients with 
hypertension were used (Lavsa et al., 2011). A sample of MMAS is provided in 
Appendix 10. BMQ is a valid and reliable scale that can be used among patients 
with diabetes (Horne et al., 1999). Its validity and reliability have been shown among 
patients with diabetes in many countries in the Middle East (Kartal and Ozsoy, 2007; 
AlHewiti, 2014; Sweileh et al., 2014). Using BMQ in this study enabled to gain an 
overall picture about the participants’ beliefs about medicines and to compare the 
participants’ beliefs with their behaviour. A copy of the scale is attached in 
Appendix 11. 
 
After conducting the interviews, the researcher asked the participants to complete 
the questionnaires (MMAS and BMQ). With regard to the administration of the 
questionnaires, the researcher adhered to the authors’ guidelines, which were e-
mailed previously. Therefore, at this point, the researcher explained to participants 
that there were no right or wrong answers, that they should complete the questions 
honestly and that the questionnaires were completely confidential. Participants were 
also informed that the questions were related to diabetes medicines only, as it was 
the focus of the study. In addition, the researcher explained the aim of each of the 
questionnaires. For example, for MMAS, the researcher identified that completing 
this questionnaire would assist in recognising the medicine-taking behaviour of 
participants, which might assist in targeting appropriate interventions. For BMQ, the 
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researcher clarified to participants that it would help to find out more about what 
they think regarding their medicines. 
  
Because the study sample included older people, some of whom could not write and 
read, and to avoid missing data if participants completed the questionnaires 
themselves, the researcher gave all participants the option whether to complete the 
questionnaires themselves, or that the researcher read the questions loudly for them 
and they give their own answers. However, all participants preferred that the 
researcher read the questions for them, and they gave their answers orally, except 
for three participants, who preferred to read and complete the questionnaires 
themselves. Therefore, the completion of the questionnaires was performed in a 
face-to-face manner. The researcher administered the questionnaires by reading 
the questions and the answer choices loudly from the sheet, the participants 
provided their own answers verbally and the researcher marked the answers. This 
manner should ensure the validity of the data collected from patients when 
completing questionnaires (Bowling, 2005).  
 
Although there was no requirement for piloting the questionnaires, as they are 
validated among Arabic patients with type 2 diabetes, and could not be modified, the 
researcher administered both of the questionnaires during the pilot period.  
 
3.4.3 Review of patients’ records 
Reviewing medical records of patients was one of the employed methods in this 
study to record the participants’ HbA1c levels. This measure is the most commonly 
used to predict blood glucose control over the previous 2-3 months, in patients with 
diabetes and is an indicator of the disease severity level (Nathan et al., 2007; 
Herman and Cohen 2012). The aim of obtaining such data was to assess the 
participants’ adherence to medicines and to relate it to qualitative data as a method 
of triangulation and to put clinical change into the context of participants’ 
experiences. The effective use of medicines is associated with low HbA1c levels 
(Hill-Briggs, 2005; Cohen et al., 2010). Thus, if a patient has a good adherence, it is 
more likely that his/her HbA1c level is within normal ranges (53 mmol/mol; 7.0%) 
(NICE Guideline 28, 2015). Whereas high HbA1c level can be a predictor of 
medication non-adherence. This also allowed the researcher to examine the 
disease progression for patients using different treatment options and assisted in 
identifying the most clinically effective method in managing this population, and 
recommending suggestions for improving health outcomes.  
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Accordingly, for all patients who consented to participate in this study, medical 
records were reviewed and HbA1c levels were obtained. The practice in Kuwait is to 
measure HbA1c levels for patients with type 2 diabetes every 2-3 months. In this 
study, the researcher obtained the latest three HbA1c readings recorded in each 
participant’s note. Other clinical information, such as blood glucose level, BMI and 
smoking status were also collected and recorded along with HbA1c levels in an 
information sheet prepared by the researcher (Appendix 12). These data were 
used to compare clinical characteristics of participants with information obtained 
from interviews regarding the participants’ health behaviours, to aid in data analysis. 
The collection of clinical data was undertaken solely by the researcher. After 
conducting the interviews, the researcher visited the clinic and obtained participants’ 
medical notes, with the cooperation of the clinic nurse.  
 
3.4.4 Translation of data collection instruments   
Since the interview schedules were developed in English to facilitate the discussions 
with the research team, but would be administered among Arabic-speaking 
populations, as Arabic is the native language in Kuwait, translation was necessary. 
However, this did not affect the fluency of the research or the quality of the collected 
information because Arabic is also the native language of the principal researcher, 
who was able to collect data herself without the need of a translator. Accordingly, 
before commencing data collection, the interview schedules were translated into 
Arabic to ensure the fluency and the interpretation of the interviews by the 
participants.  
 
Different translation methods may be adopted, but the challenge is to produce a 
comprehensible translated tool that is as close to the original instrument as possible 
(Esposito, 2001). In this study, parallel blind technique was applied. This method 
involves the translating of the instrument to the target language by two translators 
independently, comparing with each other, looking for any discrepancies and then 
agreeing on one version (Hambleton and Patsula, 1998). Because the method 
requires translators to work in parallel, it is practical, fast and has the advantage of 
acquiring an accurate translation. Therefore, the interview schedules were 
translated from English to Arabic by the main researcher, who is from Kuwait. The 
assistance of an academic bilingual professional, who is a Kuwaiti Professor (A.A) in 
the Public Authority for Applied Education and Training, and competent in the 
Kuwaiti language and culture as a native speaker, was sought. Then, the two 
translators met to agree on the translated version. Some discrepancies were noted 
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and resolved through discussions. This practicality would not have been achieved if 
other methods of translation, such as back-translation, which is time-consuming and 
has several limitations, were adopted (Behling and Law, 2000).  
For the other used instruments (MMAS and BMQ), the author (Professor Morisky) 
provided the researcher with an Arabic version for a charge of $210 for MMAS. For 
BMQ, the researcher used a previously translated version, which was employed 
within the same culture and was permitted by the author (Professor Rob Horne).  
 
3.5 Data protection and ethics approval  
Ethical issues were considered in this study, and the data collected were handled 
confidentially, coded, anonymised and only the researcher had access during the 
study period. Hand-notes of the interviews and questionnaires were kept in a folder 
by the researcher. Data were typed using the researcher computer, which was 
password protected, and saved on a secure memory stick. The data collected were 
only shown to the academic supervisors, to facilitate the analysis process and 
discussions of the study findings. All the collected data have been kept locked at all 
times in a designated cabinet for this purpose for the whole study period, and will be 
destroyed once the project is accomplished.  
  
3.5.1 Application for ethics approval 
An application was completed and handed to the UCL Research Ethics Committee 
on 20th December 2013. An ethics approval letter was e-mailed to the researcher on 
9th January 2014 (Appendix 13). In addition, the study protocol and all required 
documents, e.g. the interview topic guide, questionnaires, invitation letter and the 
consent form were prepared and an application form was completed by the 
researcher, and handed to the Standing Committee for Coordination of Health and 
Medical Research, MOH, State of Kuwait on the 29th December 2013. An approval 
letter for commencing the study was received on the 3rd February 2014 (Appendix 
14).  
  
3.5.2 Permission to use the questionnaires  
Complying copyright restrictions, permission for using the questionnaires was 
sought. The researcher sent e-mails to the questionnaires’ authors, an agreement 
form was signed and use of the BMQ was granted free of charge from Professor 
Rob Horne, Centre of Behavioural Medicine, School of Pharmacy. Permission to the 
use of MMAS was granted by Professor Donald Morisky, Department of Community 
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Health Sciences, UCLA Fielding School of Public Health, and an agreement form 
was signed by the researcher and the author (Appendix 15). 
 
3.6 Data processing and analysis  
Prior to commencing the analytical procedures, all the interviews (53 transcripts; 43 
for patients, and 10 for HCPs), which were recorded using Olympus Digital Voice 
Recorder WS-831, were downloaded onto the researcher’s computer using the USB 
memory stick of the recorder and organised in files according to the date of the 
interview. Due to the need for confidentiality and data protection, the data were 
anonymised and the files were saved with numbers, indicating the order in which the 
interviews were conducted, followed by a description of the treatment regimen or the 
speciality of the HCP. For example, a description of OHAs was related to patients 
using OHAs only, while patients using insulin, whether alone or with OHAs were 
described by their insulin delivery method. This allowed the researcher to analyse 
interviews of patients using insulin devices separately from those who did not use 
devices and enabled comparisons to be made. Then, the researcher transcribed all 
the recorded data verbatim in Arabic. Field notes taken including facial expressions, 
emotions, interruptions, additions outside the interview period and the presence of 
other individuals and their contribution, were all inserted into the interview 
transcripts. This was to ensure the inclusion of all the relevant information that might 
aid in data analysis. In order to ensure the accuracy of data and that all the 
information were included, the researcher re-listened to the audio-recorded tapes. 
Then, the transcripts were typed using Microsoft Word.  
 
As recommended by Liamputtong (2009), Computer Assisted Qualitative Data 
Analysis Software (CAQDAS) is helpful to make data processing and analysis 
faster. It is particularly helpful for large volumes of data and beneficial for 
constructing, categorising and storing data in a way that allows it to be managed 
and accessed easily and rapidly (Burnard et al., 2008; Gale et al., 2013). In this 
study, the MAXQDA-11 software was chosen because it allowed the researcher to 
collect, organise and analyse content from interviews in Arabic, in a flexible manner, 
and is available for students at a reduced price. This software creates easy to read 
reports and visualisations by: coding segments of text, forming categories and 
storing data in an organised form, which was easy for searching and retrieval. It also 
counts the frequencies of words/phrases to enable the researcher to draw up 
conclusions and search for associations between and within the interviews. In 
addition, using such software enables the researcher to add memos to the coding 
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system for clarification. All of the transcripts were imported into MAXQDA-11 and 
organised in a way that each data unit indicated a case/interview. Interviews were 
presented in the ‘document system’ arranged by number, from patient 1 to patient 
43 and the treatment regimen, e.g. patient 1 (insulin pen), and from HCP 1 to HCP 
10 and the speciality of the HCP, e.g. HCP 1 (physician).  
 
In order to answer the research questions: In what ways did health beliefs impact 
participants’ health behaviour? What were the advantages/problems of using 
technology in the management of type 2 diabetes? Did insulin pens/pumps have a 
role in improving participants’ management behaviours? What are the barriers to 
service development and improvement of health outcomes from the perspectives of 
HCPs? It was essential to adopt a systematic approach. There are different types of 
data analysis approaches that could be employed, basically, deductive and 
inductive approaches. Deductive approach depends on using a structure of a pre-
determined framework to analyse data, while the inductive approach depends on 
little or no pre-determined framework, and relies upon the actual data to derive the 
structure of analysis (Burnard et al., 2008). Although it is labour-intensive and time-
consuming, the inductive approach is commonly used in qualitative data analysis 
and was used in this study.  
 
One of the inductive approaches is the Framework Method or ‘thematic framework’, 
which is a matrix-based method that provides an instinctively systematic analysis of 
summarised data, arising out of grounded theory, and is the most common method 
of qualitative data analysis (Smith and Firth, 2011; Gale et al., 2013). The 
Framework Method has become a popular approach in qualitative pharmacy 
practice research (Harding and Taylor, 2016). The matrix output of this approach 
provided a structure, which helped the researcher to reduce data and analyse it by 
codes/themes. Also, it allowed comparison between data across cases as well as 
within individual ones (Gale et al., 2013). Therefore, the researcher commenced the 
thematic analytical procedures in three main stages: data management, data 
description, and data interpretation and explanation (Figure 3.2). 
 
 
 
 
 
Chapter 3: Methodology 
 
 
                             Analysis of research questions: 
 
                                                        
 
 
  
 
 
                                        
                                    
                                    Organisation of data 
                                                                                                                         
                                                            
                                                   
 
 
Figure 3.2: The steps undertaken for the analysis of the interview data 
 
3.6.1 Data management  
Due to the extensive amount of data collected, it was essential to undertake some 
organisational steps, in order to reduce the data and make it more manageable 
before describing and explaining it. This stage served as a systematic sifting of data. 
Therefore, a sample of 8 interviews (interviews with patients using insulin pumps) 
was selected (by activating the interview files in the ‘document system’), to ensure 
selecting a representative sample and carrying out the required analytical 
procedures that cover all the study objectives. Then, those transcripts were 
repeatedly read (from the ‘document browser’) to define recurring themes, and the 
interview texts were primary coded (by initiating codes in the ‘code system’ and 
relating each code to its relevant texts). An example of a coded transcript is shown 
in Appendix 16. Generation of themes/sub-themes involved labelling textual data, 
which could be a word, phrase, sentence or paragraph, for the purpose of 
summarising what is being said in the text, which describes and explains these data. 
This process facilitated the retrieval and analysis of data, and helped in organising it 
according to patients’ views and experiences within the context of their priorities and 
concerns.  
 
Explanatory 
accounts 
Descriptive 
accounts 
Data 
management
Raw data 
          -What were the common health beliefs among this population? 
          -How these beliefs affected patients’ management behaviours?  
          -What were the advantages/problems of insulin pens and 
           pumps? 
          -Did insulin pen/pumps improve patients’ health behaviour? 
          -What are the perspectives of HCPs on identified issues? 
          -What are the barriers to service development and 
           improvement of health outcomes? 
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In this study, coding started during the data collection period. When the pilot study 
was conducted with the first seven interviews, the researcher did a preliminary 
analysis, which informed subsequent data collection, by which the interview 
schedule was modified depending on the findings and the issues that emerged from 
the interviews. The analysis was continued after conducting all the interviews. As 
the process of coding throughout the interviews continued, new sub-codes were 
added. Therefore, by identifying further themes/sub-themes, a conceptual 
framework was developed and was applied to the whole data set, where relevant. 
For example, taking the sample of patients using insulin pumps, to achieve 
objectives 1 to 4 (Section 2.6), the thematic analysis in Table 3.3 was undertaken.  
 
However, it is worth noting that the process of coding was performed by two 
analysts; the principal researcher and other competent persons (F.A, an assistant 
professor and A.A, a diabetologist), discrepancies were then resolved through 
discussions. In addition, it should be noted that analysis of data was performed in 
Arabic, the language in which it were collected. Data were analysed in Arabic to 
avoid limitations, as the participants used culturally bound words, where if 
translated, the meaning might be affected (van Nes et al., 2010). Then, findings 
were translated into English to facilitate their discussions with the research team. 
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Table 3.3: The conceptual thematic framework/codes and sub-codes 
No. Code/sub-code 
1 
 
Impact of beliefs/culture on medicine-taking behaviour  
-Beliefs about the disease 
• Beliefs about seriousness 
• Locus of control 
-Beliefs about medicines 
• Beliefs about benefits 
• Beliefs about brands 
• Beliefs about herbal medicines  
-Perceived barriers  
• Fear of hypoglycaemia  
• Ramadan fasting 
• Adverse reactions (e.g. stomach pain, nausea, dizziness)  
-Beliefs about ability to control the disease (self-efficacy) 
2 Satisfaction & Quality of life with pump  
- The operating of the pump  
- Practicability and portability  
- Glycaemic control 
- SMBG  
- Awareness of hypoglycaemia  
- Hospital admissions  
- Hypo- and hyperglycaemic attacks 
- Infection/irritation/swelling/bruising at cannula-site  
- Pain 
- Weight gain  
- Mechanical problems  
3 Life activities with pump  
- Sleeping  
- Practising sport  
- Wearing clothes 
4 Impact of pump on social life  
- Initial worries  
- Independency/help needed  
- Embarrassment 
- Confidence  
5 Other management responsibilities  
-Diet 
• Nutritional awareness 
• Perceived benefits  
• Perceived barriers (e.g. social gatherings, lack of support, food 
cravings) 
-Exercise  
• Lack of awareness  
• Perceived barriers (e.g. lack of time, hot weather, lack of 
support) 
 
The priority in the construction of the thematic framework was derived by 
consideration of the original research objectives introduced in the topic guide. From 
the interviews with patients using insulin pumps, 5 major codes/themes were 
created. The origins from which the codes were created can be shown in Table 3.4. 
As recommended by Smith (1999), an iterative approach was considered, in which a 
constant comparison method was used throughout the analysis process. This was 
achieved by revising data each time a new code/sub-code was added. Therefore, all 
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the interviews were revisited after primary coding, and inspected for the relevance of 
these codes, until no additional codes/themes could be developed. This was 
achieved when no new issues emerged from the data set, e.g. the saturation level 
had been reached. This means that the analysis was not a linear process, and the 
researcher kept moving back and forth between the original and synthesised data 
searching for new issues, and further explaining data.  
 
Table 3.4: The origin of the codes/sub-codes*  
No. Code Origin  
1  
Impact of beliefs/culture on medicine-taking 
behaviour 
Study’s aims and objectives 
     and 
Preliminary fieldwork 
and 
Literature review 
2 Satisfaction & quality of life with pump  Study’s aim and objectives 
3 Life activities with pump Interviews  
4 Impact of pump on social life Study’s aim and objectives 
*Sub-codes were mostly generated from issues raised by participants during the interviews  
 
To achieve objective 5 (Section 2.6), which was related to the perspectives of 
HCPs, an initial framework was established using the topic guide; this was extended 
as themes emerged from the interview transcripts. For instance, when analysing the 
interview transcripts, the following codes were firstly allocated ‘facilitator’ and 
‘barrier’. Then, these were subdivided into themes and sub-themes. Themes under 
‘facilitator’ code described the views of the HCPs about the factors that facilitate the 
implementation of a particular intervention, e.g. ‘competent staff’. Themes under the 
‘barrier’ code described the perspectives of HCPs about the barriers of applying 
such intervention, e.g. ‘lack of support’, ‘lack of staff’ and ‘lack of time’. The origins 
from which the themes and sub-themes were created were the study objectives 
(objective 5) and the interviews with the HCPs. A detailed description for the 
emergent themes and sub-themes is provided in Chapter 8. 
 
3.6.2 Data description 
Because the data set collected was relatively large (n=43), further rationalisation 
was required to present data in a clear manner. In this stage, different groups of 
participants were organised to facilitate the comparison and association between 
views and experiences of these groups. For instance, for the selected interviews, 
the following groups were organised: those who achieved glycaemic control 
promptly following pump use and those who did not, those who had improved 
adherence and those who had not, and those who gained weight and those who did 
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not. At this stage, the researcher examined each theme across all the interviews, 
and checked for views that were labelled under that theme, to help gain a picture of 
the issues related to that particular theme across all cases, which was central to 
meeting the study objectives. This was applied to all the 5 themes created for the 
selected interviews (Table 3.3). By looking for overlapping, data could be 
condensed. Condensing data aided in concentrating on the important issues for the 
next stage of analysis.  
 
3.6.3 Data interpretation and explanation  
At this stage, deeper analysis to the descriptive data was undertaken. It involved an 
interpretation of the data by providing explanations (answering ‘why’ and ‘how’ 
questions) and relating findings to a theoretical framework. As will be shown in the 
results (Chapter 5), the HBM was used to determine the association between health 
beliefs and behaviour, and to identify the most influential determinants of behaviour, 
in order to inform educational interventions that address specific beliefs. This was 
achieved by looking for associations repeated across the data set or within a 
particular group of participants.  
 
Using such methods for data analysis enabled the researcher to answer the 
research questions (what were the beliefs of patients with type 2 diabetes and how 
those beliefs influenced the management of this disease? what was the role of 
insulin devices in the management of the disease? and what was recommended by 
different HCPs to develop services and improve health outcomes?) and making 
recommendations to improve the disease management and health outcomes. The 
data obtained reflect the aim and objectives of this study.  
 
3.7 Validity and reliability of the data 
To ensure that data processing and analysis are rigorous, it is important to consider 
validity and reliability issues. This section discusses the validity and reliability of this 
study in relation to aspects of conduct of interviews and data processing and 
analysis.  
 
Several steps were undertaken to ensure the validity and reliability of the results. 
Validity represents the extent to which the study findings truly interpret the issue 
being examined, while the reliability indicates the extent to which the results are 
reproducible (Smith, 2002; Smith, 2005). Although the researcher used a semi-
structured interview schedule, which allowed participants to explain issues and 
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views related to medicine/device use without adhering to a definite structure, the 
schedule served to illuminate the participants’ views regarding the relevant issues 
without influencing their responses. In addition, triangulation was employed in this 
study by using more than one data source (interviews, questionnaires and HbA1c 
measures), and findings from qualitative data (interviews) regarding health 
behaviour and factors affecting on it, were considered in conjunction with the 
quantitative data (MMAS, BMQ and HbA1c measures). 
 
Steps undertaken to ensure the validity of the findings of this study were:  
• Developing the interview schedule after conducting the literature review and the 
preliminary fieldwork, which ensured that all relevant issues about the 
investigated phenomena and Kuwait’s culture were covered. Also, leading 
questions, which may influence the participants’ responses, were avoided by 
selecting the appropriate wording.  
• Reviewing the interview schedule several times with the research team and 
modifying it accordingly.  
• Attending courses and workshops on conducting qualitative research and 
improving interviewing skills, and reading books on interviewing techniques. 
• Conducting the interviews and obtaining clinical measures alone, which 
minimised the variability if two researchers were involved in the process.  
• Testing the translated instrument in a group of the target language speakers 
(relatives of the researcher who have type 2 diabetes) to determine their 
understanding about the translated items, in order to improve the quality of the 
translation (Behling and Law, 2000), and during the pilot period, in order to 
ensure its consistency and appropriateness for use within Kuwait’s culture. 
• Undertaking a pilot period (after conducting the first seven interviews with 
patients and the first two interviews with HCPs), the researcher revised the 
interview schedules and introduced some modifications. This step ensured the 
applicability and reproducibility of the schedule.  
• Audio-recording and transcribing data verbatim, to assist in data analysis.  
• Reading books and journal articles on qualitative data analysis and undertaking 
appropriate training on the use of computer software for data analysis. 
• Using a Framework Method approach and the latest version of the computer 
software (MAXQDA-11) in data analysis, which helped in making the process 
more systematic and comprehensive.   
• Analysing data in Arabic, the language in which data were collected. Then, 
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findings were translated into English to facilitate discussions with the research 
team.   
• The analysis process was undertaken under the supervision of the research 
supervisors in UCL (F.S and K.T), who have experience in health services 
research. This peer review process reduces the potential of lone researcher 
bias.  
• Generation of codes/sub-codes was performed by three analysts separately, the 
principal researcher, a professor assistant (F.A) and a diabetologist (A.A). Then, 
comparisons and discussions on the generated codes were mad. 
• In some cases, where participants couldn’t give direct explanations regarding 
their behaviour, the researcher did some systematic interpretations across all 
cases.  
• Comparing the findings with previous studies (cumulative validity), and 
explaining conflicting responses (argumentative validity).  
• Employing a validated translation method for data collection instruments and 
during data processing and analysis.   
• Explaining in details the procedures followed in data collection and analysis, so 
that; the reader could critically examine the value of the study. 
 
As described in Section 3.3.1, the main five hospitals were chosen as the settings 
for conducting this study. This enabled the recruitment of participants from different 
demographic and clinical characteristics (e.g. age, gender, education level, 
employment status, marital status, duration of the disease, treatment regimen, 
complications and co-morbidities). In addition, the researcher undertook measures 
to ensure the reliability of the data obtained, such as: 
• Conducting all the data collection alone, which ensured the consistency of the 
procedures undertaken. For example, the same order was followed for all 
interviews, starting with briefly explaining the aim of the study, signing the 
consent form, asking the interview questions and ending with the questionnaires.  
• Using a notebook to record all issues encountered during data collection to help 
in the development of procedures in the subsequent interviews.  
• Obtaining the clinical data from medical records alone, which ensured the 
consistency of data obtained.  
• The instruments chosen (MMAS-8 and BMQ-S) had shown good reliability in 
similar study sample. 
Sample characteristics and response rate are described in (Chapter 4). 
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Chapter 4: Response rate and sample characteristics 
 
This chapter describes the response rate and the characteristics of the participants 
(patients and HCPs) included in this study. Characteristics of the patients include 
their demographic and clinical information and characteristics of HCPs include their 
speciality and working area. The chapter also explains reasons for non-participation 
and the details of the conducted interviews.   
 
4.1 Response rate and characteristics of the participants  
 
4.1.1 Characteristics of patients  
Seventy patients using OHAs and/or insulin injections/pens were approached by the 
researcher during their clinical visits and invited to take part in the study. All patients 
responded directly (response rate 100%), from which 35 agreed to participate and 
were subsequently interviewed (participant rate 50%), while 35 refused to 
participate (non-participant rate 50%). For patients using insulin pumps, of the 15 
patients who were called by the researcher and invited to take part in the study, 12 
responded directly (response rate 80%). From those who responded, 8 agreed to 
participate (participant rate 53%). Patients who did not respond to ?????????????????
phone call numbered 3 and those who refused to participate were 4 (non-participant 
rate 47%). As a consequence, the total response rate of all participants in the study 
was 97%, participation rate was 51% and non-participation rate was 49%. Reasons 
for non-participation are shown in Section 4.2, Table 4.4. The data collection 
process was terminated when a saturation level of the collected data was achieved; 
this was reached with 43 patients. 
 
Overall, a mixture of participants using different treatment regimens for the 
management of type 2 diabetes was achieved (Table 4.1). Demographic and clinical 
information obtained from medical notes and during the interviews were collected for 
patients who consented to take part and participated in the study (Table 4.2). Anti-
diabetic medications (oral and insulin injection/pen/pump) used in the management 
of type 2 diabetes by the participants are shown in (Table 4.3).  
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Table 4.1: Number of patients using each treatment option (n=43) 
Treatment option Number of patients (%) 
OHA only 9 (21) 
Insulin traditional injection +/- OHA 8 (18.5) 
Insulin pen +/- OHA 18 (42) 
Insulin pump +/- OHA 8 (18.5) 
 
 
Table 4.2: Characteristics of the participants  (n=43) 
Variable Frequency 
Mean age (years) 53  
Sex 
Male  
Female  
 
11 
32 
Ethnicity  
White  
Non white  
 
40 
3 
Nationality  
Kuwaiti  
Non-Kuwaiti  
 
36 
7 
Activity  
Employed  
Retired  
Housewife  
Student  
 
12 
14 
15 
2 
Education 
???????????????????? 
Primary school 
Secondary school  
Diploma  
University  
Postgraduate  
 
3 
13 
5 
8 
12 
2 
Area of residence  
Urban  
Rural 
 
21 
22 
Duration of disease  
1-10 years 
11-20 years 
>20 years  
 
17 
14 
12 
Number of current anti-diabetic and diabetes related 
medications (e.g. Aspirin, Statin) 
< 4 medicines  
> 4 medicines  
 
 
19 
24 
Smoking  
Smoker  
Ex-smoker  
Non-smoker 
 
6 
4 
33 
Mean BMI (ranged from 19.9 to 46.9 kg/m2) 33.5  
Mean HbA1c level 
<7.5 
>7.5 
NA 
8% 
18 
24 
1 
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Table 4.3: Details of medicines/devices used in the management of type 2 diabetes 
by the participants  
 
Route of drug administration Frequency (number of 
patients) 
Oral anti-diabetic medication  
 
8 
7 
12 
Metformin  
500 mg  
850 mg  
1000 mg  
Sitagliptin 100 mg  10 
Glimepiride  
1 mg  
2 mg 
3 mg 
 
3 
3 
1 
Gliclazide  
30 mg  
80 mg 
 
2 
2 
Acarbose 50 mg  1 
Pioglitazone 15 mg  1 
Insulin injection  
ActrapidR 1 
NovoRapidR 2 
LantusR 1 
InsultardR 1 
NovoMixR30 4 
HumalogRMix50 1 
MixtardR 1 
Insulin pen  
ActrapidR 2 
NovoRapidR 6 
LevemirR 1 
LantusR 16 
NovoMixR30 2 
HumalogR Mix25  4 
Insulin pump  
NovoRapidR 8 
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4.1.2 Characteristics of the HCPs 
All the approached HCPs responded directly and agreed to participate except one 
who did not reply (n=10; response rate 91%). The speciality of each HCP and their 
working areas/departments are shown in Chapter 3, Section 3.3.3, Table 3.2.  
 
4.2 Characteristics of non-participants  
Of the 42 patients who did not participate in the study, 29 were females and 10 were 
males (the ratio of non-participants females to males is approximately similar to that 
of participant females to males, 32 females and 11 males). The most common 
reason for non-participating given verbally by women was pending housework 
(n=20). 75% of the participants were females; most of them (24/32, three-quarter) 
were either housewives or retired, and they do housework themselves based on 
reports from the interviews. The next most common reason given by most non-
participation by women was not having a car and not being willing to make a driver 
or accompanying person wait for a long time while they participated (n=11). 
However, based on the characteristics of non-participants, there is no evidence of 
response bias. For those who did not respond (1 female and 2 males) to the 
res?????????? ?????? ??????? ???????? repeated calls at different times of the day, no 
information was obtained. Other reasons for non-participating are included in Table 
4.4.  
 
Table 4.4: Reasons for non-participating  
Reason Frequency (number of 
patients) 
Pending housework  20 
Not having a car  11 
Other hospital appointments  10 
Feels unwell (age, disability, tiredness) 6 
Going back to work/university 5 
Social circumstances (problems, death) 2 
Bringing grand daughter from school  2 
Time constraints  2 
Travel 1 
No reason given  1 
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4.3 Details of the interviews   
 
4.3.1 Interviews with patients  
As preferred by patients, who were approached during their clinical visits, the 
interviews were conducted in the hospital. For patients who were called by the 
researcher, the interviews were conducted in coffee shops as planned with the 
patients, only one interview was conducted in ???? ?????????? ?????? ???????? the 
importance of privacy in interviewing, in some cases the patients were 
accompanied by one of their family members, e.g. son, daughter, mother or 
husband. In such cases, no interrupted interactions were recorded; this was 
because in some cases (n=6), the accompanied persons were waiting outside the 
interviewing area. However, in cases (n=6) where the family member presented 
with the patient during the interview, the researcher was very careful to direct all the 
questions to the patients themselves and keep eye contacts with them only. 
However, in two cases, when the researcher asked question 19, which was about 
the needed services/problems, interventions from family members were recorded. 
This was because those members were accompanying the patients to all their 
appointments; thus, they felt that they had a valid contribution to answering that 
question. For example, in one case, a husband raised a problem that they 
perceive?? ???? ????????? ?? ???????????? ???? ???????? ??????? ????? ???? ??????????
suggestion and expressed her concern regarding that issue. In another case, a 
daughter interrupted at the same question but the patient gave no response. The 
researcher waited till the daughter finished, took her point of view into consideration 
and repeated the question to the patient in a way that asked for any additions, (e.g. 
would you like to add something else?) but the patient did not add anything and 
?????????????????????????????????n.  
 
Being accompanied with other persons was considered helpful to the study, as they 
provided reminders to the patients, especially when patients had difficulty in 
remembering an event. Generally, the conduct of the interviews went smoothly, the 
participants were pleasant to participate and talked about their disease, medicines 
and problems freely, and the interviews were interactive in most cases. However, in 
nine cases, the interview was paused briefly because patients were: called to 
collect their prescriptions from the pharmacy (n=3), called to see the consultant 
(n=2), and received phone calls during the interview (n=4). In such cases, the 
researcher switched off the audio-recorder, waited till the patient finished, and then 
completed the interview with audio-recording.  
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Overall, data needed to achieve study objectives were obtained from all the 
interviews with patients. The time required to complete the interviews with patients 
varied depending on what the patient said (the average time was 32 minutes and 18 
seconds). The shortest interview lasted for 20 minutes and 20 seconds, while the 
longest lasted for 51 minutes and 36 seconds. Patients using insulin device 
(pen/pump) required more time, as they were asked more questions than patients 
who were not using such devices. In one interview, the recorder stopped due to 
dead batteries, and the researcher used her mobile phone as a voice recorder 
instead.  
 
At the end of each interview, the questionnaires (MMAS-8 and BMQ-Specific) were 
administered to the patient (response rate 100%). The average time required to 
complete both of the questionnaires was 8 minutes (range 4 to 12 minutes). The 
completion rate was 100%, with no missing item in any of these tools in all cases. 
Overall, there were no difficulties in responding to the items of the questionnaires. 
Some demographic and clinical data were recorded by the researcher during the 
interviews, and some were collected from medical notes very soon after ending the 
interview with each patient.  
 
4.3.2 Interviews with HCPs  
The interviews with the HCPs (n=10) ????? ?????????? ??? ???? ??????
clinic/department, except three, which were conducted by telephone. Generally, 
HCPs were happy to collaborate, provide their recommendations, and to be 
interviewed and audio-recorded. The time required to complete the interviews with 
HCPs varied from 9 minutes 29 seconds to 21 minutes 31 seconds (the average 
time was 14 minutes and 22 seconds).  
 
The next four chapters include the analysis of the interview transcripts of those who 
participated in this study, and explain the results obtained from both patients and 
HCPs. Chapters 5, 6, and 7 include the results obtained from interviews with 
patients and Chapter 8 ???????????????????????????????????????????????? 
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Chapter 5: Medication adherence, health beliefs and the management of type 
2 diabetes 
 
The aim of this chapter is to estimate the level of non-adherence among patients 
with type 2 diabetes living in Kuwait, using direct self-report methods (e.g. MMAS-8, 
and semi-structured interviews) and a clinical measure (HbA1c levels). In addition, 
the chapter describes the health beliefs of the participants and how these beliefs 
along with cultural factors impacted the management of type 2 diabetes. This is to 
identify the factors that contributed to poor health outcomes by showing the ways in 
which health beliefs and culture affected the management behaviour (e.g. medicine-
taking behaviour, SMBG and lifestyle) of the participants and consequently to 
support or disapprove the hypothesis that health awareness, beliefs and culture 
have an impact on the management behaviour of patients with type 2 diabetes.  
 
5.1 Results of MMAS-8  
Assessment of non-adherence using MMAS was based on instructions provided 
from the author of the instrument. ??????????????????????????????????????????????????
was based on the total MMAS score, and ranged between low (MMAS score<6), 
medium (MMAS score 6 to <8) and high (MMAS score=8). The scores were 
calculated as follows: responses relating to items 1-7 were either (Yes), which 
denotes (0) score or (No), which denotes (1) score, with the exception of question 5, 
where a positive response equals 1. Responses to the last item were related to a 5-
point Likert scale (never/rarely=4, once in a while=3, sometimes=2, usually=1, and 
always=0). Item 8 was standardised by dividing the code by 4, in order to result in a 
scale ranging from 0-8. The participant?? responses to individual items of MMAS and 
their total MMAS scores are shown in Appendix 17 and 18 respectively. Calculating 
total MMAS scores for the study participants revealed that 17, 15 and 11 
participants achieved a MMAS score of 8, 6 to <8 and <6 respectively. This means 
that 17 (40%), 15 (35%) and 11 (25%) participants had high, medium and low 
adherence level respectively (Figure 5.1). Some authors who used MMAS in their 
studies categorised patients who achieved low and medium adherence levels as low 
or poor adherents, and only those who achieved a MMAS total score of 8 as 
adherents (AlHewiti, 2014). Other authors considered participants who achieved a 
total MMAS score of 6 to 8 as adherents, and those who had a total MMAS score of 
<6 as non-adherents (Sweileh et al., 2014).  
Chapter 5: Medication adherence, health beliefs and the management of type 2 diabetes  
 
 
Figure 5.1: Adherence levels of the participants based on their MMAS scores 
 
5.2 Adherence based on HbA1c level  
As outlined in Chapter 3, Section 3.2.4, HbA1c levels can be used as a means of 
??????????????????? adherence to their treatments. However, this measure cannot be 
the sole method for detecting non-adherence due to the possible impact of other 
factors on the results, such as chronic liver disease, chronic renal failure, 
rheumatoid arthritis and the administration of some drugs, such as aspirin, iron and 
vitamin B12 (WHO, 2011). The researcher obtained levels of HbA1c from the 
?????????????????????? ??????? ?????????? ?????? ????????? ??? ????? ????y was the mean 
value of the previous three recorded levels. The results revealed that 18 participants 
(43%) achieved target levels of HbA1c (<7.5%), 24 participants (57%) were above 
the target levels (>7.5%), and one participant had no valid result. Therefore, based 
on the clinical data, 18 participants (43%) had good adherence level, while 24 
participants (57%) had poor adherence level (Figure 5.2).  
 
 
Figure 5.2: The number of participants with poor/good adherence based on HbA1c 
level  
  
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5.3 Results of BMQ-S  
????????????????????????????anti-diabetic medications were assessed using the BMQ-
S. The scale is divided into two sub-scales: BMQ-necessity and BMQ-concern. The 
results were calculated using a 5-point Likert scale: 1 (strongly disagree), 2 
(disagree), 3 (uncertain), 4 (agree), and 5 (strongly agree). T??? ??????????????
responses to the individual items of the BMQ-subscales, and their frequency are 
shown in Appendix 19. 
 
Then, the scale scores were obtained by summing the individual item scores. The 
subscales score ranged from 5-25, the necessity-concern differential scores ranged 
from -20 to 20. Differential scores were obtained by subtracting the concern 
subscale score from the necessity subscale score, yielding to a positive, neutral, or 
negative score. T????????????????? ??????? ??????-S necessity and concern ranged 
from 5 to 25, and from -20 to 20 for the BMQ differential necessity-concern. 
Appendix 20 shows the scores of the participants. Positive score indicates that the 
participant perceives the benefits (necessity) of taking medicines to outweigh their 
risks (concern). Conversely, a negative score indicates that the participant perceives 
the risks (concern) of taking medicines to outweigh their benefits (necessity). In this 
study, 40 (93%), 2 (5%) and 1 (2%) participant achieved positive, negative and 
neutral differential score respectively (Figure 5.3). This means that the majority of 
the participants believed in the necessity of taking their medicines.  
 
 
Figure 5.3: The number of participants who achieved positive, negative and neutral 
BMQ differential necessity-concern scores  
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Chapter 5: Medication adherence, health beliefs and the management of type 2 diabetes  
 
5.4 Health beliefs based on semi-structured interviews 
The interview transcripts of the 43 participants were analysed using thematic 
analysis. Because patients used to construct models to interpret their disease and 
treatment, and this has been found to associate with treatment-related behaviour, 
such as adherence, it was crucial to explain the psychosocial factors of the 
participants (Dunning and Martin. 1998). Thus, it was decided to organise the 
?????????????? ???????? ???? ?????????? ???????????? ?????? ??? ???????????? ?????????? ???
facilitate the analysis of data and the generation of themes and sub-themes. Several 
theories have been used to explain ???? ???????????? ???????? ?????????? ??????????
such as medication adherence and their beliefs. Some of the most accepted 
theories are the self-regulation model, illness perception model, self-efficacy model 
and health belief model (Myers & Midence, 1998). In this study, the different beliefs 
that emerged during the semi-structured interviews were organised according to the 
HBM. The beliefs were about the disease, medicines, perceived barriers and self-
efficacy.  
 
5.4.1 Beliefs about the disease  
An analysis was undertaken to illustrate the beliefs of the participants about type 2 
diabetes. The results revealed different beliefs, ?????????????????????????????????????
??????????????????? ?????????????????????? 
 
5.4.1.1 Beliefs about the seriousness of type 2 diabetes  
During the semi-structured interviews, the participants were asked to provide their 
perceptions about type 2 diabetes. When analysing the interview transcripts, the 
following terms (mild, moderate and serious) were identified to assist in 
categorisa????? ??? ???? ?????????????? ???????????? ?????? ???? ????????? ??? ?????? ????????
(Dunning and Martin. 1998). The results revealed that 26 participants were aware 
about the seriousness of type 2 diabetes and that it could cause other complications 
such as retinopathy, neuropathy and nephropathy: 
?Many parts of the body can be affected by diabetes. A patient with diabetes may 
lose his kidneys and eyes. Also, it [diabetes] affects the extremities nerves, in 
which the risk of infections increases if the patient experiences wounds.? 
[Participant 8, male, age 55 years]  
  
?I have to do an operation for my eyes, it [diabetes] has affected them. I also 
know that high blood glucose levels can affect my kidneys.? 
[Participant 39, male, age 28 years]  
   
The remaining participants (n=17) believed that type 2 diabetes could affect their 
health and cause other complications, but it is not serious: 
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?Diabetes has become widespread, all Kuwaitis have diabetes, ???????????????????
????? ????? ????? ?????? ??????? ?? ? always feel lazy and tired. I have unusual 
numbness in my legs and hands and I often have headache. ????????think this is 
because of diabetes.? 
[Participant 17, female, age 37 years]  
 
?Diabetes is one of our characteristics, all Kuwaitis have it. I always try to forget 
?? ?? [diabetes] may cause nausea or hypoglycaemia.? 
[Participant 32, female, age 42 years]  
 
Of the 26 participants who perceived type 2 diabetes as a serious disease, 21 (81%) 
were using their medicines properly:  
?I always take my medicines as prescribed, even when I go outside or travel, I 
always carry my medicines in my bag. I worry from the progression of the 
?????????????????????????????[medicines] regularly.?  
[Participant 4, female, age 60 years]  
 
All the 17 participants, except 4 who perceived type 2 diabetes as not a serious 
disease did not adhere to their medicines:  
?The doctor prescribed me tablets [metformin 500 mg]?? ???? ?? ?????? ????? ?????
regularly. Sometimes, I get them and throw them away or give them to other 
patients.? 
[Participant 17, female, age 37 years] 
 
Reviewing the interview transcripts of the four participants who adhered to their 
medicines although they did not perceive diabetes as a serious disease revealed 
that another factor contributed to their adherence. The factor was social support; the 
participants received help from their family members in the administration of their 
doses. This may indicate that minimising the seriousness of type 2 diabetes is an 
important determinant of medicine-taking behaviour. This is because all the 
participants who perceived diabetes as not a serious disease did not adhere to their 
medicines except those who had an external factor (e.g. a family member who took 
the responsibility of doses administration) that might have impact on their decisions-
making:  
?I take my injection three times a day before meals. My daughter gives it to me.?  
[Participant 33, female, age 73 years] 
 
5.4.1.2 Locus of control 
During the interviews, some participants (n=7) raised some beliefs about type 2 
diabetes. For example, some believe that it is caused solely by God and that God 
has the power to cure them, others believe that stress elevates blood glucose levels 
even when taking medicines regularly:  
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?Sometimes when I feel stressed and nervous, my [blood] glucose [level] goes up 
even if I was taking my medicines as prescribed, and it remains high until I calm 
down.? 
[Participant 32, female, age 42 years] 
 
?Diabetes is from God, it suddenly affects the body without any warning. It has 
????????????????????????????????????????????????????????????????????????????? 
[Participant 43, female, age 28 years]   
 
???????????????????????????????????????????????????????????????????????????????????????
dependent on another power or factors (Norman et al., 1998). Internal locus of 
control is associated with adherence to diabetic regimens, while external locus of 
control indicates that the achievement of the goal is related to an external factor 
???????? ???? ????????????? control (Norman et al., 1998). In the current study, beliefs 
about God or stress locus of control were weak determinants of medicine-taking 
behaviour. All the seven participants except two (71%) who raised such kinds of 
beliefs were using their medicines properly despite their beliefs that God only has 
the control of their diabetes and that stress elevates their blood glucose levels even 
if they adhered to their medicines: 
???????? ????????????????????????????????????????????? ?? ???????????? ??????lly think 
about 60 things at the same time, in which I feel my [blood] glucose [level] 
??????????????????????????????????????????????????????????????ctions. He knows 
better about medicines and their actions.? 
[Participant 9, female, age 65 years]  
 
Examining the interview transcripts of the two participants who were not using their 
medicines as prescribed revealed that in addition to locus of control, there were 
several factors that might impact their adherence, such as minimising the 
seriousness of type 2 diabetes, disbelief in the benefits of medicines, low self-
efficacy and perceived side effects: 
?Diabetes comes from God; ????????????? ?????????? ?? [What do you think the 
future holds in terms of your disease?] ????????????????????????????????????????s 
help me; my [blood] glucose [level] ????? ???????????????????? [metformin 500 
mg tablet] causes stomach pain.?  
[Participant 2, female, age 65 years]  
 
5.4.2 Beliefs about medicines  
The interview transcripts were analysed to describ?? ???? ?????????????? ???????? ??????
their medicines. The emerged themes were beliefs about the benefits, beliefs about 
brands and beliefs about herbal medicines.  
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5.4.2.1 Beliefs about the benefits  
When participants were asked during the interviews about their beliefs regarding 
their diabetes medicines, whether they were helpful or not, most of them (n=27) 
believed that their medicines helped them in controlling their disease and 
maintaining glycaemic control: 
?Yes, medicines help me to control my disease.? 
[Participant 4, female, age 60 years]  
 
?Yes, medicines are helpful. I??????????????????????????????????????suffer.?  
[Participant 19, female, age 33 years]  
 
?Yes, thank Go????? ? ?????????????????????? ?????????????????????????.? 
[Participant 43, female, age 28 years]   
 
On the other hand, few participants (n=6) reported that they did not believe in the 
efficacy of their medicines because they were experiencing uncontrolled blood 
glucose levels even when they were taking their medicines regularly: 
????????? ????? that medicines help, or control my [blood] glucose [level]. ???? [blood 
glucose level] often high.?  
[Participant 22, female, age 64 years]  
 
One-fourth of the participants (n=10) were uncertain about the efficacy of their 
medicines. This was because they did not perceive the benefits of their medicines in 
reducing their blood glucose levels and maintaining glycaemic control at all times; 
however, they believed that they should take them for the benefit of their overall 
health:  
???????? feel that medicines are help me or control my [blood] glucose [level], yet I 
????????????????????????????????????????[medicines]?????????????????????????ive.? 
[Participant 16, male, age 47 years]  
  
??? ?????? ????? ???? [medicines] work. I always feel tired and the [blood] glucose 
[level] ??? ?? ?????????????????? ?? ?????? ??? much. However, I have to take them 
[medicines], they are medicines.? 
[Participant 25, female, age 58 years]    
 
Of the 27 participants who believed in the benefits of their medicines, more than half 
of them (n=17) were using their medicines regularly. This may indicate that beliefs in 
the benefits of medicines can be a crucial determinant of medicine-taking behaviour: 
?Yes, medicines help me to control [blood] glucose [level]. My blood tests 
[HbA1c] ???? ?? ???? ???????? ??? ???????? [medicines] ??????? In taking my 
??????????? ?? ??????? ???? ????????? ????????ions, even in travelling and holidays, it 
become my part of daily routine.? 
[Participant 3, female, age 56 years]  
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Examining the interview transcripts of the 10 remaining participants who were not 
using their medicines regularly despite their belief in their benefits revealed that the 
participants had other factors, which might affect their adherence, such as low self-
efficacy or other cultural factors such as social gatherings: 
?Of course medicines help, definitely they have ??????????? ?????? ??????? ????
???????????????ctions all the time, especially when travelling and in weekends. For 
example, when I g?? ??? ???? ??????? ????? ??? ????????? ?? ?????? ????? ???? ???????????
[Lantus and Actrapid; insulin pens], even the tablets [metformin 1000 mg]. I 
usually forget to carry them. Also, when ?? ? ???????? ????????????? ???????? ????????
medicines with me because ?? ?????? ?????? ????????? ???? ?? ??? ????? ?????????? ?? ?????
ignore the doses.?  
[Participant 10, male, age 58 years]   
 
On the other hand, of the 16 participants who did not believe in the benefits of 
medicines or were uncertain about them, 7 were not using their medicines properly. 
Nine participants adhered to their treatment despite their disbelief in its efficacy due 
to other factors, such as coping with the disease and the absence of side effects:  
??? ?????? ????? ??????????????? ???? ???????? ????? ?????drinking water [taking medicines 
has no effect on controlling blood glucose level], but I have to take them; ???????
life-?????????????? ???????????????????????????????????????????????????????????????
?????????????????????????????????????????????????problem with medicines.?  
[Participant 33, female, age 73 years]  
 
?Medicines are sometimes helpful, and sometimes not. When I feel stressed, my 
[blood] glucose [level] goes ?????  very careful in taking medicines regularly 
even in weekends and on ????????????????? with diabetes have to bear up with 
their disease; I already control myself to live with diabetes. I bought an ice-bag 
where I can put my insulin pens and carry them wherever I go so as to take my 
doses on time.?  
[Participant 36, female, age 51 years]  
 
5.4.2.2 Beliefs about brands  
One of the most interesting beliefs that were found in the current study was related 
to the industrialisation source of the medicine. Eleven participants (about a quarter 
of the study sample) raised some beliefs regarding the source of the medicine. 
Some of them perceived Western brands superior, more effective, and safer than 
local ones: 
?When I was in Egypt, my [diabetes] medicine ran out and I had to buy it there, 
?????????????????????????????????????? ays dizzy and tired. When I came back [to 
Kuwait], and got my Western medicines, I felt well immediately. I believe that 
local medicines are low quality.? 
[Participant 16, male, age 47 years]  
 
?Once, they [pharmacists] dispensed me a medicine from Saudi company. When 
I took it, it caused me a stomach pain and hypoglycaemia. T?????????? ?? ???????
medicines from Western sources.? 
[Participant 28, female, age 66 years] 
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Few participants (n=3) reported that they preferred to use the medicine from the 
same origin, which they were initiated on, regardless whether it was local or foreign: 
?Since my last administration to the hospital, they [pharmacists] dispensed me 
new tablets [metformin tablet 1000 mg]. Every time I told them this is not my 
?????????????????????????????????????? ?s from another company. Since then???? ???? 
feeling well and ?? ?always tired. I prefer to use my old tablets.? 
[Participant 18, female, age 65 years]   
 
Although it has not been adequately discussed in the literature, other researchers 
have also reported some perceptions among patients with type 2 diabetes regarding 
the belief about the efficacy and safety of Western brands (Lawton et al., 2005). 
However, examining such beliefs among the participants in the current study 
revealed no impact on their medicine-taking behaviour. Although there were some 
participants who preferred using medicines from specific origin, e.g. Western, no 
one reported poor adherence as a consequence of not providing them with their 
preferred option: 
?I prefer to take medicines from Western companies, but if they [pharmacists] 
??????????????????????????? ??????????????????? ????? ????? ?????? ???????? ????????? ????
same result.?  
[Participant 8, male, age 55 years]  
 
5.4.2.3 Beliefs about herbal medicines 
There was a proportion of the study participants (n=22) who believed in the safety 
and/or efficacy of alternative medicines, e.g. herbals in treating type 2 diabetes and 
achieving glycaemic control. The participants perceived them safer than 
conventional (chemical) medicines, as they cause no adverse effects:  
?If herbals [medicines] ??????? ????? [reduce blood glucose level], they wouldn???
???????????????????????????????????????? 
[Participant 7, male, age 85]  
 
Of those 22 participants, 17 reported that they used herbal medicines in the 
management of their disease without consulting their doctors:  
?I feel that herbals are effective in treating diabetes, and safer than [chemical] 
medicines. I use a mixt???????????????? ?????????????????? names. I feel that they 
reduce my [blood] glucose [level].? 
[Participant 1, female, age 40 years]  
 
???????? ??????????????????????????????????[blood] glucose [levels]????????????????????
any harm to my stomach as Glucophage [metformin 500 mg tablet] doses.? 
[Participant 2, female, age 65 years] 
 
Of the 17 participants, 14 reported some barriers to continue using herbal medicines 
such as lack of perceived efficacy (n=10), complexity of preparation (n=3), 
unpleasant taste (n=3) and perceived side effects (n=2): 
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?I used a mixt???? ??? ????????? ?? ?????? ????? ????? names, but I used them for a 
month only. I couldn??? ????????? ???????? ??? ????? complex preparation. I had to 
soak them [the raw herbs] for two hours; there were too many bags with similar 
contents, which was confusing. Besides, the herbals had a bitter taste.? 
[Participant 36, female, age 51 years] 
 
However, examining the impact of the belief in the safety and efficacy of herbal 
medicines on medicine-taking behaviour ????????????????????????????????????rence to 
conventional medicines was affected at different times, e.g. at the beginning of the 
diagnosis or during the period of medical treatment. Some participants (n=11) 
started managing their disease with herbals, and after the failure in achieving 
glycaemic control, they decided to visit the doctor to commence the medical 
treatment:  
?I was diagnosed with diabetes, ????? ????? ??? ???? ???????? ??????? ???? ?????
[pharmacists] dispensed me ?????????????????????????????????????me. I used it for 
about years but I stopped it, because ??????????????? any benefit. Then, I went to 
the doctor and he told me that I have to commence [medical] treatment.? 
[Participant 24, male, age 58 years] 
 
Other participants (n=6) abstained from their medical treatment and used herbal 
medicines for a period of time. Again, when the herbal treatment failed to achieve 
glycaemic control, they returned to their medical treatment. From the above 
statements, it can be concluded that beliefs in herbal medicines led to poor 
management behaviours. Both behaviours were unacceptable and could lead to 
serious complications. Delaying the medical treatment or discontinuing it causes 
poor glycaemic control. Poor glycaemic control accelerates the progression of 
diabetes-related complications, and reduces the life expectancy and life quality of 
the patient (Goodall et al., 2009). Two participants reported that they complained 
from short-term complications, such as blurred vision because they stopped their 
medical treatment and used herbal medicines: 
?I have started using herbals 5 years after ?????? ??????????????? ?????????? ?????
been to the herb shop and the seller told me that I can ????????????????????????????
???? ??????? ???? ??? ??????????? ??????????? ???? ?????? ? ??????? ??????? ????? ????
week, I suffered from blurred vision, and felt as if there was fog in my eyes all the 
time?? ???????????????????????????????????????????????????? [herbal preparation] and 
returned to the [insulin] injections. I then felt OK.? 
[Participant 32, female, age 42 years] 
 
5.4.3 Perceived barriers and self-efficacy   
An analysis was undertaken to identify the barriers that were experienced by the 
participants, such as side effects and other general barriers, such as social 
gatherings and social stigma. An analysis was also undertaken to identify the 
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participants who had high and low self-efficacy about their ability to manage their 
disease.  
 
5.4.3.1 Fear of hypoglycaemia  
Hypoglycaemia occurs when blood glucose levels fall below 4 mmol/L. In this study, 
there was a common belief among some participants (n=14; one-third of the 
sample) regarding hypoglycaemia. The participants believed that if they missed their 
meal/snack or even had a light fat and sugar meal, such as portions of fruit, yogurt 
and salad, they would definitely get hypoglycaemia, without checking their blood 
glucose levels or experiencing any symptom. This kind of belief had an impact on 
???? ?????????????? medicine-taking behaviour. The participants reported omitting 
doses of insulin and/or OHAs as a consequence of this belief: 
?The doctor prescribed me Glucophage [metformin 500 mg tablet] three times a 
day but I take it once only. This is because I usually have coffee and biscuits in 
the morning and go to the gym. Also, at night I just have a light dinner, and have 
the Lantus [long-acting insulin] at bedtime. So, if I take it [metformin tablet] three 
?? ?????? ????????????? ??[blood] glucose [level] will fall down very much.? 
[Participant 5, male, age 67 years]  
   
?As for the Glucophage [metformin 500 mg tablet], I take it only twice instead of 
three times ?????? ???????? ?? ?????? ????????? ??? lunch. I sometimes cancel the 
Lantus [long-acting insulin], especially if I miss my dinner or just have an apple 
because I worry from getting hypoglycaemia while sleeping.? 
[Participant 23, female, age 72 years]  
 
?I take the rapid one [insulin; Novomix 30] at morning and afternoon, and the slow 
one [insulin; Lantus] at night. Sometimes, when I wake-up late and miss 
breakfast, I just cancel the morning dose.? 
[Participant 31, female, age 40 years]  
 
Hypoglycaemia is a common problem to patients using insulin, or some types of 
OHAs such as sulphonylureas, e.g. chlorpropamide and prandial glucose regulators, 
e.g. repaglinide. Patients using these treatments should monitor their blood glucose 
levels regularly to help adjust their doses. As for insulin-dependent patients, the 
appropriate dose and time for insulin administration depends on the individual 
response, food intake and physical activity. Omitting an insulin dose because of 
missing a meal without monitoring blood glucose level could lead to hyperglycaemia 
and uncontrolled blood glucose levels. Sometimes, blood glucose levels rise even 
when the patient has not eaten. For example, blood glucose levels can be high in 
the morning because of taking little insulin in the previous evening or due to Dawn 
Phenomenon, a state of increased blood glucose level in the morning due to 
secretion of specific hormones, such as cortisol, glucagon and epinephrine. 
Therefore, patients should use insulin in a way that suits their daily routine and is in 
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line with thei????????????????????????????????). In addition to ????????????????????ar of 
hypoglycaemia, they lacked the awareness about how their medicines work, where 
they had specific practices and behaviours that were inconsistent with ???????????????
recommendations. For instance, the participants neglected their long-acting insulin 
dose because they did not know that it should be taken to regulate their blood 
glucose levels for the next 24 hours, and that it was not related to food intake (ADA, 
2015). In addition, the participants did not take their metformin doses when they 
missed their meal or had light meals to avoid hypoglycaemia because they lacked 
the awareness that metformin does not cause hypoglycaemia, unless it was 
combined with insulin or another hypo-causing OHA (BNF, 2015). As a result, the 
participants were complaining from uncontrolled blood glucose levels: 
??? ??????? ????? ???? ??????? [long-acting insulin] yesterday because I slept without 
eating dinner, I woke-up this morning and it [blood glucose level] was high. When 
I took my breakfast, it increased.? 
[Participant 23, female, age 72 years]  
 
5.4.3.2 Ramadan fasting  
Twenty three participants (nearly half of the sample) reported that fasting during the 
day and reducing the number of meals from three to two daily, would expose them 
to hypoglycaemia regardless of the amount and type of food they had in their meals 
and snacks. The fear of hypoglycaemia during Ramadan fasting affected the 
?????????????? ????????-taking behaviour. Of the 43 participants, some (n=11) 
followed their docto???????????????????????????? Islamic instructions, which allow 
patients with chronic diseases, such as diabetes, not to fast in Ramadan and thus 
can take their doses as usual: 
?I use my medicines as usual i???????????????????????????????as I have to take 
insulin 5 times a day. The doctor insists that I should not fast since I am on 
insulin 3 times a day.?  
[Participant 9, female, age 65 years]  
 
The remaining 32 participants fast in ??????????????????????????????????????????????
advice about not fasting. The participants added that they had religious beliefs in the 
benefits of fasting in Ramadan on their overall health, since it is one of the five 
fundamental pillars of Islam. In Ramadan, people refrain from food and drinks from 
dawn to sunset, and the duration of fasting may range from 12 to 18 hours, which 
makes taking medicines challenging, especially for patients who require three doses 
or more per day (Meo and Hassan, 2015). Also, if doses of OHAs or insulin were not 
changed during Ramadan, severe hypoglycaemia could occur (Salti et al., 2004).  
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Therefore, patients with diabetes should consult their doctors about their medicine 
use in Ramadan. In this study, the results revealed that of the 32 participants who 
fast Ramadan, some (n=19) used their medicines according to the??? ?????????
recommendations. Those participants either re-scheduled their doses by taking 
them during the free access hours at night or omitted ??????????????????????????????
advice. For instance, the participants explained that they took their morning doses 
immediately after Iftar (sunset time), afternoon doses between Iftar and Suhoor 
(before dawn), and the evening doses at Suhoor: 
?In Ramadan, I take Amaryl [glimepiride 1 mg table] after Iftar, and Glucophage 
[metformin 500 mg tablet] twice (after Iftar and after Suhoor) instead of three 
times. I do this becau??? ?? ?????? ???? ?? ?????????????? ?ftar and Suhoor, and if I 
take it [metfromin 500 mg tablet] without a meal it causes a stomach pain. The 
doctor knows about it [metformin dose omission].? 
[Participant 3, female, age 56 years]  
 
?In Ramadan, I re-schedule my doses. I take Glucophage [metformin 500 mg 
tablet] three times a day: one after Iftar [the morning dose], one after a snack [the 
afternoon dose] and one after Suhoor [the night dose]. Januvia [sitagliptin 100 
mg tablet], I take it once after Iftar [the morning dose].? 
[Participant 4, female, age 60 years]  
 
The other participants (n=13; one-third of the sample) changed their medicine-taking 
behaviour without consulting their doctors. Reviewing the interview transcripts of 
those participants revealed that fear of hypoglycaemia and the belief in becoming 
hypoglycaemic due to eating fewer meals per day without monitoring blood glucose 
levels to confirm hypoglycaemia, led to omitting doses of their OHAs and/or insulin:  
?In Ramadan, I take all my medicines [Lantus, Actrapid, and metformin 1000 mg 
tablet] together at Iftar time. Because at ???????????????????????????, I just have 
yogurt and fruit. So, if I took my doses [second doses of Actrapid and metformin].  
with this meal I would get hypoglycaemia.? 
[Participant 10, male, age 58 years] 
 
?In Ramadan, I take Lantus [long-acting insulin] before I go to bed, and I stop 
taking the rapid one [Humalog; rapid-acting insulin], because I don??? ?????????
food during Ramadan, and if I take it [3 doses of Humalog], it may cause 
hypoglycaemia.?  
[Participant 13, female, age 61 years] 
 
?In Ramadan, I take Glucophage [metformin 1000 mg tablet] after Iftar and 
Suhoor, Actos [15 mg tablet] after Iftar, and Lantus [long-acting insulin] after 
Suhoor. I stop taking Januvia [sitagliptin 100 mg tablet] in Ramadan because I 
worry about hypoglycaemia.?  
[Participant 24, male, age 58 years]  
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?In Ramadan, I take Glucophage [metformin 1000 mg tablet] twice a day, after 
Iftar and Suhoor instead of three times because I only eat two meals. I stop 
taking Januvia [sitagliptin 100 mg tablet] because I eat a light Suhoor, and I think 
Glucophage [metformin 1000 mg tablet] is enough to maintain [glycaemic] 
control.? 
[Participant 27, female, age 56 years] 
 
In addition to fear of hypoglycaemia because of Ramadan fasting, it was noticed 
that the participants had poor nutritional awareness. They believed that fasting and 
eating fewer meals would expose them to hypoglycaemia, without taking into 
consideration the amount and nutritional contents of the meals, e.g. carbohydrates, 
fat and sugar. Carbohydrates have the greatest effect on blood glucose levels 
(Warshaw, 2005). This lack in nutritional awareness makes the participants 
convinced that they eat less in Ramadan, are more exposed to hypoglycaemia and 
that they do not require taking their doses as usual.  
 
All the behaviours reported by the participants during Ramadan, e.g. ignoring the 
????????? ??????? ?????? ???? ????????? ???r of hypoglycaemia and omitting doses of 
OHAs or insulin without checking blood glucose levels and consulting doctors could 
be serious and may lead to serious complications. Alteration of doses without 
consulting doctors was associated with severe glycaemic complications, such as 
hypo- or hyperglycaemia (Salti et al., 2004). During Ramadan fasting, many 
hormonal changes occur including insulin hormone. As glucose levels tend to fall, 
the secretion of insulin decreases, and glucagon increases leading to breakdown of 
glycogen and augmentation of gluconeogenesis. In the case of patients with 
diabetes, the secretion of insulin is disrupted by the underlying pathophysiology and 
the pharmacological agents that enhance insulin secretion. In the case of patients 
with severe insulin deficiency, extended fasting hours with the absence of adequate 
insulin results in excessive breakdown of glycogen and enhanced gluconeogenesis 
and ketogenesis, in which hyperglycaemia and ketoacidosis can occur (Meo and 
Hassan, 2015). Rapid-acting insulin is the mealtime insulin and its action curve 
mimics the human normal insulin secretion at mealtimes; it acts within 5-15 minutes 
with overall duration of about 3-4 hours. Glucose levels start to rise in the blood 
within minutes of starting to eat and peak within 1-2 hours from eating the meal 
(BNF, 2015). Omitting rapid-acting insulin dose or stopping to take it could lead to 
sharp increase in blood glucose levels and hyperglycaemia. Patients should take 
their insulin dose that matches the type and amount of carbohydrates they eat 
(Warshaw, 2005).   
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To identify the impact ??? ???? ?????????????? ?????????? ?????? Ramadan on health 
outcomes, further examination of the interview transcripts was undertaken. It was 
found that of the 13 participants who do not use their medicines properly in 
Ramadan, ten had high HbA1c levels (>7.5%). Information about hospital 
admissions were also obtained during the interviews. Of the 13 participants, three 
reported that they had needed emergency hospital admissions due to diabetes 
complications, in which they were managed and discharged at the same day. In 
addition, records on hospital admissions due to hypoglycaemia or ketoacidosis were 
observed. According to the latest statistics, no cases of hospital admissions were 
recorded during Ramadan (Amiri Hospital Statistics, 2013). Overall, in addition to 
the impact of poor awareness about medicines actions and about nutrition and the 
fear of hypoglycaemia on medicine-taking behaviour, the lack of immediate clinical 
??????????????????????????????????????????????????ivate the participants to continue 
their poor medicine-taking behaviour during Ramadan. Feeling normal despite of 
poor medicine-taking behaviour was likely to allow the participants to downplay the 
severity of such behaviour or perceiving it as a good behaviour.  
 
5.4.3.3 Side effects: stomach pain, nausea and dizziness 
The entire sample except 11 participants reported that they had experienced side 
effects. Part from side effects of insulin, which are discussed in next chapters, the 
participants reported stomach pain and nausea from metformin tablet and dizziness 
from other OHAs, such as sitagliptin: 
??? ????????? ?????????? ??????????? [metformin 850 mg tablet], it caused me a 
stomach pain even when I took it after meals, and I felt nauseas all the time.? 
[Participant 1, female, age 40 years]  
 
?Glucophage [metformin 1000 mg tablet] causes bloating and stomach pain. 
Januvia [sitagliptin 100 mg tablet] makes me dizzy all the day.? 
[Participant 27, female, age years]  
 
Experiencing side effects had an impact on ???? ?????????????? medicine-taking 
behaviour. Of the 14 participants who reported side effects, such as stomach pain 
and dizziness, 8 were not taking their medicines properly. Some participants (n=4) 
reported omitting doses of their OHAs to become less exposed to their side effects, 
while others (n=4) reported stopping taking the medicine without consulting their 
doctors:  
?I was taking Glucophage [metformin 500 mg tablet], but I stopped it for a while. I 
felt tired when I was taking it because it caused me stomach pain.?  
[Participant 2, female. Age years]  
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?I sometimes take Glucophage [metformin 1000 mg tablet] once a day instead of 
twice, and sometim??????????????????????????e days. It causes a stomach pain.? 
[Participant 26, female, age years]  
 
5.4.3.4 Irregular daily routine, forgetfulness and social stigma  
General barriers to adherence that were reported by some participants (n=14) were 
forgetfulness, change of daily routine, social gatherings and social stigma. 
????????????? ?????? ????????? ???? ??? ? ????? ??? ???? ?????????????? ????????-taking 
behaviour and led to misuse of their medicines: 
????????  at home, there is no problem [in taking medicines]?????? ??? ?? ?????????
with my fri?????? ???????? ??????? ??? ??????? medicines [doses]. Also, sometimes I 
forget to carry my medicines with me, so I wait till I arrived home and take them, 
and sometimes I forget to do so.? 
[Participant 15, male, age 35 years] 
 
Experiencing barriers, such as change of daily routine and social stigma was an 
important determinant of medicine-taking behaviour in this study. Examining the 
interview transcripts of the participants who did not perceive such kind of barriers 
revealed that 21/29 participants were using their medicines properly, while nine 
participants of the 14 who reported such barriers had poor medicine-taking 
behaviour:  
??? ????? ???????????? ??????? ??? ?????????? ??? ???? ????????? ??? ???????????? ?? ?
invited to a dinner or a wedding party, ????????carry it [the injection] with me, and I 
wait until I get back home and take the rapid one [NovoRapid; rapid-acting 
insulin]. I usually cancel the Lantus [long-acting insulin] that night because I take 
the rapid dose very late.? 
[Participant 22, female, age 64 years] 
 
5.4.3.5 Lack of belief in the ability to manage diabetes  
Of the 43 participants, 11 (one-fourth of the sample) were not confident of their 
ability to manage their diabetes: 
?I feel very tired; my [blood] glucose [level] is always hig?? ????????? ?? ?????? ????
much! When I take the tablets [metformin 850 mg], I have nausea and stomach 
?????? ???? ????????? ?????????? ???? ????????? [rapid-acting insulin] dose for me. It 
was 15 [units] ????????????? ????????????????? [blood] glucose [level] is still high. I 
feel under stress; the [insulin] ??????????????????????? ?????????????????????????   
[Participant 25, female, age 58 years]  
 
Self-efficacy was an important determinant of medicine-taking behaviour among the 
study participants. All the participants, with the exception of three, who disbelieved 
in their ability to manage their diabetes, did not use their medicines regularly:  
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?I feel that my diabetes is uncontrolled; it [blood glucose level] swings up and 
down???????????now how to ?????????? ?????? ?? I take the injection [NovoMix 30; 
rapid-acting insulin], and ??????????[blood glucose level] low, ??????????????????????
pills [metformin tablet 500 mg].? 
[Participant 7, male, age 85 years]  
 
Examining the interview transcripts of the three participants who were using their 
medicines regularly despite their low self-efficacy revealed that other factors, such 
as social support helped them manage their diabetes:   
?When I was on tablets only [metformin 500 mg and gliclazide 80 mg], ?? ???????
have any problem, everything was OK. But the injections [Novorapid; rapid-acting 
insulin] ?????????????? ???????? ???e them myself; ??????????fficult to carry and are 
??????? ??? daughter helps me administering my doses, and sometimes my 
husband.? 
[Participant 20, female, age 50] 
On the other hand, participants who had high self-efficacy beliefs showed better 
medicine-taking behaviour than others with low self-efficacy. Of the 32 participants 
who had high self-efficacy managing their diabetes, the majority (n=21) were using 
their medicines regularly:  
?I can fit my medicines within my daily routine; I have already balanced my life 
????????????? ??? ????????????????????????????????? by my doctor. If I change 
?????????????????????????????? ????????????????????????????? travelling, the first 
thing I remember is my med???????? ???????? ???? ?????? ?????? ?? ???? ?????? ????? ?n 
holidays, when I sometimes wake-up late, I re-schedule my doses and take them 
accordingly.?  
[Participant 24, male, age 58 years]  
 
5.5 Health beliefs and other management behaviours 
 
5.5.1 Health beliefs and SMBG 
Self-monitoring of blood glucose is an integral component of diabetes self-
management behaviour; it is recommended for all patients with diabetes to achieve 
target levels of glycaemic control and prevent hypoglycaemia. It provides 
information about the blood glucose levels at different times allowing to identify the 
more precise regimen that maintain a more constant blood glucose level and delay 
complications (Kirk & Stegner, 2010). Patients, particularly insulin-dependent, 
should use SMBG to help adjusting their dietary intake, physical activity and insulin 
doses to improve their daily glycaemic control, as they experience day-to-day 
inconsistency in blood glucose levels (Silva & Bosco, 2015). Regular SMBG may 
not indicate that patients are well adhered to their treatment, but it gives an 
indication about the commitment of patients to the management of their disease 
(Shams and Barakat, 2010). As for patients with type 2 diabetes, the frequency 
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varies depending on the therapeutic regimen and whether they are in the 
adjustment or target phase for glycaemic control. For example, for controlled 
patients using OHAs only, infrequent SMBG is appropriate, while insulin-dependent 
patients with type 2 diabetes should use SMBG at least 4 times per week (Farmer et 
al., 2008).   
 
The interview transcripts were reviewed to assess the adherence of the participants 
to SMBG and examine the barriers for non-adherence. Of the 43 participants, 17 did 
not regularly monitor their blood glucose levels. To examine the factors that 
contributed to non-adherence, the interview transcripts were further analysed, and 
themes such as ?benefits? and ?barriers? emerged. The benefits theme was allocated 
to the participants who were aware about the importance of performing this 
behaviour, e.g. to identify cases of hyper- and hypoglycaemia and take appropriate 
responses towards them. Barriers theme was given to those who provided barriers 
to non-adherence, such as pain and fear of a high result.  
 
5.5.1.1 Awareness about the benefits of SMBG 
Of the 43 participants, 25 reported their awareness about normal blood glucose 
levels, what makes them hyper-/hypoglycaemic and how to take appropriate actions 
towards each case. For example, the participants reported reducing food intake, 
increasing physical activity, drinking plenty of water and adjusting insulin or taking 
correction doses in response to hyperglycaemia, while having some sweet, honey or 
juice in response to hypoglycaemia. However, it was noted that awareness about 
the benefits of SMBG was an important determinant to adherence to this 
management behaviour. Of the 25 participants who had good awareness, 15 (more 
than half) did regularly monitor their blood glucose levels: 
?I monitor my [blood] glucose [level] once on a daily basis, but when I feel tired, I 
worry and monitor it 3-4 times a day. I hope to see it [reading] between 5-6 
[mmom/L] but I often see it 7 [mmol/L]. ??????????high, I watch my diet, and care 
more about taking medicines.? 
[Participant 3, female, age 56, OHAs only] 
 
?I monitor the [blood] glucose [level] 1-???? ??????????????????????????????????
much, especially sweets, it becomes 8-9 [mmol/L], but when I reduce the amount 
of food??????????????????? ????????????????????????????at the early morning; it 
falls to 4 [mmol/L]????????????????????????????????????????? juice until it goes 
?????????? ?????????????????????????????????d the dose [basal insulin dose].? 
[Participant 37, male, age 67 years, insulin pump] 
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?I monitor the [blood] glucose [level] ???? ???????????????? ??????? ?????????????
and 6 [mmol/L]????????????????????????????????????? ???????????????????? it just 
reaches 7-8 [mmol/L]????????????????, ????????????????????????????????????????
it becomes high in the morning, I take my dose as usual and keep monitoring, if 
this happens at night, I take a correction dose.? 
[Participant 38, female, age 49 years, insulin pump]  
 
5.5.1.2 Perceived barriers to regular SMBG  
Of the 43 participants, 31 reported barriers to regular SMBG (Table 5.1). The most 
common barriers reported by the participants (n=15) were unavailability of test strips 
in the MOH, need of help, getting error readings, pain, and fear of high blood 
glucose level: 
?My daughter bought the [monitoring] device for me but I gave it to another 
????????? ?? ??????? ????????? ??????? ??? ???? ?? ?elt nervous about the needle. Also, I 
??????? ???? ??? ???????? ?? ??????? ????? ??? ??? ???????? ?? the reading [high blood 
glucose level].?  
[Participant 11, female, age 60 years, OHAs only] 
 
??????[finger pricks] annoying and painful. Sometimes I bleed.? 
[Participant 15, male, age 35, OHAs only] 
 
In addition, some participants (n=7) reported that their non-adherence to SMBG was 
because of becoming aware about hyper- and hypoglycaemic events: 
?I only monitor it [blood glucose level] ?????????????????????????????? ????????????????
my [blood] glucose [level] is low, ??????????????????????????????????? ??am aware 
??????????[blood glucose level] high or low. Also, I do the blood [HbA1c] test every 
3 months, so I think this is enough.? 
[Participant 39, male, age 28 years, insulin pump]  
 
However, although they reported similar barriers, such as pain and unavailability of 
test stripes in the MOH, 16 participants were regularly performing SMBG:  
?I monitor the [blood] glucose [level] every ????????????????????? ??????????[finger 
pricks] painful and annoying, and causes stiffness to my fingers. Besides, I have 
to buy the [test] ??????? ????? ???????? ???????????? ???????? ???????????? ??? ????
[Ministry of] Health, and they cost me 10 [Kuwaiti] Dinars.? 
[Participant 1, female, age 40 years, OHAs + insulin pen]   
 
?I monitor it [blood glucose level] 3-?? ?? ?? ??????????? [finger pricks] annoying, 
painful and leaves scars on my fingers.  
[Participant 43, female, age 28 years, insulin pump] 
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Table 5.1: Barriers to regular SMBG as reported by the participants and their 
frequency 
Barrier Frequency 
Pain 14 
Finger stiffness 3 
Stress from the result 3 
Error readings 6 
Fear of needle 1 
Too much finger pricks 3 
Bleeding 1 
Complex 1 
Unavailability of test strips in the MOH 4 
Need of help 4 
Awareness about hyper-and hypoglycaemia 7 
HbA1c is enough 2 
Forgetfulness 1 
 
Perceiving barriers can be a strong determinant to non-adherence to regular SMBG. 
In this study, the majority of the participants (10/12) who reported no barriers 
regularly monitored their blood glucose levels. Examining the interview transcripts of 
the two participants who did not perform SMBG regularly although they had no 
barriers, revealed that they had poor awareness about good blood glucose levels or 
how to respond to hyper- and hypoglycaemia:  
????????????????????[blood glucose level] regula???????????????????-6.5 is good; I 
???????????????? ?? [what do you do if you have not achieved your target?] I do 
????????????????????????????????????????? my medicine, and have my injection in 
the morning, I can do nothing.?  
[Participant 24, male, age 58 years, OHAs + insulin pen]   
  
5.5.2 Health beliefs and lifestyle  
Healthy diet helps to achieve glycaemic control, and regular physical activity helps 
the body to use the insulin efficiently (Colberg, 2008). According to the Clinical 
Practice Guidelines of Kuwait for diabetes, the diet of patients with type 2 diabetes 
should contain the minimum number of calories, which the normal person requires 
under similar conditions. As for patients who have to lose weight, a moderate 
reduction in calories of approximately 250-500 Kcal per day less than the average 
daily intake is recommended to lose 2-4 kg per month. Also, it is recommended in 
the guidelines to distribute the calories intake between carbohydrates (50-60%), 
Protein (10-20%) and fat (25-35%). Regarding the physical activity, the guidelines 
recommend that patients with type 2 diabetes should perform moderate-intensity 
aerobic physical activity (50-70% of maximum heart rate) at least 150 minutes per 
week (Al-Wotayan, 2011).   
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5.5.2.1 Diet 
Most of the participants (n=35) except those who were using insulin pumps not 
follow ???? ???????????? recommendations for diet, e.g. counting 
calories/carbohydrates due to their poor nutritional awareness. Therefore, the 
analysis of the interview transcripts to examine the adherence to diet was performed 
according to the following classification:  
? The participants who introduced changes in their diet, such as reducing fat and 
sugar in their food because of their disease and maintained this behaviour had 
good management behaviour (adherence to diet).  
? The participants who reported that they ate as before they were diagnosed with 
type 2 diabetes had poor management behaviour (non-adherence to diet).   
 
Of the 43 participants, 25 had good management behaviour, while 18 had poor 
management behaviour. To identify the factors that contributed to adherence to diet, 
the interview transcripts of the 25 participants were reviewed. The results revealed 
that awareness about the role of bad dietary habits in causing and increasing the 
prevalence of diabetes impacted the participants?? ?????????? ??????? ???? ???? to 
introduce changes in their diet:   
?????? ???? ?????????? [which causes type 2diabetes]. Nowadays, there is a chocolate 
shop between any two shops. We have an easy access to unhealthy food???????
I was diagnosed with diabetes, I have reduced the carbohydrates and sugar 
intake. I wish I could stop sugar at all.? 
[Participant 3, female, age 56 years]  
 
In addition to awareness about the importance of diet, perceiving benefits of 
adherence to diet also emerged as a contributing factor to good management 
behaviour. All the participants except four, reported that adherence to diet helped 
them to reduce their blood glucose levels and maintain glycaemic control, whether 
they maintained changes in their diet or not:  
?At the beginning of the disease, it [efficacy of medicines] was ok, but now I feel 
that without diet, it [blood glucose level] ?????????????????????????? I take my 
tablets regularly.? 
[Participant 12, female, age 34 years] 
 
Perceiving barriers to adherence to diet, such as food cravings, social gatherings 
and lack of social support were reported by 26 participants, from which 19 (about 
three-quarters) had poor management behaviour: 
?If I eat ????????????????????have told my wife to prepare specific food for me, but 
when I eat out with friends in the restaurants, or when we go to the chalet, I ??????
control my desire, so I eat whatever I like.? 
[Participant 10, male, age 58 years]  
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Few participants (n=4) reported that they believed that their eating habits are 
enough for achieving and maintaining glycaemic control: 
????????????????????????? I love Kit Kat [chocolate]; ??????? ????????????????????????
eat little, b?????????????????????????????????food or fat-free food, I like to eat whatever 
I want.? 
[Participant 21, female, age 65 years]   
 
Overall, it was noted in this study that the participants lacked the nutritional 
awareness and perceived personal and social barriers to adherence to diet. Barriers 
were mostly mentioned in Ramadan, when people fast during the day, and eat Iftar 
with their family. At Iftar, the participants drink juices, which are high in sugar 
contents, and have dates and Laban (yogurt drink). After that, they visit their 
relatives, where different kinds of desserts and savouries are usually offered. The 
late meal in Ramadan is Suhoor, which is eaten very soon before the start of fasting 
the next day. Some participants reported that they had light fat and sugar food, such 
as yogurt, fruit and salad for their Suhoor, while others reported that they ate food 
similar to their Iftar, which is rich in fat and carbohydrate count.  
 
5.5.2.2 Exercise  
In this study, 16 participants were performing the recommended level of exercise 
(150 minutes/week). The remaining 27 participants reported barriers to adherence 
to exercise. The most common reported barrier was co-morbidity followed by beliefs 
in the sufficiency of housework, lack of time and hot weather: 
?I ??????????? I have had heart attack many times. When I walk, I easily get tired 
and start coughing.? 
[Participant 22, female, age 64 years]  
 
?There are many things [barriers] in addition to the hot weather and laziness, I 
have many responsibilities-my house, family, ????????????????hey restrict me.?  
[Participant 24, male age 58 years]  
 
Because it is common in Kuwaiti culture that women perform all the house chore, 
and that men are not expected to take part, some female participants (n=5) believed 
that house chore is sufficient for maintaining glycaemic control, and that they do not 
have to do any exercise:  
?At the beginning [of diagnosis], I started walking but I stopped because I felt 
bored. I do the entire house chore myself, which I think is enough.? 
[Participant 13, female, age 61 years] 
 
Few participants (n=4) reported social factors as a contributor to their non-
adherence to exercise, such as lack of social support and social stigma:  
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?I feel that exercise is the most difficult part; our weather does?????????????????????????
go to the gym, but I feel embarrassed. Nowadays, most of people who go to 
gyms a???????????????????????????????????????????different. Besides, most gyms are 
far from my house and with traffic is terrible, so I feel lazy to go.? 
[Participant 10, male, age 58 years] 
 
?I feel that my lif?? ????????????????? ?? ? ????????? ???????? ??????????????????????
disease [diabetes]. I am responsible for three daughters. I tried to walk but 
????????, because I ????? leave my daughters alone. Sometimes, I told them to go 
and walk with me but they have homework???????????????????????????nds.? 
[Participant 16, male, age years 47]  
 
In addition to the mentioned barriers, there were other psychological factors that 
contributed to non-adherence to exercise. The participants were asked during the 
interviews about their beliefs in exercise, e.g. their perceptions about the role of 
sedentary lifestyle in increasing prevalence of type 2 diabetes, whether they 
perceived the severity of not exercising on their disease or whether they perceived 
the benefits of exercising on maintaining glycaemic control. Of the 43 participants, 
ten did not perceive sedentary lifestyle as a contributor to type 2 diabetes, and that it 
is caused solely by other factors, such as hereditary and stress. Most of the ten 
participants (n=6) who did not perceive sedentary lifestyle, as a risk factor for type 2 
diabetes did not adhere to exercise: 
??? ?????? ????? ???? ????????? ??????????? ?????? ????? ??????? ????? ???????
Nowadays, in Kuwait we have lots of sweet shops. I have it [diabetes] because of 
experiencing problems, sadness, fear and shock. I have had it since Saddam 
Husain [the Ex-President of Iraq] invaded us [Kuwait] twenty years ago?????
doctor and my family advised me to walk but I always feel tired. I just do the 
??????????????????????????time for walking.? 
[Participant 28, female, age 66 years]  
 
The belief about the benefits of exercise in maintaining glycaemic control was 
mentioned by most participants (n=38). However, this belief was not a strong 
determinant of the ?????????????? ??????????? ??? ?he majority of them (n=27) did not 
exercise due to experiencing barriers: 
?The changes [diet and exercise] are much helpful; I felt much better when I 
joined the ????? ???? ???? ?? ?????? ?????? ?? ????? ????? ??? ??? ????? ???? ??????
hypertension and diabetes.? 
[Participant 11, female, age 60 years]  
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5.6 Main findings  
? When ??????????????????????????????????? about medicines were assessed using 
MMAS-8, BMQ-S and semi-structured interviews, there were some 
inconsistencies in data obtained from each method. However, using semi-
structured interviews allowed to obtain a comprehensive data that meet the 
study objectives, as they included open questions, e.g. tell me what you did? 
why did this happen? what changes do you apply to your treatment during 
weekends and travelling? do you think your medicines are helpful?, where the 
participants were able to provide rich information about their views and 
experiences with medicine use. Unlike MMAS-8 and BMQ-S, where the 
responses are rigid, e.g. yes, no or categorised into a Likert scale. This also 
enabled the researcher to gain a complete picture about factors that impacted 
health behaviour and to identify different practices and behaviours, while with 
questionnaires, reasons behind particular behaviour were difficult to explore 
(Section 5.1). 
 
? ???????? ???????? ????? ? ??????? ???? ?????????????? ??????????? ?????????? 
(medicine-taking behaviour, SMBG and lifestyle) were identified in this study. In 
addition, it was identified which factors were more significant predictors of 
???????????????????? behaviour. For example, the most influential determinants of 
medicine-taking behaviour were lack of awareness about diabetes complications 
and minimising its seriousness followed by beliefs in efficacy/safety of herbal 
medicines, self-efficacy, lack of awareness about how medicines work, 
perceiving barriers, such as, fear of hypoglycaemia, side effects (e.g. stomach 
pain) and social stigma and beliefs about necessity/efficacy of medicines 
(Section 5.4).  
 
? Lack of awareness and beliefs of the participants affected the management of 
???????????????????????????????????????????????????????????????????????????????
management behaviours. For instance, lack of awareness about how medicines 
work and fear of hypoglycaemia led to omitting doses without consulting doctors, 
beliefs in efficacy and safety of herbal medicines led to abstaining from medical 
treatment, lack of nutritional awareness (e.g. carb counting) led to following poor 
diet and beliefs in the sufficiency of housework in maintaining glycaemic control 
led to abstaining from exercise (Section 5.4, 5.5). 
 
Chapter 5: Medication adherence, health beliefs and the management of type 2 diabetes  
 
? ??? ????????? ??? ???? ?????????????? ????????? ????????? ?????? ????? ????????? ???????? ?????
contributed to poor adherence to medicines, diet and exercise, such as social 
gatherings and social stigma. For instance, some participants, especially who 
were socially active and did not prefer to take medicines in front of others, were 
omitting their doses if they were not at home at the time of the doses (Section 
5.4, 5.5).   
 
5.6.1 Contribution of this chapter to this study 
? This chapter enabled the researcher to identify the key issues regarding the 
?????????????????-adherence, designing a list of these issues and assessing their 
importance from the perspectives of HCPs (Chapter 8, Figure 8.1). 
? ??? ???????????? ????? ??? ?????????????? ?????????? ???? ??????? ??????????? ?his 
chapter helped in constructing a list of recommendations (Chapter 8, Section 
8.1.1-8.1.7; 8.1.9-8.1.10) that are crucial for improving health behaviour of 
patients with type 2 diabetes. 
? Examining the practicality of these recommendations from the perspectives of 
HCPs helped to inform evidence-based policy (Chapter 8, Section 8.2).  
 
5.6.2 Contribution of this chapter to the literature 
? In the context of the management of type 2 diabetes in the Middle East, this 
chapter helped in identifying the most influential determinants of ??????????
management behaviour as perceived by patients. Also, this chapter describes 
?????????????????????????????????????????????health behaviour using the HBM as a 
conceptual framework through qualitative methods (semi-structured interviews) 
(Chapter 9, Section 9.2.1). This is crucial in order to design targeted 
educational interventions based on a chronic disease care model and to identify 
valuable ways for healthcare provision and resources utilisation (Chapter 8).  
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Chapter 6: Management of type 2 diabetes with insulin injections (syringe/vial 
and pens) 
 
As this study aims to inform policy and healthcare provision, in order to improve 
management of type 2 diabetes and health outcomes, this chapter and the next one 
(Chapter 7) identify whether the use of insulin devices (pens and pumps), had a 
supplemental role ???? ??????????????????????????-taking behaviour and the disease 
management, in order to inform recommendations and guidelines modifications. 
This was perform??? ??? ?????????? ???? ?????????????? ???????????? ???? ????????????
about these devices.  
 
Of the 43 participants, 34 were managing their disease with insulin with/without 
OHAs. Eight participants were using insulin pumps (Chapter 7), and 26 were on 
insulin injections (Figure 6.1). This chapter discusses the views and experiences of 
the participants (n=26) regarding the management of their disease with insulin 
injections, with particular consideration to insulin pen devices, as an option available 
for all patients with type 2 diabetes receiving treatment in secondary-care units in 
Kuwait. ????????????????????????????????????????????????????????????????????????????
devices compared to the traditional method of insulin delivery (syringe and vial), in 
terms of benefits, advantages, disadvantages, convenience, and the overall 
preference. Examining patients? views and experiences will assist in identifying 
whether insulin pens were an effective method for the management of type 2 
????????? ??? ???? ???????? ??? ?????????? daily life. Results of this chapter will inform 
decisions for achieving better disease management and health outcomes.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.1: The number of participants using each treatment regimen  
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Participants using insulin injections in this study were classified into two groups: one 
group used both delivery methods of insulin (syringe and vial and the pen device); 
the other group had an experience in one delivery method only (either syringe and 
vial or the pen device). Participants who used both delivery methods were either 
converted from syringe and vial to the pen or vice versa. Participants who used one 
delivery method were initiated on that method and continued on it. Table 6.1 shows 
the current and previous insulin delivery method used by the participants, and the 
duration of using the pen device. 
 
Table 6.1: Current and previous insulin delivery method used by the participants  
Participant Mean 
HbA1c
% 
Previous insulin 
delivery method 
Current insulin 
delivery method 
Duration of 
using insulin 
pen (years) 
1 7 S/V Pen  1 
5 7.5 S/V Pen  3 
6 7 Pen  S/V - 
7 7.5 S/V S/V - 
9 14 S/V Pen 10 
10 7 S/V Pen  3 
13 8 Pen  Pen  4 
14 4.7 Pen  S/V - 
16 14 S/V S/V - 
19 11 Pen Pen  1 
20 7.1 S/V S/V - 
21 7.4 S/V Pen  8 
22 8 S/V Pen  3 
23 9 S/V Pen  3 
24 9 S/V Pen  4 
25 13 Pen  Pen  3 
27 12.8 Pen Pen  8 
28 7.7 Pen  Pen  1 
29 9 S/V S/V - 
30 8.8 Pen Pen  15 
31 7.2 Pen  S/V - 
32 8 S/V Pen  1 
33 7.7 S/V S/V - 
34 8.8 Pen  Pen  3 
35 8 S/V Pen  2 
36 10.7 S/V Pen  3 
*S/V= Syringe and vial, Pen= insulin pen  
 
6.1 Reports of participants on overall glycaemic control and quality of life 
 
6.1.1 Glycaemic control 
To explore the benefits of insulin pens in achieving glycaemic control, the 
participants were asked during the interviews to describe their experiences 
concerning the overall glucose control and quality of life once they used insulin 
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pens. Of the 18 participants, 14 provided positive comments in terms of improving 
glycaemic control with insulin pens. This was manifested by an overall improvement 
in blood glucose levels compared to levels on their previous treatment regimen. 
Participants (n=11) who switched from the syringe and vial method, described their 
experiences about glycaemic control by comparing the two delivery methods (insulin 
pen versus syringe and vial), while some believed that other factors along with using 
insulin pens had contributed to their improvement in overall glycaemic control, such 
as adherence to diet and OHAs: 
?When I started adhering to Glucophage [metformin 850 mg tablets] this month, I 
noticed that my   [blood] glucose [level] became more controlled. Also, using the 
Lantus [pen], I feel that I can control my diabetes more.? 
[Participant 1, female, age 40]  
 
?Before using [insulin] pens, I ????????????? to my diet and I ate lots of chocolate 
and ice cream. Now I avoid all such sweets; ????????????????????????????????????????
now with the [insulin] pen.? 
[Participant 9, female, age 65 years] 
 
?Using [insulin] pens improved my life more than the traditional injections did; all 
problems which I used to face have been terminated. It [insulin pen] helped me to 
control my [blood] glucose [level] more, particularly, the Lantus [pen]; it has 
decreased my [blood] glucose [level] significantly.?  
[Participant 10, male, age 58]  
 
6.1.2 Hypoglycaemic events  
The participants were asked during the interviews to describe whether the use of an 
insulin pen had a role in reducing hypoglycaemic events. Some participants 
provided information about hyperglycaemic events as well. However, the 
participants reported conflicting results. Of the participants who were converted from 
the syringe and vial method (n=11), some (n=5) reported the same frequency of 
hypoglycaemia with both delivery methods; others (n=4) reported fewer events, 
while few (n=2) reported more hypoglycaemia on insulin pens (Table 6.2). 
Regarding hyperglycaemia, the participants (n=5) reported less hyperglycaemic 
events with insulin pen, while some (n=4) reported the same frequency of 
hyperglycaemia with both delivery methods: 
?Hypoglycaemic and hyperglycaemic episodes have significantly been reduced 
since I started using [insulin] pens. Approximately, I experience one episode in 
two months, but when I was using the traditional injections [syringe and vial], I 
experienced hypoglycaemia and hyperglycaemia. Now, with the [insulin] pens, 
?????[blood glucose level] more accurate.? 
[Participant 10, male, age 58] 
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?Before using the [insulin] pens, I experienced hypoglycaemia a lot; I felt weak 
and shivered. As I was monitoring my [blood] glucose [level], I found it 70 
[mg/dL]. ????? ????? [frequency of hypoglycaemia] reduced. Also, I experienced 
hyperglycaemia several times when I was using the [traditional] injections 
[syringe and vial]. After using the [insulin] ?????? ????? [blood glucose level] much 
better.? 
[Participant 23, female, age 72] 
 
Table 6.2: Frequency of experiencing hypo-/hyperglycaemic events on insulin pens 
by the participants, compared to syringe and vial  
         Frequency 
Event  
Less More Same 
No. participants  
Hypoglycaemia  4 2 5 
Hyperglycaemia  5 - 4 
 
??????????????????????????????????????????????????????????????????????????????????????
in reducing hypo- and hyperglycaemic events in some cases compared to syringe 
and vial. In few cases, the frequency of hypoglycaemia increased on insulin pen 
compared to syringe and vial.  
 
Of the 7 participants who initiated on insulin pens, some (n=4) reported experiencing 
hypoglycaemia sometimes, and two rarely, while one participant reported no 
hypoglycaemic event, on the insulin pen period (Table 6.3): 
?I sometimes experience hypoglycaemia, especially when I miss a meal or go for 
a walk. I rarely have [blood] high glucose [level].? 
[Participant 19, female, age 33 years]  
 
?With the [insulin] pen, I have never experienced hypoglycaemia. I always have 
hyperglycaemia even when I fast; I wake-up and find it [blood glucose level] 12-
15 [mmol/L].?  
[Participant 34, female, age 68 years]   
 
Table 6.3: Frequency of experiencing hypo-/hyperglycaemic events on insulin pen 
period  
         Frequency 
Event  
Sometimes  Rarely  Never  
No. participants  
Hypoglycaemia  4 2 1 
         Frequency 
Event  
Always  Sometimes  Rarely  
No. participants  
Hyperglycaemia  2 3 2 
 
This indicates that the use of an insulin pen did not prevent hypo- and 
hyperglycaemia, as some participants who initiated on insulin pen were 
experiencing these events sometimes.  
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6.1.3 Awareness of hypoglycaemia  
In addition, the participants were asked during the interviews to report whether the 
use of insulin pen helped them to be aware, or improved their awareness of 
hypoglycaemic events. Therefore, the researcher revisited the interview transcripts 
of all participants using insulin pens. From the 11 participants who were converted 
from the syringe and vial, some (n=6) reported an improved awareness about 
hypoglycaemia, while others (n=5) responded that they had not felt any difference in 
the awareness of hypoglycaemia between the two delivery methods. Reviewing the 
????????????????????????????????????????????????????????????????????????????????????????
most participants (n=5) mentioned that whenever they experienced hypoglycaemia, 
they were aware about it (Figure 6.2).  
 
???? ?????????????? ???????????????? ?????????????? ??? some interview transcripts. 
Of the 18 participants, 4 reported that using insulin pens improved their awareness 
of hyperglycaemia as well: 
?When I started using the [insulin] pen, I monitored my [blood] glucose [level] 
????????????????????????????????????? ???????????? ???????gh or low. Many times 
when it is high, I feel dizzy, weak and I ?????????????????????????????????????[blood 
glucose level] low although I feel dizzy as well, but I can differentiate between 
hypoglycaemia and hyperglycaemia.?  
[Participant 19, female, age 33 years] 
 
?Since I started using the [insulin] pen, I have become aware of it is [blood 
glucose level] ups and downs. When I feel tired and ????????? ?? ????? ????? ?????
whereas if I have headache and dizziness, I realise it high.?  
[Participant 22, female, age 64] 
 
 
Figure 6.2: Number of participants and their awareness of hypo-/hyperglycaemia on 
insulin pens   
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6.1.4 Hospital admissions  
To investigate the benefits of using insulin pens in terms of improving general 
health, the researcher asked the participants during the interviews whether they 
needed hospital admissions or urgent medical interventions due to diabetes 
complications. Reports on hospital admissions were also reviewed by the 
???????????????????????????????????????????????????????????????????????????????? and 
obtained during the interviews. Of the 11 participants who were converted from 
syringe and vial to insulin pen, six did not perceive any difference in hospital 
admissions between the two delivery methods. The participants provided that they 
neither had been admitted to hospital before using insulin pen nor after using it. The 
remaining five participants reported that they required hospital admissions due to 
diabetes complications during the insulin pen period. Regarding the frequency of 
hospital admissions, three participants said that they required hospital admissions 
sometimes, while two participants reported one hospital admission only. This 
indicates that the use of insulin pen instead of traditional injections helped some 
cases (n=6) to avoid diabetes complications that require hospital admissions, while 
in other cases (n=5), the hospital admissions increased: 
?I sometimes experience headache and dizziness, and when I go to the hospital 
they [the doctors] keep me in the observation room to give me [intravenous] a 
drip to reduce the [blood] glucose [level]; they discharge me the same day? 
[Participant 35, male, age 28 years] 
 
Regarding the participants (n=7) who initiated on insulin pen, all of them reported no 
hospital admissions. Two participants added that they had been admitted to the 
hospital due to severe hyperglycaemia and nephropathy before using insulin pen, 
when they were on OHAs only. This indicates that using insulin pen helped most 
participants (n=5) to avoid hospital admissions, and reduced it in few cases (n=2): 
?Once I experienced severe hyperglycaemia, and I was admitted to hospital. This 
was before using insulin pen; when I was using tablets only [metformin 850 mg 
and sitagliptin 100 mg].? 
[Participant 25, female, age 58 years]  
 
Overall, although most participants (14/18) reported improved glycaemic control with 
insulin pens, episodes of hypo and/or hyperglycaemia were reported by all of them. 
Correlating data obtained from the interviews with HbA1c levels (Table 6.1) 
revealed that not all participants achieved the target goals. Data were consistent in 
4 cases only; where the participant reported improved glycaemic control and had a 
normal HbA1c level (e.g. <7.5%). This could be because that the participants were 
comparing between their overall glycaemic control on insulin pens and their status 
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while they were using the syringe and vial, or before they were initiated on insulin, 
regardless of achieving target levels of HbA1c. Also, it could be that the participants 
were considering improved glycaemic control as a general improvement in their 
blood glucose levels, as manifested to them in SMBG, general health, or in their 
quality of life. To explore factors that affected the maintaining of good glycaemic 
control on insulin pens, the interview transcripts were reviewed, factors were 
identified, and are described in Section 6.2. 
 
6.2 Factors affecting the achievement of glycaemic control on insulin pens  
Analysing the information obtained from the interviews revealed that reasons for 
experiencing hyperglycaemia among the study participants ranged from lifestyle to 
inappropriate treatment regimen (Table 6.4). Non-adherence to diet and exercise 
was the predominant cause of hyperglycaemia identified by most participants. Most 
participants mentioned that eating sweet, fat and rice particularly, raised their blood 
glucose levels; others found that even having few portions of fruits increased their 
blood glucose levels, while some participants noticed that eating a large meal very 
late at night caused hyperglycaemia to them. However, some participants added 
that culture and traditional norms, which impose them to eat with family and to be 
engaged in lots of social gatherings, were responsible for non-adherence to diet, 
and eating as normal persons who do not have diabetes. Other participants found 
that the bad weather most of the year hindered them from practising exercise and 
walking: 
?I always try to change my dietary habits, but it changes according to 
circumstances. For instance, if at home, I ask my wife to cook a special meal for 
me, which is low in fat and sugar. However, if I eat outside, where lots of 
?????????????????????????????????????????????????????????????????????????????????????????
food, sugar and fat increase my [blood] glucose ??????? I usually spend my 
holidays in Europe, when I go there I walk a lot, from day to night. The weather is 
good and many people usually walk there, which encourages me to walk. I 
noticed that my average [blood] glucose level decreases during holidays, 
although I used to eat a heavy breakfast in the hotel.? 
[Participant 10, male, age 58]  
 
In cases where stress was identified as the contributing factor for hyperglycaemic 
events, the participants clarified that although they had adhered to diet and 
treatment, their blood glucose levels increased in particular situations, such as 
sadness, anger, or worrying: 
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?I found that sometimes, when I was tired, my [blood] glucose [level] increased 
even if I was taking my treatment, and it stayed high until I cool down. Nowadays, 
?????????? ???????????????????????????????????????????????????? ??? feel tired, 
dizzy, and numbed. I also experience headache, and blurred vision most of the 
time and when I monitor it [blood glucose level], I find it high. Once it is 
controlled, all these symptoms disappear.? 
[Participant 32, female, age 42] 
 
?Psychological factors play an important role in increasing my [blood] glucose 
[level]. ?? ? ????? ????? ??? ??????? ???? ???????? ????????? ???? ???? angry easily. 
Sometimes, my [blood] glucose [level] goes up even if I eat nothing, and take my 
doses as prescribed; that happens when I am angry or worryied about 
something.? 
[Participant 36, female, age 51] 
 
Hyperglycaemia was also common among participants who did not adhere to their 
treatment regimens as prescribed, such as taking insulin only and missing OHAs.  
  
Also, in this study, some participants were experiencing hyperglycaemia due to an 
inappropriate treatment dosage/regimen: 
???????????? ?? ??????? ???????? ?????????? ??? ?????? ???????? ?? ????? ???? ??? ?????? ????
dinner. When I woke up this morning and it [blood glucose level] was high. It 
even got higher when I had my breakfast.? 
[Participant 23, female, age 72] 
 
?Medicines [OHAs and insulin] were effective, but for some time, it [blood glucose 
level] it has become always high, the doctor therefore prescribed an extra 
injection for me to take before lunch.? 
[Participant 28, female, age 66] 
 
?I was on Glucophage [tablets] only, and my [blood] glucose [level] was good, the 
best ever. Once I had been admitted to the hospital, they [doctors] gave me 
insulin and discontinued Glucophage [tablets]. Also, when I had been discharged, 
they [pharmacists] dispensed insulin [pen] only to me, without Glucophage 
[metformin 850 mg tablets]. Then, my [blood] glucose [level] started to increase 
and became high. I told my doctor during my clinical visit, and he added it 
[metformin tablets] ?????????????????? ???????????????? [blood] glucose [level] is 
good and my diabetes is better controlled.? 
[Participant 34, female, age 68] 
 
Table 6.4: Reasons for experiencing hyperglycaemia on insulin pens, and their 
frequency  
Reason Frequency 
Non-adherence to diet  14 
Inadequate physical activity  5 
Stress 4 
Infections  2 
Non-adherence to treatment (OHA or insulin) 3 
Inappropriate dosage/treatment  5 
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However, there were other factors, which could contribute to hyperglycaemic events 
among the study participants, such as thyroid diseases (n=4), pregnancy (n=2), 
acute asthmatic attacks (n=2), and postmenopausal period (n=1).    
 
In addition to hyperglycaemic events, some participants mentioned that they 
experienced hypoglycaemia as well. Reviewing the interview transcripts, especially 
to identify reasons for experiencing hypoglycaemic events was undertaken. The 
participants raised a variety of reasons (Figure 6.3), such as missing snacks or a 
meal (n=4), avoid eating sweet (n=1), performing hard work (n=2), sport, e.g. 
spending long time in the gym (n=2), insomnia (n=1), and experiencing an accident, 
e.g. ?????? ?????? ??????? ??????????????? ???? ???????????? ??ntioned that she was 
experiencing hypoglycaemia since she started to eat large portions of Jujube fruit: 
?I have been experiencing hypoglycaemia for two months. I noticed that now ?? ?
??????? ????????? [fruit] ?? ????? ?? ????? ?????????? ????? ???????????????????he reduction in 
my [blood] glucose [level]. I also noticed that even when I had a fatty dinner and 
sweet at night, I woke up in the morning and it [blood glucose level] was below 4 
[mmol/L]. I once woke up and was shivering and sweating, and when I checked it 
[blood glucose level], I found it below 4 [mmol/L]. Even my average blood 
glucose level [HbA1c], started to decrease to 8 [%].?  
[Participant 13, female, age 61] 
 
?I usually experience hypoglycaemia, especially when I take my morning [insulin] 
dose, and work hard after that. For example, I once, while travelling by car, I took 
the insulin [dose] in the morning; I felt tired, cold, and sweaty. When I checked it, 
[blood glucose level] it was low.? 
[Participant 24, male, age 58] 
 
?It [blood glucose level] 5-7 [mmol/L] in the morning. I experience hypoglycaemia 
if I take my morning [insulin] dose, and have some work to do outside, or an 
appointment, especially if I miss breakfast. I also experience hypoglycaemia in 
the afternoon if I avoid eating for a long time.?  
[Participant 30, female, 63] 
 
 
Figure 6.3: Reasons for experiencing hypoglycaemia on insulin pens, and 
frequency of reporting them  
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Although most participants in this study commented positively, during the interviews 
on the benefits of using insulin pens in terms of glycaemic control and awareness of 
hypoglycaemia, there were difficulties in maintaining good metabolic control at all 
times, and episodes of hypo-/and hyperglycaemia were common. Factors 
contributing to hyperglycaemic events on insulin pens ranged from lifestyle factors 
to inappropriate dosage or treatment regimen, while cases of hypoglycaemia were 
common when the participants were missing a snack or a meal, and when they 
were performing works that consumed their energy. The next section (Section 6.3) 
??????????????????????????????????????????????????????????????????????????????????????
pens in terms of usage, transporting, problems, and preference. 
 
6.3 ????? ???????????????????????????????????????????? 
 
6.3.1 Ease of use, portability, and convenience of the pen 
Ease of use  
From the 18 participants who were using insulin pen in this study, 12 reported that it 
was easy to learn how to use the pen device. The participants identified that once 
they were prescribed the pen, they were taught how to use it by the doctor, 
pharmacist or the nurse, and then, when they tried it alone, they experienced no 
difficulties. For the remaining participants, there were some difficulties at the 
beginning of using the pen. One participant added that he needed to visit the nurses 
several times until he learned the correct pen use. However, to investigate what 
difficulties did the participants experience and why, the researcher reviewed the 
interview transcripts particularly for that reason. It was found that the most frequent 
?????????????????????????? ????????????????? ?????????? ?????? ??????????????????????????
explained that when they placed the needle into their skin to inject their dose, it 
bent, and the insulin dose could not be delivered and remained in the reservoir. The 
participants added that they solved the problem by changing the pen needle. 
Experiencing such problem could be due to an inaccurate injection technique, as it 
is recommended to hold the pen perpendicular to the skin, at 90-degree angle, and 
to gently press the needle into skin: 
?When I started using the [insulin] pen, every time I wanted to take my dose, it 
[the pen] ??????? ???k properly, and ?? ??????? ???? the dose. Firstly, I thought that 
there was something wrong with the [insulin] pens. I therefore threw them after 
each unsuccessful try?? ?????? ?? ?????? ??? ?????? ???? ?? ???????? ????? ??? ??????? ?????
because the needle was bended. So, I became more careful to place it [the 
needle] straight into my skin; it worked then. My sister had the same problem as 
well, and I taught her how to do it.?  
[Participant 9, female, age 65 years]   
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Although there were some difficulties at the beginning of using the pen, eventually, 
all the participants (n=11), who were converted form the syringe and vial agreed that 
using insulin pens was more comfortable, much easier, and better. To investigate 
???????? ????? ???????????? ??? ???? ?????? ????? ??? ????? ???? ????rview transcripts were 
reviewed, and the factors were identified (Table 6.5).  
 
Table 6.5: ??????????????????????????????????????????????????????????????????????? 
Factor Frequency 
Involves less steps (e.g. save time, less complex) 12 
No need to remove air bubbles  5 
No need to prepare the dose (mixing two types of 
insulin) 
2 
Dose could be administered easily (e.g. no need 
to visit the polyclinic) 
2 
 
Generally, the participants found the use of insulin pen easier because it involves 
less and simple steps. The participants explained that using the syringe and vial 
required removing the cap from the needle, withdrawing the dose from the insulin 
vial, paying attention for the correct dose in the unit marking of the syringe, 
removing air bubbles, and injecting the dose into skin. On the other hand, the use of 
pens required uncapping the pen, fitting the needle into the top of it, dialling up the 
dose, and injecting it. Many participants (n=5) mentioned discarding air bubbles as 
the most difficult step in using the syringe and vial, and that they found the pen 
easier because it helped them to avoid this step. However, although pen devices do 
not develop air bubbles, it is recommended to do an air shot (safety shot) by holding 
the pen with the needle pointing upwards, and pressing the injection button until a 
drop of insulin appeared (Luijf and DeVries, 2010). In this regard, only one 
participant mentioned that she was discarding air bubbles from her NovoRapid  pen 
only, while she was using the Lantus  pen without removing air bubbles. Two 
participants added that using the syringe and vial was more complex because they 
needed to mix two types of insulin (cloudy + clear) to prepare their doses, while with 
the pen, the dose was already prepared, and ready to inject. Although it was not a 
good practice, one participant added that he found the pen use easier because he 
was using the same needle for 3-4 days. Keeping the needle fitted into the pen 
between uses, and not changing it after each use could lead to the generation of air 
bubbles, and increases risk of contamination: 
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?Learning how to use the [insulin] ???? ???? ????? ?????? ????? [pen use] more 
comfortable than [traditional] taking injections [syringe and vial]. It doe?????????????
remove air bubbles. Besides????????????????????????????????????????? day, I use 
it for 3-4 days.? 
[Participant 5, male, age 67 years] 
 
?It was easy to learn how to use the [insulin] ????? ????? ??????? ????? [traditional] 
injections [syringe and vial]. Using the [traditional] injections was horrible and 
annoying. I have to draw the drug [insulin], and get rid of air bubbles. Also, when 
I used the injections, I felt sloppy all the time, but with the [insulin] pen, I feel 
tidier.? 
[Participant 21, female, age 65 years] 
 
To some participants (n=2), the pen was easier and more comfortable because they 
could administer their doses themselves, while on the syringe and vial; they were 
visiting their local primary care unit each time they needed to take their doses, to get 
the help of a nurse: 
?Since I started using the pen, I have realised that many times the insulin ???????
go through. I used to throw the pens and use new ones each time, and I had to 
get extra pens. Now it is [using insulin pen] became so easy; i???? ?????? than 
using the traditional injections [syringe and vial]. It was tiring and time consuming; 
I had to go to the polyclinic to get it [the dose]. The [insulin] pen is better; I can 
use it myself. I????more convenient; I just need to place it [the needle] into my 
?????????????????????????????????????????? 
[Participant 23, female, age 72 years]   
 
Of the three participants who were converted from the pen to the syringe and vial, 
two mentioned that using the pen device was much easier, due to involving less 
steps, and that they were annoyed for being converted to the traditional injections. 
Also, there was one participant who initiated on insulin pen and continued on it, but 
was able to compare between it and the syringe and vial, because she was taking 
care of her mother by administering her doses:  
?The [insulin] pen is much easier to use than the [traditional] injections [syringe 
and vial]. When I was first prescribed the pen, the nurse taught me how to use it, 
and it was OK. I found the use of [insulin] pen so easy as I gave my mother her 
doses by [traditional] injection, which was difficult. I learned how to use them 
[traditional injections] by the assistance of the nurse, who advised me to try it on 
an orange several times. So, I learned it very well. ????? [the use of syringe and 
vial] time-consuming. I have to draw the drug [insulin], check the correct dose, 
eliminate air bubbles, and inject it [dose] carefully. But using the [insulin] pen, I 
only need to adjust the dose [using the dosage knob], and gently press the 
???????????? ??????????????? ???.?  
[Participant 27, female, age 56 years] 
 
However, although one participant mentioned that the use of the pen device was 
much easier than using the syringe and vial, and that she learned how to use it from 
the nurse, she was not administering her doses alone, and she was seeking the 
Chapter 6: Management of type 2 diabetes with insulin injections (syringe/vial and pens) 
 
assistance of her daughter or the housekeeper. It was not identified why the 
participant was not administering her doses alone, but this could be because the 
participant was very obese, and experiencing pain due to spinal disc problems. 
Being very obese and having pain on movements could result in difficulties in 
reaching the body injection sites. Although that participant had ever used the 
syringe and vial, she had friends using that delivery method, thus, she was able to 
make the comparison: 
?The nurse taught me how to use the [insulin] pen; ??????????????????????????????r 
and the housekeeper how to do it. If I had to use [traditional] injections, I think 
that no one at home would ???????????????????????????????????????????? ?????
[using traditional injections] difficult; my friends use them.? 
[Participant 34, female, age 68 years]  
 
However, because it was not in the objective of this study, and was not discussed 
during the interviews, to compare between different types of insulin pens, only some 
participants (n=5) mentioned that using the disposable (prefilled) pens was much 
easier, in terms of adjusting and injecting the dose, and more comfortable, in terms 
of discarding the whole pen once it is finished instead of replacing the empty insulin 
cartridge with a new one.  
  
Portability and convenience  
????????????????????????????????????????????????????????????????????????????????????
of the pen, and to investigate factors that contributed to these characteristics 
(Figure 6.4), the researcher reviewed the interview transcripts. Regarding 
transporting the pen, most participants (n=11) found the pen suitable for 
transportation and travelling, while others (n=7) reported their annoyance from 
transporting insulin pens with them everywhere. However, although transporting 
insulin pens was troublesome to some participants, all of them were consistent in 
that carrying insulin pens was more comfortable and easier than transporting 
syringe and vial, in terms of carrying less items, and the simplicity of the 
administration of the dose. One participant mentioned that she was annoyed from 
carrying syringe and vial during travelling to the extent that she was avoiding taking 
insulin during that period, and was taking OHAs instead. Replacing insulin with 
OHAs could negatively impact on glycaemic control, and result in hyperglycaemia. 
However, the use of insulin pens improved the adherence of that participant to her 
insulin doses during travelling: 
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?It annoys me to carry the [insulin] pens i?? ??? ???? ???????????? ???? ????? ???
compared to [traditional] injections. Carrying traditional injections [syringe and 
vial] was inconvenient, especially when travelling. When I used them, I avoided 
taking insulin and took [anti-diabetic] tablets during the travel period. ? 
[Participant 1, female, age 40 years]  
 
In addition to carrying them, some participants mentioned storing of insulin pens, 
???????????????????????????????????????????????????????????????????????????????????
In this regard, most participants managed to store insulin pens in an icebox or a 
cooler bag/mug to keep them in a suitable temperature, while they were travelling or 
going outside. Only one participant reported that he had difficulties in storing insulin 
pens outside home, and keeping them in an appropriate temperature all the time:  
?The [insulin] pen is difficult to store and transport. If I leave it in the car, it 
[insulin] lose its effect because of the hot weather. When I wanted to go to the 
chalet with my family or friends I put it in my pocket, but it became hot because 
the chalet is far away. Carrying [traditional] injections [syringe and vial] is 
inconvenient as I have to carry many items.?  
[Participant 10, male, age 58 years] 
  
All the above mentioned characteristics, such as simplicity, ease of use, ready to 
use, and portability rendered administering doses outside home via the pen device 
to be more convenient than administering them using the syringe and vial. In this 
regard, most participants (n=13) mentioned that with insulin pens, they became able 
to administer their doses outside, while it was difficult with the syringe and vial, 
where they were either taking their doses earlier before going out, or delaying their 
doses until they arrived to the home: 
?Using [traditional] injections [syringe and vial] was inconvenient. It [using 
traditional injections] involves many steps to prepare the dose (withdraw the 
dose, check the accuracy, discard air bubbles, and take more care with injecting). 
In the case of the [insulin] ????? ???? ????? ??? ???????? ?????????? ???? ????? ????? ?? 
administer. I can even use it [the pen] outside. For example, today I came for my 
[clinical] appointment and I missed my morning [insulin] dose. Now I have to go 
to the ??oilet?? to take it [the dose], and then eat a sandwich.? 
[Participant 22, female, age 64 years]  
 
In addition, some participants (n=3) identified that using the syringe and vial in 
?????????????????????????????????????????????????????????????????????????????????????
? ?????????????? ?????-??????????? ???????????????????????? ???? ????????????? they were 
able to take their doses without attracting attention: 
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?The [traditional] injection [syringe and vial] is improper to use in public areas; 
you need to carry many items, in addition to the complex preparation of the dose. 
It involves many steps (removing the cap of the needle, drawing the dose from 
the vial, removing air bubbles, injecting the dose, and disposing of the syringe). 
??????? ?????????????????, you need to look for a proper place because you have 
to inject it very carefully. In addition, if you take it [the dose via the syringe and 
vial] outside, people could notice and think ????? ??????? ?? ?????-???????????? the 
[insulin] pen, I can inject myself ???????????? ??????????????without withdrawing 
?????????????????????????????ter my dose through the small aperture between my 
shirt buttons, as simple as that.?  
[Participant 9, female, age 65 years] 
 
?Using the pen [insulin] is easier than using traditional injections [syringe and 
vial]. I can ????? ????? ??? ?????? ?????? ?? ? ??????? in the car. When I used 
traditional injections [syringe and vial], I ????????? ????? ??? ?????? ???????? it 
attracted peopl?????????????????????????????????????????????? 
[Participant 30, female, age 63 years] 
 
Two participants mentioned that administering doses outside, via the pen was more 
convenient because it was safer, and that the chance for the needle contamination 
was greater with the syringe and vial: 
?In the case of traditional injections, I never administered my doses outside, 
because the needle could easily be contaminated. Once you remove the cap of 
the needle, it takes time to draw the insulin [from the vial]. Besides, it needs to be 
disposed in a special container. Using the [insulin] pen, the dose is ready to 
inject; I just need to remove the cap of the needle and inject it directly.? 
[Participant 35. Male, age 28 years] 
 
To one participant, the pen was more convenient for administering doses outside 
???????? ??? ??? ????????????????????????cipant explained that when he was using the 
syringe and vial, he experienced many times, where the vial fell off from his hands 
and smashed into pieces, in which he missed the lost dose:  
?When I used the [traditional] injections [syringe and vial], and wanted to take my 
dose outside???????????? ?????????????????????????????????????oilets?????????? ????
the vial fell off from my hands and broke into pieces, where I waited until I went 
back home to take my lost dose. The [insulin] pen is unbreakable and more 
convenient.?  
[Participant 10, male, age 58 years] 
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Figure 6.4: Factors contributing to the portability and convenience of insulin pens, 
as perceived by the participant 
 
Therefore, the ease of use, and portability of the insulin pen made it more 
convenient for administering doses outside than using the syringe and vial. The 
????????????????????? ???? ???????????????????? ? ??????? ????????????????????????????
to treatment, in which they were able to take their doses within the accurate time 
(Korytkowski et al., 2005). 
 
6.3.2 Dosing accuracy and confidence  
From the 18 participants in this study, 15 identified that they were confident about 
the accuracy of dosing with the insulin pen. Comparing with the syringe and vial 
method, some participants (n=10) found the pen device more accurate in delivering 
the required dose, and they were less confident in setting up their doses with the 
syringe and vial. This was because of the injection technique; some participants 
found that withdrawing their insulin dose using the syringe could not be completed 
without any error, and that it was difficult to withdraw the exact dose they required. 
Some participants (n=4) added that the size of the numbers listed in the syringe 
(which related to the units) was too small, so that, they had to take more attention 
for reading the accurate number. On the other hand, with the insulin pen, the 
numbers appear large and clear in the dose window, and all what the participants 
needed was to dial up their dose using the dosage knob:  
?Using [insulin] ?????????????????????worry much about how to take my dose. All 
what I need to do is to dial up the pen [dosage knob] on the [required] dose, and 
inject it.?  
[Participant 1, female, age 40 years] 
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?I have a visual impairment, and with the [traditional] injections [syringe and vial], 
I suffered from reading the correct numbers [dose units] because they were very 
small. In the case of the [insulin] pen, numbers are big and clear.? 
[Participant 24, male, age 58 years] 
 
However, one participant reported conflicting response; she found that the syringe 
was more accurate in delivering the required dose than the pen: 
?I doubt that the [insulin] pen gives me the whole dose. When I used [traditional] 
injections [the syringe and vial], I noticed that all the insulin [solution] transfer 
from the injection [syringe]. In the case of the [insulin] pen, when I shake it after 
injecting my dose, I notice that a little [insulin solution] remains [in the insulin 
reservoir], ?????????????????????????? ???????? 
[Participant 22, female, age 64 years] 
 
Also, few participants (n=2) mentioned that sometimes the insulin pen included 
more than the dose that they required, but it was difficult to administer that dose 
using the same technique. One of these participants reported that he was obliged to 
throw the pen even if it had some insulin solution remaining, while the other 
participant mentioned that she used a syringe to withdraw the remaining insulin 
solution from the reservoir, and used it for her next dose: 
?It is easy to dial up the dose with the [insulin] pen, but sometimes I only need 20 
units while the pen includes extra 5-10 units; ?????????????????? ?????????????????????
throw the pen, lose the remaining dose [insulin solution], and use a new one. 
Many times I asked the pharmacists to dispense me extra pens because of that 
problem but they refused.? 
[Participant 10, male, age 58 years]  
 
6.3.3 Problems of insulin injections  
 
6.3.3.1 Problems of pen devices  
Although the MOH in Kuwait works toward providing patients with type 2 diabetes 
with the most advanced pharmaceutical products, such as insulin pens, data on 
their efficacy and safety is lacking. Therefore, it was important in this study to 
examine whether these devices are advantageous over traditional methods of 
insulin delivery, e.g. syringe and vial, and that they cause less problems. To this 
purpose, the researcher asked the participants during the interviews to report all the 
problems they experienced during the pen use period. The participants provided two 
main problems, e.g. pain and injection-site reactions. Participants who were 
converted from the syringe and vial method reported problems of insulin pens in 
comparison with problems they experienced previously, before using the pen. In 
addition, this section includes information from participants who were using syringe 
and vial method. This is because few of them were converted from the pen device, 
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so they had the experience of both insulin delivery methods. Also, to report 
problems of syringe and vial method, as perceived by the participants, in order to 
consider all the problems caused by both insulin delivery methods.  
 
Needle anxiety and pain perception 
Of the 18 participants in this study, 10 reported pain at the administration site after 
injecting their doses using the pen. The participants provided different perceptions 
ranged from a mild sting to a moderate pain, which was leading sometimes to a 
muscle cramps. Some participants added that they could withstand the pain and did 
nothing for it, others identified that they changed the injection site every time to 
avoid the pain, and used different body sites, such as thigh, belly, or the triceps. 
Some participants added that they felt pain only when they used large needles (6 
mm), and that using short ones such as 2 mm needles did not cause any pain. 
Others noticed that injecting their dose in the belly caused less pain than other body 
sites. This could be because the belly is richer in fatty tissue especially in 
overweight or obese people. One participant commented that she was experiencing 
pain only at the beginning of using the insulin pen, and over time, she knew how to 
inject herself without causing any pain. The speed of injecting the dose could 
contribute to feeling pain at the administration site; the quicker the needle 
penetrates the skin, the less pain results: 
?When I started using the [insulin] ?????????????? ????? ???????????????????????????? 
the time, I knew how to take it [the dose]. I even feel no pain, and I accept it [the 
insulin pen].? 
[Participant 19, female, age 33 years] 
 
?The [insulin] pen sometimes causes pain, especially when they [the 
pharmacists] give me large needle (6 mm), but the small one (2 mm), I do??????
make me feel pain at all.? 
[Participant 27, female, age 56 years] 
 
However, when comparing with the syringe and vial method, some participants 
provided that because the pen needle was shorter and smoother than the needle of 
the syringe, the pen device caused less (n=6) or no pain (n=8). As a result, some 
participants (n=5) added that the pen allowed them to use different body sites to 
inject their doses without feeling any pain, while they were injecting their doses only 
in the belly, when they were using syringe and vial: 
?Using the [insulin] pen, I only feel a mild sting when I take it [the dose]. It usually 
[the pain] disappears when I stretch my skin. The [traditional] injection [syringe 
and vial] caused more pain; I only took it [the dose] in my tummy. In the case of 
the [insulin] pen, I can even take it [the dose] in my shoulders.? 
[Participant 32, female, age 42 years] 
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Overall, it was found that the factor, which contributed to less pain, or no pain on 
insulin pens was the short size of the pen needle. That characteristic of the pen 
device provided an advantage over the traditional injections by allowing some 
participants to use different injection body sites, which they were avoided due to fear 
of pain. However, factors contributed to experiencing pain on insulin pens in this 
study could be the injection technique, the injection site, and the diameter of the 
needle.  
 
Injection-site reactions  
From the 18 participants who were using the pen device in this study, 9 reported 
injection-site reactions, such as bruising. The participants added that their skin 
coloured red to blue at the administration site. Some participants mentioned that the 
problem occurred only sometimes, and that the bruising was disappeared 
spontaneously, by changing the administration site, or by using alcohol wipes. Some 
participants provided different complications, such as bleeding (n=3), and itching 
(n=1). From participants who experienced bleeding, two reported that the problem 
occurred sometimes, while one experienced the problem at the beginning of using 
the pen only. In addition, experiencing that problem affected negatively on the 
injection technique of one of the participants. Because of the compressible feature 
of insulin cartridge of the pen, insulin is delivered slowly.  
 
Thus, it is recommended that the patient hold the needle for 10 seconds after 
injecting the insulin dose to prevent leakage of insulin, and to get the optimum 
delivery of insulin (Luijf and DeVries, 2010). However, that participant stated that he 
was avoiding this step, in order to avoid injecting contaminated insulin dose: 
?They [the nurses] told me that I have to keep the needle in my skin for 10 
seconds after injecting the [insulin] dose, but I pull it out it rapidly after injecting. 
This is because I always experience bleeding, and when I keep it [the needle] 
inside [the skin] for seconds, the blood get mixed with the [remaining] insulin 
solution [in the insulin reservoir]. In this case, I need to throw the pen and use a 
new o??????????????????? [traditional] injection [syringe and vial], the [syringe] 
needle is thicker and caused more bleeding.? 
[Participant 10, male, age 58 years]  
 
Where itching was experienced, the participant added that he experienced this 
problem as a result of using the same administration site several times, and that he 
used Vaseline Jelly to solve the problem. However, it is worthy to note that the same 
participant who was experiencing difficulties in using the insulin pen, and had 
difficulties in transporting and storing it, was experiencing all the problems that 
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related to the pen use, e.g. ?????? ?????????? ????????? ???? ????????? ??????????
dissatisfaction in their treatment regimen could impact on their abilities to 
accommodate to that regimen, acceptance, and adherence, and result in 
experiencing problems. Although it is mechanically more complex than the syringe 
and vial, and is prone to malfunction over time, there were no reports of mechanical 
malfunctions in the current study. Depending on the experiences of the 21 
participants who were using the pen device during the data collection period, or had 
used it before, no one reported mechanical malfunctions during the pen use period. 
 
6.3.3.2 Problems of syringe and vial 
In order to include all the problems caused by the different insulin delivery methods, 
the researcher reviewed the interview transcripts of the participants who were using 
syringe and vial. Problems caused by the syringe and vial method were manifested 
as pain, bleeding, bruising, hypoglycaemia, and complexity of doses administration 
(Table 6.6). In addition to causing the previous problems, it was noticed that using 
the syringe and vial method annoyed some participants in terms of relying on others 
to help them in administering their doses. In this study, some participants (n=4) 
reported that they could not administer their doses themselves, and they had to wait 
for their sons/daughters to help them. One participant mentioned that she used to 
go to the local primary care unit to obtain help from nurses in administering her 
doses: 
???????????????????????????????????????????????????????? [insulin] injections; ????????
annoying, painful, and sometimes they cause bleeding and bruising. In addition, 
??????????????????to use in transportation when I want to be away from home. They 
have to be kept in a cold place, but the tablets can be taken everywhere. Also, 
[insulin] ???????????????????????????????? ??????? linked with the food. Every time I 
want to eat, I have to wait for my husband or daughter t get back so as to give 
me the injection. ?? ?????? ????? ??? [the dose] ??????? ????? ??????????? ?very time they 
??????????????????????????????? give me the injection [dose], I turn my face to the 
opposite side.? 
[Participant 20, female, age 50 years]  
 
Table 6.6: Problems caused by using the syringe and vial method and their 
frequency  
Number Problem Frequency 
1 Hypoglycaemia 1 
2 Pain 6 
3 Bruising 3 
4 Bleeding 2 
5 Time-consuming/complex 4 
6 Inconvenience for transporting 5 
7 Dosing inaccuracy 2 
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Overall, insulin pens were not free from problems and side effects (problems 1-4; 
Table 6.6), such as pain and bruising but depending on reports from participants, 
the effects were much less in frequency and severity compared to those cause by 
the syringe and vial method. Furthermore, insulin pens helped to eliminate other 
problems caused by the syringe and vial (problems 5-7; Table 6.6), such as 
complexity of doses administration and difficulty in transporting. Although it is 
mechanically more complex than the syringe and vial, insulin pen was not 
susceptible to mechanical malfunctions, and there were no reports of malfunctions 
in the current study. 
  
6.3.4 Overall preference and acceptance  
In order to investigate the preferred insulin delivery method, the participants were 
asked during the interviews, whether they accepted the pen device and continue on 
it. All the 18 participants reported that the pen was comfortable, and they were 
happy using it. The 11 participants who were converted from the syringe and vial 
method added that they never thought about returning to that method. In regard to 
recommending the pen device to other patients, all the participants reported that 
they recommend the pen to other patients; some of them (n=2) had already 
recommended it to their families or friends, who were using traditional injections. 
Two participants added that the pen would be easy to use for old and young people, 
while one commented that old people might find it difficult, especially if they cannot 
read, as they would have difficulties in dialling up their doses using the dosage 
knob, while with the syringe, they could count the number of lines, which related to 
the units:   
?I feel comfortable using the [insulin] pen. No, no, ?????????????????????????????????
another patient using insulin, I would advise him to ask his doctor to prescribe the 
[insulin] pen to him. It [insulin pen] can be used effectively, and easily; ????????????
something good, good, good.? 
[Participant 24, male, age 58 years] 
  
??? ??????????? the [insulin] pen; ???????????and I can inject my dose easily. It is 
???????????????????????????????????????????????????????????[traditional injections] but 
I helped my mother with ??????????? ????? [insulin pen] really a good invention for 
everybody, old and young. I would recommend it, but there are some people who 
are more familiar with the tradi??????????????????????????????????????????? ?used to 
the [insulin] pen.? 
[Participant 27, female, age 56 years] 
 
Of the participants who were using syringe and vial in this study, two switched from 
the pen to the syringe and vial. One participant stated that he was prescribed the 
insulin pen in a period of time but he returned it to the pharmacy, and dispensed the 
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traditional injections instead. The participant reported that he had a difficulty in using 
the pen, and felt uncomfortable with it. It was not clear why that participant did not 
like the pen use, although he was educated and could read the unit marking in the 
dose window, and dial up his dose using the dosage knob easily. Impaired vision 
and/or dexterity could be a reason but are excluded, because the participant 
preferred the use of traditional injections.  
 
Administering doses using the syringe and vial required good vision to read the 
small numbers listed in the syringe, and proper dexterity to withdraw the insulin 
using the syringe and injecting the dose. However, reasons that made that 
participant disliking the pen could be that he was more familiar with the syringe and 
vial, as he used them since he diagnosed with type 2 diabetes (e.g. approximately 
for 10 years), so, when he was prescribed the pen at the middle of his diabetes, he 
did not like to change his treatment regimen, or to learn a new method. In addition, 
this participant was 77 years old; some old people might find it difficult to use 
technical devices, and preferred traditional methods, although there were many old 
participants in this study who adapted the use of technology of the pen. The other 
participant who switched to the syringe and vial provided that she preferred the pen, 
but this was because she required a higher insulin dose, which could not be 
delivered via the pen, and that she had to inject herself twice, if she want to keep 
using the pen. With the syringe and vial, the participant could withdraw the required 
dose and inject herself at one time: 
?I used to have the [insulin] pen, but now ?? ? ?????? ???? ???????????? ???????????
[syringe and vial]. This is because the doctor increased my [insulin] dose, but the 
[insulin] pen includes a limited dose, less than what I need. Therefore, instead of 
using the [insulin] pen twice, I chose to use the [traditional] injection [syringe and 
vial] because it provides with me the dose I need at one time.? 
[Participant 6, female, age 56 years] 
 
Overall, insulin pen was considered the preferred insulin delivery method among the 
study participants. To identify the factors that contributed to its preference, a 
comprehensive analysis to the interview transcripts has been undertaken, which 
provided the broad picture of the characteristics of insulin pens. The dominant 
factors that contributed to the preference of insulin pen in this study, as reported by 
the participants are outlined in Figure 6.5.  
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Figure 6.5: Factors that contributed to the preference of the insulin pen 
 
Results of the current study revealed that using insulin pen had many advantages in 
?????????? ??????????????????????????? ???????????????????????????????????????????????
and transporting, convenience, dosing accuracy, with less problems than those 
caused by the syringe and vial. However, it is worth to note that reports on improved 
glycaemic control were not supported with clinical data, e.g. HbA1c levels. Most 
participants, who reported improved glycaemic control on insulin pen, had poor 
blood glucose levels (e.g. HbA1c> 7.5%). 
 
However, some participants (n=3) clarified that they had been offered the pen 
device but they needed to switch to syringe and vial due to different reasons, such 
as the requirement for higher insulin dose that could not be delivered via the pen, or 
due to having difficulties in using the pen. To one participant, it was not clear why 
she had been converted from the pen to syringe and vial, and she reported her 
annoyance during the interview for being transferred to the traditional injections. 
Other participants (n=5) did not use the pen device at all; reasons for not being 
dispensed the pen device were neither raised during the interviews nor identified by 
the participants. 
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6.4 Main findings  
? Findings of this chapter revealed that using the pen device was more acceptable 
and preferred among the participants than traditional injections. Of the 21 
participants who were prescribed and used insulin pens for a period of time, or 
at the time of data collection, only two switched to syringe and vial deliberately 
(Section 6.2.4). Overall, reports of participants who used insulin pens and 
continued revealed that the pen was more advantageous in terms of ease of 
use, portability, convenience, accuracy of dosing, and caused less pain and 
injection-site reactions. As a consequence, most participants reported improved 
adherence with the insulin pen.  
 
6.4.1 Contribution of this chapter to this study 
? Describing the participa?????????????????????????????????the use of insulin pens 
and comparing their use with traditional injections enabled the researcher to: 
-Inform policy to consider insulin pens as a part of a comprehensive diabetes 
management approach. 
-Highlight a key information gap for physicians regarding the benefits of insulin 
pens, in order to extend their prescribing.  
-Discuss a recommendation of (informing patients about the availability of an 
insulin pen and involve them in decision-making) and obtain its importance and 
practicality from the perspectives of HCPs (Chapter 8, Section 8.1.8). 
 
6.4.2 Contribution of this chapter to the literature  
? Although there were many international published studies revealing consistent 
results with this study ?????????? ?????????? ????????????? convenience and 
acceptability to insulin pens, ?????????? ???????????? ???? ????????? ??? ????????????
injection have not been adequately reported in the Middle East (only two 
studies). This study provides an update data among Eastern Mediterranean 
patients with type 2 diabetes that may add a benefit to the local literature 
(Chapter 9, Section 9.2.2).  
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Chapter 7: Management of type 2 diabetes with insulin pumps 
 
This chapter investigates views and experiences of adults with type 2 diabetes 
(n=8), about the use of insulin pumps, in terms of glycaemic control and problems 
associated with their use. Also, it describes the impact of using such devices on 
?????????????????????????????????????????????????????????????????????Describing the 
?????????????? ???????????? in this study will help in understanding whether insulin 
pumps are effective options for this group of patients, and making recommendations 
for better management of this disease and improved health outcomes.  
 
7.1 Glycaemic control with insulin pumps  
 
7.1.1 HbA1c levels from medical records  
To evaluate the benefits of using insulin pumps in terms of achieving glycaemic 
control, HbA1c levels of the participants during the insulin pump period were 
reviewed. Table 7.1 shows the HbA1c and blood glucose levels of the participants, 
in addition to other characteristics, such as gender, age, education level, BMI, and 
other co-morbidities. 
 
Table 7.1: HbA1c ????????????????????????????????????????????????????????????????? 
 
Patient 
 
Gender 
 
Age 
(years) 
 
Education 
level 
 
Mean 
HbA1c 
(%) 
Blood 
glucose 
level 
(before 
meal) 
(mmol/l)  
 
BMI 
(kg/
m2) 
 
Co-
morbidity 
26 F 47 Secondary 
school 
12* 5 30.1 Nil 
37 M 67 University 6.8 4 38 CVD 
38 F 49 Diploma 7.5 6.3 46.9 CVD 
39 M 28 University 7 6 35.1 Nil 
40 F 34 Diploma 7.1 6.5 26.7 Nil 
41 F 25 Primary 
school 
NA^ 7 24.9 Nil 
42 F 28 University  5 4.2 28.1 Nil 
43 F 28 Postgraduate 5.7 7 25.7 Nil 
* Old data, collected two months ago  
^ No reading during the pump period was available 
 
All participants were on intensified insulin regimen, either injections and/or pens 
before switching to insulin pump. The duration of using insulin pump and the 
previous insulin regimen of each participant, as reported during the interviews are 
provided in Table 7.2. 
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Table 7.2: The duration of using insulin pump and the previous insulin regimen as 
reported by the participants 
Patient Previous insulin regimen Duration on insulin 
pump (year) 
26 Injection ? pen 2 
37 Pen  0.5 
38 Injection 6 
39 Injection ? pen 6 
40 Pen 1  
41 Pen 1 (month) 
42 Pen 1.5 
43 Injection ? pen  2 
 
In patients with type 2 diabetes, it is ideal to aim for an HbA1c of 6.5-7.5% or less 
(BNF, 2015). From Table 7.1, it seems that of the 8 participants, 6 achieved target 
levels of HbA1c (<7.5%). For the two remaining patients, one still above the target 
levels (patient 26; HbA1c=12%), and for the other patient (patient 41), there were no 
valid HbA1c level during the data collection period. Therefore, according to HbA1c 
levels, all participants except one (excluding patient 41 to avoid bias of the results) 
had achieved glycaemic control on insulin pump. Data of blood glucose levels, as 
monitored in the clinic were also collected. Blood glucose targets for patients with 
type 2 diabetes before meals are 4-7 mmol/l (Peragallo-Dittko, 2006). Thus, it 
seems that all participants had achieved normal blood glucose levels. However, 
some participants were using the insulin pump for a long period (e.g. more than a 
year) rendering their data collected before the pump period very old and difficult to 
obtain from medical notes. Therefore, relying on clinical data only does not help in 
?????????? ???? ? ???????? ???????????????, and understanding the efficacy of insulin 
pump in achieving glycaemic control. Thus, in order to understand the role of insulin 
pump in achieving glycaemic control compared to MDI, and to identify why not all 
the participants achieved target HbA1c levels, it was important to revise data 
obtained from the interviews. Information revealed from analysing the interview 
transcripts are provided in Section 7.1.2. 
 
7.1.2 Reports of participants on overall glycaemic control  
 
7.1.2.1 Achieving glycaemic control  
To investigate the benefits of using insulin pump, compared to other insulin delivery 
methods, in improving and maintaining good blood glucose levels, the participants 
were asked during the interviews to describe their experiences regarding the 
effectiveness of the pump in achieving glycaemic control. Because all participants 
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were transitioned from insulin injections and/or pens (Table 7.2), they were able to 
compare between insulin pump and the other insulin delivery methods. Exploring 
participa???????????and experiences revealed that the entire sample (n=8) reported 
improved blood glucose levels on insulin pumps compared to previous insulin 
therapy:  
?Compared to insulin pens, my average blood glucose level has become good 
since I used the pump.?  
[Male, age 67 years, 6 months of pump use; interview no. 37] 
 
?When I was on [insulin] pens, my blood glucose level always fluctuated, ups and 
??????? ???? ???? ????? ????? ???????? ???? ????? ?????? ??? ???? ????????? ?????
according to the carbohydrate counting.?  
[Female, age 28 years, 18 month of pump use; interview no. 42] 
 
Two participants added that the pump helped them to achieve glycaemic control to 
the extent that they felt became uncontrolled and their health deteriorated when they 
replaced the pump with insulin pens temporarily: 
?I tried to stop using it [the pump] for a week and use [insulin] pens instead, but 
my health deteriorated; ???????????control my blood glucose levels. It went up and 
down.? 
[Female, age 47 years, 12 months of pump use; interview no. 26] 
 
?I once stopped using it [the pump] for one day, and returned to [insulin] pens. 
???? ?????? ? ?????? ???? ??? ??????? ????????????? ???? ??? ?????? ???????? ??????
fluctuated between ups and downs. It was only for one day!?  
[Female, age 34 years, 12 months of pump use; interview no. 40] 
 
7.1.2.2 Reducing hospital admission  
Reports from interviews with the participants and clinical data suggested that insulin 
??????? ?????????????????????????(n=6) general health compared to previous insulin 
therapy, and they did not need hospital admissions due to hypo-/hyperglycaemia or 
any other diabetes complications. In some cases (n=3), the use of insulin pump 
even reduced hospital admission rate (Table 7.3).  
 
The participants reported several hospital admissions due to experiencing diabetes 
complications on previous insulin therapy:  
?Before using the pump, you ????????? ??????? how many times I had been 
admitted to the hospital, ??????????????????????????????????? [hospital admission].? 
[Female, age 34 years, 12 months of pump use; interview no.40] 
 
?When I was on [insulin] pens, I had been admitted to the hospital many times. I 
had acidity in the blood [ketoacidosis].? 
[Female, age 25 years, 1 month of pump use; interview no. 41] 
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Table 7.3: Reported hospital admission rate, due to diabetes complications, on 
insulin pump compared to previous insulin therapy 
Patient Hospital admission rate  
26 Increased  
37 Did not change 
38 Increased 
39 Did not change 
40 Reduced 
41 Reduced 
42 Reduced 
43 Did not change 
 
7.1.2.3 Onset of glycaemic control  
Regarding the onset of glycaemic control, most participants (n=6) noticed the 
improvement in their blood glucose levels promptly, at the start of using the pump 
therapy (Table 7.4). The remaining two participants reported experiencing hypo-
/hyperglycaemic episodes at the onset of commencing treatment with insulin pump, 
in which their hospital admission rate increased (Table 7.3): 
?At the beginning, it [the pump] ???????????????????????????????????????????????
?? ????????????????????????????????????????????????? ?????????????????????????????
blood sugar level. After two months achieved good glycaemic control.? 
[Female, age 47 years, 24 months of pump use; interview no. 26]  
 
?When I started using the pump, I suffered from low blood glucose levels to the 
extent that I lost my consciousness, in which I needed to be admitted to the 
hospital. It [achievement of glycaemic control] took a long time (about one year), 
but now everything is OK.? 
[Female, age 49 years, 72 months of pump use; interview no. 38]  
 
Table 7.4: The onset of glycaemic control after using insulin pump, as reported by 
patients   
Patient Onset of glycaemic control Evidence of the control  
26 Worsened (for 22 months), then 
improved  
SMBG/Interview  
37 Promptly improved SMBG/HbA1c/Interview 
38 Worsened (for 12 months), then 
improved 
SMBG/HbA1c/Interview 
39 Promptly improved SMBG/HbA1c/Interview 
40 Promptly improved SMBG/HbA1c/Interview 
41 Promptly improved  SMBG/Interview 
42 Promptly improved SMBG/HbA1c/Interview 
43 Promptly improved SMBG/HbA1c/Interview 
 
7.1.2.4 Maintaining glycaemic control 
The aim of using insulin in type 2 diabetes is to achieve and maintain glycaemic 
control in poorly controlled patients. However, not all patients with type 2 diabetes, 
who are insulin-dependent, could maintain normal blood glucose levels at all times. 
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In addition, intensifying insulin regimen in patients who did not meet target levels is 
associated with increased risk of hypoglycaemia (Reznic et al., 2014). Therefore, in 
this study, it was crucial to assess whether the use of insulin pumps had a role in 
maintaining glycaemic control at all times, and avoiding hypoglycaemia. In this 
study, cases of hypo-/hyperglycaemic episodes at particular times of the day, or at 
special occasions were reported: 
?With [insulin] pens, I always got hypoglycaemia, it [blood glucose level] reached 
less than 1 [mmol/l]. ???? ????? ??. Using the pump, I sometimes have 
hyperglycaemia; it [blood glucose level] goes up to 8-9 [mmol/l].? 
[Female, age 34 years, 12 months of pump use; interview no. 40] 
 
Overall, all participants reported an overall improvement in their glycaemic control 
after using insulin pump. In most cases (n=6), the control was achieved promptly, at 
the onset of commencing insulin pump therapy, and the improvement in HbA1c 
readings was instantaneous. In two cases, where no valid HbA1c levels were 
available, the improvement was manifested by normal blood glucose levels as 
monitored by the participants and in the clinic. The participants who achieved a 
prompt glycaemic control added that they had not been admitted to the hospital due 
to diabetes complications, and compared to previous insulin therapy; the hospital 
admission rate was reduced in some cases (n=3). The remaining two participants 
who had delayed achievement of glycaemic control reported worsened glycaemic 
status during the transition period, the period when they switched from insulin 
injections/pens to insulin pump therapy. The participants reported that they 
experienced a period of erratic blood glucose levels, with hypo-/hyperglycaemic 
episodes, and increased hospital admission rate. The period required to gain 
glycaemic control was different between the two patients, and ranged from 12-22 
months. Despite achieving an overall good glycaemic control, hypo-/hyperglycaemic 
episodes were reported through all the cases.  
 
Correlating clinical data and data obtained from the interviews revealed that insulin 
pumps were effective in achieving glycaemic control (target HbA1c levels and/or 
normal blood glucose readings). Although the control with insulin pump had been 
achieved since a short period in two cases (patients 26 and 41), both patients 
reported stable glycaemic status at the time of the interview. Data obtained from the 
interviews were consistent with HbA1c levels in the majority of cases (n=6). In the 
remaining two cases, valid data on HbA1c level were not available due to not 
performing the HbA1c test during the control period (patient 26), or at the pump 
treatment period (patient 41). Patient 26 reported that she had just achieved 
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glycaemic control, two months before her interview date, and that her last HbA1c 
test was performed before that period. Patient 41 used the insulin pump a month 
before conducting the interview, and her last HbA1c level was collected before she 
started using insulin pump. Participants who needed time to achieve glycaemic 
control were within the same age range, and both were female and obese. 
However, to explore factors that hindered achievement of glycaemic control on 
insulin pumps, and reasons for not maintaining the control at all times throughout 
the day, the interview transcripts were reviewed through all the cases, factors were 
identified and are described in Section 7.1.3. 
 
7.1.3 Factors affecting the achievement of glycaemic control with insulin 
pumps  
This section is divided into two parts; the first part describes reasons that impeded 
achievement of glycaemic control in the two cases. The second part describes 
factors contributed to irregular blood levels, and hypo-/hyperglycaemic episodes 
across all cases.  
 
7.1.3.1 Reasons for not achieving glycaemic control at the onset of insulin 
pump therapy   
The justification for not achieving good blood glucose levels, at the transition period 
(Table 7.5) could be due to experiencing difficulties in working out how the pump 
works, inadequate awareness about the tasks required with the pump therapy, such 
as carbohydrate counting, doses calculation (bolus and correction doses), and 
depending solely on the doctor in adjusting doses (basal insulin): 
?When I received the training from the company, it was OK, but when I tried it [the 
pump] myself, I felt nervous, an????????????????????????????????????????????? ????
experienced hyperglycaemia I went to my doctor to adjust my doses [basal 
insulin], but now I am used to it.? 
[Female, age 47 years, 24 months of pump use; interview no. 26]  
  
?At the beginning, it [the pump] ??????? ????????? ???? ?????? ?? had learned how to 
count carbohydrate and take correct doses, it became much better.? 
[Female, age 49 years, 72 months of pump use; interview no. 38]  
 
The use of the pump technology requires the patient to learn all the tasks that are 
linked to its use. Lack of awareness of these tasks contributed to a failure in 
achievement of glycaemic control. Furthermore, the timing of the transition to the 
pump therapy is important. One participant reported that she started on the pump 
when she was pregnant. Pregnancy causes hormonal and metabolic changes 
followed by insulin resistance, in which insulin requirements increased:  
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?When I switched to ?????????? ??? ??????? ?????????????? ?? ???? ??? ??? my doctor 
many times to adjust the doses [basal insulin] for me. It [blood glucose level] 
became OK for 1-2 weeks, but then it returned to high levels. I was admitted 4 
times to the hospital to reduce acetone and blood glucose levels as I was 
pregnant. I should get my blood glucose level reduced for the sake of my baby.?  
[Female, age 47 years, 24 months of pump use; interview no. 26] 
 
Table 7.5: Reasons for delayed achievement of glycaemic control on insulin pumps  
Reason Frequency 
Inadequate awareness of all tasks  
Difficulties in working the pump 
Timing of the transition 
2 
1 
1 
 
7.1.3.2 Reasons for not maintaining good blood glucose levels at all times 
throughout the day 
The participants identified several reasons for experiencing hypo-/hyperglycaemic 
episodes on insulin pump. Reasons for experiencing hyperglycaemia ranged from 
lifestyle to pump-related factors (Table 7.6). Non-adherence to diet was reported by 
the majority of participants, as the contributing factor for high blood glucose levels. 
Non-adherence to diet was manifested by eating large portions of food during social 
gatherings, consuming more sweets or having a very late dinner: 
?When I eat large meals, especially sweets, my blood glucose level goes up.? 
[Male, age 67 years, 6 months of pump use; interview no. 37] 
 
?My blood glucose level is usually fine, but I noticed that if I have my dinner very 
late at night, I experience hyperglycaemia.? 
[Female, age 49 years, 72 months of pump use; interview no. 38]  
 
In some cases, where non-adherence to diet was mentioned, it was accompanied 
with other factors, such as forgetting to administer the bolus dose or not counting 
carbohydrates: 
?When I am invited to weddings, I usually eat lots of fats and sweets. Sometimes, 
I forgot to press the button [take the bolus dose], at such occasions; I lose control 
on my blood glucose level and it becomes high.? 
[Male, age 28 years, 72 months of pump use; interview no. 39] 
 
?When I eat a lot ?????????????????????????????????[blood glucose level] goes up, 
but if I adhere to my diet, eat wisely and count the carbohydrate, everything is 
OK.? 
[Female, age 25 years, 1 month of pump use; interview no. 41] 
 
Other factors, which were related to the female gender, were irregular menstruation 
and childbirth: 
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?I feel that because my period is irregular, my blood glucose level is not good all 
the time. Also, every time I have an exam, my blood glucose level becomes high, 
even if I do????????anything.? 
[Female, age 28 years, 18 months of pump use; interview no. 42] 
 
?Sometimes, I get shocked by the readings [blood glucose monitoring]; I feel that 
because I have recently had a new baby. My hormones changed; I think I need to 
adjust it [basal insulin rate].? 
[Female, age 28 years, 24 months of pump use; interview no. 43]  
 
Other factors influenced glycaemic control could be the presence of other co-
????????????????????????????????????????????????????????????????????????????????????
changed. However, in some cases, participants could not identify specific reasons 
for not achieving good glucose control.  
 
Table 7.6: Reasons for experiencing hyperglycaemic episodes, and their frequency   
Reason  Frequency 
Non-adherence to diet  
Non-adherence to therapeutic regimen: 
? Forgetting to take bolus doses 
? Not counting carbohydrates  
Need of dose adjustment (basal insulin) 
Stress due to exams  
Recent child birth   
Irregular menstruation   
Unknown reason  
6 
 
1 
4 
2 
1 
1 
1 
2 
 
In this study, cases of hypoglycaemia, where blood glucose level dropped below 4 
mmol/l were also identified. Hypoglycaemia is the dominant complication of 
intensive insulin therapy (Herman et al., 2005). However, the majority of participants 
(n=6) reported less hypoglycaemic episodes on insulin pump compared to their 
previous insulin therapy (Table 7.7). Insulin pump not only reduced hypoglycaemia, 
but also lessened the severity of the episode in some patients (n=3). In addition, 
three participants added that insulin pump helped to eliminate these episodes at all:  
???????????????????????????????????when I was on the pump, but when I was on 
[insulin] injections and pens, I experienced many times of hypoglycaemia.? 
[Male, age 28 years, 72 months of pump use; interview no.39]  
 
?Hypoglycaemia had been greatly decreased using the pump. When I was on 
[insulin] pens, I always had hypoglycaemia, and sometimes I lost consciousness, 
and was admitted to the hospital many times.?  
[Female, age 28 years, 18 months of pump use; interview no. 42] 
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Table 7.7: Frequency and severity of hypoglycaemia on insulin pumps compared to 
previous insulin therapy  
Patient  Frequency of hypoglycaemia  Severity of hypoglycaemia 
26  Less Same  
37 More  Same  
38 More To Less Same  
39 Less To Nil  Same  
40 Less To Nil  Less  
41 Less To Nil  Less 
42 Less Less 
43 Less  Same  
 
On the other hand, cases of more frequent hypoglycaemic episodes on insulin pump 
were reported. Participants who experienced more hypoglycaemia on insulin pump 
????????????????????????????????????????????????????????????rticipant mentioned that 
she was administering her doses (bolus doses) without counting carbohydrate in her 
???????????????????????????? ????????? ????????????????????????????????????????????
and act as an overdose. The other participant thought that the way in which the 
pump works, secreting insulin continuously, and during sleeping, made him 
vulnerable to overdosing and experiencing hypoglycaemia early at morning:  
?I feel that hypoglycaemia increases when I use the pump. I usually have it early 
in the morning when I wake-up to pray. It goes down to 3-4 [blood glucose level 
in mmol/l], and it lasts about 15 minutes, but after I drink a juice, I feel OK. This is 
because the pump gives me insulin ?????????????? talked to my doctor and he 
said that the dose [basal insulin rate] should be reduced?.  
[Male, age 67 years, 6 months of pump use; interview no. 37] 
 
To consider all the reasons that contributed to hypoglycaemic episodes on insulin 
pumps, all the interview transcripts were revisited, even for patients who 
experienced less hypoglycaemic episodes. Reasons why participants experienced 
hypoglycaemia on the pump therapy are summarised in Table 7.8. In participants 
who were uncertain about the cause of their hypoglycaemia, the reason was 
??????????????????????? 
 
Table 7.8: Causes of hypoglycaemic episodes on insulin pumps and frequency of 
reporting them  
Reason Frequency 
Overdosing  2 
Forgetting to adjust the pump when exercising  1 
Not eating for a long time before sleep  1 
Unknown reason  3 
 
In addition to exploring the effect on hypoglycaemic episodes, participants were 
asked to report whether insulin pumps improved their awareness of hypoglycaemia. 
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Of the 8 participants in this study, five reported better awareness of hypoglycaemia 
on insulin pump, while three stated that their awareness about hypoglycaemia 
remained the same, and they sometimes had low blood glucose levels without 
recognising it (Table 7.9). Moreover, one participant commented that she observed 
a remarkable improvement in recognising hypoglycaemia at all times throughout the 
day, as she was experiencing different symptoms in the morning than in the night:  
?Yes, now I can ????? ???? ????????? ??? ??????????????? ????? ?ifferent [the 
symptoms] in the morning than at night. In the morning, I have a headache and 
nauseas, while at night, I feel ill.? 
[Female, age 47 years, 24 months of pump use; interview no. 26] 
 
Because it was not included in the study objectives, participants were not asked 
during the interviews about their awareness of hyperglycaemia. Thus, not all 
participants discussed it; only one participant added that his awareness of 
hyperglycaemia was improved on the pump: 
?Being on the pump, I can tell whether my blood glucose level is high or low. 
When I need to urinate more frequently, ?????[blood glucose level] high but when I 
feel fatigued and tired, ????????.? 
[Male, age 28 years, 72 months of pump use; interview no. 39] 
 
Table 7.9: Awareness of participants about hypoglycaemic episodes on insulin 
pumps compared to previous insulin therapy 
Patient Awareness of hypoglycaemia 
26 Improved 
37 Improved  
38 Did not change 
39 Improved  
40 Did not change  
41 Improved  
42 Improved 
43 Did not change  
 
7.2 Problems of insulin pumps  
It was crucial to determine safety of insulin pumps in this study, due to the lack of 
data and published studies around the efficacy and safety of this technology among 
adults with type 2 diabetes in similar population. Therefore, during the interviews, 
the researcher asked the participants to report the problems they experienced 
during the pump therapy. Various problems were obtained and identified from the 
interviews; these were classified into clinical, such as inflammation, weight 
gain/loss, and mechanical.  
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7.2.1 Carb counting and weight gain  
Insulin pumps are devices that provide insulin, and could cause side effects, such 
as those occurred with other forms of insulin. In this study, using insulin pumps was 
associated with some clinical problems, such as weight gain/loss, and mechanical 
problems, as emerged from the interviews.  
 
One of the prevalent clinical problems of using insulin pumps in this study was the 
change in participa????????????????????rticipants were divided into two groups, one 
group gained weight and the other maintained or lost weight. The majority of 
participants (n=5) reported a considerable weight gain after the initiation of insulin 
pump therapy, and some added that they even tried to lose weight many times but 
they failed. From the remaining participants, two noticed no changes in their body 
weight, while one reported loss of weight. Because it was evident among this study 
sample, it was crucial to identify factors contributed to weight gain on insulin pumps. 
Therefore, the interview transcripts of participants who reported weight gain were 
reviewed. Likewise, transcripts of other participa???? ?????? ?????? ???????????
remained the same or reduced were examined to explore the reasons behind not 
putting some weight as others. The main reason behind weight gain on insulin 
pumps was non-adherence to diet as a consequence of pump-related factors. Two 
participants mentioned that the effectiveness of the pump in reducing blood glucose 
level, even if they eat large portions and variety of food at anytime, made them feel 
more flexible with eating without blaming themselves. Two other participants stated 
that the simplicity in the pump use was the reason for eating more comfortably, 
having more dietary freedom, and consequently, putting on some weight. Those 
participants explained that the pump helped them in avoiding complex doses 
calculation (bolus and correction doses), which were required with insulin 
injections/pens, and that all what they needed was to press few buttons to 
administer their doses:  
?I have started eating a lot since I put the pump. I???? [the pump] so simple, one 
only need???????????????? blood glucose level and the calories, and it [the pump] 
gives one the correct dose. When I was on [insulin] pens, I needed to calculate 
the dose that matched my blood glucose level and the calories; this is rather 
difficult as one has to try several times until gets it [insulin dose] right! I avoided 
eating enough because of this reason.?  
[Female, age 34 years, 12 months of pump use; interview no. 40] 
 
Other reasons for gaining weight, as raised by the participants could be the reduced 
level of movement deliberately or due to an accident, and to some participants, the 
reason was unknown (Table 7.10). On the other hand, participants who maintained 
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or lost weight on insulin pumps emphasised their adherence to appropriate 
regimens of diet and exercise: 
??? ?????? ???? ???????? ?? ?????? ????? ?????? ?? ?????? ????? ????? ??????? ????? ??? ? ?????? ???
artificial juices either. They contain too much sugar. ????????????????????????????? 
had practised walking 3 days a week before I used the pump, ?????? ????????????
exercising.? 
[Female, age 28 years, 24 months of pump use; interview no. 43] 
 
7.2.2 Skin reactions at cannula-insertion site  
Other clinical problems identified by the participants were related to inflammation 
and bruising resulting from administration procedures. In this study, from the entire 
sample, one participant mentioned that she experienced inflammation at the 
cannula-insertion site, where her skin became red, swollen and painful. This 
participa????????????????????????????????????????????????????????????????????????????
regarding changing the site frequently, every 2-3 days. However, it is worth noting 
that this participant had not achieved glycaemic control for a period of time. 
Therefore, other justification for not achieving good control, in addition to factors 
mentioned in Section 7.1.3 could be due to an occlusion. An occlusion is a common 
problem with insulin pumps, in which a blockage preventing the proper delivery of 
insulin is occurred, and this is usually resolved by changing the infusion site (Ross 
et al., 2015). Three participants in this study reported that they experienced bruising 
at the cannula-insertion site. No reason was identified from the interview transcripts, 
but the participants mentioned resolving this problem by rotating the site regularly. 
One participant added that massaging the coloured skin with ice relieved his 
bruising: 
?It [the pump] colours my skin; it changes it to red, then green, but it [skin marks] 
gets back to normal when I put some ice on. I keep injecting myself in different 
places.?  
[Male, age 28 years, 72 months of pump use; interview no. 39] 
 
A summary of the experienced clinical problems, frequency of reporting them, and 
the reasons for gaining weight in this study are provided in Table 7.10. 
Table 7.10: Clinical problems of insulin pumps and their frequency  
Problem  Frequency  
Bruising  3 
Inflammation and redness  1 
Weight gain 5 
Reasons of weight gain  
Non-adherence to diet  
Reduced level of movement  
Unknown 
4 
3 
2 
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7.2.3 Mechanical problems  
Some participants (n=4) reported mechanical malfunctions, from which three 
required replacing their pumps with new ones. The main problem reported by those 
participants was technical, affecting the pump functions, in which the pump stopped 
working completely. One participant added that her problems started with 
experiencing bolus-delivery problems (the pump was recording bolus doses 
incorrectly), giving false alarms (the pump gave alarms about the need to fill-in the 
?????????????????????????????????????????????????????????????????????????????????????????
then the pump stopped working. It is worth noting that this participant reported not 
achieving glycaemic control for a long period on insulin pump. Therefore, in addition 
to factors mentioned in Section 7.1.3 and Section 7.2.1, the participant thought that 
the mechanical problem she experienced had also contributed to her blood glucose 
deterioration at that period, as she was using her pump for duration of time before it 
had been stopped working completely and replaced: 
?Yes, I feel that my blood glucose level is getting better, although I went through 
times of high [glucose] levels. Perhaps this was because of the malfunction of the 
first pump; I might have been taking inaccurate doses [bolus doses].? 
[Female, age 47 years, 24 months of pump use; interview no.26] 
  
Another participant added tha?????????????????? ? ???????? ????????????????????????
????????? ???????? ??? ?????? ??? ???? ?????? ?????? ???? ????? ???????? ????????? ????
participants replaced them with new ones from the MOH. In one case, a spare pump 
was provided to the participant temporarily until she received the new one, while in 
another case the participant needed to use insulin injections, as she was abroad, 
until she returned to the country and got a new pump: 
?It once stopped working when I was abroad. I called my doctor and he advised 
me to use injections instead. I did that until I came back to Kuwait and replaced it 
[the pump] with a new one.? 
[Female, age 49 years, 72 months of pump use; interview no.38]  
 
One participant reported a different problem from the others, the participant 
explained that her pump stopped working temporarily each time she took it off, to 
swim or take a shower, and re-connect it. This was manifested to the participant 
when she monitored her blood glucose level and found it high. The participant 
reported that she changed the infusion site to resolve this problem. However, it was 
not clear to the participant why this was happening, but the justification could be due 
to a failure or deficiency in delivering insulin into her blood, as a result of an 
occlusion, which is usually resolved by changing the infusion site:  
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?When I want to take a shower or swim, I remove it [the pump] for 1-2 hours, and 
then re-fit it. I have noticed that it [the pump] ???????????????????????????????????
times. If you asked me how I knew that, I would say that I detected it when I 
monitored my blood glucose level that day and found it high. It dropped down 
when I took it [the pump] off and re-connected it.? 
[Female, age 34 years, 12 months of pump use; interview no. 40] 
 
Insulin pumps are new devices that deliver insulin in a continuous manner, which is 
different than any other traditional method. Using such technology requires the 
patient to gain some technical skills, in order to run the device and mange the 
disease during the daily life. Accordingly, patients might need to introduce some 
changes into their daily routines or require assistance from other family members. 
The next two sections Section 7.3 and Section 7.4 describe the experiences of the 
participants in using insulin pumps during their daily life, and whether it had an 
impact on their family members. 
 
7.3 The impact of using insulin pumps on patien????????? 
 
7.3.1 Psychological wellbeing  
The participants were asked during the interviews to describe whether the use of 
insulin pump had an impact on their social lives. Particularly, participants were 
????????????????????????????????????????????????????????????????????????????????????
????? ????????????? ??????? ???????? ?????? ????? ????? ??? ??? ??????? ???????? such as 
??elf-?????????????????????-????????????????????also emerged.  
 
All the participants (n=8) reported their feelings of normalcy in living with the pump. 
Two participants mentioned that at the start of using the pump, they were bothered 
from it being attached all the time, but then they get used to it: 
?At the beginning, I felt bothered wearing it [the pump] all the time, but then I 
used to it???????? ????????????????????? it.? 
[Male, age 67 years, 6 months of pump use; interview no. 37] 
  
In most cases (n=7), the pump had no impact on participa????? ????-confidence. 
Participants reported feeling confident and not ashamed with administering their 
doses via the pump in front of people. From which, two participants added that they 
were embarrassed from using the pump or showing it to others, at the beginning of 
pump use but this feeling was relieved over time:  
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?At the beginning, I tried to hide it [the pump] so as not to be bothered by the 
questions (Why? How? What is this?) ???????????????????????????????????????ind 
showing or using; ????????????????????????????????? 
[Female, age 28 years, 24 months of pump use; interview no.43] 
 
Factors that contributed to participa????? ??????????? ??? ?????? ?????? ??????????? ????
wide prevalence of diabetes in the country, and the expansion in using insulin 
pumps among patients. Having a peer group, persons in the same age range, 
????????????????????????????????????????????? ???????????????????????????????????????-
???????????? 
?Sometimes, the tube of the pump comes out of my cloths, ???? ?? ?????? ????????
Nobody says anything or comments. I feel that diabetes is common nowadays; 
????? ????? ????? ??? ???? ?????????? ????? ???????????? ??????? ???????????????? ?????? ??
know many patients using the pump in the presence of people.? 
[Female, age 28 years, 18 months of pump use; interview no.42]  
 
Insulin pumps were also found to have psychosocial benefits over insulin injection 
and pens. In this regard, one participant reported feeling embarrassed from 
administering her doses in public settings when she was on insulin injections, while 
with the pump it was fine. On the other hand, one participant reported that he had 
not got the confidence to administer his doses even in front of his close family and 
friends, and neither via insulin injections, pens, nor with the pump.  
 
?????? ??? ???? ?????? ???? ???? ??????????? ??? ??????? ???????????? ??? ??rticipa?????
stigmatisation and feeling self-consciousness. Some participants (n=3) reported that 
people were staring on them. However, one participant added that this happened 
long time ago, when she was feeling over looked by others, and this feeling relieved 
over time. The other participants revealed that the pump looks unacceptable, 
particularly, in weddings and parties, when they liked to wear tight dress or jeans 
and t-shirt:  
?The pump is annoying, especially if I want to go to a party and wear a night 
dress, or jeans and T-??????? ???? visible and looks unacceptable. One can easily 
recognise that there is something wrong.? 
[Female, age 34 years, 12 months of pump use; interview no.40] 
 
7.3.2 Daily activities  
In this study, insulin pumps affected the participa?????????????????ties in various ways. 
Some of the activities were listed in the interview schedule, and discussed with the 
participa?????????????????????????????????????????????????? ??????????????????????????????
were emerged ??????????????????????????????????????????????????????????????rticipants 
about sleeping with their insulin pumps were obtained, and it was found that only 
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two participants were still not used to it. The cause of the inconvenience was related 
to the tubing of the pump, where the participants wake-up with their tubing wrapped 
around them:  
?For the whole day, the pump ??? ????????? ???? ??????? ????????? ????? ?????????? ??
always find myself tangled up in the pump tube.? 
[Male, age 28 years, 72 months of pump use; interview no.39]  
 
Although sleeping with insulin pump was initially bothersome, some participants 
found that they get used to it immediately, or they created positions in which they 
sleep with their pumps comfortably. One participant explained that she rolls a lot 
during sleeping, and the pump tubing was bothering her. Interestingly, this 
participant added that over time; her body tended to adjust to the position of the 
pump, and naturally turned in response to discomfort:  
?At the beginning, it was very annoying, especially because I move a lot in bed. I 
find myself wrapped with the tube every day. But now, I got used to it; I 
spontaneously turn right and left. Also, I tend to move the pump according to my 
position; all this happens ???????? ??????????????????[patient laughed].?  
[Female, age 34 years, 12 months of pump use; interview no.40] 
 
?I heard that I have to put it [the pump] under my pillow, but I felt I would be tied 
to it and uncomfortable. Then, I started clipping it to my pyjamas bottom; this 
position is much better.?  
[Female, age 28 years, 24 months of pump use; interview no.43] 
 
Surprisingly, participants (26 and 39) who were still annoyed from sleeping with their 
pumps were not recent pump users, as they were using it long time ago (2-6 years), 
Table 7.2. Thus, sleeping comfortably with the pump is not related to the duration of 
using it rather than being adapted to it, and finding the most convenient position for 
it. For example, wearing the pump belt, to keep it in a fixed position (fastened 
around the waist) or clipping the pump in the pyjama pant (as practised by some 
girls). All these are suitable options, especially for participants who roll a lot. Other 
options, such as putting the pump in the bedside table or under the pillow, as 
practised by some participants could be suitable options for patients with a little 
movement.  
 
Participa???????????????????????????? ??????????????????????????????????????????????
obtained, and from the 8 participants in this study, six mentioned that they were 
exercising happily. Activities mentioned by the participants were walking, going to 
the gym or swimming. Participants were either disconnecting their pumps during the 
exercise and then reconnecting them, or suspending the delivery of insulin for one 
hour. However, the most activity affected by the use of insulin pump mentioned by 
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participants was swimming. Two participants reported that they still feeling upset 
because they have to disconnect the pump and reconnect it afterwards, and pay 
attention not to stay long in the water. From those participa????? ?????? ??? ?????? ????
pump was disadvantageous for practising water-based activities and swimming, and 
that insulin pens were more convenient in these contexts. One participant added 
during the interview that she even thought about turning to insulin pens on the days 
of the sport: 
?My favourite sport is swimming. When I became on [insulin] pens, I swam as 
much as I liked. There were no worries, but with the pump, I have to take care 
not to stay in water more t????????????????????????????????? even been thinking of 
switching to [insulin] pens in order to be able to go swimming.? 
[Female, age 28 years, 24 months of pump use; interview no.43] 
 
Findings of this study suggest that exercising with insulin pumps among the study 
participants was safe, and no problems were raised by any of them. However, one 
participant explained that she was experiencing hypoglycaemia while she was 
???????????????????????????????????????????????????????????????????????????????????
factor was identified to contribute to her blood glucose level going too low, thus, the 
reason was unknown. This participant added that she resolved that problem by 
suspending insulin delivery during her exercise and it went well. However, reasons 
that contributed to that participa?????????????????????????????????????????????? ???????
reducing the basal insulin delivery rate, or not taking carbohydrate before exercise. 
 
Regarding wearing clothes with insulin pumps, the participants in this study were 
divided into two groups. One group (n=4) neither had complaints, nor were they 
annoyed from wearing the pump. The participants mentioned that they could wear 
whatever they want, as before using the pump. They put the pump inside their 
pockets, fastened it around their waist using its belt, or clipping it in their trouser/skirt 
and cover it. The other group of participants (n=4) expressed their dissatisfaction 
from wearing the pump because it limited them to wear particular types of clothes. 
For example, one participant reported that wearing the pump obliged her to wear 
either a trouser or a skirt, to clip her pump in, because she felt uncomfortable when 
she wore Abaya, a traditional women dress, and fixed the pump around her waist 
under the dress. On the other hand, other participants found that wearing traditional 
clothes, e.g. Dishdasha, a traditional men dress, and Abaya, was more suitable for 
the pump, as these dresses are long and wide enough to cover it, in which they 
would be avoided from overlooking.  
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However, only one participant in this study reported a problem with wearing the 
pump. The participant mentioned that at the start, he used to clip his pump to a thigh 
garter, but this option was inconvenient because he suffered from a swollen thigh. It 
was unclear why the participant suffered from such problem. The justification could 
be that the garter was too small and affected the blood flow to his thigh. 
Interestingly, this participant used his sewing skills and modified all his clothes 
(Dishdashas) to a style that allowed him to pass the pump from his pocket, to 
facilitate the administration of his doses (bolus doses): 
?Since I used the pump, I have been wearing it around my thigh, using a garter to 
fix it in. But it was annoying at the beginning, and over time, my thigh became 
larger. Then, I tore-up all the pockets of my Disdashas so as to I can clip it [the 
pump] in my underwear. I passed it [the pump] through the torn pocket easily.? 
[Male, age 67 years, 6 months of pump use; interview no.37] 
 
Some participants (n=4) provided information about travelling with the pump, while 
others did not discuss about it. This could be because the activity was not 
mentioned in the interview schedule, or that the participant had not travelled since 
she/he used the pump. However, there were different viewpoints, some participants 
provided positive comments, while it was bothersome to others. The most common 
???????? ???? ????????? ???? ????? ??????? ??????????? ????? ???? ???????????? ??? ???? ????????
availability of the required insulin (ActrapidR) in pharmacies abroad, and the 
maintained metabolic control:  
?I travell?????? ?? ??? ?????? ?? ????? ???? ?????? ????? ????? ??? ?????????? ???????????
Iran. I liked it [the pump]; ?????????????????????????????????????[insulin] pens. ????????
need to carry too many items anymore, only the pump, which is attached, and the 
insulin ampoule [ActrapidR], which is small. Also, with [insulin] pens, I was always 
worried about how to store them. When I was carrying them in my pocket, I 
??????????????????????????????????????????????????????????????????sually forget my 
medicines at home, when I was on [insulin pens]; I tried my best to get them 
abroad, but they were not available in all countries. On the other hand, the insulin 
used in the pump is available everywhere.? 
[Male, age 67 years, 6 months of pump use; interview no.37] 
 
?I ?????????? ???????? ?? ???????? ???? ?????? ???? ?????????????????? ??????????????
??????????????n Island as well and swam a lot; ????????????????????????????????? 
[Female, age 34 years, 12 months of pump use; interview no. 40] 
 
? ?????????? ???? ????? ???? ?????????d to the annoyance that the participants 
experienced from the security in some airports, and the unsuitability of the pump in 
wearing particular types of clothes: 
??????[the pump] annoying with travelling. At some airports they do???? ????????????
before being examined [scanned with the machine] several times, and they keep 
questioning me about the ???????????????????????????????????????????????????????  
[Female, age 47 years, 24 months of pump use; interview no. 26] 
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?????????? ????????????????????????????????????????made me liable to investigation a 
lot at the security points; they [security] ?? ????????????????? ?????????????????????
Also, in travelling, I like to wear jeans and t-shirts but with it [the pump], I could???? 
it would be visible and looks unacceptable.? 
[Male, age 28 years, 72 months of pump use; interview no. 39] 
 
7.4 The impact of using insulin pumps on family 
 
7.4.1 Worrying about the patie???????????? 
Since the technology of pump therapy was different from other traditional methods, 
the use of such devices prompted family members to worry about their patients. In 
this study, families responded variously regarding the use of insulin pumps. In two 
cases, families were anxious about using a new device. On the other hand, two 
participants mentioned that their families were happy for them being improved and 
satisfied on the pump. One participant reported that her family was ambitious to find 
the solution, which is good glycaemic control with the pump. In two cases, families 
had no response, while in one case, the family had mixed feelings, as they were 
satisfied at the beginning but worried at special occasions. Analysing the interview 
transcripts helped in identifying the factors that affected ?????????????????ns towards 
using insulin pumps (Table 7.11). 
 
Table 7.11: ????????????????????????????????????????????????????????????????????????
feelings, and their frequency  
?????????
perception 
Reason Frequency 
Satisfied 
for pump 
use 
Participant was uncontrolled on insulin injections and 
pens 
1 
Participant achieved glycaemic control on pump  2 
Participa??????????????????? ??????????????????????? 1 
Worried 
about 
pump use 
A new device  3 
Participant experienced irregular blood glucose levels for 
a period of time 
2 
The pump is complicated  1 
Changes in the participa??????????????????pregnancy  1 
 
One participant explained that being uncontrolled for a long time even under 
intensive insulin regimen with injections and pens, prompted her family to 
encourage her using insulin pump. The participant added that her family were 
yearning for reaching normal blood glucose levels with the pump. However, having 
a period of erratic blood glucose levels disappointed the family. Surprisingly, there 
were conflicting views about the use of pump within this participa????? ???????? ????
participa????? ????????????????????????????????????????????????????????????????????????
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device, while her husband, sons and daughters are encouraging her to continue on 
the pump: 
?My husband and family encouraged me to use the pump. I feared from using it 
at the beginning but they supported me. At the same time, they were 
disappointed because they were looking for reaching good blood glucose levels, 
??????????????????????t for a long period. My mother and siblings still feel upset for 
my situation: changing the needle [infusion site], disconnecting and reconnecting 
the pump, and they keep asking me when I discontinue using it??  
[Female, age 47 years, 24 months of pump use; interview no. 26] 
 
In cases (n=2) where families were worrying about using a new device, the 
participants explained that this was because they were insulin injections/pens users 
for a while, and so, families were uncertain about the results they would get from the 
pump. One of those participants added that her family disagreed with her to use the 
pump, and were insisting on discontinuing it, particularly, when the participant 
experienced severe hypoglycaemic episodes at the transition period: 
?When I thought about using the pump, they [her family] ????? ?????? ????????????
device; ????? ??????? ???? ??? ???? ????? ???????????? ????? ?? ???? ?????????????
hypoglycaemia and needed hospital admi???????? ?????????? ???????????????????? ????
[the pump]!?  
[Female, age 49 years, 72 months of pump use; interview no.38] 
 
??? ???? ?????? ???? ??????? ??? ????????? ????????? ???? ???? ??????? ??? ???? ??rticipa?????
situation. The participant reported that her family was not worrying at the start of 
using the pump, but when she became pregnant, she and her family started 
worrying: 
?At the beginning, everything was ok, but when I became pregnant, me and my 
family began to worry. There were lots of question marks because I needed 
caesarean operation. We were worried about how it [the pump] would go during 
the operation? Would I disconnect it? What about after the operation? How I 
would adjust it [basal rate]?? 
[Female, age 28 years, 24 months of pump use; interview no. 43] 
 
On the other hand, families of two participants were satisfied with using insulin 
pumps because the participants themselves were more satisfied and controlled 
compared to insulin injections and pens: 
?Nobody worried about me; I explained to them that it was [the pump] more 
convenient for tra?????????????????????????????????????????????????????????????????
from several injections, so they felt happy.? 
[Male, age 28 years, 72 months of pump use; interview no. 39] 
 
?It has no effect on my family; they only ask me from time to time?????? ????? [the 
pump] going with you? But when I was on [insulin] pens, they were always 
worried, because I looked tired and fatigued.? 
[Female, age 34 years, 12 months of pump use; interview no. 40] 
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However, two participants reported no response from their families regarding the 
use of insulin pumps. One participant added that the concern of his family was 
related to diabetes more than to the pump, especially, if he experienced irregular 
blood glucose levels.  
 
7.4.2 Involvement in the management responsibilities  
Participants were asked during the interviews whether they could manage all the 
tasks associated with insulin pump use, such as doses calculation, carbohydrate 
counting, operation of the pump, changing the infusion set and checking the needle 
site, or that a family member needed to be involved in any of these tasks. A new 
item was emerged during the interviews?????????????????????????????????????????????
study, all participants (n=8) were able to perform all the tasks (e.g. doses 
calculation, carbohydrate counting, operation of the pump, and changing the 
infusion-set and checking the needle site) independently: 
?I was able to do all the pump-related work alone, from A to Z; I needed no help. I 
tried to teach my husband but it was difficult to him? 
[Female, age 34 years, 12 months of pump use; interview no. 40] 
 
For doses calculation, such as insulin boluses and correction doses, almost all 
participants (n=6) explained that they used the Bolus Wizard; a system by which the 
required insulin dose is calculated automatically after typing the blood glucose level 
and the amount of carbohydrate in the meal and snack. However, two participants 
mentioned nothing about carbohydrate counting, and presumably they were taking 
their bolus insulin doses manually by pressing the button after each meal/snack: 
?I know how to make correction doses; I only needed them sometimes, 
particularly, if I was invited to a wedding and had a fatty dinner, where my blood 
glucose level went high. So, I press the button to administer the correction dose.? 
[Male, age 28 years, 72 months of pump use; interview no. 39] 
 
With regard to the pump operation, including setting and re-setting basal insulin 
according to activities, no participant reported intervention from family members. 
However, it is worth noting that in most cases (n=5), participants were still 
dependent on their doctors in adjusting their basal insulin rates. Participants were 
uncertain about their ability to set/re-set their basal doses due to different reasons, 
such as being new to the pump technology, experiencing hormonal changes due to 
recent childbirth, or preferring to double-check doses with the doctor at special 
occasions, e.g. travelling: 
?Before I travel, I visit my doctor to show him my readings [SMBG], and let him 
check my pump and adjust the doses [basal rates] if this was necessary.? 
[Female, age 28 years, 18 months of pump use; interview no. 42] 
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Carbohydrate counting is an important step for patients using insulin pumps, where 
the patient needs to evaluate the amount of carbohydrate in the food; accordingly 
insulin bolus dose is calculated and administered. In this study, all the participants 
mentioned that they did not receive any assistance in performing such task. 
However, it should be noted that not all the participants were completely aware 
about how to calculate carbohydrate. From the 8 participants, three were confident 
in performing such step, and they knew the basic information about it. The 
remaining participants were either knowing nothing about it or misunderstanding it. 
One participant mentioned counting the amount of calories instead of carbohydrate, 
?????? ???????? ?????????? ??????????? ??? ???? ????????? ???? ??????????????? ??? ????????
during the interview:  
?During the appointment, the doctor takes my bloo?????????? ????????????? ??? ?????
not normal, he checks the blood glucose monitoring card [SMBG] with me. Also, 
he [the doctor] asks me about ?????? ? ????????????????????????has taught me 
carbohydrate counting.? 
[Male, age 28 years, 72 months of pump use; interview no. 39] 
 
???????????? ???????????????????????????????????????? ????? [the pump] so simple. One 
only needs to calculate the calories i??????? meal, and it [the pump] calculates 
the dose.? 
[Female, age 34 years, 12 months of pump use; interview no. 40] 
 
Apparently, there was a relation between carbohydrate counting and weight gain 
(Section 7.2.1). All participants who lacked the awareness ?????? ??????????????
????????????????????????????? (e.g. counting calories instead) had gained weight. So, 
they presumed that they were counting carbohydrate but they were not. On the 
other hand, participants who maintained or lost weight were certain about their 
information and demonstrated their adherence to counting carbohydrate contents of 
their meals and snacks. Lack of awareness of carbohydrate counting or not counting 
carbohydrate at all could contribute to excessive consumption of carbohydrate, and 
consequently weight gain (Johnson, 2000).  
 
Using insulin pumps requires that patients change the infusion set regularly (every 
2-3 days), in order to avoid side effects, such as infection, allergy or irritation. 
Infusion-set is a tubing system that connec???????????????????????????????????????????
and attaches to a cannula that should be inserted subcutaneously in fatty-rich 
tissues, such as the abdomen. In this context, all participants revealed that they 
could change the infusion set, and checked the cannula-insertion site themselves. 
However, as emerged from the interviews, the family role was centred on providing 
support to participants and reminding. Support provided by most families (families of 
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5 patients) was related to the management of the disease more than to the pump 
tasks, as it was around encouraging and motivating patients towards adherence to 
healthy diet and exercise.  
 
In addition, some participants (n=5) revealed that their family members were 
accompanying them during exercise or were eating like them. Also, the participants 
revealed on other kinds of support, such as taking care of them when experiencing 
hypoglycaemic episodes (n=3), or accompanying them to the doctor appointments 
or to the pharmacy to collect their prescriptions (n=5). Interestingly, one participant 
stated that she and her sisters, as all were patients with type 2 diabetes, usually talk 
and advise each other regarding their blood glucose readings and other 
management responsibilities. Moreover, the closest family member to the participant 
???????????????????????????????????????????????????????????????????????????????????
was checking blood glucose levels (n=3), followed by administration of bolus doses 
(n=2), and changing the infusion set (n=1). Three participants reported not receiving 
any reminding messages from their families.  
 
7.4.3 Factors that helped patients to perform all pump-related tasks 
To perform all the pump-related tasks, the patient requires technical skills for 
administration of doses, changing and checking the infusion site, and cognitive 
thinking for calculation of doses and carbohydrate counting. As it is obvious from 
Table 7.1?? ??????????????????????? ??????? ??om 25-67 years old. All the participants 
reported their ability to carry out all the pump-related tasks alone without the need of 
any assistance regardless of their age. The competency of the study participants 
and their ability to use electronic devices might be related to their education level, as 
most of them (n=6) had Diploma and Bachelor degrees.   
 
Regarding the ease/difficulty of learning how to use the insulin pump, the 
participants reported that tasks were considered easy to learn. Although there were 
some difficulties from the viewpoint of some participants (n=4), these were at the 
start of using the pump only. Tasks that were considered difficult were doses 
calculation (bolus/basal insulin), and carbohydrate counting: 
?It was easy to learn how to use it [the pump]; ???????mple. The only difficult thing 
was carb counting. It always needs refreshing and following-up ?????????????????
eat the same food everyday. But I can do it; there are many books and 
applications for how to calculate it [carb].?  
[Female, age 28 years, 24 months of pump use; interview no. 43] 
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The infusion set of the pump can be attached in any fatty part of the body, such as 
the abdomen, thighs, buttocks, hips, upper arms or lower back (Rice and Sweeney, 
2008). Although not all participants mentioned about it, some reported that they 
used to choose their abdomen, thighs or hips as sites for the infusion. All these 
parts are considered accessible, which allowed patients to change their infusion 
sets themselves without the need of any assistance. Although this was not raised 
??????? ???? ???????????? ????? ???? ?????????????? ???????? ?????????? ????????? ????????
showing parts of body to others could be a factor that contributed to not involving 
family members in helping with pump-related tasks, such as changing the infusion 
set. Unlike children, adults may feel sensitive from showing parts of body to other 
people.  
 
7.5 Insulin pumps and adherence to treatment  
When comparing between insulin pumps and the previous insulin therapy, 
participants raised information regarding their adherence to treatment and SMBG. 
Analysing the interview transcripts systematically across all cases revealed factors 
that affected adherence to treatment and management responsibilities, which were 
related to the pump technology. 
 
The majority of the participants (n=6) reported more flexible life with insulin pumps 
than with injections and pens. Factors contributed to rigorous life with injections and 
pens were doses schedules, and difficulty in transporting and storage. When they 
were using insulin injections or pens, three participants reported difficulties in 
transporting and storing of items, forgetting items was mentioned in two cases as a 
contributing factor for non-adherence to doses, and one participant stated that 
administering doses in public areas was inconvenient, as it should be taken in parts 
of body, which should be covered according to Islam: 
?It [the pump] eases my life, unlike insulin injections; I was always worrying about 
administering my doses outside home. To take my dose via injection or pen, I 
needed to discontinue the gathering and look for a private place, while with the 
????????? more comfortable.? 
[Female, age 47 years, 24 months of pump use; interview no. 26] 
 
?When I used the [insulin] pens, I was a little bit relieved, but it was still annoying 
in terms of carrying them all the time, and keeping them away from sun light and 
hot weather. Sometimes, I was putting them in my pockets, and when I wanted to 
take my dose, I found the needle bended or broken due to sitting on it. With the 
?????? ?? ?????? ???e any of these worries, and I got used to it; ????? ??????? ?????
injections/pens.? 
[Male, age 28 years, 72 months of pump use; interview no. 39] 
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?Life now is easier. When I was on [insulin] pens, I was always worrying about 
taking my doses outside, especially if I wanted to go to the university. It needed 
to be stored in a fridge, which was difficult to find everywhere. I had to take all my 
lectures in the morning to get back home early and taking my doses.? 
[Female, age 28 years, 18 months of pump use; interview no. 42] 
 
?The pump makes ????????? ?????attached to me all the day, so there is no way to 
forget it. Injections and pens were annoying because I had to carry and use them 
5 times a day. I forgot the needles or the insulin ampoule or everything at home 
many times.? 
[Female, age 28 years, 24 months of pump use; interview no. 43] 
 
Being attached all the time, having the feature of continuous administration of insulin 
doses, the vibrating alarm, and the requirement to change the infusion set every 2-3 
days only, made the use of insulin pumps more flexible than injections and pens. 
Although they are small items, insulin injections or pens require carrying many items 
(e.g. insulin vial and syringe, prefilled pen and needles, or insulin cartridge and 
refillable pen), and paying attention to doses schedules, in which stress could be 
initiated, and the possibility of forgetfulness increased. All those factors in addition to 
difficulty in administering doses outside, particularly for women constituted barriers 
to adherence to treatment.  
 
Other reasons related to the complexity of doses preparation and calculation with 
????????????????????????????????????????????????????????????????????????????????rapy. 
In this study, most participants (n=6) reported that simplicity of doses administration 
via insulin pumps, by pressing few buttons, and having the feature of automatic 
doses calculation (the pump Bolus Wizard) contributed to reducing the complexity of 
the treatment regimen. The use of injections and pens required participants to 
perform several steps, e.g. dose calculation, withdrawal of dose with caution, and 
inserting the needle, in addition it requires paying attention and accuracy. The use 
of insulin pumps helped the participants to avoid laborious dose calculations, and 
enhanced their beliefs about accuracy in dosing. In addition, the participants 
reported their ability to adjust their bolus doses according to their meals and 
activities easily. Taking correction doses, which was a dilemma to most participants 
(n=7) with insulin injections and pens, became easier with the pump. The 
participants reported that they only needed to monitor their blood glucose level and 
immediately adjust their insulin level accordingly. Thus, simplicity of the pump use, 
and its developed technology contributed to improved adherence of most 
participants in this study: 
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?Using the pump is better and easier than using injections. With the injections, I 
??????? ?????????? ?????? ??? ??????????????????? [blood] glucose level, especially at 
??????????????????????????????????????????????????????????????????????????????????
dose or how to calculate it. The pump gives insulin over ??????????????????????????
terms of correction doses. Also, I can adjust it [basal rate] according to my 
activity level.? 
[Female, age 49 years, 72 months of pump use; interview no. 38]  
 
?[Insulin] pe??? ?????? ?????????? ?????, my [blood] glucose level was always 
uncontrolled. The pump calculates and administers the correct dose, according to 
the calories one eats?? ???? ??????? ???? ???? ????? ????? ?????? ????? ???????????? ????
accurate.? 
[Female, age 34 years, 12 months of pump use; interview no. 40] 
 
?It [the pump] gives the accurate dose according to the carbohydrate percentage 
??????????????????[% carb] already written [in the food label]; I just need to type it [in 
the pump]. With [insulin] pens, I might inject more/less than what I need?? ???????
why my [blood] glucose [level] deteriorated. But with the pump, it became ok.?  
[Female, age 28 years, 18 months of pump use; interview no. 42]  
 
Unwanted side effects, such as pain, swelling, bleeding and bruising were reported 
to contribute to treatment non-adherence with insulin injections and pens. Two 
participants mentioned that they were deliberately omitting doses due to fear of side 
effects. Anxiety about self-injection created a barrier to adherence to treatment 
(Brunton, 2008). In contrast, with insulin pumps, the side effects were either reduced 
or disappeared: 
?With [insulin] pens I never felt comfortable, 4 injections [doses] per day; it was 
painful. Sometimes I got swelling I skipped doses to avoid pain and swelling. 
With the pump, there is no pain or swelling.? 
[Female, age 25 years, 1 month of pump use; interview no. 41].  
 
The use of insulin pumps not only improved participa????????????????????????????????
also improved their self-care behaviour, such as SMBG. Frequent monitoring of 
blood glucose level during the day is recommended with insulin pumps to avoid risk 
of diabetic ketoacidosis (Brunton, 2008; Didangelos amd Iliadis, 2011). The majority 
of the participants (n=6) provided different reasons behind this improvement. For 
instance, one participant reported that when she was on injections, she was 
avoiding monitoring her blood glucose level regularly, due to fear of detecting 
hyperglycaemia, in which she needed to take a correction dose via the injection, and 
being vulnerable to its side effects: 
?Before I use the pump, I rarely monitored my blood glucose level because I was 
always worrying about getting high reading, in which I needed to take a 
correction dose, which I hated. With the pump, I monitor my blood glucose level 
2-3 times a day.? 
[Female, age 47 years, 24 months of pump use; interview no. 26]  
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Other reasons provided by the participants were realising the importance of such 
task, and fear of hypoglycaemia. One participant felt that monitoring blood glucose 
level is connected to the use of the pump and is necessary. Another participant 
believed that the continuous delivery of insulin exposed her to hypoglycaemia, in 
which she needed to monitor her blood glucose level more frequently: 
?????? ????????? ???????????? ???????????????? my blood glucose level, but with the 
pump, I monitor it 8 times on daily basis; I believe ???????????????? 
[Female, age 49 years, 72 months of pump use; interview no. 38] 
 
?Before using the pump, I monitored my blood glucose level twice a day, but now 
I monitor it more frequently, because I heard that the pump delivers insulin 24 
hours, so, I worried about getting hypoglycaemia.?  
[Female, age 28 years, 18 months of pump use; interview no. 42] 
 
However, two participants reported that the pump impacted negatively on their 
adherence to SMBG. Factors contributed to reduced adherence were the improved 
awareness of hypo-/hyperglycaemic episodes and the improvement in general 
health:  
?Before using the pump, I monitored my [blood] glucose [level] more frequently. 
Now, I feel safe, comfortable and strong most of time, and that my [blood] 
????????????????????????????????????????????????????????????????? 
[Male, age 67 years, 6 months of pump use; interview no. 37] 
 
?????? ???? ?????? ?? ? ????? ??????? ???????? ???? ???????????? ??poglycaemia and 
???????????????????????????????????????????????[blood] glucose level frequently; I 
only monitor it when I feel the symptoms, just to double-check.?  
[Male, age 28 years, 72 months of pump use; interview no. 39] 
 
One participant mentioned that although it was sometimes annoying, she gets used 
to monitor her blood glucose level regularly. However, the participant reported that 
she heard about the pumps that outfitted with sensors, which gives a continuous 
measurement of blood glucose levels, and liberates the patient from performing 
SMBG several times during the day, and that she would like to use it.  
 
7.5.1 Factors contributed to improved adherence on insulin pumps   
As determined by the WHO, adherence is a multidimensional phenomenon 
???????????????????????????????????????????????????????????????? ???????? (Chapter 1; 
Table 1.2). In this section, the focus will be on dimension four, therapy-related 
factors. Examining t??? ???????? ?????? ????????-???????? ?? ???????? (Table 1.2) 
?????????? ???? ???? ?????????????? ?????????? ??? ???????? ???? ? ??????? ??? ????????
pumps. Correlating between these factors and reports of participants (Section 7.5) 
revealed the reasons for the better adherence on the pump. For instance, the 
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complexity of the treatment regimen, in terms of doses calculation and 
administration, and number of daily doses were less with insulin pumps compared to 
injections and pens. Regarding the techniques required to operate the pump, the 
majority of participants found it easy. Although there were some difficulties in some 
cases, these were at the start of using the pump and became easier over time 
(Section 7.4.3).  
 
Insulin pumps avoided the participants from frequent changes in their medications, 
and all changes they required were in their doses only, which they were able to 
adjust according to their meals and activities. Moreover, with insulin pumps, the 
participants could adjust their doses themselves, without returning to the doctor, 
which enhances the flexibility of the treatment. The majority of participants 
perceived the immediate benefit of insulin pumps, manifested in their improved 
HbA1c levels, blood glucose readings and general health. However, even when 
there were cases in which a period of poor control was experienced at the 
beginning, a subsequent improvement in HbA1c level and/or blood glucose 
monitoring was reported.  
 
In this study, insulin pumps had almost no impact on participa????? ??????????????
wellbeing, and did not cause any stigmatisation for the majority of participants. 
Regarding side effects, insulin pumps were not free from these effects (e.g. 
??????????? ???? ?????? ??? ???? ?????????????? ?????? they were much less than those 
caused by injections and pens (e.g. pain, swelling, bleeding and bruising). Although 
the use of insulin pumps introduced mechanical problems, which were not 
experienced with injections and pens, the occurrence of these problems was 
uncommon, no serious consequences were reported, and replacing the pump with a 
new one was easy and feasible.   
 
With regard to weight gain, the most perceived clinical problem with insulin pumps, 
the participants were not completely depressed for putting some weight. This could 
be because weight gain did not cause an immediate harm, and that the participants 
perceived the benefits of insulin pumps in achieving better control easily with less 
and/or no side effects or psychological impact, and providing a more flexible life 
outweigh the risk of weight gain. The last factor in the dimension, interference of the 
treatment with lifestyle, was more experienced with injections and pens. The 
majority of the study participants reported that the insulin pump was more 
convenient for daily routine, and provided a more flexible life.  
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Before ending up the interviews, the participants were asked whether they prefer to 
continue on insulin pumps or return to insulin injections or pens. All the participants 
commented that they were happy with using the pump, and never thought about 
switching to injections or pens. Reasons identified for preferring insulin pumps 
ranged between glycaemic control and flexible lifestyle. Two participants added that 
they had negative experiences with replacing the pump with insulin pens 
temporarily. The participants commented that their health had deteriorated and their 
blood glucose levels fluctuated during that period. However, two participants 
mentioned occasions, in which they would like to replace the pump with insulin 
pens. One participant reported that annoyance in some airports, and look of the 
pump with wearing casual clothes discouraged him from using it during travelling. 
The other participant mentioned that she would like to replace the pump with insulin 
pens when she wants to practice her favourite sport, swimming. Although it was 
possible to disconnect the pump for an hour and re-connect it, the participant 
reported her frustration from this time limit.  
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7.6 Main findings  
? Insulin pumps offered advantages for participants with type 2 diabetes, and were 
superior to insulin injections and pens in improving ?????????????? ???????
behaviour. Causing weight gain, being worn around-the-clock and inconvenient 
in swimming and wearing particular clothing were counterbalanced by achieved 
good glycaemic control, lifestyle flexibility, freedom from pain, and the portability 
of the pump. Overall, insulin pumps improved the satisfaction of the participants 
and their adherence to doses (Section 7.5).  
 
7.6.1 Contribution of this chapter to this study 
? Describing the participa????? ?????? ???? ???????????? ?????? the use of insulin 
pumps and comparing their use with MDIs enabled the researcher to: 
-Inform policy and guidelines modifications to consider insulin pumps as an 
option for adults with type 2 diabetes. 
-Appraise which groups of patients should be offered the pump therapy based 
on the study findings. For example, to avoid weight gain, the most serious 
problem associated with the pump use, insulin pump should be considered for: 
? A patient with type 2 diabetes who is poorly controlled with MDIs AND 
? Has the commitment to perform all the pump tasks (e.g. carb counting, 
frequent checks of blood glucose) AND 
? Maintain a good health behaviour (e.g. adhering to dietician visits, diet 
and exercise)   
-Discuss a recommendation of (informing patients about the availability of an 
insulin pump and involve them in decision-making) and obtain its importance 
and practicality from the perspectives of HCPs (Chapter 8, Section 8.1.8). 
 
7.6.2 Contribution of this chapter to the literature  
? Although there were many international published studies revealing consistent 
results with this study regarding efficacy, convenience and acceptability of 
insulin pumps among adults with type 2 diabetes, ?????????? ????????????
characteristics and problems associated with the pump use have not been 
adequately reported in the Middle East (only two studies). This study provides 
an update data among Eastern Mediterranean patients with type 2 diabetes that 
may add a benefit to the local literature (Chapter 9, Section 9.2.3).  
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Chapter 8: The perspectives of healthcare providers on the key findings and 
their recommendations  
 
This chapter describes the results of the interviews with HCPs, which were 
conducted at the final stage of this research. As outlined in Chapter 2; Section 2.6, 
the aim of this stage was to explore the perspectives of HCPs on the issues 
identified from the interviews with patients, in wording the key findings, concerns of 
the participants and problems experienced in the management of type 2 diabetes in 
the MOH. Also, it aimed to include recommendations from different HCPs, and 
obtain their views and experiences about the practicality of the recommendations 
made by the researcher, in order to propose service development.  
 
Ten HCPs were interviewed, specialities and working areas of the HCPs is outlined 
in Chapter 3, Section 3.3.3, Table 3.2. Overall, when statements 1 to 10 were 
discussed with the HCPs, half of the statements were agreed by most HCPs (n=6-
10), while the remaining five statements were appropriate from the perspectives of 
some HCPs (n=3-5). Responses of the HCPs to the listed statements and their 
frequency are shown in Appendix 21. Figure 8.1 shows the number of agreements 
for each of the identified issue.  
 
 
Figure 8.1: Number of HCPs who agreed with the provided statements  
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Statements: 
1. Non-adherence to treatment and healthy lifestyle is due to specific  
beliefs about the normalcy of the disease and lack of awareness about 
 its seriousness and complications.  
2. Non-adherence to treatment and healthy lifestyle is due to cultural  
factors, e.g. fasting in Ramadan, use of herbals and social gatherings.  
3. Non-adherence to treatment is due to personal factors, such as  
forgetfulness, laziness, fear of or perceived side effects. 
4. Non-adherence to diet is due to lack of individualised diet plans,  
which conform to patient's social and educational requirements. 
5. Delivery of healthcare services is delayed, especially when referrals 
 are needed. 
6. Pen devices are not prescribed/dispensed for all insulin-dependent  
patients with type 2 diabetes in hospitals. 
7. Certain items, such as small-sized pen needles are mostly unavailable  
in the pharmacy. 
8. Although it is available in Medical Stores, VictozaR pen is not  
dispensed to patients treated in the MOH. 
9. Patients using insulin pumps gain weight due to different reasons,  
e.g. non-adherence to diet and exercise due to belief in control provided  
by the pump, lack of awareness about carb-counting and not using  
pump properly.  
10. Consultation time is not enough to discuss all pump-related issues 
 with the doctor.  
 
Statements  
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8.1 The perspectives of the HCPs about the provided recommendations  
Depending on the issues raised from the interviews with patients, the researcher 
highlighted some recommendations that were derived from data to improve the 
delivery of healthcare services, patie????????????????????????????health outcomes. 
During the interviews with HCPs, the researcher asked them to obtain their views 
and perceptions about the recommendations, in order to describe their importance, 
practicality, relevance and acceptability. Furthermore, the HCPs were asked to add 
further recommendations that were not included when they believed would be 
valuable. Information obtained at this stage helped to identify the most effective and 
locally workable interventions, which were believed likely to improve ??????????????, 
and to address the barriers of employing such services. Generally, most of the 
???????????????? ????? ?????? ??? ????? ????? ????? ??? ?????? ??? ? ???? ? ?????????
(Appendix 22).  
 
A description of the views and experiences of the different HCPs regarding the 
importance of the recommendations, and the facilitators and barriers for applying 
each recommendation is provided below.  
 
8.1.1 Recommendation 1- to improve ?????????? ???????ss about the 
seriousness of type 2 diabetes and its complications  
Half of HCPs (n=5) reported that education is already feasible via lectures and 
campaigns. However, during the interviews with nurses, dieticians and pharmacists, 
themes, such as ???????????????????????????????????????????????????????????????????????????
??? ????????? ????? ???? ???? ???? ??????? as barriers for developing education 
programmes in the MOH:   
?When the information or advice is delivered more frequently, the patients could 
feel how serious their disease is. The main persons who can provide patients 
with continuous education are educators; there are no educators in the Ministry 
[MOH]. Patients see their doctors every 3 months or less, but the educators can 
follow-up patients more frequently via telephone calls, visits, etc.? 
[HCP 3, nurse, urban area] 
 
?We need help from media, radio and TV to show warning video clips. Also, 
before launching any campaign, we need an approval letter from the Ministry 
[MOH], and you know how long these procedures take. Campaigns are already 
doable in public areas, such as the World Diabetes Day, but ??????????t specific 
to educating patients about how serious diabetes is. Besides, campaigns need a 
budget from the Ministry [MOH] or sponsors.? 
[HCP 8, pharmacist, urban area]  
 
A dietician believed group-sessions are the most effective way for educating 
patients with diabetes. If these served, individuals will have the opportunity to share 
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their experiences and thoughts about the disease and its treatment. However, there 
?????????????????????????????? ??????????????????????????????? ????????????????????????
and the appropriate facilities?? 
?Lectures and campaigns are already available but not in a continuous manner. 
Group-sessions are really helpful for patients, especially ?????????????????????????
age group, and have different experiences according to the duration of their 
??????????????? ???????????????????????? ??? ??lk about their disease with family 
?????????????????????????????????????????????????????????????????????????have the 
same condition. The big challenge to apply these [group-sessions] in the 
Ministry [MOH] is that it needs time, staff, place, and complete organisation and 
commitment. Once, we tried to do it [group-session] here in the hospital but it 
????????????oothly. There were not enough facilities; the area was crowded, and 
there was disorganisation: some rooms were occupied by other departments 
without previous reservation. Also, some patients asked for these [group-
sessions] in the evening because they were not able to come in the mornings, 
but we [staff] ?????????????????? working hours; we need approval from the Ministry 
[MOH]. We also need staff who agree to work evenings.? 
[HCP 1, dietician, urban area] 
 
????? ?? ??????????????? viewpoint, to make patients with type 2 diabetes feel the 
seriousness of their disease, they should be aware about its influence not only on 
their health by causing other co-morbidities but also on their family and social life. In 
addition, the psychologist emphasised the importance ??? ? ???????? ??????????
awareness about their mental health, as it could affect the management of their 
disease:  
?We should improve the awareness of patients about the seriousness of type 2 
[diabetes] because it really affects the pati?????????????????????know many cases of 
???????????????????????????????????? ??????????????????????????????????????ess 
about the importance of mental health as well; cases of fear and obsessions 
could make the disease worse.?  
 [HCP 7, psychologist, urban area]   
 
Overall, all HCPs believed that educating patients about the seriousness of their 
disease is a very important issue to consider. Some HCPs reported that education is 
already doable in the MOH, others added that it needs improvement, in terms of 
quantity and quality. Providing patients with general information about diabetes only 
when they firstly diagnosed with the disease is insufficient. Also, the MOH should 
allow diversity in interventions, e.g. supporting education through group-sessions 
and TV programmes. Helping patients to recognise the psychological impact of their 
disease on their lives was also recommended by HCPs to improve the awareness of 
patients about how serious is their disease.  
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8.1.2 Recommendation 2- to address the social and cultural beliefs and the 
lifestyle of patients  
Social and cultural barriers can interfere with diabetes self-management and quality 
of life (Glasgow et al., 2001). Because patients have different socio-cultural lives 
and needs, it was found that identifying social and cultural beliefs and practices of 
patients, including them in their medical notes, and applying them in constructing 
their care plans would optimise the management of the disease, and help patients in 
maintaining behavioural change. Eight HCPs rated this r?????????????? ??? ? ????
? ????????? ???? ???? ??????????? ????? ???? ???????????? ??? ???????? ??????????? ????
???????????????????????????? ???????????????????????????????? 
?Doctors definitely talk about these things [cultural/social beliefs], ???????????????
have time to write these down in the notes. Doctors spend about 15 minutes with 
each patient, and focus more on clinical investigations.?   
[HCP 3, nurse, urban area] 
 
?Lack of time, diabetes coaches, and social workers are big challenges for 
addressing the socio-cultural factors of patients.? 
[HCP 10, pharmacist, mixed area] 
 
One physician commented that some HCPs neglect the socio-cultural part of the 
patients?? ????????? because they are unaware about its significance in the 
management process: 
?The medicine family, such as doctors and nurses need to be aware of the 
importance of considering the cultural and social beliefs in the management of 
diabetes; most of them are unaware of it.? 
[HCP 6, physician, rural area] 
 
Although most HCPs recognised the importance of taking socio-cultural aspects of 
patients into consideration when constructing their care plans, one physician 
outlined that not all HCPs are aware about its significance in the management 
process. However, some HCPs found this recommendation difficult to achieve, 
??????????? ??? ?????????????? ?? ??????????????????????????? and involving them in 
the healthcare team was recommended to ????? ??? ??? ???????? ???? ?????? ??? ?? ?? 
barrier.  
 
8.1.3 Recommendation 3- to initiate ????-??????????????????????????????????? 
During Ramadan fasting, many physiological changes occur in patients with 
diabetes. The secretion of insulin is disrupted leading to increased gluconeogenesis, 
hyperglycaemia and ketoacidosis (Meo and Hassan, 2015). Therefore, medicine-
taking behaviour of some patients during Ramadan could be dangerous, leading to 
serious complications. Different HCPs should be aware about the physiological 
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changes and help patients in managing their disease properly during fasting. From 
the perspective of different HCPs, training courses are helpful to update their 
information and generate consistency in advice that they will provide to patients, 
which helps patients taking the appropriate actions during this month: 
?We all [medical staff] should make sure that we are not providing patients with 
conflicting information, which confuses them.? 
[HCP 1, dietician, urban area] 
 
From the perspective of a dietician, these courses are available in the MOH since 
last year and that the ???????bility of diabetes ????????????? ???????????? ????
implementation of such intervention: 
?????????????[pre-Ramadan training course] doable; it started last year. I attended 
it; it was a 1-day lecture in one of the primary-care units. The audience was the 
junior physicians, dieticians, and nurses, and the lecturers were diabetes 
consultants. They [consultants] talked about how to help patients in managing 
their disease during Ramadan, their diet and medicines.? 
[HCP 2, dietician, rural area] 
 
On the other hand, physicians found that ?lack of resources, educators, incentives 
???? ?? ??? was the main barrier for developing such an intervention, and they 
believed that it might need 5-10 years to be developed: 
?Lack of resources is the big barrier to provide such programmes. To educate a 
huge number of doctors, we need educators; ???????t have well-trained doctors 
who are ?????????????????????????????????????????????????? the consultants receive 
their salaries whether they provide this education or not, some consultants 
would say: why should I educate? Also, it needs commitment from all the staff; 
not all of them wish to attend workshops because of their busy schedules.? 
[HCP 5, physician, urban area] 
 
Generally, all HCPs found that conducting Pre-Ramadan courses for HCPs is very 
important ??? ? ?????? ?????????? ?????????? ??????? ???????? ???????. However, 
although physicians and dieticians emphasised the availability of these courses 
since a year, most HCPs reported challenges. The limited number of diabetes 
consultants and lack of support from the MOH may interrupt the development of 
these courses.  
 
8.1.4 Recommendation 4- to reinforce motivation and education verbally and 
in writing  
??????????????????????????????????????????????????????????????????????????? motivation 
????????????????????????????????????????????????? provided were the main challenges 
in educating patients in the MOH:  
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?These [brochures and leaflets] are available but not continuously. Also, patients 
need something more specific to their cases, and not just general advice. Each 
patient has a ?????????? ??????? ????? ???? ??????? ????????? ????? ?????? ???? ???? ???
beneficial for patients who are just diagnosed with diabetes. So, it needs to meet 
all the population needs. Also, some patients are uneducated, and they interpret 
pictures more than writing.? 
    [HCP 7, psychologist, urban area] 
 
During the interviews with nurses and dieticians, ????????????????????????????????as 
????????????????? ??????????????? education, from which the following sub-th???????????
of resources, incentives, nurses and ?? ?? emerged:  
?We should have more nurses. Nurses can follow up patients??????? more than 
doctors; they can call them every 3 days, once a week, or every 2 weeks and 
have a chat with them about their medicines or any query. Our nurses do this 
themselves; they have a list of the registered patients, and they call them 
?????????????????????????????????????????????????????????????????????????????????? 
[HCP 2, dietician, rural area]    
 
?We need a budget for this. Sometimes we receive brochures and leaflets from 
the pharmaceutical companies. If we have time, we print-out some advice from 
the Internet and distribute this to patients. I????????????????????????? 
    [HCP 4, nurse, rural area] 
 
Physicians and pharmacists commented that reinforcing motivation and education 
might take as long time as 5-10 years. From the perspectives of those HCPs, ??????
of an ??????????????????????????????????????????????????????????????????????????????
barriers: 
?We need educators; ????????????????? ? ??????????????????????????????????????
The Ministry of Health must be aware that lack of educators may affect 
adherence and reduce the efficacy of the treatment.? 
[HCP 5, physician, urban area] 
 
?The big challenge that we face is the ratio of patients to the number of doctors; 
????? ?????????? ????? ???? ????? ?????????????????? ???????? ????? ???? ??? ?????? ?? ?????? ?????
how we can manage that [reinforcing education with each visit] easily. We need 
an education department to work in collaboration with the clinical department of 
diabetes in each hospital.? 
     [HCP 6, physician, rural area]  
 
?We lack the availability of trained professionals in patient motivation and 
empowerment.? 
[HCP 9, pharmacist, mixed area] 
 
Overall, most HCPs (n=7) rated reinforcing education verbally and in writing as 
? ????? ?????????recommendation. Regarding the practicality of such an intervention, 
most HCPs reported that lack of educators who can help in taking the responsibility 
of educating patients continuously and relieve the burden on other HCPs is the main 
barrier.  
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8.1.5 Recommendation 5- to train dieticians to individualise care plans that 
recognise the socio-cultural needs of patients 
From the perspective of physicians, psychologists and pharmacists, it is crucial that 
dieticians undergo training to know how to deal with each patient as an individual 
case, in order to help patients maintaining their behavioural change. However, from 
physicians?? ???? ????????????? viewpoints, this recommendation might take 5-10 
years to be implemented due to ?lack of qualified personnel?, who can provide 
training for dieticians and shortage of staff:  
?I think the problem is the staff shortage. For example, here [in the hospital] we 
have only 4 dieticians, but according to the increasing number of patients, we 
need 10. Sometimes, the staff takes sabbatical leave, or maternity leave, which 
further reduces the number of staff.? 
     [HCP 6, physician, rural area]   
 
?To provide dieticians with the required training, we need qualified dieticians to 
educate others, dieticians who are specialised in diabetes care.? 
[HCP 8, pharmacist, urban area]   
 
When dieticians were asked during the interviews about the importance of applying 
such recommendation, they commented that they are aware of the importance of 
taking socio-cultural factors of patients into consideration. They also added that they 
managed ?????????????????????????????????????????????????? 
?We have fixed diet plans of 1200, 1500, and 1800 calories. I meet with the 
patient and discuss his/her lifestyle, then, decide which regimen I should give 
?? ??????????????? ??? ?????? ??????????? ??? ????????????s lifestyle is unsteady and very 
changeable, I bring an A4 paper and try to create a diet plan specific to the 
???????????????????????? 
[HCP 1, dietician, urban area]   
 
The role of dieticians in providing patients with the appropriate advice, in terms of 
their socio-cultural needs, was supported by the perceptions and views of nurses. 
Nurses commented that the dieticians are competent, and well educated about the 
management of patients according to their needs. However, one dietician reported 
????? ????????? ?? ??????? ????????? ??????? ?????????????? ????????????????????????????
according to their needs all the time: 
?We are well educated about how to treat each patient as an individual case, but 
sometimes the time limits us. Sometimes, we have many patients on the waiting 
list. Attending training courses is beneficial for refreshing our information, but if 
we would attend courses, then, we should run more clinics to serve the high 
number of patients, which means we need more staff.?  
     [HCP 2, dietician, rural area] 
 
Although training dieticians how to individualise care plans accordin?? ??? ??????????
socio-cultural needs was perceived as ? ????? ???????????????????????barriers such 
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as lack of qualified dieticians and time identified to interrupt the practicality of 
implementing this recommendation. Dieticians believed that they were meeting the 
???????????????????????????????????????????????????????????????????????????????????
during clinic rush hours. However, dieticians were eager to attend training regularly 
if this is supported by the MOH.  
 
8.1.6 Recommendation 6- to involve family members when constructing care 
plans  
Adherence to lifestyle modifications, e.g. diet and exercise and maintenance of 
appropriate behaviour requires support and encouragement from the family. Low 
levels of family support constitute a strong psychosocial barrier that could impact 
self-management and quality of life (Glasgow et al., 2001). In the current study, 
awareness of family members about the patients? needs helped them in changing 
and maintaining their behaviour.  
 
From the perspective of the majority of HCPs (n=9), this was a very important 
recommendation, as they believed that social support could help patients in making 
decisions and maintaining behavioural change. The HCPs were aware about the 
importance of social support, and they were attempting to involve family members in 
their appointments:  
?I usually tell my patients to ask one of their family members, or their partners to 
accompany them in the counselling session, specially if the member is part of 
???????????????????????????????????????????? 
[HCP 7, psychologist, urban area] 
 
A dietician found that involving a family member would be helpful only if she/he has 
the responsibility for managing the patient. For instance, in Mediterranean culture, it 
is common that women are responsible for cooking. Therefore, the dietician 
believed that making those responsible women aware about what should be eaten 
and what should be avoided would help in the management of patients. Therefore, 
that dietician was asking male patients to invite their wives to accompany them, but 
was not asking women to invite their husbands, as this was perceived as unhelpful:  
?It depends on the patient. For example, for men, I ask them to bring their wives 
????????????????????????????????????????????????????????????????????????????? ????
???????????????????????????????????????????????????????????????????????????????????
?????? ?????? ???? ???????? ?? ?????? ???? ????? ??? ????? ????r husbands, but sometimes, 
especially if they have other family members having diabetes, they ask me to 
allow them to come along and share the consultation. ???????? ???????, I tell them 
?????????????????????????????????????s you.?  
     [HCP 2, dietician, rural area]  
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Overall, involving family members in the management of patients was perceived 
important by the majority of HCPs. However, some HCPs, such as nurses and 
??????????? ????????? ??? ?-?????????????? ???????????????????????? ?????-relia??? ?????????????
the barriers to involve family members in the consultation. The HCPs added that 
patients frequently give excuses that their family members have no time to 
accompany them, as they have their jobs, or housework. Also, the patients feel they 
are independent, and that the presence of a family member was unnecessary or an 
intrusion. In addition, in the Mediterranean culture, females usually feel jealous of 
other females, especially if they were younger than them and more attractive. So, 
they do not prefer to bring their husbands with them during the visits:  
?Sometimes when I asked female patients to tell their husbands to accompany 
them on their visits, they stared at me and said: Why do you want my husband??  
[HCP 3, nurse, urban area] 
 
????? ????????? ??????????? ?????? ????? ??? ??????????? ????? ??? ??? ????? ??????????
them about to ask their family members to accompany ???????????????????????????
us. T??? ????????? ????? ???????? ????????????? ???? ????? ????? ????? ??? ????? ????
information and go.?  
[HCP 6, physician, rural area]  
 
Therefore, the presence of these personal and cultural barriers hindered some 
HCPs from involving family members ??? ???? ????????????? ??? ?????????? ????? ??????
although they believed in its significance.  
 
8.1.7 Recommendation 7- to coordinate the delivery of healthcare services 
between different departments  
Delays in the delivery of healthcare services, particularly when patients were 
referred to other departments, e.g. cardiovascular, renal or the ophthalmology 
department was prevalent in this study. The researcher explored ??????
perspectives on the importance and practicality of coordinating the care services to 
? ????????????????????. HCPs such as dieticians, nurses and physicians working in 
different areas (e.g. urban and rural) reported several challenges. From the 
responses of HCPs, it was concluded that the failure was not perceived to originate 
with the diabetes team. Different HCPs that they make referrals for patients 
immediately when they required it, because they were aware of how significant is to 
refer patients with diabetes, in order to prevent disease complications: 
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?In the case of my patients, if I find the patient needs a referral to other 
department or doctors, I refer him/her for further investigations without any delay. 
However, the appointments schedule there is crowded [other departments]! I 
?????????? what to do, and I can????????????. For example, if the patient needs to 
see a cardiologist, I refer him/her to the cardiovascular diseases department, but 
making an appointment is not my business. ???????????????? 
[HCP 5, physician, urban area] 
 
However, the HCPs reported some barriers, which were out of their control and 
needed input from the MOH. Physicians, dieticians and nurses reported a ?????????
???????????? ???????? ?????????? ????????????? ?????? ??? ??????????? ????? ??? ????????
???????????????????????? ?????????an ??????????????????????????????????????? ????????????
all the departments that patients with type 2 diabetes need, such as cardiovascular 
and renal departments. One nurse reported that when some patients were referred 
to other departments or for further investigations, they were annoyed because 
buildings are too distant from each other: 
?We need more staff, and we need to be linked to other departments/clinics, 
???????? ????????????????? ??? ?????????????????????? ???????????????????????????
different departments.? 
     [HCP 1, dietician, urban area]   
 
?For each speciality we only have one doctor. One doctor only in the whole 
hospital! For example, there is only one ophthalmologist for the ophthalmological 
examination, the fundoscopy, and the fundus photography. This doctor now is on 
study leave, and the Ministry [MOH] ???????????????????one instead. So, if the 
case is urgent, we refer the patient to Al-bahar Hospital [the Ophthalmology 
Hospital], which is so far from here. Also, there is delay in fixing machines. Once, 
the fundoscopy machine stopped working, so, we postponed the appointments 
until they [MOH] sent the technician to fix it. So, we need more staff.? 
     [HCP 3, nurse, urban area]   
 
?????? ????? ? ???????? ??????? ???? ??????????????????????? ???????????????????????????
need, in one building, such as the foot care, ophthalmology, diet, etc., to facilitate 
patients adhering to their appointments. The patients excuse their non-adherence 
??? ??????? ?????????? ???????? ????? ???? ????? ?????? ????? ???? ???? ???? ??????????
?????????????????????????? ????? ??? ??????????????? [Department] in the Ministry 
[MOH] many times but no one replied to us. In this hospital, we barely got these 
two rooms [clinics] for receiving our patients; one room for the doctor and the 
other for the nurse. Sometimes, if we have enough staff [doctors], we use the 
rooms [clinics] of other departments, such as the Internal Medicine Department to 
receive our patients there. Also, we need cooperation from the MOH. Once we 
ordered a blood pressure monitor but no one replied to us, we waited for 2 years 
until one of the companies provided it to us!? 
[HCP 4, nurse, rural area] 
 
?We have limited resources, for instance, we have only one machine for the x-ray 
and MRI [Magnetic Resonance Imaging] in the hospital for examining diabetic 
feet.? 
     [HCP 6, physician, rural area]   
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One dietician added information regarding coordinating delivery of healthcare 
services within the same department. This dietician mentioned that patients 
sometimes avoided dietician appointments because they were on different days to 
their appointments with doctors, and they could not attend to the hospital frequently. 
Also, the dietician found that sending reminder messages to patients played a role 
in improving their adherence to appointments. However, the ?????? ??? ???????????
theme repeatedly emerged, as the dietician mentioned that she was using her 
private mobile phone:  
?Healthcare professionals should cooperate together and be more flexible with 
patients in arranging their appointments. Patients usually skip their appointments 
????? ??? ???????? ??? ??????t match with their appointments with physicians, and 
??????????????????????????????????????????????????????????????????? ??ts were on 
the same day, they would be more likely to be adherents. Also, sending 
reminding messages to patients is useful; patients like it when they feel that the 
staff are taking care of them. Yet, we need support from the Ministry of Health. I 
used to text patients from my mobile phone because the land line here [in the 
hospital] has not been working for a while, and no one has taken care of it yet!? 
[HCP 1, dietician, urban area]  
 
Generally, all HCPs believed that coordinating delivery of healthcare services is an 
important issue to improve pati???????????????????????????????????????????????????
The majority of HCPs reported deficiencies in the healthcare system, such as lack of 
equipment and appropriate facilities, which should be taken into consideration by 
policy makers in the MOH.  
 
8.1.8 Recommendation 8- to inform patients about different insulin delivery 
methods and involving them in decision-making 
When HCPs were asked during the interviews to provide their perceptions about 
informing patients about different insulin delivery methods, conflicting opinions 
emerged. For example, some HCPs, such as nurses and physicians disagreed with 
this recommendation. Those HCPs reported that patients were not sufficiently aware 
of the issues to select the appropriate method, and that prescribing and deciding on 
?????????????????????????????????????????????????? 
??????????????????????????be applicable. For example, the pump only suits patients 
who are dedicated to perform all the tasks related to it, such as carb counting. 
Some patients might choose the pump, but then ???????????????????roperly, which 
causes problems such as hypoglycaemia and coma.? 
[HCP 4, nurse, rural area]  
 
?We know better than patients, and we have to decide, not they.? 
[Physician 5, physician, urban area] 
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Other HCPs, such as dieticians, psychologists and pharmacists emphasised the 
importance of involving patients in deciding on the appropriate method. They argued 
that patients would choose the option that is acceptable to their psychosocial needs, 
and it would help them in adherence to their treatment: 
?I think this is very important; the patients should use the method which they feel 
more confident about, and not be embarrassed or stigmatised using it in public 
areas. If they [patients] were involved in the decision, it would much improve 
their adherence.? 
[HCP 7, psychologist, urban area]  
 
However, those HCPs believed that implementing this recommendation would need 
a time, in order to overcome the cultural barriers, ????? ??? ???? ??????????-patient 
??????????????????????????????????????????????????????????????????????????????????????? 
?Our doctors ????? ??? ?????????? ????? ????? ????? ??? ????? ?????? ?????? ?????? ???
discuss it with the patients. They [doctors] might discuss the ????????????????????
but at the end they believe they are prescribing the best for the patient.? 
[HCP 8, pharmacist, urban area] 
 
Generally, dieticians, pharmacists and psychologists believed that involving patients 
in deciding the appropriate insulin delivery method is an important issue that should 
be considered by doctors. On the other hand, doctors and nurses believed that 
doctors could decide the most appropriate method for patients better than patients 
themselves. This informs an implication towards the paternalistic approach of 
doctors.  
 
8.1.9 Recommendation 9- to reinforce pharmacists/nurses/psychologists? 
roles in the management of type 2 diabetes 
Roles of HCPs in the MOH compared to doctors is very limited and services, such 
as pharmacist/nurse-led diabetes clinics are lacked in Kuwait. Providing patients 
with such services was efficacious in improving health outcomes in different 
countries in the world and the Middle East (Gill et al., 2008; Al Mazroui et al., 2009). 
Therefore, the researcher listed this recommendation (reinforcing roles of all HCPs 
in the disease management) in the interview schedule for HCPs to discuss it with 
them and obtain challenges of implementing such services in the MOH. All the 
HCPs considered this a crucial issue, as it would improve the awareness of patients, 
their adherence, the management of the disease and consequently health 
outcomes. Also, this would relieve the burden on doctors as well:  
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?Patients must be referred to pharmacists. This is doable abroad, where patients 
meet with the pharmacists and discuss with them different treatment options, 
side effects, and interactions. The patients there are so educated about their 
??????????? ????? ????????? here [in Kuwait]; the patients are not given more than 
?????????????????????? ???????????????????????????????????????????????????? ????????
go for.? 
[HCP 1, dietician, urban area]     
 
?Psychologists are strongly needed to deal with patients with diabetes; I 
experienced many cases, where the patients thought of committing suicide, at 
least once in their life. Also, amongst the important staff is educators.? 
[HCP 3, nurse, urban area]  
 
?This will have a great value as it will allow doctors to spend more time with each 
patient, and discuss more important issues.? 
[HCP 6, physician, rural area]  
 
One dietician reported that including other HCPs, such as psychologists in 
managing patients with type 2 diabetes could be they key for improving ??????????
adherence and health outcomes. The dietician reported that she experienced many 
cases of mild depression, stress or anxiety, for which patients were not having any 
treatment or counselling sessions:  
?I think that involving psychologists would further help patients. There are some 
patients who are difficult to treat because they feel stressed and depressed.?  
[HCP 2, dietician, rural area]    
 
However, there were some differences between urban and rural areas in this issue. 
For instance, the role of psychologists was more apparent in urban areas than in 
rural:  
?We have a psychologist who comes every Thursday, and follows up our 
patients in the clinic, but this is not the case in other hospitals. There, they refer 
the patients who have depression or anxiety to the Psychiatric Hospital.? 
[HCP 5, physician, urban area]   
 
Most HCPs (n=6) reported that there were barriers to implementing clinics led by 
HCPs other than doctors. These were related to patients and the healthcare system. 
???? ????????? ????? ?????????????? ???? ???????? viewpoints, patients have cultural 
beliefs, which prohibited them from visiting HCPs?? ????? ??? ???????? ???????? ????
?????????????????????????? 
?The patients here might reject this idea, or they might not participate in it 
[nurse/pharmacist-led diabetes clinic], because they only trust the doctors. Many 
times when I gave the patients information, they said: We??? ????? the doctor to 
confirm it, or they just listened but then, they would return to the doctor.? 
[HCP 4, nurse, rural area] 
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?The problem is with our patients; they feel stigmatised visiting the psychologist. 
M?????????????????????????????????????????????????????? ????????????????????????
when they visi????? ??????????? ??? ??? ?????????? but they see me only when they 
have time or when they have a problem.? 
[HCP 7, psychologist, urban area] 
 
In addition to the patient-related barriers, there were healthcare system-related 
barriers, such as ????????????????????????????????????????????????? 
?We asked the Ministry [MOH] many times to qualify us [nurses experienced in 
diabetes] ??? ?????????? ????????s?, but the discussion is useless. The process 
just needs criteria for testing nurses, and if the nurses pass the exam, they get 
a certificate for this qualification. Here [in Kuwait], there are no criteria or test for 
this purpose. Once nurses are employed, they just give them a license for 
practisi???????????????????????????????????????????? any follow-up training or tests 
to become diabetes-specialists or educators!? 
 [HCP 3, nurse, urban area] 
 
???????????????????? [clinics led by HCPs other than doctors] would be workable at 
the moment because we have shortage in qualified persons. For instance, the 
pharmacist-led clinic needs a qualified pharmacist to manage the patients, not 
just a general pharmacist. Pharmacists should do a training programme, and be 
experienced in the management of diabetes, but we ?????? ???????? ?????
programmes at the Ministry [MOH]. It might be a matter of time; perhaps it takes 
5-10 years.? 
[HCP 10, pharmacist, mixed area] 
 
On the other hand, from the perspective of a dietician there were some facilitators 
for having pharmacist-led diabetes clinic in the MOH?? ????? ??? ???????????
????????????????????????????????????????????????????????????????????? 
?We have enough pharmacists; all they need is a corner in the pharmacy where 
they can meet the patients to discuss their treatments. Our pharmacists are 
good; they [MOH] should employ some full-time pharmacists for this purpose.? 
[HCP 1, dietician, urban area]     
 
Overall, involving different HCPs in the management of type 2 diabetes was agreed 
??? ???? ???? ????????????? ???? ?????????? ??? ?? ???????? ?????? ??? ? ?????? ??????????
awareness and adherence. However, most HCPs believed that lack of staff and the 
image of HCPs other than doctors would be the main problems to implementing 
such services. This informs an implication to modify the HCPs-patient relationship 
and improv?? ?????????? ?????????? ?????? ???? ??????????? ??? ???? ????? ???? ??????
significance in managing their disease. 
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8.1.10 Recommendation 10- to initiate a 24-hours help-line service managed 
by diabetes specialists  
In this study, some HCPs were very cooperative with patients to the extent that they 
provided them with their private phone numbers, in order that they could be called 
with any query. However, these personal efforts from the HCPs were mostly limited 
to working hours. Therefore, the researcher recommended establishing a 24-hours 
service managed by diabetes specialists. However, HCPs provided conflicting views 
regarding this proposed service. Most HCPs (n=6) found it important to be 
implemented: 
?Sometimes the patient?????????????? ????????????????????????????????????????
all the way to the hospital to discuss it.? 
[HCP 1, dietician, urban area]  
 
One pharmacist and one physician commented that a help-line service managed by 
???????????? ??? ?????? ? ?????????? ???????? ????? found that general practitioners, who 
work in the Emergency Department of the hospitals and those who work in the call 
centre of the MOH are competent and could manage urgent cases of diabetes 
temporarily until they could see their doctors: 
?????? [help-line service managed by specialists] not important. In each hospital, 
we have an Emergency Department. The physicians who work there are able to 
treat all the cases, and to stabilise the patient until the next working day, when 
the diabetes consultant attends.? 
[HCP 6, physician, rural area]   
  
????????? ??phone-line (105) in the Ministry [MOH], which general practitioners 
use to answer ???????????????????????????????????????nts with diabetes. I think this is 
fine; all physicians have the urgent information that any patient needs, not 
necessarily diabetes specialists.?  
[HCP 10, pharmacist, mixed area]    
 
To identify the feasibility of implementing such a service, t?????????????? ?????????
???????????????????????????????????????????????????to this service in the MOH: 
?No, I don???????????????????????????????? such a service needs staff able to work 
night shifts, and they must be paid.?  
[HCP 6, physician, rural area]   
 
?I think such a service needs many resources: computers, a system including all 
???????????????????????????????????????????????????????????????????????????????????-
10 years to be implemented.? 
[HCP 7, psychologist, urban area] 
 
From the interviews with some nurses, physicians and dieticians, it was found that 
? ??????????? ????????????? ???? ??????? ??????????? ??????????? ???? ? ?????????????????????
service. It was noted that most HCPs were eager to help patients. ????????????????? 
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???????????? ???? ?????????? ??? ?????? ????? ??? ?? ???????? ???? ???????ning such 
assistance, and that lack of awareness of policymakers about the importance of the 
service might prevent its implementation: 
?Such a service needs a budget from the Ministry of Health. The policymakers 
need to initiate it; it requires a special team, doctors, nurses and dieticians 
????????????????????????????????????????????????????????????????????????????  
[HCP 1, dietician, urban area]  
 
?We [dieticians] and the nurses usually provide patients with our mobile phone 
numbers to call us or send a WhatsApp for any query, during 12 working hours. 
???? ??? ??? ????????? ???????? ????????????? ???? ????? ???? ???? ?????????? ??? ?? ?????? ????
Ministry [MOH] will recognise the importance of such a service and utilise it.? 
[HCP 2, dietician, rural area] 
 
Although a 24-hour help-line service managed by diabetes specialists was 
perceived important by most HCPs, they reported different challenges to 
implementing such service, e.g. lack of staff and resources. 
 
Overall, recommendations provided in this study were discussed with different 
HCPs who were involved in the management of adults with type 2 diabetes. The 
recommendations were examined by the HCPs for significance (e.g. whether they 
are needed ??? ? ?????????????????????????) and practicality (e.g. whether there are 
barriers to implementing these recommendations). In order to identify the most 
important and feasible interventions, Table 8.1 was constructed.  
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Table 8.1: The importance and practicality of the recommended interventions from 
the perspective of HCPs 
 
???????????????????????????????????????????????
? ?????????? 
Barriers Facilitators 
1. Health awareness of patients, e.g. awareness 
about short and long-term diabetes-related 
complications needs to be improved continuously 
through campaigns, group sessions or lecture 
courses at hospital clinics, primary-care units, 
KDS, or via audio-visual aids, e.g. educational 
programmes in radio and television. (10)  
-Lack of educators  
-Shortage of staff  
-Lack of HCPs? time  
-Inappropriate facility  
-Lack of cooperation from 
MOH to support out of 
working hours sessions  
-Motivated 
HCPs  
2. Social and cultural beliefs and lifestyle concerns 
should be addressed and included ?????????????
medical notes. (8) 
-Lack of social workers 
-??????????????time  
-Poor awareness of some 
HCPs  
-Awareness of 
some HCPs 
3. HCPs should undergo Pre-Ramadan training 
programme, and cooperate together, in order to 
optimise care provided to patients during this 
month. (6) 
-Lack of incentives  -Availability of 
consultants  
4. Educational and motivational advices regarding 
adherence to treatments should be provided 
verbally and written (e.g. brochures/leaflets), and 
reinforced with each clinical visit/prescription of 
medicines. (7) 
-Lack of incentives  
-Lack of support from 
MOH (budget) 
-Needs preparation  
-Lack of time  
-Lack of educators  
-Needs education 
departments 
-Motivated 
HCPs 
5. Dieticians need to be educated about the 
educational and social differences when dealing 
with patients, and how those differences could 
impact self-management behaviour of patients. 
Also, they need to be aware about how to 
individualise care plans that conform to each 
??????????????????????????(6) 
-Shortage of staff  
-Lack of qualified 
personnel to train 
dieticians  
-????????????????????time  
-Competent 
dieticians  
6. Family members should be involved when 
constructing care plans and lifestyle modifications. 
(5) 
-Cultural beliefs of 
patients (women jealous)  
-Time-constraints of 
family members  
-Self-reliant feeling of 
patients  
-Awareness 
and 
commitment of 
HCPs  
7. The delivery of healthcare services should be 
further coordinated particularly, when patients 
needed referrals to different HCPs/department. (8) 
-Lack of connection 
between departments  
-Shortage of staff  
-Lack of medical 
equipment  
- 
8. Patients initiated on insulin should be informed 
about the different methods that are available for 
insulin delivery, e.g. pens and pumps. Also, they 
should be involved in making decisions related to 
the selection of the device. (4) 
-Doctors? oppression  - 
9. Services, such as pharmacist/nurse-led 
diabetes clinics, or psychological interventions that 
take care of this group of patients by incorporating 
different HCPs in the management process should 
be implemented. (7) 
-Lack of training 
programmes for HCPs to 
be more qualified  
-Beliefs of patients in 
doctors experience only  
-Social stigma about 
visiting psychologists  
-Motivated 
staff (nurses, 
pharmacists 
and 
psychologists) 
10. A 24-hours help-line service managed by 
diabetes specialists for urgent and between 
appointments enquiries should be considered. (6)  
-Lack of awareness 
about its importance  
-Lack of resources 
(computer system, staff, 
salaries) 
- 
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Most HCPs identified improving ?????????? awareness about diabetes-related 
complications continuously through campaigns, group sessions or lectures, 
addressing socio-cultural beliefs of patients in their medical notes to consider them 
when managing patients, coordinating care services between different HCPs and 
departments, reinforcing motivational advices verbally and written with each clinical 
visit/prescription of medicines and reinforcing roles of other HCPs by establishing 
diabetes-led clinics, as the most important interventions that need to be considered 
??? ? ?????? ?????????? ??????????? ?????????? (Table 8.1). However, there were 
challenges for implementing such recommendations, these are discussed in 
Section 8.2. 
  
8.2 Theory-informed behavioural change intervention  
This stage enabled the researcher to develop a theory-informed behavioural change 
intervention to implement evidence into practice. For this purpose, the Theoretical 
Domains Framework was used (French et al., 2012). The steps of the framework 
are outlined in Table 8.2, and below is an explanation for how this framework was 
adopted in this study.  
 
Table 8.2: Steps for developing a theory-informed intervention 
Step 1 Who needs to do what differently? 
Step 2 Using a theoretical framework, which barriers and enablers 
need to be addressed? 
Step 3 Which intervention components could overcome the modifiable 
barriers and enhance the enablers? 
Step 4 How can behaviour change be measured and understood?  
 
From findings of this study and the perspectives of HCPs, ????????? poor 
management behaviour (e.g. non-adherence to treatment and lifestyle) was due to: 
specific beliefs about the normalcy of the disease and lack of awareness about its 
seriousness and complications, cultural factors (e.g. fasting in Ramadan, use of 
herbals and social gatherings) and personal factors (e.g. forgetfulness, laziness, 
fear of hypoglycaemia and perceived side effects). Therefore, most HCPs agreed 
with recommendations: 1, 2, 4, 7 and 9 (Table 8.1), in order to improve ??????????
management behaviour and health outcomes. The researcher examined the 
implementation of those recommendations in the light of the Theoretical Domains 
Framework, in order to further assess the practicality of the interventions and inform 
specific recommendations (Table 8.3).  
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Table 8.3: A description of the steps used to choose the behavioural change 
techniques  
Target groups  Domains  Intervention 
components  
Patients with poor HbA1c levels, 
who have: 
 
 
 
1. Knowledge 
2. Beliefs 
-Continuous/attractive 
educational/motivational 
advices delivered via 
lecture, campaigns, 
group-sessions, 
brochures and leaflets.  
 
1. Low awareness about seriousness 
of diabetes and its complications  
2. Beliefs about fasting in Ramadan  
3. Beliefs in efficacy and safety of 
herbal medicines  
4. Forgetfulness, laziness and fear of 
side effects  
 
 
HCPs with poor awareness about 
importance of ??????????????????????
socio-cultural factors  
 
 
 
Knowledge 
-Training 
courses/workshops for 
HCPs to improve their 
awareness, delivered by 
senior consultants. 
-Observations of 
??????????????????????? 
 
 
 
 
Policy makers  
 
 
 
Governmental 
context 
-Addressing ??????
needs to policymakers 
in the MOH, e.g. employ 
educators, increase 
staff, increase resources 
(equipment, hotline, 
facilities) and incentives.   
-Enhancing role of 
psychologists, 
pharmacists and nurses 
via diabetes-led clinics. 
Outcome measures  
Primary  
- Improved adherence measured via interviews with patients  
- Improved HbA1c level measured via blood test  
Secondary  
- Reduced rate of hospital admissions measured via medical records  
 
Table 8.1 summarises the barriers that need to be addressed and modified, such as 
shortage of staff, lack of educators and social workers, poor awareness of some 
????? ?????? ?????????? socio-cultural needs, lack of education departments and 
disconnection between different departments. Also, it clarifies the factor that may 
facilitate behavioural change, which was the competent HCPs (e.g. dieticians, 
physicians and nurses), who had the willingness to educate patients and follow 
them up. Table 8.3 shows the intervention components that may overcome the 
modifiable barriers and enhance the enablers. For instance, to overcome lack of 
?????? ?? ???????????????????????????????????????????? ??? ???????? ???? ? ????????????
employing more staff and involving all the healthcare team in the management 
process. Also, to enhance the enablers (e.g. motivated HCPs) for implementing the 
interventions, incentive and compensation plans need to be designed by the 
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government. The outcome measures would be assessing adherence to medicines, 
diet and exercise via self-report methods, e.g. interviews, and measuring HbA1c 
levels as primary outcome measures and rate of hospital admissions as secondary 
outcome measures. Overall, in this section the required recommendations for 
? ???????? ?????????? ??????????? ?????????? ????? ???????????? ?????????? with the 
HCPs and the most practical interventions were addressed. Barriers to implement 
these interventions were identified from the perceptions of the HCPs.  
 
8.3 Discussion  
This chapter helps to inform healthcare provision through recognising the 
interventions required to initiate behaviour change in patients with type 2 diabetes to 
improve their health outcomes. Most HCPs recommended improving educational 
programmes and involving all the health team in the management process by 
establishing services, such as nurse/pharmacist led-diabetes clinics. To assess the 
benefits of these services, the researcher examined the fundamental parts in 
improving ???????? ??? ??????????? ?????????? ????? ????????????? ?????? ????????? ??? ?????
2012). The results revealed that implementing such services in the MOH would 
need more resources including staff and facilities. Details of the process of each of 
the services are shown in Appendix 23. The outcomes of implementing those 
services would be improvements in health outcomes, in terms of glycaemic control 
and HbA1c levels ??? ?? ???????????? ??? ? ?????????? ??? ?????????? ?????????? ????
adherence to treatment and lifestyle modifications. In the management of diabetes, 
providing education by a multidisciplinary team help in exploring barriers that 
physicians failed to diagnose and consequently promote behavioural change 
(Bernabeo and Holmboe, 2013).  
 
However, a service such as pharmacist-led diabetes clinic may need more than the 
required resources of staff and facilities. To implement such service in Kuwait, the 
pharmacy practice and policy need to be modified and the concepts of 
pharmaceutical care????????????????????the responsible provision of drug therapy for 
the purpose of achieving definite outcomes that improve the patient?s quality of life??
should be interpreted by the government and policy makers (Harding and Taylor, 
2016). Although there are different classifications for pharmacists working in the 
MOH (e.g. pharmacist, chief pharmacist and consultant pharmacist), there is no 
legislation that defines the professional roles of each category (Katoue et al., 2014). 
For instance, the role of pharmacists, in all categories, is limited to dispensing 
prescribed medicines to patients and giving instructions on how to use them, in 
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addition to preparing formulations and other administrative procedures, such as 
annual counting of medicines and registering orders of medicines. In addition, there 
is no national policy that distinguishes between pharmacy technicians and 
pharmacists duties, and both of them can undertake the same responsibilities 
(Katoue et al., 2014). Health care is continuously developing and pharmacists 
should take new responsibilities, in order to influence in their occupation. For 
instance in the UK, consultant pharmacist has advanced roles in patient care, 
professional education and research. Independent pharmacist prescriber can 
prescribe any medicine autonomously for any condition, with the exception of 
controlled drugs for the treatment of addiction (Harding and Taylor, 2016).  
 
In Kuwait, the pharmaceutical care concept is not yet interpreted and further 
improvement in terms of pharmacist-physician and pharmacist-patient relationship is 
needed. In 2006, a study describing the pharmacy practice in hospitals in Kuwait 
revealed that lack of time and lack of staff were the main barriers to implementation 
of pharmaceutical care practice (Awad et al., 2006). In 2014, a study conducted 
among hospital pharmacists to evaluate their contribution to the management of 
patients with type 2 diabetes (Al-Taweel et al., 2014). The study showed that 
pharmacists were enthusiastic to contribute to delivery of pharmaceutical care. 
However, the pharmacists reported barriers to implementing pharmaceutical care 
services, such as pharmacist-?????????? ????????????? ????????????? ??????????? ????
?????????????? ??e by patients.  Pharmaceutical care requires development of inter-
professionalism by reinforcing pharmacist-physician partnership, in which both take 
responsibility of patient care (Katoue et al., 2014). Pharmacists in Kuwait believed 
that continuous training and education would help them in increasing their 
confidence when discussing pharmaceutical care issues with physicians. 
Pharmacists are still seen by patients and doctors as dispensers. To change this 
image, the role of pharmacists needs to be improved to include other services, such 
as prescribing and medication review. 
 
Clinical pharmacy in Kuwait is still not well established. Hospital pharmacists cannot 
???????????????????????????????????????????????????? ????????????????????? ????????and 
monitoring drug therapy until a proper job classification is set. Pharmacists can only 
dispense medicines through typical dispensing windows. This approach of 
medication delivery limits the privacy of counselling and constitutes a barrier in the 
pharmacist-patient relationship (Katoue et al., 2014). Services, such as Medicines 
Use Reviews (a consultation between a pharmacist and patient about the prescribed 
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medications, and giving feedback to the prescriber) and New Medicines Service 
(providing support to patients with long-term conditions receiving new medicines 
aiming to improve their adherence) are internationally accepted (Harding and 
Taylor, 2016). The paternalism of doctors in Kuwait constitutes a barrier to 
implement pharmaceutical care services. From the perspectives of pharmacists, 
doctors will not accept their new responsibilities and roles (Katoue et al., 2014).  
 
Effective team working requires that HCPs understand the roles of each other, 
combine their knowledge and skills, and share the responsibility for outcomes 
(Harding and Taylor, 2016). However, the leadership concept of doctors in Kuwait 
may introduce tensions within the team. This concept is historical and needs time to 
be changed. Doctors need to recognise the importance of inter-professional 
communication. For instance, in hospitals in Kuwait, patients with type 2 diabetes 
are still managed through manual medical notes and prescriptions, which written by 
doctors. Even for a repeated prescription, pharmacists have to obtain ?????????
approval to dispense it. The complete authority of doctors imposes the 
communication between them and pharmacists in different situations. For example, 
to discuss unclear handwriting, unavailable prescribed medicine/item, etc. 
Communications between doctors and pharmacists usually ended up with 
????????????? ????????????? ??? ?? ??????? ??? ????????? ?????????? This may reduce the 
motivation of pharmacists to be involved in communication with doctors. Lack of 
communication may create situations of medication errors and constitute a threat to 
???????????????????????????????????Gallagher & Gallagher, 2012).   
 
Putting patients at the heart of care delivery, working in partnerships with them and 
ensuring that their care choices are respected, which is identified as the patient-
centred professionalism, is recommended in all aspects of health professions 
(Hutchings and Rapport, 2012). The significance of engaging patients in their 
treatment choices, after being provided sufficient information, should be addressed. 
In the UK, embedding the patient-centred professional approach became a part of 
good medical, nursing and pharmaceutical practice (Hutchings and Rapport, 2012). 
In order to provide the best healthcare?? ??? ??? ???????? ????????????????????perceptions 
about what is important in the treatment they receive. For example, in the USA, it 
was reported that good communication skills and compassion was what patients 
perceived important in their doctors (Wiggins et al., 2009). In the UK, in the context 
of pharmacy, receiving the correct prescription was perceived as the patient-centred 
professionalism to patients (Rapport et al., 2010).  
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In Kuwait, moving from paternalistic approach, where clinicians make decisions with 
little or no input from patients, toward patient-centred professional approach should 
be emphasized. Nowadays patients have broader access to information (e.g. 
Internet), so, they prefer to work in partnerships with their doctors and make their 
health-related decisions based on their beliefs and preferences (Bernabeo and 
Holmboe, 2013). To implement such approach in the MOH, efforts need to be 
?????????????????????????????????????HCPs will need specific knowledge, beliefs and 
attitudes to engage patients and identify the degree of engagement. Cultural 
?????????????????????????????????????????????????????????????????????????????????? 
Lack of knowledge and self-efficacy and the perception about ????? ??? ???????????
respect to their preferences may all impact the engagement of patients in their 
treatment choices (Bernabeo and Holmboe, 2013). This may inform implications for 
future research, policy makers and the government. Future research should be 
conducted to identify skills required by patients, HCPs and healthcare system to 
adopt such an approach. Policy makers should then organise consultation 
workshops to professionals and stakeholders to inform them about these skills and 
make it a part of continuous professional development. The government should 
ensure introducing such information in the development of medical curricula.  
 
Different organised approaches towards delivering high quality diabetes care can be 
used as alternat????? ??? ???????????? ??????????? ??? ????????? ???????????????
Implementing models that promote empowerment, such as Shared Medical 
Appointments (SMAs) have been identified superior in improving knowledge and 
behaviour of patients with type 2 diabetes than traditional provider visits (Ridge, 
2012). SMAs involve the implementation of educational interventions, which through 
behavioural strategies enhance ?????????? coping and problem-solving, leading to 
behavioural change. There are no standards for delivering such model of care, and 
it can be applied in different ways. For instance, it can be delivered as a group of 
10-20 patients. Various HCPs can be a component of the healthcare team of this 
model, such as physicians, nurses, dieticians and psychologists. Implementing such 
model does not require any training beyond standards of diabetes care. Taking into 
consideration such model of care by policy makers in the MOH will facilitate the 
interactions between patients and their HCPs and support the cooperation between 
them (Ridge, 2012).  
 
From findings of this study and the perspectives of the HCPs, this chapter 
introduced a theoretical framework for what should be done and how, in order to 
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improve the management of type 2 diabetes in Kuwait. The interviews with HCPs 
confirmed the issues emerged from this study regarding the prevalence of non-
adherence and misuse of medicines and devices by adults with type 2 diabetes. It 
has been concluded from this chapter that improving health awareness and beliefs 
about type 2 diabetes is the key towards improving medicine-taking behaviour of 
?????????? ???? ?????? ??????? ?????????? ???????????? ?????????? ?????????? ???? ????????
about their disease and treatment by HCPs is crucial to promote behavioural 
change and treatment adherence as a consequence to improved satisfaction 
(Wens, et al., 2005; Bernabeo and Holmboe, 2013).  
 
Implementing educational services, which are not based on research evidence may 
not give the desired outcomes (Cooper et al., 2008). In Kuwait, diabetes education 
is provided to all newly diagnosed patients with type 2 diabetes but no 
comprehensive evidence-based programme is used. Therefore, the potential 
behaviour change techniques that were identified in this study and discussed with 
HCPs will assist in informing the most practical and locally relevant interventions. 
Many barriers were identified, which makes the implementation of such 
interventions and partnerships between patients and professionals challenging. 
These barriers should be targeted by the government, in order to improve the quality 
of diabetes care and the health outcomes.  
 
An overall discussion and conclusion is provided in the next chapter (Chapter 9). 
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Chapter 9: Discussion and conclusion  
 
This chapter provides an overall review of the study findings, discusses the results 
in the light of literature and highlights the policy and practice implications of the 
study.  
 
9.1 Overview of the study findings  
Conducting this study was vital as there is a lack of published studies that explore 
??????????????????????on the use of medicines and devices in the Middle East and 
particularly in Kuwait. Targeting patients with type 2 diabetes was significant, as this 
disease becomes a pandemic in the Arab world (Chapter 1). Although care services 
are accessible to all patients in Kuwait, health outcomes are not propitious and the 
majority of patients could not achieve target levels of HbA1c. This study aimed to 
explore the factors that impacted the ????????????????????????????????????????????
???? ????? ??? ???????? ???????? ??? ? ???????? ?????????? ?????????? ???? ??? ????????? ????
perspectives of HCPs on the issues identified. This is crucial for revealing the 
factors that contributed to poor health behaviour, highlighting the benefits of insulin 
devices and proposing service development, in order to improve health outcomes. 
Evaluating the implementation of targeted interventions was also considered. This is 
important to inform the concerns of the HCPs and the utilisation of healthcare 
resources.  
 
Assessing non-adherence to medicines, using different methods in this study 
showed that there was a proportion of patients who did not use their medicines 
properly. MMAS-8 ??????????????????????????????????????? level from low to high; the 
majority of participants (n=26) had low to medium adherence level. Obtaining data 
on HbA1c levels revealed that more than half of participants (n=24) had uncontrolled 
disease. When assessed using semi-structured interviews, 19 participants reported 
different practices and behaviours that were inconsistent with ?????? ?????????
recommendations. 
 
??? ??????????? ???? ???????? ????? ??????????? ?????????? ??????????? ?????????, a 
systematic approach to data analysis was undertaken. This revealed a number of 
overarching themes, such as impact of beliefs/culture on medicine-taking behaviour, 
? ????? ??? ?????? ?????????????????????? ?????????? ???????????? ??????????? ????????????
using insulin pens/pumps and other self-care behaviours. To understand the factors 
that impede the delivery of a high quality diabetes care, from the perspectives of 
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HCPs, the overarching themes (facilitators/barriers to implementing behavioural 
interventions) were firstly allocated. Designating the overarching themes aided in 
understanding the broad picture of the topic and allowed to confirm that all the study 
objectives have been met. Also, it helped to identify factors of different levels (e.g. 
health profession, social, personal) that might influence behavioural change and to 
avoid overlooking important factors. This was important, as it led to identifying all the 
techniques that might work and assessing their acceptability and feasibility. As data 
analysis processed, new themes were identified and fitted into the overarching 
themes. For example, beliefs about the disease, medicines and self-beliefs were 
fitted under (impact of beliefs/culture on medicine-taking behaviour). Shortage of 
staff and lack of time were allocated under (barriers to implementing behavioural 
interventions). Table 9.1 shows a comprehensive data on the identified themes as 
reported in the result chapters of this thesis.  
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Table 9.1: The themes identified under each overarching theme  
No. Overarching themes/Themes  Chapter (where 
themes have 
been discussed) 
(1) Impact of beliefs/culture on medicine-taking 
behaviour 
Themes: 
-Beliefs about the disease  
-Beliefs about medicines  
-Perceived barriers  
-Self-beliefs  
5 
(2) 
 
I???????????????????????????????????????????????
life/health behaviour 
Themes:  
-Glycaemic control/hypoglycaemia  
-Ease of use and convenience  
-Dosing accuracy and confidence  
-Daily activities  
-Impact on family members  
-Overall preference and acceptance  
6+7 
(3) Problems of using insulin pens/pumps 
Themes:  
-Pain 
-Injection-site reactions  
-Weight gain  
-Mechanical problems  
6+7 
(4) Self-care behaviours 
Themes: 
-Awareness about the benefits of SMBG, diet, 
exercise  
-Perceived barrier to regular SMBG, diet, exercise  
5 
(5) Facilitators to implementing behavioural 
interventions 
Themes: 
-Availability of consultants 
-Motivated HCPs (physicians, nurses, pharmacists 
and dieticians) 
8 
(6) Barriers to implementing behavioural 
interventions 
Themes: 
-Lack of educators 
-Shortage of staff 
-Lack of facilities  
-Lack of support/incentives  
-Cultural beliefs  
-Time-constraints  
8 
 
The HBM was used in this study as a tool to help in constructing the emerged 
themes under the identified components of the model. For instance, under 
perceived threat, beliefs about the disease were organised. Under the perceived 
benefits, different beliefs about medicines were explained. Adverse effects, fear of 
Chapter 9: Discussion and conclusion  
 
hypoglycaemia and social gatherings were considered as perceived barriers. Self-
beliefs about the ability to control the disease were explained according to self-
efficacy construct of the model. The HBM is the most comprehensive model for 
understanding the predictors of health-related behaviour. It provides a systematic 
method of moving from the belief to the motivation to do the action to the target 
health behaviour. It has been recommended to use the HBM as a framework for 
explaining and improving the behaviour of patients with diabetes by focusing on 
relevant attitudes and beliefs (Jalilian et al., 2014). In this study, the use of such 
model enabled to identify minimising the severity and low self-efficacy as the most 
influential predictors of poor heath behaviour. However, there is a limitation in using 
the HBM, as it does not predict the impact of subjective norms, although the role of 
social support in predicting health behaviour has been identified in this study. 
Overall, taking into consideration the factors that affected ??????????management 
behaviours, the advantages of using insulin devices and the recommendations of 
the HCPs will assist in improving the management of type 2 diabetes and health 
outcomes.  
 
9.2 Study findings in the context of published literature  
 
9.2.1 Medication adherence and health beliefs   
Results of this study, about non-adherence to treatment among the participants, 
were not surprising and were comparable to results obtained from other researchers 
in the Middle East. Many authors who assessed adherence of patients with type 2 
diabetes reported poor adherence levels (Shams and Barakat, 2010; AlHewiti, 2014; 
Sweileh et al., 2014; Ashur et al., 2015). For instance, Shams and Barakat (2010) 
reported that 61% of participants had poor adherence. However, that study included 
patients using OHAs only, and used invalidated questionnaire for assessing 
adherence (the Measure Treatment Adherence scale). In Saudi Arabia, about 43-
51% of participants had low adherence scores on MMAS, while in Libya 36% of 
participants had low medication adherence (AlHewiti, 2014; Ashur et al., 2015). Only 
one study, which was conducted in Qatar, reported good adherence among patients 
with diabetes (Bener et al., 2014). However, Those authors did not provide an 
overall percentage of adherence but reported the responses to each individual item 
of MMAS-8. Also, that study included patients with both type 1 and type 2 diabetes.  
 
Assessing adherence of patients would have no advantage if reasons behind non-
adherence were not explored. Thus, the focus of this study was to examine the 
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factors that impacted health behaviours of participants, in order to propose target 
interventions. Particularly, the study explored factors related to health awareness, 
beliefs and culture. Results of this study revealed that lack of health awareness 
about diabetes and its complications resulted in normalising the disease and 
underestimating its seriousness, and consequently non-adherence to treatment. 
Type 2 diabetes is a silent disease, the lack of unpleasant symptoms might make 
the disease seen as not serious by the patients and consequently reduce their 
motivation to adhere to self-management behaviour (Dunning and Martin, 1998; 
Virginia, 2013). Realising the seriousness of diabetes motivate patients to 
accommodate diabetes and its treatment, and to introduce necessary changes in 
their daily ro??????? ??? ?????????????????????Poor awareness about medicines was 
also identified. In this study, some insulin-dependent participants were omitting their 
insulin doses when they missed their meals or snacks without monitoring their blood 
glucose levels, due to fear of hypoglycaemia. Patients using insulin perceive the 
disadvantages to outweigh the benefits (Dunning and Martin, 1998). Other authors 
also reported an a??????????? ???????? ?????????? ?????????? ?????? ????????? ???? ????
complications, the awareness about the consequences of poor adherence, beliefs 
about medicines and adherence to OHAs (Shams and Barakat, 2010). 
 
Sweileh et al. (2014) reported that patients with low beliefs about the necessity of 
medicines, and high concern about their adverse effects were more likely to misuse 
their medicines. Another study reported low adherence prevalence among patients 
with negative beliefs about medicines as a consequence of inadequate information 
???????? ???? ??????? ?????????? ??? ???????????? ???????? ?????????? ?????????? ??????
their treatment, their beliefs about medicines and adherence (AlHewiti, 2014). When 
patients were given sufficient information about the use of their medicines and their 
potential problems, they had strong beliefs about the necessity of taking them, and 
low concerns about their adverse effects (Khan et al., 2012).  
 
One of the common beliefs expressed in this study, which was specific to patients in 
all Middle-Eastern countries and impacted their medicine-taking behaviour, was 
belief about herbal medicines. People in the Middle East use herbal medicines in 
the treatment of minor ailments, such as common cold and flu and for treating 
chronic diseases, such as hypertension, asthma and diabetes (Saad et al., 2005). In 
a study by Abahussain and El-Zubier (2005) in Saudi Arabia, it was found that 
patients stopped taking their anti-diabetic treatment, and controlled their diabetes 
with herbals only. The authors commented that the behaviour of those patients was 
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a consequence to their lack of awareness about the role of medical medicines. 
Results of the current study were consistent with what was found in the literature. A 
significant proportion, nearly half of the study sample, used herbal medicines to 
manage their diabetes. Some participants delayed their medical treatment until the 
failure of the herbal treatment, or they abstained from their medical treatment while 
using herbals. The strong belief in the efficacy and safety of herbal medicines, and 
the confidence in what people negotiate between each other encouraged the 
participants to attempt these products without informing their doctors. Although 
there were no hazards as a consequence to the use of herbals from the perspective 
of some participants, their use should be addressed and further regulated.  
 
Practising holy ordinances such as fasting in Ramadan could affect adherence 
behaviour of patients; a study revealed that 25-33% of patients using OHAs or 
insulin changed their medicine use, e.g. reducing their OHAs intake in Ramadan 
(Salti et al., 2004). In that study, it was found that 20% of patients using OHAs and 
37% of patients using insulin have changed their doses in Ramadan without 
experiencing severe complications due to these changes. Some patients feel more 
comfortable consulting their friends or family rather than HCPs regarding their 
behavioural changes with respect to Ramadan and medicines. Only few patients 
??????????????????????????????????????????????????????????????????????????????????
(Mygind et al., 2013). However, one of the explanations that patients made to 
explain their behaviour is that during fasting, they do not eat traditional foodstuff, 
thus, taking their OHAs as usual will affect them and expose them to side effects 
(Lawton et al., 2005).  
 
Results of the current study were very similar to those obtained by other authors 
(Lawton et al., 2005; Mygind et al., 2013). Most participants reported behavioural 
changes, e.g. missing OHAs and/or insulin doses in Ramadan without consulting 
their doctors. The participants believed in the necessity of making such changes, 
otherwise they would be more likely to get hypoglycaemia. From the perspectives of 
participants, eating fewer meals in Ramadan exposes them to hypoglycaemia; thus, 
they were missing doses of OHAs and/or insulin without checking their blood 
glucose levels and without considering the amount and type of food they were 
eating during this month. However, it can be predicted that lack of severe 
complications during this month could contribute to continue on poor management 
behaviours.  
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As this study examined health behaviours in the light of HBM, other studies that 
used this model to examine behaviour of patients with diabetes were reviewed. In 
one study, it was found that patients with type 2 diabetes who perceived that 
diabetes is a serious disease, had less perceived barriers, and who were given 
more frequent information, were most likely to engage in diabetes self-management 
behaviour (Ayele et al., 2012). The study suggested that social cues or prompts to 
self-management were most important for determining the behaviour. This is a 
construct that is considered within the HBM but has not been adequately studied 
(Jones et al., 2015). Low social support, low self-efficacy and barriers to self-care 
were also determinants of poor management behaviour in Hispanic women with 
diabetes (Mansyur et al., 2015). According to findings of Harwood and colleagues in 
2013, in a Cambridgeshire practice, it was suggested that all patients with diabetes 
should be screened for perceived barriers to self-management behaviour, and that 
this information should be used to tailor patients care to suit their individual needs 
(Harwood et al., 2013). Perceived barriers, such as weight gain and hypoglycaemia 
were found to be significant risk factors for insulin injection omission among patients 
with type 2 diabetes (Farsaei et al., 2014).   
 
In the current study, viewing the results through the lens of the HBM suggests that 
perceived severity and beliefs about the seriousness of type 2 diabetes are strong 
predictors of medication adherence followed by high self-efficacy. Perceived 
barriers, such as fear of hypoglycaemia, side effects and social stigma were 
equivalent in importance as beliefs about the benefits of taking medicines in 
influencing ?????????????? ??????? ?????????. These results are slightly different than 
what Dehghani-Tafti et al. (2015) found in their study. When they examined the 
impact of the HBM constructs on self-care behaviour of patients with diabetes using 
a questionnaire, self-efficacy and perceived barriers were the strongest predictors of 
??????????????-care behaviour and that severity and benefits were of less significance. 
Self-????????????? ????? ?? ??????? ?????????? ??? ?????????? ????-management behaviours 
and glycaemic control in Jordan and Libya (Al-Khawaldeh et al., 2012; Elkharam et 
al., 2013). Other authors found that patients with type 2 diabetes who went through 
an educational programme to improve their knowledge about severity, susceptibility, 
benefits, barriers and self-efficacy showed significant improvements in self-
management behaviour (Jalilian et al., 2014). On the other hand, although they 
perceived the seriousness of type 2 diabetes, and believed in the benefits of 
medicines, patients in Saudi Arabia had poor glycaemic control and developed 
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complications, as a consequence to poor adherence to treatments (de Villiers and 
Halabi, 2015).  
 
Because they are integral parts in the management of type 2 diabetes, the current 
study investigated to a less extent the impact of knowledge, beliefs and culture on 
adherence to other self-management behaviours, such as SMBG, diet and exercise. 
Many participants in this study were not performing SMBG regularly because they 
lacked the awareness about its importance. Also, there were other barriers, such as 
pain and unavailability of the test stripes in the MOH. Although most of the study 
participants were aware and confident in the role of diet and regular physical activity 
in achieving and maintaining glycaemic control, they poorly adhered to healthy 
lifestyle. It was found that the participants lacked the nutritional awareness and 
believed that abstaining from sweets and fatty food is sufficient to provide control. In 
addition to poor health awareness there were some specific beliefs, which reduced 
the participants motivation to adherence to healthy lifestyle such as God-locus of 
control, stress as a contributor to elevated blood glucose levels, and the sufficiency 
of housework in providing control, particularly in women. Moreover, cultural factors 
?????????? ?????? ??? ??????? ?????????????? ?????????? ??? ????? ?????????????????? ?????l 
gatherings, lack of time and hot weather. This was supported by findings of Shams 
and Barakat (2010), where about three-quarter of the participants found to poorly 
adhere to SMBG, diet and exercise because they lacked the awareness of their 
importance in managing and controlling diabetes.  
 
Type 2 diabetes is a psychologically and behaviourally challenging chronic disease 
????? ???????? ???? ?????????? ???????? ??? ?????? ??? ?????? ??? ???????? ?????????? ???????? ????
avoid the disease complications, such as retinopathy, nephropathy and peripheral 
neuropathy, patients are required to follow a lifelong and complex treatment regimen 
including daily taking of medications and or insulin administration, SMBG, regulation 
of diet and regular exercise. Coordinating all these behavioural tasks is challenging 
to many patients (Peyrot et al., 2005). This study supported the hypothesis 
regarding the role of illness and treatment perceptions in explaining behavioural 
changes, and that health beliefs and culture affected the management behaviour of 
the participants.  
 
9.2.2 Insulin pens in the management of type 2 diabetes  
The role of pen devices in insulin delivery has become vital, and outweighs the use 
of syringe and vial in many parts of the world. It has been found that pen devices 
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enhanced patient comfort and reduced the daily burden of diabetes management 
(Luijf and DeVries, 2010). To compare the investigated results with those existed in 
the literature, a comprehensive literature search was performed. Initially, the search 
was limited to studies conducted in the Middle East, but due to the scarcity of the 
published studies; only two studies (Hamdy et al., 1994; Tschiedel et al., 2014), the 
search was extended to international areas. 
 
Glycaemic control 
Although the current study revealed improved glycaemic control on insulin pen, this 
was only reported by the participants during the interviews, and was mostly 
???????????????????????????????????????????????????????????????????????????????????????
from the literature had revealed no significant differences in glycaemic control when 
a group of insulin-dependent patients were randomised to use insulin pen, and the 
results were compared with a control group who continued using the syringe and 
vial. Hamdy and colleagues (1994) in their study reported non-significant changes in 
HbA1c levels after the 3-months study period. The authors added that changes in 
the mean daily plasma glucose were also non-significant (8.5 +/- 2.3 at baseline 
versus 8.2 +/- 2.1 mmol/l after the pen use). However, in some studies where the 
use of insulin pen was examined on patients over 60 years old, it was associated 
with perceived clinical efficacy, quality of life, and an improvement in metabolic 
control as measured in HbA1c levels (Corsi et al., 1997; Rubin and Peyrot, 2004). In 
addition, in a study by Lee et al. (2009), a significant reduction in fasting blood 
glucose levels has been reported in the group who used insulin pen than the group 
who continued using syringe and vial, reduction in HbA1c levels has also been 
reported but were not significant.  
 
Regarding hypoglycaemic events, the current study reported less or the same 
frequency of hypoglycaemia in most participants, who were converted from syringe 
and vial to insulin pen. From participants who directly used insulin pens, about half 
of them reported no or rare hypoglycaemic events, while the other half reported 
experiencing hypoglycaemia sometimes. Consistent results were also reported in 
other studies, where the substitution of syringe and vial with insulin pen provided 
patients with better metabolic control and fewer hypoglycaemic episodes (Albano 
and Orbiter Study Group, 2004; Lee et al., 2006; Cobden et al., 2007; Bastian et al., 
2011). However, Hamdy and colleagues (1994) reported that using insulin pen 
caused no clinical differences in the frequency and severity of hypoglycaemia in 
Egypt.  
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Quality of life  
Quality of life is distinctly reduced in patients with diabetes, particularly those who 
are treated with insulin. Developing flexible and easy to use devices, such as insulin 
??????????? ??? ? ?????????????????? ? ???????n about low quality of life (Albano and 
Orbiter Study Group, 2004). Switching from syringe and vial to pen devices had a 
???????????? ????????? ? ????? ??? ?????????? ????????????? ?nd improved their health-
related quality of life  (p<0.05) (Albano and Orbiter Study Group, 2004; Lee et al., 
2009). In a study by Hamdy et al. (1994), quality of life was determined by how 
?????? ??????????????????????????????? ?????????? ?????? ??????????? ??at they have good 
control over their symptoms. The previous authors reported a significant 
improvement in the quality of life in the studied group. In other studies where no 
clinical differences were reported between the syringe and vial and pen devices, 
more than half of patients were more confident in their ability to control their blood 
glucose levels with using the pen than with using the syringe and vial (Korytkowski 
et al., 2003).  
 
The current study revealed compatible results with those reported in the literature, 
where 14/18 participants perceived better control on their symptoms when using 
insulin pen. In addition, in the current study quality of life was determined by how 
??????????????????? ???????????????????????????????????????????????????????? their 
hospital admissions due to diabetes complications. The study revealed that of the 
18 participants, only four required hospital admissions due to experiencing hypo- or 
hyperglycaemic events. Other authors have also reported that the replacement of 
syringe and vial with pen device significantly reduced the utilisation of healthcare 
resources due to hypoglycaemic events, emergency department visits, and 
physician visits (P<0.05). Also, there was a reduction in the hospitalisation rate and 
outpatient visits due to hypoglycaemia, but the change was not significant (Lee et 
al., 2006; Cobden et al., 2007). 
 
Ease of use, portability, convenience, and dosing accuracy  
The current study showed that using insulin pens was simple, in terms of involving 
less steps than those required with the syringe and vial, and more convenient for 
transporting and using in public, in terms of carrying less items, being more hygienic 
in use and less conspicuous than syringe and vial. Other authors have also reported 
consistent results where the use of insulin pen was simple, easy, more convenient 
for transporting and using in public, especially for socially active patients, and it 
????????????????????????????????????????????????????????mdy et al., 1994; Bohannon et 
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al., 2000; Albano and Orbiter Study Group, 2004). In a review of literature 
comparing the dose accuracy between the pen device and syringe and vial, pen 
injection devices showed better dose accuracy (Pfutzner et al., 2008). It has been 
reported that 80% of patients with diabetes incorrectly administer their insulin doses 
using the syringe and vial. Errors are more common in old people who are over 60 
years of age, or when administering low doses of insulin (Korytkowski et al., 2005).  
 
In the current study, almost all the participants were more confident about the 
accuracy of their insulin doses with the insulin pen than with the syringe and vial. 
The participants added that it was more common to administer an inaccurate insulin 
dose using the syringe due to different reasons, such as drawing up less or more 
than the required amount of insulin due to mistakes in reading the unit markings of 
the syringe, which were too small, and discarding the air bubbles, which sometimes 
led to expelling some units. On the other hand, with the insulin pen, doses are easily 
dialled-up and read. Only one participant in this study was more confident about the 
accuracy of dosing with the syringe and vial, as she was observing a little of insulin 
remaining in the reservoir of the insulin pen after each injection. However, the 
results of this study are relatively comparable to those obtained in Korytkowski et al. 
(2003) study, where 82% of patients felt more confident in setting the required dose 
on a pen, and that the pen device delivered the accurate dose of insulin versus 11% 
who were more confident with using the syringe and vial. Furthermore, in that study 
85% of patients reported that the dose scale was easier to read on the pen.  
 
In a qualitative study by Tschiedel et al. (2014), the patients identified the ease of 
use, such as ease of dialling and reading the dose, and the correct dose delivery 
provided by the pen device, as the essential characteristics of insulin pen, which 
contributed to the ease of self-injection. Hamdy and colleagues (1994) have also 
found that insulin pen delivered the accurate dose properly, and that it was 
recommended for delivering less than 36 units per injection. However, in the present 
study, insulin doses administered by the participants ranged from 8-80 units. There 
were complaints from few participants that administering small doses (e.g. 5-10 
units) via the pen was difficult to the extent that one participant was disposing of the 
pen and used a new one to administer the next dose, and another participant was 
withdrawing the remaining amount of insulin with a syringe. In order to obtain the 
factors that contributed to those difficulties, a search was undertaken regarding the 
accuracy of pen devices in delivering small units. Some studies have shown that 
insulin pen had greater accuracy than the syringe and vial in the delivery of 10 units 
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doses (Asakura et al., 2009). Other studies reported that administering small doses 
(e.g. 1-2 units) via the pen was more accurate than via the syringe and vial, while 
both methods were equal in accuracy when a 5-units dose was administered (Keith 
et al., 2004).   
 
Problems of insulin pen use 
Problems of insulin pen and barriers to appropriate injection have not been widely 
discussed in the literature, particularly in the Middle East. In the current study, using 
insulin pen was not free from side effects, such as pain and bruising but when 
compared with the problems of the syringe and vial, the frequency and severity of 
the side effects were much less. Being less painful is not a surprising feature of the 
pen device. It has been found that the disposable needles that are available with 
insulin pens are shorter (2-8 mm) than the standard-length needles (12 mm) and 
less painful. In addition, the pen needles does not have to puncture a stopper before 
injection as in the syringe and vial, and the needle keeps its sharpness and bevelled 
angle to increase patient comfort. Patients perception of pain was significantly 
reduced when using a pen, compared with the syringe and vial (Korytkowski et al., 
2005).   
 
Although it is mechanically more complex than the syringe and vial and is prone to 
malfunction over time, there were no reports of mechanical malfunctions in the 
current study. This is in agreement with the results revealed by Hamdy et al. (1994), 
where the use of insulin pen was associated with minimal mechanical problems, and 
less pain. In another study, where patients who used insulin pen reported adverse 
events to their physicians, none were related to the pen use (Bohannon et al., 
2000). However, there were reports of mechanical malfunctions of insulin pen, 
which contributed to deterioration of metabolic control in patients. In a group of 10 
patients who were converted from syringe and vial to pen device, one experienced 
technical difficulty with the pen, and 10 pens needed to be replaced for 7 patients. In 
another study, 3 cases of metabolic deterioration in pregnant women have been 
reported due to pen malfunction (Korytkowski et al., 2005).  
 
Insulin pen and adherence to treatment  
Generally, insulin pen was associated with great acceptance; especially for those 
who were using MDIs, and it reduced resistance to insulin therapy, improved 
?????????? ????????????? ????? ????? ????? ???? subsequently improved medication 
adherence and glucose control (Hamdy et al., 1994; Bohannon et al., 2000; 
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Korytkowski et al., 2005; Shaghouli and Shah, 2009; Farsaei eta al., 2014). In many 
parts of the World, trials that examined the use of pen for the delivery of insulin 
reported greater adherence with the pen than with the syringe and vial (Hamdy et 
al., 1994; Asche et al., 2010; Baser et al., 2010; Bastian et al., 2011; Farsaei eta al., 
2014). Different features contributed to the improved adherence with the insulin pen, 
such as portability, convenience, simplicity and ease of use. In the current study, 
most participants reported that using insulin pen helped them in administering their 
doses in time, while before using the pen, they were re-scheduling doses due to 
difficulties in carrying and using the syringe and vial when they were away from 
home. Patients with diabetes do not like self-injection in public areas, due to fear of 
stigmatisation as a ?sick person? or a ?drug user?, which may result in missing 
doses. Insulin pen is compact in size, more portable, and diminish social anxiety 
associated with using the syringe in public (Korytkowski et al., 2005). 
 
The results of this study are consistent with those reported by other authors. It has 
been reported that the ease of use, convenience and flexibility of insulin pen 
devices, in terms of transportation and using in public led to a significant 
? ?????????? ??? ?????????? ?????????? ???? ????????????? ??????? ?????????? ????rol 
(Albano and Orbiter Study Group, 2004; Rubin and Peyrot, 2004; Lee et al., 2006; 
Asche et al., 2013). Using the syringe and vial required titrating doses, mixing two 
types of insulin (if necessary), drawing up and injecting insulin, which is time-
consuming (Lee et al., 2006; Asche et al., 2013).  Insulin pen is accurate, easier to 
use, time saving, and provide more convenience (Korytkowski et al., 2005). 
Complexity of the treatment regimen is associated with non-adherence to treatment 
(WHO, 2003; Asche et al, 2013). In addition, experiencing side effects, such as pain 
causes fear of injection and anxiety of self-injection, which could negatively affect on 
medication adherence. Insulin pen helped in lowering injection pain and improved 
?????????? ???????? ??? ????? ????? ??? ???? ?????? Farsaei an?? ???????????? ?????? ?????? ????
psychological barriers to adherence to insulin injections revealed on different 
factors. Some of these factors were dissatisfaction, embarrassment and difficulties 
in preparing injections, which could all be alleviated by changing to insulin pens 
(Farsaei et al., 2014).  
 
????????????????????? 
Overall, the participants of the current study reported their preference to continue 
using insulin pen, and not returning to the syringe and vial, also, they had the 
willingness to recommend it to other patients. This was due to different reasons, 
Chapter 9: Discussion and conclusion  
 
such as the ease of use of the pen, its convenience and accuracy in dosing. Being 
combined in a single item, e.g. the insulin reservoir and the needle, the pen 
? ??????? ??????? ?????????? ????????????? ?????????? ???????????? ??????????
satisfaction, user confidence, ease of use, and provided greater stability during 
injection (Lee et al., 2006; Bastian et al., 2011; Asche et al, 2013). In a review of 29 
studies, 28 studies reported that a majority of patients preferred pen devices to 
syringe and vial, and would like to continue on it, some of the studies identified the 
?????????????????????????????????????????????????????????????????????????Molife et al., 
2009). In the study of Albano and Orbiter Study Group (2004), the analysis of the 
Diabetes Treatment Satisfaction Questionnaire (DTSQ) revealed positive results, 
particularly in the ?continuation? and ?recommendation? parameters, as a result of 
the flexibility and convenience of the pen device. In another study, when patients 
were asked to provide their views about managing their type 2 diabetes with insulin 
pen compared to previous treatment regimen, the patients reported that they 
vigorously preferred the pen to their prior treatment strategies (Rubin and Peyrot, 
2004). Likewise, about three quarter of the participants preferred using the pen to 
the syringe and vial, they would continue using it in the future, and recommended it 
to other patients (Bohannon et al., 2000; Korytkowski et al., 2003).  
 
9.2.3 Insulin pumps in the management of type 2 diabetes  
Although it accounts for 90-95% of all diabetes cases, and that number of patients 
using insulin pumps is growing, studies discussing the use of these devices in the 
treatment of type 2 diabetes are scarce. This is because the use of insulin pumps is 
mostly recommended for patients with type 1 diabetes in several countries around 
the world, supported by the extensive evidence on their effectiveness particularly for 
this type (Barnard and Dixon, 2010; Wolff-McDonagh et al., 2010; Didangelos and 
Iliadis, 2011; Reznik et al., 2014). The National Diabetes Information Service Insulin 
Pump Audit reported 35 patients with type 2 diabetes using insulin pumps in 
England in 2009 versus 5,667 patients with type 1 diabetes. In Turkey, 99.5% of 
pump users have type 1 diabetes. The literature search of studies that discuss the 
use of insulin pumps in adults, which conducted among populations similar to the 
present study, resulted in three studies only (Wainstein et al., 2005; Merheb et al., 
2008; Reznik et al., 2014). However, as the focus of this study was type 2 diabetes, 
one study was excluded because it was conducted on patients with type 1 diabetes. 
Therefore, it was necessary to extend the search further to include studies that were 
conducted internationally, taking into considerations the differences in the 
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populations and lifestyle (Raskin et al., 2003; Herman et al., 2005; Nielsen et al., 
2005; Berthe et al., 2007; Wolff-McDonagh et al., 2010).  
 
Efficacy of insulin pump use  
Findings of this study suggest that insulin pump therapy for adults with type 2 
diabetes, who were poorly controlled on insulin injections and pens, can be effective 
overall. In the current study, all the participants who had valid clinical data achieved 
good glycaemic control, manifested by HbA1c readings of 7.5% or less. In addition, 
the participants reported that the achievement of target blood glucose levels was 
easier with the pump compared to injections and pens, and that control was 
maintained longer. Although there was a debate regarding the benefits of these 
devices over injections and pens, insulin pumps were found to be valuable in the 
treatment of type 2 diabetes, in terms of improving HbA1c levels (Nielsen et al., 
2005; Wainstein et al., 2005; Berthe et al., 2007; Wolff-McDonagh et al., 2010; 
Reznik et al., 2014). When Reznik and colleagues (2014) examined outcomes for 
HbA1c in patients with poor glycaemic control randomised to either insulin pump or 
MDI, significant reductions in HbA1c levels for the insulin pump group (55%) 
compared with the MDI group (28%) were reported. Because insulin resistance is a 
major component of type 2 diabetes, especially in obese patients, the achievement 
of target levels with insulin pumps could be attributed to the enhancement of insulin 
absorption and sensitivity. In light of data provided by that study, insulin pumps 
should particularly be considered in patients with type 2 diabetes, who have 
consistently experienced challenges in achieving glycaemic targets. However, some 
researchers showed conflicting results, where both therapies, insulin pump and 
MDI, found to be equally effective in improving HbA1c levels (Raskin et al., 2003; 
Herman et al., 2005). In addition, those researchers indicated that the safety profile 
was similar for both therapies, and that insulin pumps were not superior to MDI, 
especially in patients who were able to control their glycaemic level well with daily 
injections. This indicates that insulin pumps may not be required in some patient 
groups. 
 
However, in the current study, there were cases of delayed achievement of 
glycaemic control. Also, there were cases in which the participants experienced 
hypo-/hyperglycaemic episodes during the pump therapy. Based on reports from the 
participants, the episodes were fewer in frequency and severity compared to those 
that occurred with injections and pens. In addition, the majority of participants 
noticed improvements in their awareness of hypoglycaemic episodes on insulin 
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pumps. Results of this study are consistent with Berthe ???? ???????????? study, 
where reduced rates of hyperglycaemia were reported with insulin pump use. 
Experiencing less hyperglycaemia on insulin pumps could be attributed to the easier 
access to insulin due to being attached all the time, so that doses are less likely to 
be omitted. The results on reduced hypoglycaemic episodes on insulin pumps might 
be predictable because the continuous delivery of insulin with the pump simulates 
the work of pancreas of normal persons who do not have diabetes (Berthe et al., 
2007). Traditional delivery of insulin with injections or pens cannot simulate the body 
in the same way, and larger doses are injected daily over periods of time, in which 
probability of hypoglycaemia increased (Barnard and Dixon, 2010; Didangelos and 
Iliadis, 2011). This was supported in this study by reports of some participants who 
identified reasons for experiencing poor glycaemic control on insulin injections and 
pens, which were related to lack of awareness in calculating doses according to 
meals and body requirements, in which the participants were injecting either less or 
more insulin than what did they actually need. However, results found by other 
???????????? ????? ?????????? ??????????? ????? ????? ???????? ???????????????? ????????????
reported less hyperglycaemic episodes on insulin pumps, but no significant 
differences in the occurrence of hypoglycaemia between insulin pump and MDI 
groups (Raskin et al., 2003; Reznik et al., 2014). Likewise, studies by Herman et al. 
(2005) and Wainstein et al. (2005) reported no significant differences in 
hypoglycaemic episodes between insulin pump and MDI groups.  
 
Exploring why glycaemic control was not achieved promptly, and at all times, in the 
current study revealed different reasons related to the pump technology, lifestyle or 
?????????????????? ???????? ?????????? ??? ???? ??????????????????????? ????????? ??????????
insulin basal rates, non-adherence to diet, and pregnancy were some of the 
identified reasons. This study found that the overall improvement in glycaemic 
???????? ??? ??????????????????????????????????????????????????????? ??? ?????????????????
health, manifested by reduction in hospital admissions due to diabetes 
complications. 
 
Problems associated with insulin pump use 
In the present study, mechanical problems were experienced by half of the study 
sample, and were related to button problems. The risk of mechanical malfunction is 
that it might cause a complete lack of insulin delivery, in which ketoacidosis could 
occur (Barnard et al., 2007). However, although the encountered mechanical 
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problems led to suspended pumps (n=3), no serious effects were reported in this 
study, and new pumps were provided to the participants easily. 
 
The most prevalent clinical problem associated with insulin pumps was weight gain 
(n=5) followed by bruising, and inflammation at the administration site (n=4 and 1, 
respectively). Barnard and Skinner (2007) reported a small possibility of marking 
and scaring at cannula insertion sites with insulin pumps. However, based on 
reports from the participants in the current study, bruising and inflammation resulted 
from administering injections or pens were worse than those caused by the pump, 
also, they could resolve it by changing the infusion site. Similarly, Raskin et al. 
(2003) reported episodes of skin reactions, such as redness or soreness with insulin 
pumps, which were mild and resolved spontaneously by patients. 
 
Regarding the findings of weight gain in this study, these were consistent with the 
results of Wolff-McDonagh et al. (2010), who noticed significant increase in BMI of 
patients with type 2 diabetes after the initiation of insulin pump therapy. Use of 
insulin in general leads to hyperinsulinemia and weight gain due to increased 
appetite and low thermogenesis (Russell-Jones & Khan, 2007). However, 
continuous delivery of insulin could result in better control using less insulin, and 
thus, causing less weight-gain (Wainstein et al., 2005; Didangelos and Iliadis, 2011). 
While this was not the case in the present, and in Wolff-McDonagh et al. (2010) 
studies, other researchers provided different results. When comparing insulin pumps 
and MDI in a group of 40 obese patients with type 2 diabetes, no significant 
changes in weight were reported for both groups (Wainstein et al., 2005). Similarly, 
other researchers observed no differences in weight between patients who 
randomised to use insulin pump and those who continued on injections (Herman et 
al., 2005; ??????? ??? ????? ???????????????? ?????? ????????????? ????????????????? ?????
reported for patients using insulin pumps may not differ from weight gain that would 
occur if the patient had continued to use MDI. This means that treatment of patients 
with type 2 diabetes with insulin may result in weight gain regardless of the insulin 
delivery method. However, examining factors that contributed to weight gain in most 
participants of the current study revealed that lack of nutritional awareness, health 
beliefs and lifestyle were major reasons for gaining weight on insulin pumps.  
 
To further explain and validate these factors, a comparison between the affected 
group and the non-affected one was performed, and the following results were 
obtained. Participants who gained weight on the pump lacked the awareness of 
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carbohydrate counting. Participants were misunderstanding the importance of this 
task, and were either not counting carbohydrate or counting calories instead. Not 
counting carbohydrate could lead to consuming more carb from food, and 
consequently increases bodyweight (Johnson, 2000). In addition, some participants 
believed that cutting down sugar is enough to maintain glycaemic control and 
bodyweight, and they were consuming the other elements of nutrition, such as 
carbohydrate, fat and protein as usual. Other kind of belief, which was raised by 
some participants, was the belief in the efficacy of the pump, and the accuracy of its 
insulin dosing. Having this belief in mind along with achieving improved glycaemic 
control with less complications encouraged patients to enjoy eating as normal 
persons, who do not have diabetes. Consumption of calories due to fear of 
hypoglycaemia could be a factor for gaining weight in insulin-dependent patients, 
but this was not raised in this study. Non-adherence to diet and exercise was 
prevalent among the participants who gained weight. Consumption of calories more 
than burning them increases bodyweight, while regular and moderate physical 
activity helps in losing weight (Lee et al., 2010).   
 
?????????????????????? 
Being a relatively new treatment option, with little information regarding their use in 
similar populations, it was interesting in this study to examine the impact of insulin 
??????????????????? ????????????? ??????????????????? ????????? ???????? ??????? ????????
and body image play a role in the success of treatment. There are few studies, 
which examined how insulin pump affects ???? ?????????? ?????? ????????????? ???????
(Ritholz et al., 2007). However, being worn around-the-clock, it was presumed that 
insulin pumps caused a dilemma to their users, whether in special occasions or at 
particular times. Findings of this study revealed that insulin pumps had no impact on 
?????????? ???????????? ???????????????? ???????????????????? ??????????????? ?????????????
from administering their doses in front of people. In addition, a psychosocial 
improvement, compared to insulin injections was reported by one participant. The 
high prevalence of type 2 diabetes among adults, and the popularity of insulin 
pumps avoided the participants from feeling stigmatised. While this was consistent 
with Merheb et al. (2008) study, where all patients reported satisfaction in terms of 
emotional and social well-being on insulin pumps, in Turkey, patients using insulin 
pumps felt different than others (Yilmaz and Oguzhan, 2008).   
 
Moreover, this study suggested that insulin pumps were almost convenient during 
sleeping and exercising, and caused no problems. However, in half of the cases, 
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insulin pumps were found inconvenient in wearing particular clothes. The 
participants provided conflicting point of views; some participants found the pump 
more suitable with traditional dresses (Dishdasha for men and Abaya for women), 
as it would be well covered, in which the sense of self-consciousness would be 
decreased. Others found it uncomfortable to wear the pump with traditional dresses, 
as they preferred to clip it in a trouser or a skirt rather than using its belt. However, 
the public image of being noticed due to wearing the pump was raised in three 
cases. Those participants explained that the pump was visible, annoying, and 
looked unacceptable in wearing particular clothing, e.g. dresses for women and 
jeans and t-shirt for men. In this study, women were more concerned about body 
image than men (2 women versus a man). This could be because females are more 
concerned about body esteem and fashion inconveniences than males.  
 
Conflicting results were equally obtained regarding the suitability of the pump for 
travelling. Some participants found insulin pump more suitable for travelling due to 
achievement of good glycaemic control, improvement of general health, and the 
convenience of the pump for transport. In contrast, insulin pumps were 
disadvantageous during travelling due to the difficulties experienced in some 
airports, and the unsuitability of the pump in wearing casual clothes. Use of insulin 
pumps had no impact on family members; most families were neither worrying about 
the patient nor involved in the management responsibilities. In some cases, 
worrying and helping of family members were even reduced compared to insulin 
injections and pens. Achieving good glycaemic control, improving general health, 
and causing less hypoglycaemic events were all contributed to reduce anxiety and 
help of some families, in terms of reminding the patient about doses administration, 
and taking care of the patient when experiencing hypoglycaemia.  
 
Pa??????????????????????????????????????????? ????? 
Although the use of insulin pump was associated with many tasks, participants in 
this study showed better adherence to treatment and SMBG compared to insulin 
injections and pens. The improved adherence of most participants was attributed to 
the improvement in their satisfaction. Reduced burden of dose tracking and 
scheduling, and enhanced flexibility ??? ???? ?????????????? ????? ??? to improved 
?????????????? ??? ????????? ???????? ?????????? ?????????? ???????????? ?f advantages of 
insulin pumps reported more flexibility, better freedom, ease with meals, and 
consequently better quality of life (Ritholz et al., 2007; Brunton, 2008; Yilmaz and 
Oguzhan, 2008; Didangelos and Iliadis, 2011). Barnard and Skinner (2007) also 
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????????? ??????????????????????? ????????? ???????????????? ??????????????????????????
freedom from interruptions of insulin injections. In addition, reduced side effects with 
insulin pumps relieved patients from fear of needles, and contributed to better 
satisfaction and adherence as well. In this study, most cases found the pump more 
convenient, and consistent with daily routines than injections and pens, which were 
associated with greater workload and side effects. These results are consistent with 
Reznik et al. (2014) study, which concluded that insulin pumps were more 
convenient than injections. Also, in another study, patients who randomised to 
insulin pump reported higher satisfaction scores for convenience, flexibility, and 
ease of use. Overall, satisfaction of patients indicates their acceptance to treatment 
and consequently their adherence (Raskin et al., 2003; Yilmaz and Oguzhan, 2008). 
Patients who are satisfied with their treatment in relation to low burden and easy 
consolidation with daily routine will likely to better manage their treatment, and 
consequently maintain positive physical and psychological health (Anderson et al., 
2004). However, Herman et al. (2005) in their study, which compared the 
satisfaction of older patients with type 2 diabetes using insulin pumps with those 
using MDI, revealed a high level of satisfaction in both groups.  
 
Non-adherence to doses due to forgetfulness was also raised in the current study, 
the participants reported better adherence with insulin pumps due to being attached 
all the time. Insulin doses omissions, mainly due to forgetfulness contributed to lack 
of glycaemic control and an increase in HbA1c levels (Randlov and Poulsen, 2008). 
Although some had a generally favourable view of insulin pump, and others 
fluctuated between a favourable and an unfavourable view, all the participants in 
this study reported that they never thought about switching back to insulin injections 
or pens. Participa????? ??????????? ??? ????????? ??? ???? ????? ??? ??? ????????? ??? ??????
satisfaction with the therapy. This is nearly consistent with Barnard et al. (2007) 
study, where only 1-2% of patients who used insulin pump switched back to MDI. In 
contrast, in Turkey, about 15% of patients discontinue using insulin pumps yearly 
(Yilmaz and Oguzhan, 2008).  
 
Because not all the participants in the current study achieved target levels of HbA1c, 
at the onset of pump use, this indicates that insulin pump may not be a panacea for 
addressing the needs of every patient receiving this therapy. Drawbacks associated 
with the use of insulin pumps including challenges related to maintaining 
bodyweight, consistency in glycaemic targets throughout the day, mechanical 
failure, and annoyance from using the pump in situations, such as swimming and 
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wearing certain clothing suggest that introducing this therapy may, in some 
instances, further complicate the care of the patient.  
 
However, although there were some caveats involved in utilising insulin pump 
therapy, this study reported an overall better glycaemic control, quality of life, 
satisfaction and consequently adherence of patients who were poorly controlled on 
insulin injections and pens. The main alert raised in this study was weight gain. 
Weight gain may consequently lead to obesity, which can exacerbate the ability of 
patients to achieve good glycaemic control. However, the health benefits of insulin 
pumps, which perceived in this study, outweigh the potential of weight gain. 
Because glycaemic control is a crucial issue for maintaining health and preventing 
development of serious complications, there is an impetus to ensure that those 
having difficulties achieving target HbA1c levels are provided with the resources 
needed to better accomplish these goals. In patients experiencing difficulty 
controlling their blood glucose targets, insulin pump therapy may provide the most 
effective tool for achieving these goals. In addition, glycaemic control is associated 
with better quality of life, which is an important health outcome, measured by 
perceived physical and mental well-being (Rubin, 2000). Complications of diabetes 
???? ????????? ????????????? ??? ???????? ??? ?????? ????? ???? ???? ??????? ?????????? ???????????
and adherence to treatment are essential for achieving and maintaining glycaemic 
control.  
 
????? ??????????????????????????????????????????n and adherence to treatment in this 
study emphasises the need for further studies to be conducted on a larger sample of 
poorly controlled adults with type 2 diabetes, to evaluate the onset and risk of weight 
gain. In addition, further research is essential to understand whether the use of 
???????????????????????????????????????????????????????????????????????????????????????
self-care behaviour, e.g. diet and exercise. Although it was not the aim to evaluate 
the cost effectiveness of insulin pumps, generally, this study reported less hospital 
admissions due to diabetes complications. Reduced rate of emergency department 
visits and inpatient admissions after initiation of insulin pump therapy were also 
reported by lynch et al. (2010). Preventing complications is more cost effective than 
treating them (Gray et al., 2000). In addition, a study conducted by Medtronic in the 
United States revealed that the number of OHAs used by patients with type 2 
diabetes had decreased by 46%, and more than one-third of patients had 
discontinued their oral treatment after the initiation of insulin pump therapy. 
Therefore, it is essential to perform studies that identify whether insulin pumps are 
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more economically effective than the use of injections and pens in patients with type 
2 diabetes in the Middle East. 
 
9.2.4 Perspectives of HCPs   
Results of this study revealed that there were deficiencies in the management of 
type 2 diabetes in Kuwait. From the perspectives of HCPs, shortage in staff, 
patients-to-HCPs ratio, the limited role of some professionals (e.g. pharmacists and 
psychologists), lack of time, expertise, resources and incentives, and lack of 
awareness about cultural beliefs amongst some HCPs were the main barriers to 
providing patients with better management, and improving their health outcomes. 
International physicians also identified time and remuneration as the main barriers 
to optimum diabetes management (Wens et al., 2005). However, when searching in 
Middle Eastern countries, those results were not surprising, and were consistent 
???????????????????? ?????????? ??????????? ??????????? ??????? ??? ?????????????? ??????-
Operation Council for the Arab States of the Gulf reported that the quality of the 
management of type 2 diabetes was sub-optimal, and needs to be improved (Alhyas 
et al., 2011). Alhyas and colleagues (2012) also recommended enhancing the 
quality of diabetes care in UAE, in terms of glycaemic control.  
 
In the current study, lack of appropriate facilities, such as enough rooms for doctors 
or nurses or for using in patients education and group-sessions, and delays in 
appointments were mentioned by some HCPs as barriers for good management of 
type 2 diabetes in the MOH. In Oman, a study reporting factors that contributed to 
poor management of type 2 diabetes from the perspectives of patients revealed on 
delays in getting appointments, lack of proper utilisation of waiting areas for 
education, and lack of group-?????? ??????????? ?????????? ?????????? ??? ???? ???? ????
initiating behavioural changes and improving adherence. Using waiting areas for 
targeting education, and conducting group-sessions showed to be effective in 
improving the knowledge and building the confidence of patients with type 2 
diabetes about their disease and treatment (Al-Azri et al., 2011). The importance of 
educational interventions in improving health outcomes was also mentioned by 
international HCPs, who described educational centres as valuable resources for 
referring patients with type 2 diabetes (Wens et al., 2005). 
 
The lack of patient-centred care was also raised in this study, where the socio-
cultural beliefs of patients were not taken into consideration by all HCPs, and 
involving patients in decision-making was unacceptable to some of them. This was 
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consistent with Alhyas and colleagues study (2013), where lack of cultural 
understanding of health beliefs among HCPs was reported to reduce the quality of 
care provided. Treating patients as full partners with the doctors in taking decisions 
about their treatments improve their medicine-taking behaviour (Bernabeo and 
Holmboe, 2013). Other issues, which reported by some HCPs in this study, were 
lack of educators in the MOH and the limited role of pharmacists and psychologists 
in the management process. This lack in the teamwork increased the workload on 
doctors and nurses, and reduced the quality of care provided. A multidisciplinary 
team approach is highly recommended especially in diabetes care, as it facilitates 
providing patients with better management and high quality services (Alhyas et al., 
2013).  
 
In Oman, consistent results, in terms of short consultation time, lack of teamwork, 
lack of patient-centred care, and inappropriate facilities were reported as barriers to 
better management of type 2 diabetes. In that study, it was found that only in one 
out of ten consultations, the patient was asked about the possible effects of his/her 
medicines. Fear or perceived side effects impacted the ?????????? ????????-taking 
behaviour, and reduce their adherence to treatment. Some patients would not talk 
about such issues, if not investigated by doctors themselves (Abdulhadi et al., 
2006). Although it was not investigated in the current study, whether doctors discuss 
adverse effects with patients, non-adherence to treatment because of fear/perceived 
side effects emerged among most participants.  
 
Poor management of type 2 diabetes is prevalent in the Middle East, particularly in 
the GCC countries, and needs many steps to be improved (Alhyas et al., 2011; 
Klautzer et al., 2014). Findings of this study emphasised that management of type 2 
diabetes is sup-optimal. Barriers to optimum management were identified from the 
perspective of HCPs. Taking these barriers into consideration and attempting to go 
beyond them could help in improving management of this disease in the MOH. The 
government has to increase staff and resources to meet the tremendous expansion 
in patient population. One of the factors that may contribute to reduced quality of 
care provided at secondary levels in Kuwait is the poor care services at primary 
levels. Some participants in this study highlighted the poor management of diabetes 
in primary-care units. Some participants reported their dissatisfaction when they 
were managing their disease in primary care, explaining that competency and 
motivation of doctors working in primary care is low compared to that of doctors 
working in hospitals. A study evaluated quality of diabetes care at primary levels in 
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Kuwait, in terms of glycaemic, lipid, and blood pressure control and the screening of 
nephropathy revealed that more than half (55%) of patients with type 2 diabetes had 
poor control with regard to HbA1c levels. In 2012, only 25% of patients performed 
kidney function testing as part of their annual check, which reflected the poor 
management of patients in those settings (Badawi et al., 2015). Poor management 
of type 2 diabetes was also mentioned in primary clinics in Saudi Arabia (Ali et al., 
2012). In UAE, patients with type 2 diabetes preferred to manage their disease in 
more specialised units rather than primary care, which increased the workload on 
secondary-care units, and reduced the quality of care provided to patients (Alhyas et 
al., 2013). 
 
Summary of study findings are shown in Table 9.2. 
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Table 9.2: Summary of study findings  
 
 
43 patients with type 2 diabetes have:  
 
Knowledge?lack of awareness about disease/nutrition 
(e.g. diabetes-related complications, nutritional information) 
Beliefs?Specific beliefs about disease and medicines  
(e.g. HLOC, necessity/safety) 
Culture?barriers to adherence to medicines, diet and exercise  
(e.g. social gatherings, Ramadan fasting, lack of time) 
 
      Treatment        
         regimen    
  
Finding  
 
 
 
Syringe/vial (S/V) 
 
 
Insulin pen 
 
 
Insulin pump  
Preference  Least preferred 
insulin delivery 
method  
More preferred than 
S/V 
Most preferred 
insulin delivery 
method 
Adherence  Depends on 
perceived barriers  
Depends on 
perceived barriers 
Eliminate barriers & 
improved adherence 
than MDIs 
Problems  -Pain and bruising at 
injection site  
-Dosing inaccuracy   
-Complex 
preparation  
-Inconvenient in 
transportation & 
travelling  
-Stress of injection 
times  
-Pain & bruising at 
injection site  (less 
than S/V) 
-Unavailability of fine 
needles (2-8 mm) 
-Stress of injection 
times 
-Weight gain 
-Mechanical 
problems 
Satisfaction  Least satisfaction 
level 
Better satisfaction 
level 
Best satisfaction 
level 
Advantages   
 
- 
-Convenient in 
transportation & 
travelling 
-Dosing accuracy 
-More convenient in 
transportation & 
travelling 
-Easy to use  
-Automatic 
calculation of doses  
-Improved glycaemic 
control  
-Less hypo-
/hyperglycaemia  
-Eliminate stress of 
injection times  
 
10 HCPs involved in the management of type 2 diabetes: 
 
? Approved the identified issues  
? Discussed recommendations 
? Identified barriers to better management  
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9.3 Study strengths and limitations  
 
9.3.1 Strengths of the study  
This study primarily depended on semi-structured interviews in collecting data, 
?????? ????????? ?? ??????? ?????????????? ??? ???? ?????????????? ???????????? ????
experiences. Also, this is the first paper to incorporate self-management behaviour 
of patients with type 2 diabetes in the Middle East within the context of the HBM. 
This provided a framework to assist in understanding the complexity of illness and 
treatment representation in patients with type 2 diabetes who had poor management 
behaviour, and helped in proposing the most effective interventions and services.  
 
In addition, this study is the first to examine the use of devices (insulin pens and 
pumps) among this group of patients. Insulin pens were introduced approximately 
15 years, prescribed, and dispensed to patients with type 2 diabetes in secondary-
care units in the MOH. Insulin pumps were introduced approximately 10 years, 
prescribed and dispensed by diabetes consultants to patients with type 1 diabetes, 
according to Kuwaiti Clinical Practice Guidelines for diabetes (Al-Wotayan, 2011), 
and to patients with type 2 diabetes, based on decision agreed by two consultants. 
The study reviewed the use of such devices by the patients and provides a broad 
picture on how patients perceived benefits, advantages and disadvantages of such 
devices. Furthermore, the study identified the barriers to optimum management of 
type 2 diabetes in the MOH from the perspectives of HCPs. Addressing such 
barriers to policy makers may assist in targeting the defects in the healthcare 
system and contribute to the development of services and health outcomes. 
 
Finally, participants in this study were from different backgrounds, using different 
treatment options and recruited from all health regions, which indicates the 
generalizability of findings to all patients with type 2 diabetes in Kuwait and in the 
Middle East.   
 
9.3.2 Limitations of the study 
? As this study primarily depended on semi-structured interviews in collecting 
data, it was time-consuming and expensive in terms of collection and analysing. 
Also, this is may be prone to recall bias, as self-reporting may overestimate 
adherence.  
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? The recruitment of the participants in this study was undertaken from hospitals, 
which means that only patients who visit their doctors were included. This might 
introduce bias to results, as those participants might indicate the proportion of 
patients who adhere to their appointments and treatment. This means that 
results may not be generalised to other patients who did not adhere to their 
appointments and treatment.  
? Few participants were illiterate, in which they could not understand some of the 
questions. 
? The validity of the Arabic version of both, the adherence and beliefs scales has 
not been confirmed among patients in the Arab world.  
? Other factors that could contribute to non-adherence, such as age, sex, 
education, duration of the disease, control status, presence of other 
complications and polypharmacy were not fully investigated.  
? Adherence of the participants to other management behaviours, such as regular 
check-ups to blood pressure, feet, cholesterol and kidney test were not 
investigated. 
? Due to lack of published studies on the use of insulin pens/pumps in adults with 
type 2 diabetes in similar populations, the results of this study were mostly 
compared with international studies. Therefore, the differences between the 
populations in socioeconomic, cultural, and lifestyle factors should be taken into 
considerations.  
? Data on HbA1c levels was recorded retrospectively and this may bias results 
about achievement of glycaemic control with insulin devices. This is because 
HbA1c readings were not measured or obtained within particular timelines of the 
treatment (e.g. before and during the period of using insulin device) and the 
researcher depended mainly on reports from participants.  
? In addition, the retrospective collection of the clinical data (HbA1c levels) might 
bias the results when they were triangulated with self-report methods.   
 
9.4 Implications for practice and policy  
First of all, type 2 diabetes should be a priority at the governmental level. It is crucial 
that the MOH realises the importance of education for this group of patients. In order 
to provide the required education, the MOH has to employ adequate numbers of 
staff in each hospital, in order to lower patient-to-staff ratio, develop the role of 
HCPs, such as pharmacists and psychologists, and employ educators. 
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HCPs should be trained to address the health beliefs of patients in a way that meets 
all educational levels, in order to modify erroneous beliefs and improve medicine-
taking behaviour. Taking into account the health beliefs that emerged in this study, 
and were specific to patients in Kuwait, the following evidence-based 
recommendations might be effective:  
 
? ?????????? ?????????? ?????????? ?????? ???? ?????? ???? ????-term complications of 
type 2 diabetes, to help in enhancing their perception of the severity and 
seriousness of their disease. HCPs, especially physicians should convey the 
message clearly to the patients regarding the seriousness of type 2 diabetes. 
??????????????? ?????????????????? found to discourage patients from engaging 
in self-management behaviour, and increased their risk of developing diabetes 
complications (Dunning and Martin, 1998). Introducing insulin as a possible 
treatment option that may be needed at some stage could encourage patients 
using OHAs only to adhere better to their treatment and lifestyle modifications.  
? The importance of perceived barriers in the current study suggests that HCPs 
should regularly ask patients whether they have barriers to self-management 
behaviour and make recommendations to support them in overcoming these 
barriers.  
? ?????????? ?????????? ?????????? ?????? ?????? ??????????? ???? ????????? ??????? ???
aware about benefits of taking their medicines, their common side effects, and 
how they work, e.g. how rapid- and long-acting insulin works, so that, patients 
can make the appropriate adjustments to their doses, and be more careful 
regarding doses omissions.  
? Improving pa???????? ???????????? ?????????? ??? helping them to recognise and 
consume food with low glycaemic index and high fibre content and reduce 
consumption of food of higher glycaemic index and lower fibre content.  
 
One of the most prevalent problems in this study was the inappropriateness of the 
meal plan provided by the dietician. The majority of participants explained that they 
were provided with a general, rigid meal plan, which was distributed to all patients 
regardless of their gender, age, bodyweight, psychosocial characteristics, and other 
co-morbidities. Adherence to healthy diet could be highly improved by individualising 
healthy eating to patients and providing flexibility, in order to meet the needs of all 
individuals depending on their education and socio-economic level (Johnson, 2000). 
Also, it is recommended that nutritional education should involve patient-centred 
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approach and a variety of learning styles, such as educating patients how to read 
????? ???????? ??? ?????? ????? ???????? ???????? ?????????? ???????? ????? ???? ?????? ??????
structured meals, and some patients might be overwhelmed with carbohydrate 
counting. With these patients, using the food pyramid for carbohydrate servings, or 
developing a structured meal plan on the individual basis is recommended. One of 
the effective tools that could be practised is suggesting that patients write food 
diaries on their meals/snacks for a week, in which the dietician can make 
adjustments based on them, and relating these adjustments to pre-and post-meal 
blood glucose levels (Johnson, 2000). Involving other family members in the 
education could also improve the self-efficacy of patients and assist in the 
management process.   
 
However, it is worth noting that there were a big proportion of patients who fail to 
appreciate the role of dietician and HCPs other than doctors. In this study, many of 
the participants did not keep their appointments with the dietician. Because most 
????????? ??????? ???? ??????? ?????? ????????? ???????? ?his imposes an implication for 
doctors to take more care in making important referrals to other HCPs continuously 
and emphasising their significance.  
 
? The awareness about herbal medicines, their risks and problems, should be 
improved among HCPs. The use of such medicines among patients should be 
addressed and taken into consideration. Doctors and pharmacists should 
increase their efforts in questioning patients about any other medicines that they 
use, to help in avoiding the delayed onset of treatment and the possible serious 
interactions with other conventional medicines.    
? ??????? ?????????? ???????? ???? ???????????? ?????????? ???????? ???????? ?????
account. For example, instead of preventing patients from fasting according to 
???? ?????????????????????? ??????????? ?????????????????????????? ??????? ??? ????? ???
keep monitoring their blood glucose levels and visit their primary care-units 
when they feel unwell, or break their fast and take their medicines. Most recent 
studies supported that fasting in Ramadan is clinically acceptable as long as the 
patient receives counselling on use of medicines and glucose monitoring during 
fasting (El-Taher and Zabut, 2013).  
? Helping patients in planning for their medicine use during Ramadan, by making 
appropriate change?? ??? ???? ?????????? ????? ???? ???? ???? ????? ?? ?? ???
administration, and doses adjustments according to their individual needs, e.g. 
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food intake and physical activity.  Also, providing patients with nutritional advices 
such as consuming complex carbohydrates at the predawn meal and more 
simple ones at the sunset meals.  
? Improving adherence of patients to the other management behaviours, such as 
SMBG, diet and exercise by improving their awareness about their importance. 
For example, in the current study, some doctors were asking patients to monitor 
and record their blood glucose levels in the yellow booklet, which is provided to 
all patients with diabetes in the MOH, then they discuss the results with them in 
each visit, if possible. The implementing of such practice by all doctors would 
have a great role in keeping patients aware about their disease by investigating 
the effect of their behaviours on their blood glucose levels.  
 
However, implementing good practices could not be fruitful at all times. Interestingly, 
in this study, there was a case in which a mother of one participant who came to the 
??????? ???? ????????? ????? ???? ????????? ???? ????????? ??? ?????????? ???????? ???????
blood glucose levels. The mother reported that her daughter was cheating because 
she was afraid that the doctor becomes angry on her if he detected her bad 
behaviour or non-adherence. This case may highlight the importance of improving 
the consultation skills of some HCPs. 
 
Pen devices were firstly introduced in the MOH in 2000, and have only been 
dispensed in secondary-care units. To date, syringes and vials are dispensed for 
insulin-dependent patients in primary-care units. Reasons for not introducing the 
pen devices in primary care units were neither established nor examined in this 
study. Policy makers should consider policies for the distribution of insulin pens to 
all levels of healthcare units. For instance, there are numbers of primary care units 
in each health region of Kuwait, from which some are specialised and others are 
general. Specialised primary care units are the first line treatment options that 
deliver healthcare services to patients with type 2 diabetes. Therefore, distributing 
pen devices to primary care units, mainly specialised ones may have an impact on 
?????????? ?????????????? ?????????? ??? ????? ????? ???? ????????????? ??? ???????
outcomes.  
 
In addition, many patients may benefit from using insulin pens particularly, old 
patients with impaired vision and dexterity, and those who have difficulties in 
administering their doses using the syringe and vial, and do not have any one to 
help them. Also, another suggestion for starting the distribution of pen devices in 
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primary-care units could be through helping those patients who cannot self-
administer their doses, do not have carers to help them, and visit their primary-care 
unit to administer their doses. The service could be initiated by recruiting patients 
who are still administering their insulin doses in the primary-care unit, offering them 
the pen device, and allowing them to use it for a period of time. Then, if the patient 
prefers the device and knows how to use it, he/she can continue on it. Patients who 
do not prefer the pen should have the opportunity to return to the syringe and vial. 
Applying such service could save the time of nurses who help the patients in 
administering their doses, and spend time in registering their information. Also, it 
could reduce the congestion of the patients in the primary-care unit, and save the 
energy and time of all patients.   
 
Although this study was carried out in secondary-care units, where insulin pens are 
available as an option for all patients with type 2 diabetes, it was noted that some 
participants were still using syringe and vial. Because it was not an objective of this 
study to investigate the factors that affect the prescribing of insulin pen, this could 
be due to a lack of knowledge of physicians about the potential benefits of pens, so 
they do not consider them as an option, or that patients are unaware about the 
availability of these devices, so they do not discuss about them with their doctors. 
This raises an implication for the MOH to monitor healthcare services, in terms of 
prescribing and dispensing pen devices in hospitals. 
 
Doctors should discuss with patients the available options of insulin delivery 
methods, identify the benefits of pen devices, leave the choice for the patient to 
decide on the appropriate method for him/her, and allow them a trial period, by 
which they can decide on the delivery method that they prefer to continue on. 
Because they are associated with greater preference and social acceptability, less 
painful, and may improve glycaemic control, insulin pens should be considered 
when prescribing insulin (McCoy and Wright, 2010). In addition, providing patients 
with insulin pens could also help in saving doctors time, because the pen is easy to 
train and requires less time for teaching instructions on use than the syringe and 
vial. Thus, doctors may have more time to address other concerns related to the 
management of the disease or to the initiation of insulin (Bohannon et al., 2000; Lee 
et al., 2006).  
 
It has been found in this study that some participants were not being dispensed the 
adequate amount of insulin pens which they required, and had been prescribed by 
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their doctors. For example, when participants were prescribed insulin pens for 2 
months, the pharmacy dispensed to them an amount for 1 month or two weeks only. 
One participant mentioned that he required additional amount of insulin pens in 
cases of travelling. In addition, some participants reported that they were always 
being dispensed the large needles of the pen (5-6 mm), which causes pain to them, 
while they preferred the small ones (2-4 mm), and some were even buying them 
from private community pharmacies. One participant mentioned that he required the 
larger needles (8-12 mm), particularly if he wants to administer his doses in the 
belly, but he was always given the 5-6 mm ones. This raises an implication for 
pharmacists working in hospitals to review the availability of the required items 
regularly and inform pharmacists in Medical Stores about the unavailability of any 
item, in order to discuss the feasibility of providing adequate amount of insulin pens 
to the patients, and to provide them with the small or large needles according to 
their requirements.  
 
In addition, patients need to be well educated about the injection technique using 
the insulin pen, such as renewing the needle before each use, perform air shots and 
leave the needle in place after injection for 10 seconds to achieve the optimum 
delivery of insulin. If pharmacists emphasise this information with each prescription, 
this ??????? ???????????????????????????????????????????????????????? ??????????????
its accuracy. Accuracy of insulin doses is important for achieving glycaemic control 
and avoiding hypoglycaemia (Luijf and DeVries, 2010).  
 
This study showed that 16/26 participants, who were using insulin injections or 
pens, were above target levels of HbA1c (>7.5%). Insulin pump therapy proved to 
be as or more effective than MDI in lowering HbA1 levels, in poorly controlled 
patients with type 2 diabetes. Particularly, there is a proportion of patients with type 
2 diabetes, in whom insulin pump works well, such as patients with high HbA1c 
levels on MDIs, patients with very high insulin requirements, and those who suffer 
from other conditions, which contribute to difficulty in controlling diabetes (Chait, 
2006). This informs an implication to policy makers to introduce insulin pump 
therapy in these groups of patients, as this will help them in achieving glycaemic 
control, and avoiding other complications. Despite the small sample size enrolled in 
the present study, results are suggestive for modifications of current guidelines to 
consider a group of poorly controlled patients, who are using large amount of basal 
insulin daily, for insulin pump therapy.  
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In Kuwait, insulin pumps were firstly introduced in 2005/2006, and are provided free 
from the MOH for patients based on their suitability and personal choice, regardless 
of their region. Due to lack of evidence on the effectiveness of insulin pumps in type 
2 diabetes, the guidelines for insulin pumps coverage have been strict for type 1 
diabetes to date. The guidelines indicate that candidate for insulin pump therapy 
should have type 1 diabetes, evaluated by a diabetes specialist. In addition, the 
patient should have history of hypoglycaemia or hypoglycaemia unawareness, 
history of dawn phenomenon, extreme insulin sensitivity or willingness to comply 
with self-care behaviours related to the pump, in addition, pregnant women can 
apply for the pump therapy (Al-Wotayan, 2011). In some practices, adults with type 
2 diabetes, who had been uncontrolled with MDI for a period of time, and had the 
willingness to comply with the pump-related tasks, were provided insulin pumps. So, 
insulin pumps are provided to patients with type 2 diabetes on a case-by-case basis, 
and two specialists should agree on their prescription.  
 
The results of this study revealed that insulin pumps were effective in achieving an 
overall improvement in glycaemic control, satisfaction, and consequently adherence 
of adults with type 2 diabetes, who were poorly controlled on insulin injections and 
pens. Therefore, the guidelines could be re-evaluated and further developed to put 
this group of patients in the line of insulin pump therapy, and expand their access to 
this delivery tool. Although there were cases of type 2 diabetes, who were offered 
the pump therapy in some practices, modifying the guidelines will result in extending 
the recruitment of this group of patients to such therapy, and make it more 
accessible to them. However, based on the study findings, 5/8 participants reported 
weight gain after initiating the pump therapy. These results have implications for the 
treatment of obese patients in particular. Weight gain is an independent risk factor 
for coronary artery diseases, hypertension, dyslipidaemia and other co-morbidities 
(Ezzati and Riboli, 2013). In addition, obesity was prevalent among the study 
participants regardless of their treatment regimen. Therefore, selecting candidates 
for the pump therapy is of paramount importance. Some cautions could be 
introduced, such as for morbidly obese patients, with BMI>40 kg/m2, or for those 
with other disorders that promote weight gain, such as hypothyroidism.  
 
Another implication for doctors with regard to weight gain in patients using insulin 
pumps could be suggesting a combination therapy with OHAs during the day, for 
patients willing to use insulin pump, and who are at risk of weight gain. OHAs were 
found to reduce weight gain, particularly in patients who still had some response to 
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sulphonylurea or had evidence of relative endogenous secretion ability (Wainstein et 
al., 2005). In addition, doctors should address ??????????????????????????????????????????
freedom before initiating the pump therapy, in order to reduce the possibility of 
gaining weight. Doctors also should emphasise on the demand of a high level of 
commitment from the patient to maintain good health on the pump by constant 
balancing mealtimes and energy consumption.  
 
Although there were no reported serious consequences among participants who 
had experienced mechanical malfunction of their insulin pumps, and that they 
replaced it easily, this has an implication to pharmacists. Patients using insulin 
pumps could be supplied with insulin injections or pens, or allowed to have access 
??? ????? ??? ???? ?? ???? ??? ?? ???????????? ???? ???????? ?????????????????? ???? ??????????
pump data, if possible may play a role in addressing issues related ?????????????????
adherence, and help the HCPs to mediate with personalised educational 
intervention (Reznik and Cohen, 2013).  
 
One of the main concerns of the participants was the disorganisation of clinical 
visits. The participants reported that they were given appointments as other patients 
with diabetes, who were not using insulin pumps, and they spent as much as their 
time in the consultation. Most participants were concerned about the limit of the 
consultation time, and they mentioned that they required a special day for them to 
discuss more issues related to the pump. Currently, there is no particular 
programme followed in the MOH for providing care to patients using insulin pumps.  
 
A major drawback of diabetes care in this study was the lack of diabetes educators, 
which was a problem in other Middle Eastern countries as well, such as UAE 
(Assaad-Khalil et al., 2013). The shortage in numbers of diabetes educators leaves 
doctors in a one-to-one situation with the patients. Therefore, based on the study 
findings, it would be feasible to establish a nurse clinic particularly for patients using 
insulin pumps, run one or two days a week, and managed by at least two diabetes 
nurses specialised as educators. So, after the specialist decides on dispensing 
insulin pump to the patient, the patient could be directly enrolled to the nurse clinic 
for further investigations. The following protocol could be initiated and adapted in the 
nurse clinic, to improve care services and outcomes (Figure 9.1). The involvement 
of nurses in the care of patients using pumps will help in filling the gaps in their 
knowledge, receiving the required monitoring to reduce incidence of problems such 
as weight gain, reducing the burden on doctors, and allowing patients to discuss 
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other important issues during their clinical visits, to get the maximum benefit. 
Patients with diabetes control their disease better with the support of 
multidisciplinary medical team (Wilmot et al., 2014).   
 
 
*Issues to consider in fine-tuning visits: review records of SMBG, doses 
(bolus/basal/correction) checking/adjustments, carb counting, monitoring for mechanical 
functions.  
 
Figure 9.1: Protocol for treatment and management of patients with type 2 diabetes 
using insulin pumps in the nurse clinic  
 
One of the main findings in this study was the non-adherence of most participants to 
SMBG due to perceiving barriers, such as pain, annoyance and marks on fingers 
and unavailability of test stripes in the MOH. This inform an implication for 
pharmacists or policy makers to consider providing the stripes in the MOH and the 
sensor-augmented insulin pumps, which provide continuous glucose monitoring 
would be of a great value. Currently, all insulin pumps provided to patients are 
without sensors, in which patients needed to carry out at least 4-8 times finger 
pricks. There is clinical evidence that sensor-augmented insulin pumps provide 
better glycaemic control, and eliminate several finger pricks during the day 
(Bergenstal et al., 2011). The significant role of dieticians in teaching and educating 
patients using insulin pumps was manifested in this study. The insufficient and 
inappropriate education provided by dieticians contributed ??? ????? ??? ??????????
awareness regarding important pump-related tasks, such as carbohydrate counting. 
Most participants emphasised on their needs for more education. This problem 
could be resolved by firstly providing continuous training and education to the 
Before the 
pump 
?Evaluation of patient's health parameters, e.g. BMI, BP, cholesterol  
?Evaluation of the patient's cognitive awareness 
?Evaluation of the patient's motivation to perform all the tasks 
On the 
pump 
?Liaise with the pump company, and enroll the patient to a 3-days training 
programme: technical part, carb counting, and hypo-/hyperglycaemia  
?Fine tuning* visits weekly for the first month, then monthly 
On the 
pump  
?Monitoring BMI, BP, and cholesterol monhtly for the first 3 monhts, then 
quarterly   
?Perform HbA1c blood test every 3 months  
?Funduscopy prformed yearly  
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dieticians themselves. Then, dieticians should educate patients the basic nutritional 
information, emphasising on the importance of counting carbohydrate, and re-
enforce education with each visit.  
 
9.5 Suggestions for future work  
It is hoped that this study findings prompted further studies on diabetes 
management in Kuwait, with particular attention to cultural beliefs of adults with type 
2 diabetes and the use of technology among them. Also, it is recommended to use a 
behavioural change model to predict health-related behaviour of patients in Kuwait. 
Below is a description of some recommendations: 
 
? As it was not considered in this research because it is time-consuming, future 
research should consider recruiting patients who do not adhere to their clinical 
visits. This can be achieved by identifying those patients from medical records 
and collecting data from them through home-visits. This will ensure including the 
proportion of patients who experience more barriers to adherence and therefore 
more reliably describing the non-adherence phenomenon.   
 
? As the study had a cross-sectional design, the views and experiences of 
participants on medicine/device use represented those at the time of the study 
and could be changed over time. Therefore, conducting a longitudinal study 
??????????????????????????????????????????????????????ceptions and beliefs over 
?? ??? ????? ??? ? ???????? ??? ?????? ??? ??????? ???????? ??? ?????????? ?????????? ????
linking these changes to a circumstance or a characteristic (e.g. to conclude 
cause-and-effect relationships).  
For example: 
???? ??????????? ?? ????????????? ?????? ??? ???????? ?????????? ???????????? ??? use of 
OHAs and insulin over a specific period of time. So that, Patien?????????????????????
assessed at the start of the diagnosis with type 2 diabetes, after a year and after 5 
??????? ???????? ??? ?????????? ???????? ?????? ??? ????? ??????? ????? ?????? ?????????
characteristics/presence of complications and medicine-taking behaviour. This will 
assist HCPs to identify when patients require more interventions (e.g. at the 
diagnosis, or after a period of time) and to identify targeted educational interventions 
to each group of patients (e.g. those with/without complications, those who use 
OHAs or insulin). 
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(2) Conducting a longitudinal study on the use of insulin pens/pumps on adults with 
type 2 diabetes for a period of 12 months. This will allow detecting changes in 
patie????????????????????????????????????????? with HbA1c levels at the onset of the 
device use, and as the use continued over time. This is crucial to inform HCPs 
about the time that those patients need educational interventions (e.g. at the 
beginning of the device use).   
(3) Conducting a longitudinal study on the use of insulin pump and its impact on 
????????????????. This can be achieved by examining a group of obese patients (e.g. 
BMI>35 Kg/m2) with type 2 diabetes for a period of 12 months. This will allow 
detecting changes i????????????????????starting at the onset of using the pump and as 
the use continued over time and interpreting the causes behind weigh gain. This is 
important to inform healthcare provision and guidelines modifications. 
 
? Although it has not been investigated in this study, it has been reported that 
switching from syringe and vial to insulin pen/pump is associated with a 
reduction in the overall health care costs (Lee et al., 2006; Bastian et al., 2011; 
Asche et al., 2013; Pickup, 2014). Use of insulin pumps in this study helped 
participants to achieve lower HbA1c levels and decrease the recurrence of 
hypoglycaemic episodes. Research evaluating the cost-effectiveness of insulin 
pens and pumps in the Middle East should be conducted. This is important to 
help in resource allocation decisions, estimate future healthcare expenses and 
improve the quality of diabetes care delivery.   
 
? Researchers should consider the effect of demographic variables, such as age, 
sex, and educational level on patie????????????????????????????????????????????????
to inform policy, identify which group of patients needs particular attention and to 
design targeted interventions that meet needs of each group of patients (e.g. 
males/females, those with high/low education level, etc.).    
 
? In the current study, it was found that semi-structured interviews were better at 
describing medicine-taking behaviour of patients and obtaining health beliefs 
that impacted health behaviour. In addition, it was noted that some participants 
were not interested in the completion of questionnaires. Future research may 
focus on interviews only, as this would be more practical and minimise 
paperwork.  
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? Studies about clinical benefits of herbal medicines should be conducted to affirm 
their role in the management of type 2 diabetes, their efficacy and safety. This is 
crucial to inform policy (e.g. restrict their widespread and inappropriate use 
among patients with type 2 diabetes). 
 
? Studies ??????????????????????health behaviour during Ramadan and examine the 
impact of such behaviour on health outcomes should be performed. This is 
important to identify the clinical effects of ?????????? poor behaviour during this 
month and target educational interventions that motivate patients to follow their 
????????? ??????? ?????????? ???aking fast during Ramadan or using medicines 
according to their instructions.  
 
? As this is the first study that examined the advantages and disadvantages of 
insulin pumps in the management of adults with type 2 diabetes in the Middle 
East, it will be interesting to conduct more studies on larger sample of the same 
population. Although insulin pumps showed comparable efficacy and safety to 
MDI therapy for type 2 diabetes internationally (Raskin et al., 2003; Pickup and 
Renard, 2008), conducting studies on the efficacy and cost-effectiveness of this 
technology will be of a great interest, given that the socio-cultural backgrounds 
of Mediterranean patients is different from those in published international 
studies.  
 
? Although services and interventions recommended in this study were assessed 
for practicality from the perspectives of HCPs and were effective in other 
countries (Chapter 8, Sections 8.2, 8.3), the efficacy of these services should 
be assessed in Kuwait among adults with type 2 diabetes. For example, 
research should be conducted on the efficacy of pharmacist/psychologist led-
diabetes clinic for a period of 12 months. This can be achieved by recruiting 
patients to these clinics and examining changes in their clinical characteristics 
(e.g. HbA1c levels, blood pressure, cholesterol level, BMI) and adherence at the 
beginning of visiting the clinic, and thereafter until the end of the study. Then, 
?????????? ???????????????? ??????? with a control group. This is crucial to inform 
policy and better healthcare resources utilisation.  
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9.6 Conclusion  
Many factors were found to affect the management behaviour and health outcomes 
of adults with type 2 diabetes in Kuwait. The current study provided evidence that 
non-adherence to medicines among adults with type 2 diabetes is a significant 
problem, with a rate of 44.2%. Lack of health awareness, specific health beliefs and 
????????? ???????? ????? ? ??????? ?????????? ????????-taking behaviour and other 
management responsibilities, such as SMBG, diet and exercise were identified in 
this study. In addition, it was found that using insulin devices, such as pens and 
??????????????? ????? ??? ? ?????????????????? ????????-making and health outcomes. 
From the perspectives of patients, use of pens and pumps had many advantages 
over traditional injections and a role in improving their medicine-taking behaviour. 
 
??????????? ???????? ?????? ???????? ? ??????????????????management behaviour is to 
???????? ???? ????? ??? ?????????? ??????????? ?????? ??????? ???????? ???? ?????-cultural 
needs by different HCPs. In addition, extending the use of insulin devices among 
this group of population may have a role in improving health outcomes. From the 
perspectives of HCPs, there are many barriers that impede the employment of 
services and targeted interventions. By addressing HCPs? concerns and make the 
policy makers in the MOH aware about them, findings of this study will inform 
decisions for service development, better healthcare resources utilisation and 
consequently better management of type 2 diabetes and health outcomes.  
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Appendix 1: Studies of determinants of adherence to treatment and self-
management behaviour among patients with diabetes in Middle Eastern countries 
 
Study/setting/country Sample Methods/measures Study findings and 
conclusions 
Abahussain & el-Zubier. 
2005 
School health clinic, 
Saudi Arabia  
91 patients 
with diabetes  
Knowledge of females 
with diabetes, school 
teachers about the 
disease and 
adherence to 
medications, diet and 
exercise measured by 
a structured 
questionnaire.  
73% of patients know 
about the symptoms of 
hypoglycemia, 52.7% of 
patients complied with 
treatments, 50% followed 
diet and 5.5% complied 
with exercise. 25% using 
herbs for the management 
of diabetes.   
Abdulhadi et al 2006 
Primary health care 
clinics, 
Oman  
 
 
 
 
 
 
90 
consultations 
between 
doctors and 
nurses 
involved in the 
management 
of patients 
with type 2 
diabetes  
 
Observational study.  
Healthcare providers 
interactions with 
patients focusing on 
consultation 
environment and 
some aspects of care 
and information 
measured by 
checklists. 
????????????????
consultations were sub-
optimal.  
 
 
 
 
 
 
 
 
Abdulhadi et al 2007 
Primary health care 
clinics, 
Oman  
27 patients 
with type 2 
diabetes  
Qualitative research. 
Perceptions of 
patients with type 2 
diabetes regarding 
quality of care 
provided measured 
through focus group 
discussions.  
Weaknesses identified by 
patients include: health 
education and 
professional competency 
of healthcare providers.  
Aflakseir 2012 
Outpatient clinic, 
Iran 
102 patients 
with type 2 
diabetes  
Not stated. 
Illness perceptions, 
beliefs about 
medicines and 
medication adherence 
measured by IPQ, 
BMQ and MARS.  
Patients having concerns 
about negative effects of 
medicines show low levels 
of adherence to 
medications.  
Aflakseir 2013 
Retirement club,  
Iran  
178 patients 
with diabetes, 
coronary heart 
disease, 
chronic pain 
and 
hypertension 
Not stated. 
Illness perceptions 
and medication 
adherence using IPQ 
and MARS.  
42% of patients reported 
non-adherence to their 
prescriptions, 58% adhere 
to their medicines.  
Illness perceptions such 
as timeline, perceived 
consequences and 
treatment control 
????????????????????
adherence to their 
medications.  
AlHewiti 2014 
Family medicine clinics,  
Saudi Arabia  
408 patients 
with chronic 
diseases 
including 
diabetes  
Cross-sectional study. 
Adherence to 
treatment and beliefs 
about medicines using 
MMAS-8 and BMQ.  
51% of participants who 
had diabetes were low 
adherents. Low adherence 
was associated with 
negative beliefs about 
medicines.  
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Study/setting/country Sample Methods/measures Study findings and 
conclusions 
Alhyas et al 2013 
Diabetes centre, 
United Arab Emirates  
9 healthcare 
professionals 
providing care 
to patients 
with 
type 2 
diabetes  
Qualitative research. 
Barriers to healthcare 
???????????????
motivation measured 
by semi-structured 
interviews with 
healthcare 
professionals.  
Barriers that affect 
??????????????????????????
motivation in providing 
good quality care are: 
heavy workload, lack of 
patient compliance, 
awareness and cultural 
beliefs and attitudes about 
diabetes.  
Ali et al 2010 
Primary health care 
clinics 
United Arab Emirates  
75 women at 
high risk of 
type 2 
diabetes  
Qualitative study. 
Weight management 
behaviors and 
perceptions of women 
at high risk of type 2 
diabetes using 
focused-group 
interviews. 
Low motivation, lack of 
social support, competing 
demands, lack of culturally 
sensitive exercise facilities 
and sociocultural norms 
are the main barriers cited 
by participants.  
Al-Kaabi et al 2008 
Diabetes Outpatient 
Clinics 
United Arab Emirates  
 
 
 
 
409 patients 
with diabetes 
Cross-sectional study. 
Dietary practices and 
risk profile measured 
by an interviewer-
administered 
questionnaire.   
24% of patients read food 
labeling, 76% reported 
being unable to distinguish 
between high and low 
carbohydrate index food 
items and no one reported 
counting calorie intake, 
46% reported never seen 
by a dietician since their 
diagnosis.   
Al-Khawaldeh et al 2012 
A national diabetes 
centre  
Jordan 
223 patients 
with type 2 
diabetes  
Cross-sectional study. 
Diabetes self-efficacy 
& self-management 
behaviours using 
structured interviews 
& a questionnaire 
including self-efficacy 
scale & self-
management 
behaviour scale.  
Patients with higher self-
efficacy showed better 
self-management 
behaviours than those 
with low self-efficacy.  
Al-Qasem et al 2011 
Middle Eastern countries 
 
 
 
 
Patients with 
chronic 
diseases  
Review.  Non-adherence to 
medications among 
patients with chronic 
diseases in Middle 
Eastern countries 
constitutes a problem.   
 
Al-Saeedi et al 2002 
Primary health care  
clinics, 
Saudi Arabia  
1039 patients 
with diabetes 
Cross-sectional study. 
Patterns of treatment-
related 
misconceptions 
measured by 
interviews using a 
structured 
questionnaire.  
39% of patients had a high 
treatment misconception 
score. 16.5% think that 
cure from diabetes is 
expected following a short 
course of treatment and 
23% think that they could 
eat as long as medications 
are taken.  
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Study/setting/country Sample Methods/measures Study findings and 
conclusions 
Al-Saeedi et al 2003 
Primary health care 
clinics  
Saudi Arabia  
1039 patients 
with diabetes  
Not stated. 
Beliefs in traditional 
herbal medicines 
measured by a 
structured 
questionnaire. 
 
 
15.6% of patients believe 
in the safety and efficacy 
of traditional medicines. 
25.8% believe that they 
might be beneficial.  
Al Shafaee et al 2008 
Health care centres 
Oman  
563 adults 
(general 
populations) 
Not stated.  
Knowledge & 
perception of diabetes 
using a questionnaire.  
Knowledge of diabetes 
was suboptimal. Only 
47%, 58% and 55% 
responded correctly to 
questions on diabetes 
definition, symptoms and 
complications 
respectively. Only 5, 21 
and 17% identified 
obesity, physical activity 
and family history 
respectively, as risk 
factors for diabetes.  
Al-Shookri et al 2011 
Oman  
Patients with 
type 2 
diabetes  
Review.  Lifestyle and behaviour of 
patients with type 2 
diabetes in Oman and 
other Middle East 
countries contribute to the 
high prevalence of this 
disease.  
Ashur et al 2015 
A national centre for 
diabetes & 
endocrinology, 
Libya  
Patients with 
type 2 
diabetes  
Cross-sectional study. 
?????????????ness 
perceptions using the 
Revised Illness 
Perception 
Questionnaire & 
adherence to 
treatment using 8-
MMAS.  
Low adherence to 
medicines was found in 
36.1% of the sample. 
The participants reported 
high perception of 
diabetes timeline as 
chronic & a moderate 
perception of the diabetes 
course as unstable.   
Badran & Laher 2012 
Arabic-Speaking 
Countries 
Patients with 
type 2 
diabetes  
 
Review. Several socioeconomic, 
dietary and lifestyle factors 
are associated with type 2 
diabetes in Arabic-
speaking countries.  
Biderman et al 2009 
Health care 
organizations, 
Israel  
 
 
 
 
 
 
 
 
 
 
 
 
630 patients 
with diabetes, 
hypertension 
or ischemic 
heart 
diseases  
Systematic random 
sample from computer 
database. 
Diabetes treatment 
satisfaction measured 
by telephone 
interviews using 
DTSQ and adherence 
to treatments and 
lifestyle measures.  
51.9% reported difficulties 
in changing their dietary 
habits, 50.3% in changing 
their physical activities, 
22.7% in attending follow-
up visits and 9.8% in 
taking medications. 
Patients taking OHAs 
were more satisfied than 
those taking OHA and 
insulin.  
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Study/setting/country Sample Methods/measures Study findings and 
conclusions 
de Villiers et al 2015 
Ambulatory care clinics, 
Saudi Arabia  
1,409 patients 
with type 2 
diabetes  
Descriptive-
correlational study. 
Adherence to 
treatment & factors 
affecting on it using a 
questionnaire.  
Findings revealed on 
different factors that 
???????????????????
adherence, such as poor 
knowledge about diabetes 
and external locus of 
control.  
Elis et al 2008 
Maccabi healthcare 
services, 
Israel 
41,936 
patients with 
diabetes  
Cross-sectional study. 
Rate of reaching all 
glycemic, lipids and 
blood pressure target 
levels among diabetic 
patients. 
13% of patients achieved 
all three target levels. This 
was significantly 
associated with 
compliance to treatments 
and medical visits.  
Elliott et al 2013 
Primary health care 
clinics,  
Oman 
 
 
 
 
309 patients 
with type 2 
diabetes  
Prospective survey. 
Diabetes self-
management and 
education assessed 
by a questionnaire.  
26% of patients unaware 
how to recognize/respond 
to hypoglycemia, 49% and 
60% do not recognize 
hyperglycemia/respond to 
it respectively, 62% do not 
monitor their blood 
glucose levels, one-third 
of patients using insulin, 
independently adjust 
dosages.   
Hui et al 2010 
 
 
 
 
Patients with 
type 2 
diabetes 
Review. Structured education 
should be focused to 
patients who wish to fast 
in Ramadan, for better 
managing their condition 
while fasting. 
Ibrahim et al 2011 
Al-Qassimi hospital, 
United Arab Emirates 
 
 
  
240 patients 
with chronic 
diseases  
Cross-sectional study. 
Factors affecting 
?????????????????????
to treatments 
measured by a 
validated 
questionnaire. 
Forgetfulness is the main 
reason for non-intentional 
non-compliance (75%) 
and polypharmacy is the 
main cause for intentional 
non-compliance (13.3%). 
Jamous et al 2011 
Military medical services 
clinic, 
Palestine  
131 patients 
with diabetes 
Cross-sectional 
descriptive study. 
Adherence and 
treatment satisfaction 
using MMAS-8 and 
treatment satisfaction 
questionnaire.   
38% of patients had high 
adherence, 58% had 
medium and 16.9% had 
low adherence rates.  
Jeragh-Alhaddad et al 
2015 
Primary health care 
clinics and hospitals,  
Kuwait  
 
 
 
20 patients 
with type 2 
diabetes  
Qualitative study. 
Assessing adherence 
to medicines and 
health beliefs of 
patients using face-to-
face interviews.   
Many factors were found 
???? ???????????????
adherence to medicines. 
These were related to 
healthcare providers and 
system, culture and the 
patients themselves.  
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conclusions 
Jimmy et al 2014 
Household 
Oman  
158 patients 
with type 2 
diabetes   
Cross-sectional study. 
Adherence to 
medicines using 
questionnaire-based 
pilot survey.  
Adherence to medicines of 
patients with type 2 
diabetes was good. 
Forgetfulness was the 
main factor that 
contributed to non-
adherence followed by low 
beliefs about the necessity 
of taking medicines, and 
the perceived side effects.  
 
Kamel et al 1999 
Diabetes clinic,  
Egypt  
 
 
300 patients 
with diabetes 
Cross-sectional study. 
Adherence to 
medication measured 
?????????????????-report 
using questionnaire.  
1.7% of patients had poor, 
20% satisfactory and 
78.3% very good 
compliance. 
Khattab et al 1999 
Primary health care 
centre, 
Saudi Arabia  
294 patients 
with diabetes 
Cross-sectional study.  
Adherence to 
medications 
measured by self-
report questionnaire 
and pill count. 
1.4% of patients had poor 
compliance, 14% fair 
compliance and 84.2% 
good compliance.  
Khattab et al 2010 
The National Centre for 
Diabetes, Endocrinology, 
and Genetics,  
Jordan  
917 patients 
with type 2 
diabetes  
Systematic random 
sample. 
Medication 
adherence, barriers to 
adherence and 
attitude towards 
diabetes measured by 
pre-structured 
questionnaires. 
65.1% of patients not 
following eating plan as 
recommended by 
dietician, had negative 
attitude towards diabetes, 
increased barriers to 
adherence scale scores 
and poor glycemic control.  
Mabry et al 2010 
Gulf Cooperation Council  
Not stated  Review.  The physical activity, 
which is a modifiable risk 
factor for several chronic 
diseases, of patients in the 
GCC States is very low.  
Mishali et al 2011 
Maccabi health care 
services, 
Israel 
 
119 patients 
with diabetes 
Not stated. 
Self-efficacy 
measured by 
questionnaires and 
resistance to 
treatments measured 
by RTQ.  
 
 
 
 
 
Self-efficacy impacts on 
???????????????????????
their treatments.  
Roaeid & Kablan. 2007 
Diabetes centre, 
Libyan Arab Jamahiriya  
805 patients 
with diabetes  
Cross-sectional study. 
Adherence to 
treatment measured 
?????????????????-report 
using interviews and 
questionnaire.  
 
 
 
 
27.1% of patients do not 
take their treatments 
regularly.  
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conclusions 
Salti et al 2004 
13 Eastern 
Mediterranean countries  
12,243 
patients with 
diabetes 
Retrospective 
transversal survey.  
Fasting and 
adherence of patients 
to medications in 
Ramadan. 
 
42.8% of patients with 
type 2 diabetes and 78.7% 
with type 2 diabetes fasted 
for at least 15 days. Less 
than 50% changed their 
treatment dose (one-fourth 
treated with oral anti-
diabetic drugs and one-
third using insulin.  
Serour et al 2007 
Family practice health 
centers  
Kuwait  
334 patients 
with type 2 
diabetes, 
hypertension 
or both  
Prospective study. 
Adherence and 
barriers of complying 
with lifestyle 
recommendations 
measured by a 
structured 
questionnaire.  
Barriers to adherence to 
diet: unwillingness, 
difficulty adhering to a diet 
different than rest of 
family, social gatherings. 
Barriers to adherence to 
exercise: lack of time, co-
existing diseases and 
adverse weather 
conditions. 
Shams and Barakat 2010 
Specialized medical 
hospital, 
Egypt  
226 patients 
with type 2 
diabetes  
Cross-sectional study. 
Adherence to 
treatment and other 
self-care behavior (eg, 
diet and exercise) 
using a multi-ple-
choice graded 
questionnaire.  
Adherence to treatment, 
diet and exercise were 
sub-???? ??????????????
knowledge about the 
disease and beliefs about 
medicines significantly 
affected therapeutic 
adherence.  
Sweileh et al 2014 
Primary health care clinic  
Palestine  
405 patients 
with type 2 
diabetes   
Cross-sectional study. 
Adherence to 
medicines using 
MMAS-8, beliefs 
about medicines using 
BMQ and diabetes-
related knowledge 
using MDKT.  
42.7% of the participants 
were non-adherents 
(MMAS-8 score<6). Non-
adherence was 
significantly associated 
with disease-related 
knowledge, beliefs about 
necessity of medicines 
and concerns about 
adverse consequences of 
medicines.  
Turan et al 2002 
Outpatient clinic at a 
government university 
hospital, 
Turkey 
196 patients 
with diabetes 
Cross-sectional study. 
Coping with diabetes 
using a Diabetes 
Coping Measure & 
adherence to diabetes 
treatment regimen 
using a questionnaire 
adapted from the 
Summary of Diabetes 
Self-Care. 
Coping with diabetes was 
a good predictor of 
outcome. The effect of 
coping with diabetes on 
HbA1c levels was 
mediated by adherence to 
treatment.   
Yekta et al 2011 
Health care clinics, 
Iran  
400 patients 
with diabetes  
Cross-sectional study. 
Factors influencing 
self-care practices 
measured by a 
questionnaire.  
??????????????-care 
practices were good in 
15.1%, moderate in 58.7% 
and poor in 26.2%.  
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?The Ministry of Health (MOH), Kuwait in cooperation with the School of 
Pharmacy, University College London (UCL) are conducting this study for 
healthcare, research and educational purposes?  
 
The purpose of the study  
Diabetes is rapidly increasing in the world and particularly in Kuwait, which suggests 
a defect in the management process. Patients behave differently regarding their 
diseases, medicines and in taking management responsibilities. It has been 
?????????? ????? ?????????? ????????-taking behaviour may have an impact on the 
disease management.  
 
I am conducting this research to explore how patients with type 2 diabetes manage 
their disease during their daily lives, and what problems they are experiencing, in 
terms of medicine-taking and other self-care behaviours. Results of this research 
will hel?? ??? ???????????? ???? ????????????? ??? ?????????? ????? ??????? ?????????? ????
recommending targeted interventions that could be applied in the MOH to help the 
provision of healthcare services and improving health outcomes.  
 
If you have any further query, please do not hesitate to contact the project 
team.  
 
Researchers contact details  
 
Mrs Zahra Alsairafi, UCL, School of Pharmacy  
Tel: 66464640 
E-mail: ucnvzka@ucl.ac.uk  
 
Professor Felicity Smith, UCL, School of Pharmacy 
E-mail: f.j.smith@ucl.ac.uk 
 
Professor Kevin Taylor, UCL, School of Pharmacy 
E-mail: k.taylor@ucl.ac.uk  
 
 
Thank you 
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THE SCHOOL OF PHARMACY 
UNIVERSITY COLLEGE LONDON 
MINISTRY OF HEALTH (KUWAIT) 
 
 
 
Use of medicines and devices by adults  
in the management of type 2 diabetes  
in Kuwait  
 
 
{Thank you for taking time in reading this leaflet} 
 
 
?I would like to invite you to participate in a research study. Information provided in 
the leaflet explains the purpose of the study and what it is required; please take your 
time in reading and understanding the information?. If you have any query, please 
do not hesitate to contact me or my supervisors: 
 
 
 
Mrs Zahra Alsairafi, UCL, School of Pharmacy  
Tel: 66464640 
E-mail: ucnvzka@ucl.ac.uk  
 
Professor Felicity Smith, UCL, School of Pharmacy 
E-mail: f.j.smith@ucl.ac.uk 
 
Professor Kevin Taylor, UCL, School of Pharmacy 
E-mail: k.taylor@ucl.ac.uk  
 
 
To participate in the study is NOT OBLIGATORY and will not affect the delivery of 
the healthcare services, also you can withdraw at anytime. Your participation will 
help in improving the quality of care provided to patients with type 2 diabetes in 
Kuwait, and is greatly appreciated. 
 
 
Please make sure that the information you will provide will be handled safely by the 
researcher, and nobody such as your doctor will know about it. 
 
 
Thank you  
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Appendix 4: ?????????????????????????????????  
 
 
?The Ministry of Health (MOH), Kuwait in cooperation with the School of Pharmacy, 
University College London (UCL) are conducting this study for healthcare, research 
and educational purposes?  
 
 
The purpose of the study  
Diabetes is rapidly increasing in the world and particularly in Kuwait, which suggests a defect 
in the management process. Patients behave differently regarding their diseases, medicines 
and in taking management responsibilities during their daily lives. It has been suggested that 
??????????medicine-taking behaviour may have an impact on the disease management. In this 
research, I am interested to know how are you managing your disease (e.g. how do you take 
your medicines, use you device, perform other management responsibilities). Results of this 
????????? ????? ????? ??? ???????????? ????????????? ??? ?????????? ?????????? ???? ?????????????
targeted interventions.  
 
Why I have been chosen 
In this study, we are interesting to include patients with type 2 diabetes using different 
treatment options. All patients who are visiting diabetes outpatient clinics are invited to take 
part. 
 
If I agree to participate, what it will involve 
As a participant, you will be interviewed by the researcher, who will ask you some questions 
regarding your anti-diabetic medications/device use, and the management responsibilities 
you are taking daily. Your personal views and experiences are our focus and there are no 
right or wrong answers. For your convenience, you will decide on the time and place of the 
interview, the estimated time for the interview is 20-30 minutes, followed by 10 minutes to 
answer two questionnaires. Also, the researcher will obtain some clinical data from your 
medical note.  
 
For research purposes, the interviewer will ask you to audio-record the interview, only the 
researcher will access the information, and it will be wiped immediately after transcription.  
 
 
Thank you 
 
 
Appendices 
 
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???????????????????????????????????????????????????????????????????? 
 
 
????????????????? 
 
??????????????????????????????????????????????????????????????? ????????????????????? 
?????????????????????? 
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Appendix 5: ??????????????????????????? 
                                                                        
                                                                                       
                                                                             
Invitation letter for healthcare professionals 
 
Dear Sir/Madam; 
?? ? ?????? ??????????? ?? ??????????? ??? ???? ???? ???? ?? ???? ???????? ??? ???????????
College London. I conducted a research project around the management of type 2 
diabetes in Kuwait. I obtained the perspectives of patients about the use of their 
medicines during their daily life, and investigated the problems they were 
experiencing, in terms of disease management. In addition, I examined the use of 
technology (insulin pens and pumps) in the management of type 2 diabetes, and 
how the patients perceived their use.  
 
I would like to take this opportunity to discuss with you the main findings of my 
research, to benefit from your experience, and to obtain your reflections and 
thoughts about these findings. The interview will last about 10-15 minutes, face-to-
face or by telephone depending on your preference and at a convenient time for 
you.  
 
If you have any further enquiries please do not hesitate to contact any of the 
research team: 
Zahra Alsairafi 
Mobile: 6 6464640 
E-mail: ucnvzka@ucl.ac.uk  
Academic supervisors: 
Professor Felicity Smith  
E-mail: f.j.smith@ucl.ac.uk  
Professor Kevin Taylor  
E-mail: kevin.taylor@ucl.ac.uk  
Thank you 
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Appendix 6: ?????????????????????????????? 
Information leaflet for healthcare professionals                                               
1. All patients  
Findings:  
? More than half of the study sample had low-medium adherence to medications, 
HbA1c>7.5%, and diabetes-related complications.  
? Most participants had difficulties in adhering to healthy diet and exercise, which 
impacted the management of their disease and health outcomes. 
Issues: 
???????? ?????? ??? ? ????? ?????????? ????????-taking behaviour were lack of health 
awareness, health beliefs and cultural factors: 
? The majority of participants perceived their disease as a normal, prevalent and 
common health status, and not as a serious chronic disease, were only slightly 
concerned about its risk on their future health, and were unaware about the 
long-term complications.  
? Patients did not have the motive to adhere to healthy lifestyle, and they thought 
??????????????????????????????????????????????????????????????????????????????????
????? ???? ??????????????? ??? ???????? ????? ????? ?????????? ???????????? ?????? ??? 
social life. 
? ????????? ???????? ?????????? ?????????? ????????-taking behaviour: fasting in 
Ramadan, social gatherings, irregular daily routine, use of herbals, lack of 
connection between the provided healthcare services, and discontinuation of 
care when referred to other specialists. 
? ?????? ????????? ???????? ?????????? ?????????? ????????-taking behaviour: 
perceived/fear of side effects, unexpected hyperglycaemia, forgetfulness and 
laziness.  
 
2. Patients using syringe/vial and pen for insulin delivery  
Finding: Insulin pens were advantageous compared to syringe and vial in terms of 
ease of use, portability, convenience, and overall preference. 
Issues: 
? Insulin pens are neither available in primary-care units nor dispensed to all 
patients in hospitals.   
? Small-sized pen needles, which cause less or no pain, are mostly unavailable.  
? VictozaR pen is available in Medical Stores, and helped in improving glycaemic 
control, particularly for obese patients but not dispensed for patients. 
 
3. Patients using insulin pump 
Finding: Insulin pump was an effective option, six of the eight participants using 
insulin pump could achieve HbA1c<7.5%, it provided patients with more flexibility in 
life, without increasing risk of side effects, and was the preferred option over 
multiple daily injections.  
Issues:  
? Five of the eight participants gained extra weight (BMI>30 kg/m2) because they 
believed that as long as the pump controls the disease and maintains good 
blood glucose levels, diet and exercise could be neglected. 
? Patients lacked the knowledge of carb counting, and they were either counting 
calories/or taking insulin shots without introducing their carbohydrate intake.  
? Limit of consultation time, and not specifying particular days for patients using 
pumps. 
? The prescription of insulin pumps for patients with type 2 diabetes is still limited. 
Thank you for taking time in reading this leaflet 
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Appendix 7: The ineterview schedule of patients  
 
 
 
Interview schedule for patients with type 2 diabetes using oral hypoglycaemic 
agents, insulin (injections/device) or both 
 
 
Participant No.: ______                                                        Date: _____/_____/2014             
 
Place: ____________________                                            Time: _________ 
 
 
Before we start the interview, I would like to remind you briefly what the study 
is about 
 
Diabetes is rapidly increasing in Kuwait, and we know very little about how patients 
are managing their disease, and what problems and difficulties they encounter. The 
results of this research will help us to suggest recommendations and target specific 
interventions to patients. So, we would like to know your views and experiences 
about your disease, medicines/device, healthcare providers and system.   
 
Consent Form  
 
Now before we start, we need to fill out this form. It confirms that you are happy to 
talk with me today, but you can stop the interview anytime you wish. Are you happy 
to sign the form? 
 
Consent to audio-record the interview 
 
I would like to audio-record this interview, I will be the only person who will listen to 
the record. This will help me to listen to you carefully now and then write down 
??????????? ????? ???? ?????????? ??????? ???? ??? ???? ?????? ????? ??? ????-record the 
?????????????????????????????????????????rd it? 
 
Would you like to ask me anything before we start?  
 
There are no right or wrong answers; I am interested to know your views and 
experiences regarding the use of your medicines/device. 
 
 
 
Prompts are small and in italics 
Blue texts are questions for patients using device (pen/pump) ONLY  
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General views and experiences  
1. What do you know about the possible long-term effects of diabetes/what do 
you think the future holds in terms of your disease?  
 
2. Diabetes is increasing nowadays in our country, why do you think this is 
the case? 
? Some people think that God is important in determining who gets diabetes; others 
believe it is more to do with heredity/themselves, what do you think?  
? Some patients try to forget that they have diabetes, because ???????????????????????????
if they worried about it, what do you think?  
? How do you think we should address the problem in Kuwait? 
 
Day-to-day life  
3. What effect has having diabetes had on your life? 
? Tell me about any changes you have made in your diet (the way you buy, cook and 
eat your food)   
? Can you describe changes you have made in your physical activity, if any 
? If you are a smoker, do you still smoke, have you attempted to stop, if you have quit, 
why? 
? Have you made any other lifestyle changes?  
? How do these changes fit within your daily routine? 
? For all the changes that you have attempted, what has helped you to make them? 
? For all the changes that you have attempted, what has been the easiest/most 
difficult thing to apply? 
? In what ways it was easy/difficult?  
? ???? ???? ???????? ????? ???? ????????? ??????? ????? ???? ???? ????????? ??? ??????? ??????
changes (barriers to: following healthy diet, practising exercise or stop smoking)?  
? To what extent do you think that your lifestyle modifications are helping you manage 
your diabetes?  
 
Therapeutic regimen 
4. For your diabetes, what medicines/device are you using currently?  
? Please, can you show me your medicines/device 
? How do you use them?  
? How long have you been using this device? 
? Before using this device, how were you managing your diabetes? 
? Tell me in what ways have you found your medicines helpful 
? Are there any problems with taking your medicines, what are these? 
? How do you feel about taking your medicines for a long period? 
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? What do you think the future holds in terms of your treatment, how do you feel about 
it (for patients using OHAs only)?  
? Have you had a time when you got a different brand of your medicines? How did you 
feel about it? 
? Have you experienced any problem while using your device (pain, skin infection, 
irritation, bruising, mechanical problems, others)? 
? What did you do to solve these problems?   
 
5. How easy or difficult do you find using your device? 
? Was it easy/difficult to learn how to use it   
? Any difficulty in measuring insulin dose correctly/other difficulties 
? Are there things you find easier/harder to do now, compared to your previous 
therapy 
? What are these and how are they easier/harder?  
 
6. How would you describe your life while using this device? 
? Is it easy/normal life, you can do what you want 
? Do you feel stressed or overwhelmed because of using this device? 
? Do you feel psychologically or physically uncomfortable because of using this 
device? 
 
7. Does your device interfere with your normal life activities? 
? Wearing clothes  
? Eating  
? Exercise  
? Practising hobbies  
? Sleep  
? How does this compare to your previous therapy  
 
8. How do you fit taking your medicines into your daily routine?  
? Tell me how did you use your medicines yesterday  
 
9. In order to make life easier, patients sometimes use their medicines in their 
own ways. Do you remember a time when you have not used your medicines 
as prescribed, please tell me what you did, and why did this happen? 
? Do you change the way you take your medicines when you travel/at weekends?  
 
10. Tell me about changes you make in taking your medicines during the holy 
month of Ramadan. 
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? Why are you making these changes? 
? Do you think this has an impact on your diabetes?   
 
11. What do you think about the role of herbal medicines in the treatment of 
diabetes?  
? Have you ever used them, what did you use?  
? When did you start using it? 
? How often do you use it, instead of/with your regular medicines?  
? How helpful do you think they are?  
 
Blood glucose monitoring & glycaemic control   
12. Tell me about monitoring your blood glucose level. 
? How often do you monitor your blood glucose level and when?  
? What result are you aiming for, and what do you consider a good/bad result? 
? How often do you achieve your target, and what helps you achieving it?  
? What do you do if you have not achieved your target?   
? What hinders you from regularly monitoring your blood glucose level (lack of time, 
forgetfulness, impaired manual/visual dexterities, too complicated, too painful, 
stress, lack of awareness)?  
? Do you feel that your device requires you to monitor your blood glucose level more 
often than you would like? 
? How does this compare to your previous therapy?  
 
13. Describe how your device helps you in controlling your diabetes? 
? Achieving good blood glucose control 
? Having hyper/hypoglycaemia  
? Improving awareness of hypoglycaemia 
? Avoiding weight gain 
? Having hospital admissions due to poor control 
 
Social support  
14. Can you tell me how your family and friends support you in managing your 
diabetes? 
? Calculating doses  
? Administering doses 
? Checking site of injection  
? Monitoring blood glucose level 
? Eating special food  
? Exercising 
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? Accompanying you in your appointments  
? Collecting your prescriptions  
? How does this compare to your previous therapy? 
 
15. How do you feel about talking with others regarding your disease or 
administering your medicines/using your device in front of others? 
? Embarrassed 
? Different from others 
? Does diabetes interfere with your social life (social gatherings)? 
 
16. Does using your device have an effect on other family members?  
? How much they need to help 
? How much they are worrying about you  
? How does this compare to your previous therapy? 
 
Healthcare providers 
17. Describe your experience with healthcare providers (physicians, 
ophthalmologists, dieticians, pharmacists, nurses,).  
? Who have you spoken with, and how regularly do you see them?   
? What information have you been given (education about diabetes, complications, 
medicines use, insulin requirements, carbohydrate counting, lifestyle modifications 
and check-ups) 
? Have you received sufficient training for the use of your device?  
? Do you think that healthcare providers are helpful? In what ways?  
? Does your physician discuss with you your treatment plan, how do you feel about it? 
? Have you experienced a time when HCPs were unhelpful? In what ways? 
 
Healthcare system  
18. Tell me about healthcare services that you have received. 
? Are there any services that you would like to get all the time?  
? What other services you would like to have (receiving reminder phone calls for your 
appointment, telephone helpline)?   
? Have you experienced any problems in accessing to health services, what are these 
      (unavailability of medicines, inflexibility of appointments, discontinuity of care)?   
 
Final questions  
19. In general, are you happy with your current device? 
? Do you think that you may change it at any time? 
? Would you recommend your current device to other patients? 
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20. Finally, would you like to add anything about your disease, 
medicines/device, healthcare providers or system that we have not 
discussed? 
? Any other good things 
? Any other concerns/problems 
 
 
 
????????????????????? 
How old are you/date of birth? 
How long have you had diabetes? 
Sex: Male     Female  
Nationality: Kuwaiti     Non-Kuwaiti  
Residence area: rural     urban   
Occupation: Student     employed     un-employed     retired        
What is your educational level?  
? Cannot read and write  
? Primary school  
? Secondary school  
? Diploma 
? University  
? Postgraduate  
 
 
Thank you for your participation 
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Interview schedule for healthcare professionals 
 
 
 
 
 
 
 
 
 
 
Healthcare provider:  
? Physician  
? Psychologist  
? Pharmacist  
? Dietician  
? Nurse  
 
Area: 
? Urban  
? Rural  
 
Signature:                                                                              
 
 
Date: 
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I would like to know you views and experiences regarding the following statements, in 
terms of agreement and importance.  
 
 
 
Statement 
Agreement Importance of consideration  
1= 
Agree 
2= 
Agree 
to a 
certain 
extent 
3= 
Dis-
agree 
4= Un-
certain 
1= 
Most 
import
-ant 
2= Very 
important 
3= 
Important  
4= Least 
important 
1. Non-adherence to 
treatment and healthy 
lifestyle is due to specific 
beliefs about the 
normality of the disease 
and lack of awareness 
about its seriousness 
and complications. 
        
Comment:  
2. Non-adherence to 
treatment and healthy 
lifestyle is due to cultural 
factors, e.g. fasting in 
Ramadan, use of 
herbals and social 
gatherings. 
        
Comment: 
3. Non-adherence to 
treatment is due to 
personal factors, such 
as forgetfulness, 
laziness, fear of or 
perceived side effects. 
        
Comment: 
4. Non-adherence to diet 
is due to lack of 
individualised diet plans, 
which conform to 
?????????????????????
educational 
requirements. 
        
Comment: 
5. Delivery of healthcare 
services is delayed, 
especially when referrals 
are needed. 
        
Comment: 
6. Pen devices are not 
prescribed/dispensed for 
all insulin-dependent 
patients with type 2 
diabetes in hospitals. 
        
Comment: 
7. Certain items, such as 
small-sized pen needles 
are mostly unavailable in 
the pharmacy. 
 
        
Comment: 
8. Although it is 
available in Medical 
Stores, VictozaR pen is 
not dispensed to 
patients treated in the 
MOH. 
        
Comment: 
9. Patients using insulin 
pumps gain weight due 
to different reasons, e.g. 
non-adherence to diet 
and exercise due to 
belief in the control 
provided by the pump, 
lack of awareness about 
carbohydrate counting, 
and not using the pump 
properly. 
        
Comment: 
10. Consultation time is 
not enough to discuss all 
pump-related issues 
with the doctor.  
        
Comment: 
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Would you please provide with your opinion regarding the following 
recommendations, in terms of their importance and practicability.  
 
 
Recommendation 
Importance Feasibility 
1= 
Most 
2= 
More 
3= 
Less 
4= 
Least  
1= 
Yes, 
now 
2= 
Yes, 
within 
a year 
3= 
Yes, 
within 5-
10 years  
4=No  
1. Health awareness of patients, e.g. 
awareness about short and long-term 
diabetes-related complications needs 
to be improved continuously through 
campaigns, group sessions or lecture 
courses at hospital clinics, primary-
care units, KDS, or via audio-visual 
aids, e.g., educational programmes in 
radio and television. 
        
Challenges:  
2. Social and cultural beliefs and 
lifestyle concerns should be addressed 
?????????????????????????? ???????
notes. 
        
Challenges: 
3. HCPs should undergo Pre-
Ramadan training programme, and 
cooperate together, in order to 
optimise care provided to patients 
during this month. 
        
Challenges: 
4. Educational and motivational 
advices regarding adherence to 
treatments should be provided verbally 
and in writing (e.g. brochures/leaflets), 
and reinforced with each clinical 
visit/prescription of medicines. 
        
Challenges: 
5. Dieticians need to be educated 
about the educational and social 
differences when dealing with patients, 
and how those differences could 
impact self-management behaviour of 
patients. Also, they need to be aware 
about how to individualise care plans 
?????????????????????????????????????
and life. 
        
Challenges: 
6. Family members should be involved 
when constructing care plans and 
lifestyle modifications. 
        
Challenges: 
7. The delivery of healthcare services 
should be further coordinated 
particularly, when patients needed 
referrals to different HCPs/department. 
        
Challenges: 
8. Patients initiated on insulin should 
be informed about the different 
methods that are available for insulin 
delivery, e.g. pens and pumps. Also, 
they should be involved in making 
decisions related to the selection of 
the device.    
        
Challenges: 
9. Services, such as pharmacist/nurse-
led diabetes clinics, or psychological 
interventions that take care of this 
group of patients by incorporating 
different HCPs in the management 
process should be implemented. 
        
Challenges: 
10. A 24-hours help-line service 
managed by diabetes specialists for 
urgent and between appointments 
enquiries should be considered. 
 
 
       
Challenges: 
Do you have any further recommendation (s) that you would like to add in order to:  
? ???????? ?????????? ??????????? ??????? ?????? ???????? ???? ????????????? ?????? ????????-taking 
behaviour,  
? Help patients to manage their disease during certain circumstances, e.g. Ramadan and social 
gatherings, 
? Improve the delivery of healthcare services and linked them together, 
? Expand the prescription of insulin devices (e.g. pens and pumps),  
? Improve health outcomes of patients with type 2 diabetes.                              Thank you 
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Appendix 9: The participant consent form  
 
 
Use of medicines and devices  
by adults in the management of type 2 diabetes  
in Kuwait 
 
Researcher: Zahra Alsairafi, MSc. Clinical Pharmacy International Practice & 
Policy, UCL 
Co-researchers: Prof. Felecity Smith (UCL) and Prof. Kevin Taylor (UCL) 
 
 
Consent Form  
 
Please tick  
   box 
? I confirm that I have read and understand the information sheet for the above    
study and have had the opportunity to ask questions. 
? I understand that my participation is voluntary and that I can withdraw at any 
time. 
? I understand that my refusal to take participate will not affect the delivery of 
healthcare services.  
? I agree to be interviewed and answered questions at any convenient time to 
me, and that the interview being audio-recorded. 
? I understand that the researcher will access my medical notes.  
? I agree for using anonymised quotes in publications.  
? I agree to take part in the above study.  
 
 
 
Name of participant:    
Date:   
Signature:                           
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??????????????????????????? 
 
 
 
????????????????????????????????????????????????????????????????????????????? 
????? ?????????????????????????????????? ??????????????????????????? 
?????????????????????? ????????????????????????????????????????????????????????????????????????
???????????????? ?????????????????????????  
 
 
 
 ??????????????????????????????????????????????????????????????????????????? 
 ??????????????????????????????????????????????????????????????????????????? 
 ?????????????????????????????????????????????????? 
 ????????????????????????????????????????????????????????????? ????????????????????????
???????????????????????? 
 ?????????????????????????????????????????????????? 
 ???????????????????????????? 
 
 
 
???????????? 
???????? 
???????? 
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Appendix 10: Morisky Medication Adherence Scale (MMAS-8) 
 
              
  8.  How often do you have difficulty remembering to take all your medication(s)?                                               
                                                                          (Please circle your answer below) 
   Never/R???????????????????...4 
   ?????????????????????????????3 
   ?????? ???????????????????.2 
   ?????????????????????????.1 
   ?????????? ?????????????????0 
 
 
 
 
 
 
 
 
Appendix 11: Beliefs about Medicines Questionnaire (BMQ-S) 
Morisky Medication Adherence ScaleMMAS-8-Item). This is a generic adherence scale.    
 
? 



? 


  
   





               
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YOUR VIEWS ABOUT  
MEDICINES PRESCRIBED FOR YOU 
 
? We would like to ask you about your personal views about medicines prescribed for 
you. 
? These are statements other people have made about their medicines.   
? Please show how much you agree or disagree with them by ticking the appropriate 
box. 
 
There are no right or wrong answers.  
We are interested in your personal views  
 
 
 
 
Views about MEDICINES PRESCRIBED 
FOR YOU: 
Strongly 
Agree 
Agree Un-
certain 
Disagree Strongly 
Disagree 
N1 My health, at present, depends on 
these medicines 
     
C1 Having to take these medicines 
worries me 
     
N2 My life would be impossible without 
these medicines 
     
C2 I sometimes worry about long-term 
effects of these medicines 
     
N3 Without these medicines I would be 
very ill 
     
C3 These medicines are a mystery to 
me 
     
N4 My health in the future will depends 
on these medicines 
     
C4 These medicines disrupt my life      
C5 I sometimes worry about becoming 
too dependent on these medicines 
     
N5 These medicines protect me from 
becoming worse 
     
C6 These medicines give me 
unpleasant side effects 
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?? 
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?
 
 ?????????????????????????
?????
??????????
?????
??????? ????
?????
*N1 ????????????????????????????????????????? ?????
*C1 ??????????????????????????????????? ?????
*N2 ??????? ????? ??????????????????? ?????
*C2 ???????????????????????????????????????????????????????????????????????
*N3 ????????????????????????????????????????? ?????
*C3 ??????????? ??????????????????? ?????
*N4 ???????????????????????????????????? ?????
*C4 ?????????????????????????? ?????
*N5 ???????????????????????????????????????????????? ?????
*C5 ????????????????????????????????????????? ?????
© Rob Horne, School of Pharmacy 
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Appendix 12: The clinical information sheet  
 
Completion form (to be completed by the interviewer) 
 
Total interview time: -----------minutes  
Was any person (other than patient) present at this interview: Yes No. If yes, 
comments on their participation: 
 
Was the interview audio-recorded: Yes   No. If no, state the reasons:  
 
 
*Latest HbA1c level(s): --------------------Date of measurement: -------------------- 
*Latest blood glucose level(s): -----------mmol/l. Date of measurement: -------------  
*BMI=----------Kg/m2 
*Smoking status:  
Smoker (------cigarettes/day)     Non-smoker     Ex-smoker  
*Current anti-diabetic treatment: 
 
 
 
 
*Clinical data to be obtain????????????????????????????????? 
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Appendix 13: UCL Research Ethics Committee Approval Letter  
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Appendix 14: Ministry of Health Approval Letter 
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Appendix 15: An agreement form for the use of MMAS-8 
 
  
 
 
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Appendix 17: ???????????????????????????????????????????????????-8 
 
Responses to items 1 to 7 
 
1. Do you sometimes forget to take your diabetes medicines? 
2. People sometimes miss taking their medicines for reasons other than forgetting. Thinking over 
the past 2 weeks, were there any days when you did not take your diabetes medicines? 
3. Have you ever cut back or stopped taking you diabetes medicines without telling your doctor, 
because you felt worse when you took it? 
4. When you travel or leave home, do you sometimes forget to bring along your diabetes 
medicines? 
5. Did you take your diabetes medicines yesterday? 
6. When you feel like your diabetes is under control, do you sometimes stop taking your 
medicines? 
7. Taking medicines everyday is a real inconvenience for some people. Do you ever feel hassled 
about sticking to your diabetes treatment plan?  
 
Responses to item 8  
 
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Question 8: How often
do you have difficulty
remembering to take all
your medicines?
No. participants 
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Appendix 18: ??????????????????????????????? and adherence level  
 
Participant Total MMAS score Adherence level* 
1 4.5 Low 
2 7 Medium 
3 8 High 
4 8 High 
5 8 High  
6 8 High 
7 7 Medium 
8 5.5 Low 
9 8 High 
10 4.5 Low 
11 8 High  
12 7 Medium 
13 6 Medium 
14 8 High 
15 7.75 Medium 
16 5 Low 
17 5.5 Low 
18 8 High 
19 8 High 
20 6.75 Medium 
21 8 High 
22 7 Medium 
23 6.75 Medium 
24 8 High 
25 8 High 
26 5.75 Low 
27 7 Medium 
28 5.5 Low 
29 6.75 Medium 
30 8 High 
31 3.5 Low 
32 8 High 
33 6.75 Medium 
34 8 High 
35 4.25 Low 
36 8 High 
37 6.75 Medium 
38 6.75 Medium 
39 5.75 Low 
40 7 Medium 
41 7 Medium 
42 8 High 
43 5.75 Low 
*MMAS=8, 6 to <8, <6 indicates high, medium and low adherence level respectively 
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Appendix 19: ??????????????????????????????????????????????????-subscales  
 
 
 
BMQ-necessity Strongly 
agree 
Agree Un-
certain 
Disagree Strongly 
disagree  
(1) My health at present 
depends on this medicine  
31 9 2 0 1 
(2) My medicine controls my 
diabetes 
32 8 2 1 0 
(3) Without this medicine I 
would be very ill 
29 9 4 1 0 
(4) My health in the future 
depends on this medicine  
19 15 7 1 1 
(5) My medicines prevent my 
blood sugar from becoming 
too high  
22 17 3 0 1 
BMQ-concern  
(1) Having to take these 
medicines worries me  
5 6 2 9 21 
(2) I sometimes worry about 
the long-term effects of these 
medicines  
10 13 3 7 10 
 
(3) Diabetes medicines are a 
mystery to me  
5 6 6 9 17 
(4) These medicines disrupt 
my life 
2 5 0 12 24 
(5) I sometimes worry about 
becoming too dependent on 
these medicines 
11 6 2 7 17 
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Appendix 20: ?????????????????-S necessity, concern and differential necessity-
concern scores  
 
Participant Total 
necessity (25) 
Total concern 
(25) 
Necessity-concern  
(-20-20) 
1 24 19 5 
2 25 15 10 
3 23 21 2 
4 24 8 16 
5 13 5 8 
6 20 9 11 
7 25 11 14 
8 20 18 2 
9 20 8 12 
10 23 20 3 
11 25 5 20 
12 21 12 9 
13 24 11 13 
14 25 5 20 
15 21 14 7 
16 22 23 -1 
17 19 19 0 
18 23 17 6 
19 24 10 14 
20 23 13 10 
21 23 5 18 
22 21 25 -4 
23 22 8 14 
24 19 14 5 
25 25 5 20 
26 23 14 9 
27 20 14 6 
28 24 7 17 
29 24 16 8 
30 24 9 15 
31 20 18 2 
32 21 6 15 
33 19 12 7 
34 25 11 14 
35 25 14 11 
36 24 14 10 
37 25 13 12 
38 25 11 14 
39 22 13 9 
40 23 6 17 
41 24 6 18 
42 19 7 12 
43 23 15 8 
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Appendix 21: The perspectives of HCPs on the identified issues and their 
evaluation in terms of agreement and importance   
 
 
 
Statement 
Agreement Importance of consideration  
1= 
Agree 
2= 
Agree 
to a 
certain 
extent 
3= 
Dis-
agree 
4= 
Un-
certain  
1= 
Most 
import
-ant 
2= 
Very 
important 
3= 
Important  
4= 
Least 
important  
1. Non-adherence to 
treatment and healthy 
lifestyle is due to specific 
beliefs about the 
normality of the disease 
and lack of awareness 
about its seriousness 
and complications. 
7 2 1 - 8 1 1 - 
2. Non-adherence to 
treatment and healthy 
lifestyle is due to cultural 
factors, e.g. fasting in 
Ramadan, use of 
herbals and social 
gatherings. 
6 2 1 1 5 3 - 2 
3. Non-adherence to 
treatment is due to 
personal factors, such 
as forgetfulness, 
laziness, fear of or 
perceived side effects. 
6 4 - - 5 5 - - 
4. Non-adherence to diet 
is due to lack of 
individualised diet plans, 
which conform to 
?????????????????????
educational 
requirements. 
1 5 4 - 7 3 - - 
5. Delivery of healthcare 
services is delayed, 
especially when referrals 
are needed. 
2 2 3 3 4 5 1 - 
6. Pen devices are not 
prescribed/dispensed for 
all insulin-dependent 
patients with type 2 
diabetes in hospitals. 
3 1 5 1 7 2 1 - 
7. Certain items, such as 
small-sized pen needles 
are mostly unavailable in 
the pharmacy. 
 
2 3 3 2 6 2 2 - 
8. Although it is 
available in Medical 
Stores, VictozaR pen is 
not dispensed to 
patients treated in the 
MOH. 
6 - 1 3 4 - 5 1 
9. Patients using insulin 
pumps gain weight due 
to different reasons, e.g. 
non-adherence to diet 
and exercise due to 
belief in the control 
provided by the pump, 
lack of awareness about 
carbohydrate counting, 
and not using the pump 
properly. 
1 2 4 3 7 3 - - 
10. Consultation time is 
not enough to discuss all 
pump-related issues 
with the doctor.  
1 4 3 2 8 2 - - 
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Appendix 22: The ??????responses to the provided recommendations, in terms of 
importance and feasibility 
 
 
 
Recommendation 
Importance Feasibility 
1= 
Most 
2= 
More 
3= 
Less 
4= 
Least  
1= 
Yes, 
now 
2= 
Yes, 
within 
a year 
3= 
Yes, 
within 5-
10 years  
4=No  
1. Health awareness of patients, e.g. 
awareness about short and long-term 
diabetes-related complications needs 
to be improved continuously through 
campaigns, group sessions or lecture 
courses at hospital clinics, primary-
care units, KDS, or via audio-visual 
aids, e.g., educational programmes in 
radio and television. 
10 - - - 5 3 2 - 
2. Social and cultural beliefs and 
lifestyle concerns should be addressed 
?????????????????????????? ???????
notes. 
8 1 1 - 5 2 3 - 
3. HCPs should undergo Pre-
Ramadan training programme, and 
cooperate together, in order to 
optimise care provided to patients 
during this month. 
6 4 - - 4 4 2 - 
4. Educational and motivational 
advices regarding adherence to 
treatments should be provided verbally 
and in writing (e.g. brochures/leaflets), 
and reinforced with each clinical 
visit/prescription of medicines. 
7 3 - - 4 3 3 - 
5. Dieticians need to be educated 
about the educational and social 
differences when dealing with patients, 
and how those differences could 
impact self-management behaviour of 
patients. Also, they need to be aware 
about how to individualise care plans 
?????????????????????????????????????
and life. 
6 - 4 - 4 1 5 - 
6. Family members should be involved 
when constructing care plans and 
lifestyle modifications. 
5 4 1 - 3 2 4 1 
7. The delivery of healthcare services 
should be further coordinated 
particularly, when patients needed 
referrals to different HCPs/department. 
8 2 - - 1 3 6 - 
8. Patients initiated on insulin should 
be informed about the different 
methods that are available for insulin 
delivery, e.g. pens and pumps. Also, 
they should be involved in making 
decisions related to the selection of 
the device.    
4 3 2 1 4 3 - 3 
9. Services, such as pharmacist/nurse-
led diabetes clinics, or psychological 
interventions that take care of this 
group of patients by incorporating 
different HCPs in the management 
process should be implemented. 
7 3 - - 4 1 5 - 
10. A 24-hours help-line service 
managed by diabetes specialists for 
urgent and between appointments 
enquiries should be considered. 
6 2 2 - 1 3 3 3 
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Appendix 23: The structure, process and outcomes of the recommended 
healthcare services  
 
Behavioural intervention 
 
Structure  Process  Outcome  
-Interventionist 
 
-Questionnaire 
+ phone calls  
-Baseline assessments 
(Including Demographic/Profile 
Questionnaire, The Summary of Diabetes 
Self-Care Activities Questionnaire, The 
Kristal Food Habits Questionnaire, The 
Gormally Binge Eating Scale, The 
Physical Activity Scale for the Elderly 
Questionnaire, and Rosenberg Self-
Esteem Scale).  
  
-Meeting with the interventionist  
(Patient participation in goal setting, and 
selecting personalised strategies to 
overcome barriers).   
 
-Ten minutes follow-up phone calls at 1, 3 
and 7 weeks post assessment  
(Concentrating on the extent to which 
patients have achieved their goals since 
last contact, and reinforcing or helping 
patients in problem-solving strategies, if 
needed).  
 
-12, 24 and 52 week assessment visits  
(Reviewing what has worked, setting 
further goals, and receiving written 
materials concentrating on lapse and 
relapse, key targets for changing eating 
and physical activity habits, and the 
importance of these changes in the 
management of the disease).  
-Patients were able 
to remember and 
achieve the specific 
goals (e.g. 
eating/physical 
activity) that they 
established at the 
beginning of the 
intervention.  
Clark and Hampson, 2001 
 
Nurse-led clinic 
 
Structure  Process Outcome  
-Two nurses. 
  
-Nurse-led protocol and 
education system.  
-18-months follow-up 
programme  
(Education, drug type/dosage 
change).  
-Glycaemic control 
(HbA1c reduction 
11.6% vs. 7.7%). 
 
-Self-reported 
hypoglycaemia did not 
increase.  
Gill et al., 2008  
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Pharmaceutical care programme  
 
Structure Process Outcome 
-One clinical 
pharmacist. 
 
-Follow-up 
care 
programme 
(12-month 
period), on 
monthly 
basis.  
-A 20 minutes face-to-face interview 
with patients  
(Obtaining demographic and clinical 
details, assessing medication 
knowledge and adherence, completing 
QoL questionnaire).   
 
-??????????????????????????????????????? 
(Recommending intensive 
management to hypertension, 
reviewing the latest diabetes 
guidelines, and recommending 
simplification of dosage regimen, 
where appropriate). 
 
-A structured patient education  
(Including diabetes complications, 
proper dosage, side effects, healthy 
lifestyle, management of symptoms, 
self-monitoring).  
 
-Supplementary leaflets 
(Containing information about 
hypertension and hyperlipidaemia). 
 
-Behavioural modifications 
(Regarding monitoring of glycaemic 
control and recording levels in a 
record book, initiation of an exercise 
plan, improving understanding of food 
choices, discussing barriers to 
medication adherence, advising on 
stopping smoking).  
-HbA1c reduction (8.5% 
vs. 6.9%). 
 
-BP reduction (131.4/85.2 
mmHg vs. 127.2/76.3 
mmHg). 
 
-Framingham risk 
prediction score (10-year 
coronary heart disease 
risk score) reduction 
(10.56% vs. 7.7%).  
Al Mazroui et al., 2009  
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